0001140361-14-019389.txt : 20140507 0001140361-14-019389.hdr.sgml : 20140507 20140507164039 ACCESSION NUMBER: 0001140361-14-019389 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20140331 FILED AS OF DATE: 20140507 DATE AS OF CHANGE: 20140507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DELCATH SYSTEMS, INC. CENTRAL INDEX KEY: 0000872912 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 061245881 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-16133 FILM NUMBER: 14821568 BUSINESS ADDRESS: STREET 1: 810 SEVENTH AVENUE STREET 2: 35TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: (212) 489-2100 MAIL ADDRESS: STREET 1: 810 SEVENTH AVENUE STREET 2: 35TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: DELCATH SYSTEMS INC DATE OF NAME CHANGE: 19990607 10-Q 1 form10q.htm DELCATH SYSTEMS INC 10-Q 3-31-2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2014

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission File Number: 001-16133

DELCATH SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Delaware		06-1245881
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

810 Seventh Avenue, 35^th Floor New York, NY 10019

(Address of principal executive offices)

(212) 489-2100

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o	Accelerated filer o
Non-accelerated filer x (Do not check if a smaller reporting company)	Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o No x

As of May 6, 2014, 9,442,197 shares of the Company’s common stock, $0.01 par value, were outstanding.

DELCATH SYSTEMS, INC.

Table of Contents

PART I—FINANCIAL INFORMATION			Page

Item 1.	Financial Statements (Unaudited)
		Condensed Consolidated Balance Sheets as of March 31, 2014 and December 31, 2013	2
		Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2014 and 2013	3
		Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2014 and 2013	4
		Notes to Condensed Consolidated Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		14
Item 3.	Quantitative and Qualitative Disclosures about Market Risk		26
Item 4.	Controls and Procedure		27

PART II—OTHER INFORMATION

Item 1.	Legal Proceedings		28
Item 1A.	Risk Factors		30
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		30
Item 3.	Defaults upon Senior Securities		30
Item 4.	Mine Safety Disclosure		30
Item 5.	Other Information		30
Item 6.	Exhibits		31

SIGNATURES			32

Table of Contents

DELCATH SYSTEMS, INC.

Condensed Consolidated Balance Sheets

(Unaudited)

(in thousands, except share data)

	March 31, 2014			December 31, 2013
ASSETS
Current assets
Cash and cash equivalents	$	31,254		$	31,249
Accounts receivables, net		181			349
Inventories, net		619			719
Prepaid expenses and other current assets		1,292			1,711
Total current assets		33,346			34,028
Property, plant and equipment, net		2,738			3,069
Total assets	$	36,084		$	37,097

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable	$	334		$	582
Accrued expenses		3,476			3,740
Warrant liability		2,399			2,310
Total current liabilities		6,209			6,632
Other non-current liabilities		225			366
Total liabilities		6,434			6,998

Commitments and contingencies (Note 11)		–			–

Stockholders’ equity
Preferred stock, $.01 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2014 and December 31, 2013		–			–
Common stock, $.01 par value; 170,000,000 shares authorized; 9,433,703 and 8,394,397 shares issued and 9,431,907 and 8,392,641 shares outstanding at March 31, 2014 and December 31, 2013, respectively *		94			84
Additional paid-in capital		263,923			259,102
Accumulated deficit		(234,410	)		(229,132	)
Treasury stock, at cost; 1,757 shares at March 31, 2014 and December 31, 2013 *		(51	)		(51	)
Accumulated other comprehensive income		94			96
Total stockholders’ equity		29,650			30,099
Total liabilities and stockholders’ equity	$	36,084		$	37,097

* Reflects a one-for-sixteen (1:16) reverse stock split effected on April 8, 2014.

See accompanying Notes to Condensed Consolidated Financial Statements

Table of Contents

DELCATH SYSTEMS, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(in thousands, except share and per share data)

	Three months ended March 31,
	2014			2013
REVENUES
Product revenues	$	310		$	81
Other revenues		–			300
Total revenues		310			381

COSTS OF SALES
Costs of goods sold		93			31
Gross profit		217			350

OPERATING EXPENSES
Selling, general and administrative		3,819			6,083
Research and development		1,457			4,469
Total operating expenses		5,276			10,552
Loss from operations		(5,059	)		(10,202	)
OTHER INCOME (EXPENSE)
Change in fair value of warrant liability, net		(205	)		(2,272	)
Interest income		1			10
Other expenses		(15	)		(381	)
Net loss	$	(5,278	)	$	(12,845	)

LOSS PER COMMON SHARE
Basic and diluted loss per common share *	$	(0.57	)	$	(2.40	)

WEIGHTED AVERAGE COMMON SHARES
Basic and diluted weighted average common shares outstanding *		9,300,078			5,342,976

OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustments	$	(2	)	$	364
Comprehensive loss	$	(5,280	)	$	(12,481	)

* Reflects a one-for-sixteen (1:16) reverse stock split effected on April 8, 2014.

See accompanying Notes to Condensed Consolidated Financial Statements

Table of Contents

DELCATH SYSTEMS, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

	Three months ended March 31,
	2014			2013
Cash flows from operating activities:
Net loss	$	(5,278	)	$	(12,845	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense		178			467
Restricted stock compensation expense		42			197
Depreciation expense		249			298
Warrant liability fair value adjustment		205			2,272
Loss on write-downs and disposal of equipment		82			—
Non-cash interest income		—			(2	)
Changes in assets and liabilities:
Decrease (increase) in prepaid expenses and other current assets		419			(248	)
Decrease in accounts receivable		169			85
Decrease (increase) in inventories		99			(97	)
Decrease in accounts payable and accrued expenses		(512	)		(764	)
Decrease in other non-current liabilities		(140	)		(300	)
Net cash used in operating activities		(4,487	)		(10,937	)

Cash flows from investing activities:
Purchase of property, plant, and equipment		—			(34	)
Net cash used in by investing activities		—			(34	)

Cash flows from financing activities:
Net proceeds from sale of stock and exercise of stock options and warrants		4,495			30,018
Net cash provided by financing activities		4,495			30,018
Foreign currency effects on cash		(3	)		31
Net increase in cash and cash equivalents		5			19,078

Cash and cash equivalents:
Beginning of period		31,249			23,726
End of period	$	31,254		$	42,804

Supplemental non-cash activities:
Fair value of warrants exercised	$	116		$	214

See accompanying Notes to Condensed Consolidated Financial Statements

Table of Contents

DELCATH SYSTEMS, INC.

Notes to the Condensed Consolidated Financial Statements

(1)

General

The interim Condensed Consolidated Financial Statements of Delcath Systems, Inc. (“Delcath” or the “Company”) for the three months ended March 31, 2014 and 2013 should be read in conjunction with the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K (“Annual Report”) for the year ended December 31, 2013, which has been filed with the Securities Exchange Commission (“SEC”) and can also be found on the Company’s website (www.delcath.com). In these notes the terms “us”, “we” or “our” refer to Delcath and its consolidated subsidiaries.

On February 24, 2014, shareholders of the Company approved, through a shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Delcath’s common stock at a ratio within a range of one-for-eight (1:8) to one-for-sixteen (1:16). The reverse stock split became effective on April 8, 2014 at which time Delcath’s common stock began trading on the NASDAQ Stock Exchange on a one-for-sixteen (1:16) split-adjusted basis. All owners of record as of the close of the NASDAQ market on April 8, 2014 received one issued and outstanding share of Delcath common stock in exchange for sixteen issued and outstanding shares of Delcath common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-sixteen exchange were rounded up to the next whole share. The reverse stock split had no impact on the number of common shares authorized or the par value per share of Delcath common stock, which remain 170,000,000 and $0.01, respectively. All current and prior period amounts related to shares, share prices and earnings per share, presented in these Condensed Consolidated Financial Statements and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split.

Description of Business

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Our proprietary product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan HDS)—is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. The Company's principal focus is on the treatment of primary and metastatic liver cancers.

In the United States, the Melphalan/HDS system is considered a combination drug and device product, and is regulated as a drug by the United States Food and Drug Administration (FDA). The Melphalan/HDS system has not been approved for sale in the United States. In Europe, our proprietary system to deliver and filter melphalan hydrochloride is marketed as a device under the trade name Delcath Hepatic CHEMOSAT^® Delivery System for Melphalan (CHEMOSAT). In April 2012, we obtained authorization to affix a CE Mark for the Generation Two CHEMOSAT system. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT system in Europe. The Company has initiated plans to investigate the Melphalan/HDS system for primary liver cancer.

The Company has incurred losses since inception. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. Management believes that its capital resources are adequate to fund operations through the first half of 2015, but anticipates that additional working capital may be required to continue operations. To the extent additional capital is not available when needed, the Company may be forced to abandon some or all of its development and commercialization efforts, which would have a material adverse effect on the prospects of the business. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainties and risks related to product development; regulatory approvals; technology; patents and proprietary rights; comprehensive government regulations; limited commercial manufacturing; marketing and sales experience; and dependence on key personnel.

Basis of Presentation

These interim Condensed Consolidated Financial Statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all entities controlled by Delcath and all significant inter-company accounts and transactions have been eliminated in consolidation.

Table of Contents

DELCATH SYSTEMS, INC.

Notes to the Condensed Consolidated Financial Statements

The preparation of interim financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim Condensed Consolidated Financial Statements, in the opinion of management, reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended March 31, 2014 and 2013; however, certain information and footnote disclosures normally included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year.

Significant Accounting Policies

A description of our significant accounting policies has been provided in Note 3 Summary of Significant Accounting Policies to the Consolidated Financial Statements included in our Annual Report.

Recently Adopted Accounting Pronouncements

In March 2013, the FASB issued ASU 2013-05, which permits an entity to release cumulative translation adjustments into net income when a reporting entity (parent) ceases to have a controlling financial interest in a subsidiary or group of assets that is a business within a foreign entity. Accordingly, the cumulative translation adjustment should be released into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided, or, if a controlling financial interest is no longer held. The revised standard became effective for fiscal years beginning after December 15, 2013. The Company adopted this guidance effective January 1, 2014. The Company’s adoption of this standard did not have a material impact on its consolidated financial statements.

(2)	Inventories

Inventories consist of the following:

(in thousands)	March 31, 2014		December 31, 2013
Raw materials	$	232	$	249
Work-in-process		268		364
Finished goods		119		106
Total inventory	$	619	$	719

(3)	Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:

(in thousands)	March 31, 2014		December 31, 2013
Insurance premiums	$	310	$	407
Professional fees		75		377
Income tax credits receivable		297		326
Kits for clinical use		295		287
Other¹		315		314
Total prepaid expenses and other current assets	$	1,292	$	1,711

¹ Other consists of various prepaid expenses and other current assets with no individual item accounting for more than 5% of the total balance at March 31, 2014 and December 31, 2013.

Table of Contents

DELCATH SYSTEMS, INC.

Notes to the Condensed Consolidated Financial Statements

(4)	Property, Plant, and Equipment

Property, plant, and equipment consist of the following:

(in thousands)	March 31, 2014			December 31, 2013
Leaseholds	$	1,748		$	1,749
Furniture		957			957
Equipment		1,487			1,552
Enterprise hardware and software		2,009			2,143
Buildings and land		603			603
Property, plant and equipment, gross		6,804			7,004
Accumulated depreciation		(4,066	)		(3,935	)
Property, plant and equipment, net	$	2,738		$	3,069

Depreciation expense for the three months ended March 31, 2014 and 2013 was $0.2 million and $0.3 million, respectively.

(5)	Accrued Expenses

Accrued expenses consist of the following:

(in thousands)	March 31, 2014		December 31, 2013
Compensation, excluding taxes	$	1,853	$	1,866
Deferred rent		483		485
Professional fees		323		360
Other¹		817		1,029
Total accrued expenses	$	3,476	$	3,740

¹ Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at March 31, 2014 and December 31, 2013.

In November 2013, the Board of Directors approved an Employee Retention Program for certain key employees, including the Company’s executive officers. The executive officers will be eligible to receive a cash retention bonus payment equal to fifty percent (50%) of their current annual salary if they remain employed by the Company through March 31, 2015. The expense related to this program is being accrued ratably over the required service period and has been included in Accrued expenses on the Condensed Consolidated Balance Sheets and in both Selling, general and administrative and Research and development on the Condensed Consolidated Statements of Operations.

(6)	Restructuring Expenses

During 2013, the Company implemented workforce restructurings to better focus its organizational structure, increase efficiency and concentrate financial resources on its clinical development program and European commercialization activity. This resulted in a total reduction in the Company’s workforce by 50 employees. As a result of termination benefits provided to these employees the Company incurred a total restructuring charge of approximately $4.0 million related to severance expenses. At March 31, 2014, the remaining restructuring reserve of $1.4 million is included in Accrued expenses and Other non-current liabilities on the Condensed Consolidated Balance Sheets for $1.2 million and $0.2 million, respectively.

The following table provides the total severance expense incurred and payments made by the Company through March 31, 2014 as a result of the workforce restructurings implemented in 2013:

(in thousands)	March 31, 2014
Restructuring reserve balance, gross	$	3,974
Restructuring expenses paid		(2,606	)
Restructuring reserve balance, net	$	1,368

Table of Contents

DELCATH SYSTEMS, INC.

Notes to the Condensed Consolidated Financial Statements

(7)	Stockholders’ Equity

Stock Issuances

Reverse Stock Split

At-the-Market (“ATM”) Programs

In December 2011, the Company entered into an agreement with Cowen and Company, LLC (“Cowen”) to sell shares of its common stock, par value $.01 per share, from time to time, through an ATM equity offering program having aggregate sales proceeds of $39.8 million, under which Cowen would act as sales agent. During the three months ended March 31, 2013, the Company sold approximately 0.9 million shares of its common stock under this ATM program for proceeds of approximately $20.9 million, with net cash proceeds after related expenses of approximately $20.8 million, and successfully completed the program. As of March 31, 2014, there were no shares of common stock of the Company remaining for sale under this ATM program.

In March 2013, the Company entered into a new agreement with Cowen to sell shares of the Company’s common stock, par value $.01 per share, from time to time, through an ATM equity offering program having aggregate sales proceeds of $50.0 million, under which Cowen will act as sales agent. During the year ended December 31, 2013, the Company sold approximately 1.0 million shares of its common stock under this ATM program for proceeds of approximately $5.0 million, with net cash proceeds after related expenses of approximately $4.8 million. During the three months ended March 31, 2014 the Company sold an additional 1.0 million shares of its common stock under this ATM program for proceeds of approximately $4.4 million, with net cash proceeds after related expenses of approximately $4.4 million. The shares were issued pursuant to an effective registration statement on Form S-3 (333-187230). The net proceeds will be used for general corporate purposes, including, but not limited to, commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures and working capital. As of March 31, 2014, the Company has approximately $40.4 million remaining under the program.

Committed Equity Financing Facility (“CEFF”) Program

In December 2012, the Company entered into an agreement with Terrapin Opportunity, L.P. (“Terrapin”) for a CEFF program. Under the agreement Terrapin committed to purchase up to $35.0 million of Delcath common stock over a 24-month term. Since inception, the Company has sold approximately 0.5 million shares of its common stock through the program for total proceeds of approximately $11.1 million, with net cash proceeds after related expenses of approximately $10.8 million. As a result, there was approximately $23.9 million available under this CEFF program as of March 31, 2014. The shares were issued pursuant to an effective registration statement on Form S-3 (333-183675). The net proceeds will be used for general corporate purposes including, but not limited to, commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures and general working capital needs.

Table of Contents

DELCATH SYSTEMS, INC.

Notes to the Condensed Consolidated Financial Statements

Warrants

In June 2009, the Company completed the sale of 0.1 million shares of its common stock and the issuance of warrants to purchase 0.1 million common shares (the “2009 Warrants”) pursuant to a subscription agreement with a single investor. The Company received proceeds of $3.0 million, with net cash proceeds after related expenses from this transaction of approximately $2.7 million. Of those proceeds, the Company allocated an estimated fair value of $2.2 million to the 2009 Warrants. As required by the 2009 Warrant agreement, the exercise price of the warrants was adjusted following the Company’s October 2013 sale of common stock and warrants. At March 31, 2014, the 2009 Warrants were exercisable at $2.56 per share with approximately 40,000 warrants outstanding. The 2009 Warrants have a five-year term. The shares and warrants were issued pursuant to an effective registration statement on Form S-3. During the three months ended March 31, 2014, 25,000 2009 Warrants were exercised for net proceeds of approximately $0.1 million.

In May 2012, the Company completed the sale of 1.0 million shares of its common stock and the issuance of warrants to purchase 0.3 million common shares (the “2012 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $21.5 million, with net cash proceeds after related expenses from this transaction of approximately $21.1 million. Of those proceeds, the Company allocated an estimated fair value of $3.4 million to the 2012 Warrants. As required by the 2012 Warrant agreement, the exercise price of the warrants was adjusted following the Company’s October 2013 sale of common stock and warrants. At March 31, 2014, the 2012 Warrants were exercisable at $2.56 per share with 0.3 million warrants outstanding. The 2012 Warrants have a three-year term. The shares and warrants were issued pursuant to an effective registration statement on Form S-3. During the three months ended March 31, 2014, approximately 13,000 2012 Warrants were exercised for net proceeds of approximately $34,000.

In October 2013, the Company completed the sale of 1.3 million shares of its common stock and the issuance of warrants to purchase 0.6 million common shares (the “2013 Warrants”) pursuant to a placement agency agreement. The Company received proceeds of $7.5 million, with net cash proceeds after related expenses from this transaction of approximately $6.9 million. Of those proceeds, the Company allocated an estimated fair value of $1.9 million to the 2013 Warrants. The 2013 Warrants will become exercisable at $7.04 per share on April 30, 2014. The 2013 Warrants have a five-year term. The shares and warrants were issued pursuant to an effective registration statement on Form S-3.

Stock Incentive Plans

The Company established the 2004 Stock Incentive Plan and the 2009 Stock Incentive Plan (collectively, the “Plans”) under which 187,500, and 406,250 shares, respectively, have been reserved for the issuance of stock options, stock appreciation rights, restricted stock, stock grants and other equity awards. The Plans are administered by the Compensation and Stock Option Committee of the Board of Directors which determines the individuals to whom awards shall be granted as well as the type, terms, conditions, option price and the duration of each award.

A stock option grant allows the holder of the option to purchase a share of the Company’s common stock in the future at a stated price. Options granted under the Plans vest as determined by the Company’s Compensation and Stock Option Committee and expire over varying terms, but not more than ten years from the date of grant. Stock option activity for the three months ended March 31, 2014 is as follows:

	Stock Option Activity under the Plans
	Stock Options			Exercise Price per Share		Weighted Average Exercise Price		Weighted Average Remaining Life (Years)
Outstanding at December 31, 2013		252,133		$	4.80—$248.64	$	57.90		7.36
Granted		—			—		—
Forfeited		(14,304	)	$	7.36—$248.64	$	109.54
Expired		—			—		—
Outstanding at March 31, 2014		237,829		$	4.80—$248.64	$	54.79		7.13

Table of Contents

DELCATH SYSTEMS, INC.

Notes to the Condensed Consolidated Financial Statements

For the three months ended March 31, 2014 and 2013, the Company recognized compensation expense of approximately $0.2 million and $0.5 million, respectively, relating to stock options granted to employees.

There were no options granted during the three months ended March 31, 2014. The estimated fair value of each option award granted during the three month period ended March 31, 2013 was determined on the date of grant using an option pricing model with the following assumptions:

		Three months ended March 31, 2013
Dividend yield		None
Expected volatility		86.16% — 86.51%
Weighted average volatility		86.20%
Risk-free interest rates		1.16% — 1.36%
Expected life (in years)		6.8

No dividend yield was assumed because the Company has never paid a cash dividend on its common stock and does not expect to pay dividends in the foreseeable future. Volatilities were developed using the Company’s historical volatility. The risk-free interest rate was developed using the U.S. Treasury yield for periods equal to the expected life of the stock options on the grant date. The expected option term for grants made during the second half of 2012 and thereafter is based on actual historical results. The expected option term for grants made prior to that was developed based on the mid-point between the vesting date and the expiration date of each respective grant as permitted under ASC 718. This method of determining the expected holding period was utilized at that time because the Company did not yet have sufficient historical experience from which to estimate the period.

Restricted stock activity for the three months ended March 31, 2014 is as follows:

	Restricted Stock Activity under the Plans
	Restricted Stock			Weighted Average Grant Date Fair Value
Non-vested at December 31, 2013		20,358		$	16.88
Granted		—			—
Vested		(1,624	)		75.32
Forfeited		(71	)		39.26
Non-vested at March 31, 2014		18,663		$	11.71

For the three months ended March 31, 2014 and 2013, the Company recognized compensation expense of approximately $0.04 million and $0.2 million, respectively, related to restricted stock granted to employees.

(8)	Fair Value Measurements

Derivative Warrant Liability

As disclosed in Note 7 Stockholders’ Equity of these Condensed Consolidated Financial Statements, the Company allocated part of the proceeds of public offerings in 2009, 2012 and 2013 of the Company’s common stock to warrants issued in connection with those transactions. The valuation of the warrants was determined using an option pricing model. This model uses inputs such as the underlying price of the shares issued when the warrant is exercised, volatility, risk free interest rate and expected life of the instrument. The Company has determined that the warrants should be classified as liabilities and has accounted for them as derivative instruments in accordance with ASC 815. Additionally, the Company has determined that the warrant derivative liability should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the option pricing model against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification as called for in ASC 820. There are six inputs: closing price of Delcath stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of Delcath’s stock over that term; annual rate of dividends; and the riskless rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrant agreements. The annual rate of dividends is based on the Company’s historical practice of not granting dividends. The closing price of Delcath stock would fall under Level 1 of the fair-value hierarchy as it is a quoted price in an active market (ASC 820-10). The riskless rate of return is a Level 2 input as defined in ASC 820-10, while the historical volatility is a Level 3 input as defined in ASC 820. Since the lowest level input is a Level 3, Delcath determined the warrant derivative liability is most appropriately classified within Level 3 of the fair value hierarchy.

Table of Contents

DELCATH SYSTEMS, INC.

Notes to the Condensed Consolidated Financial Statements

For the three months ended March 31, 2014, the Company recorded pre-tax derivative warrant expense of $0.2 million. The resulting derivative warrant liabilities totaled $2.4 million at March 31, 2014. In the event of a hypothetical 10% increase in the market price of our common shares on which the March 31, 2014 valuation was based, the value of the derivative liability would have increased by $0.3 million. Management expects that the warrants will either be exercised or expire worthless. The fair value of the warrants at March 31, 2014 was determined by using an option pricing model with the following assumptions:

	2013 Warrants		2012 Warrants		2009 Warrants
Expected volatility		91.53%		114.33%		101.78%
Risk-free interest rates		1.52%		0.21%		0.05%
Expected life (in years)		4.58		1.17		0.21

Money Market Funds

The Company has determined that the inputs associated with the fair value determination of its money market funds are based on quoted prices (unadjusted) and, as a result, the investments have been classified within Level 1 of the fair value hierarchy.

The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2014, aggregated by the level in the fair value hierarchy within which those measurements fall.

	Assets and Liabilities Measured at Fair Value on a Recurring Basis
(in thousands)	Level 1			Level 2			Level 3			Balance at March 31, 2014
Assets
Money market funds		$	1,945		$	—		$	—		$	1,945
Liabilities
Warrant liability		$	—		$	—		$	2,399		$	2,399

The table below presents the activity within Level 3 of the fair value hierarchy for the three months ended March 31, 2014:

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
(in thousands)	Warrant Liability
Beginning balance as of December 31, 2013	$	2,310
Total change in the liability included in earnings		205
Fair value of warrants exercised		(116	)
Ending balance as of March 31, 2014	$	2,399

Table of Contents

DELCATH SYSTEMS, INC.

Notes to the Condensed Consolidated Financial Statements

(9)	Net Loss per Common Share

Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all common stock options and warrants are deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. However, in certain periods in which the exercise price of the warrants was less than the last reported sales price of Delcath’s common stock on the final trading day of the period and there is a gain recorded pursuant to the change in fair value of the warrant derivative liability, the impact of gains related to the mark-to-market adjustment of the warrants outstanding at the end of the period is reversed and the treasury stock method is used to determine diluted earnings per share. For the three month periods ended March 31, 2014 and 2013, there were no securities that were dilutive.

For the three month periods ended March 31, 2014 and 2013, the following potentially dilutive securities were excluded from the computation of earnings per share because their effects would be anti-dilutive:

	March 31,
	2014		2013
Stock options		237,829		349,635
Unvested restricted shares		18,663		25,676
Warrants		891,368		340,254
Total		1,147,860		715,565

DELCATH SYSTEMS, INC.

Notes to the Condensed Consolidated Financial Statements

(10)

Taxes

As discussed in Note 13 Income Taxes of the Company’s Annual Report, the Company has a valuation allowance against the full amount of its net deferred tax assets. The Company currently provides a valuation allowance against deferred tax assets when it is more likely than not that some portion or all of its deferred tax assets will not be realized. The Company has not recognized any unrecognized tax benefits in its balance sheet.

The Company is subject to income tax in the U.S., as well as various state and international jurisdictions. The Company has not been audited by the U.S. Internal Revenue Service, international tax authorities, or any states in connection with income taxes. The Company’s New York State tax returns have been subject to annual desk reviews which have resulted in insignificant adjustments to the related franchise tax liabilities and credits. The Company’s tax years generally remain open to examination for all federal, state and foreign tax matters until its net operating loss carryforwards are utilized and the applicable statutes of limitation have expired. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations.

(11)	Commitment and Contingencies

The Company is a party to several legal proceedings. Refer to Part II, Item 1 Legal Proceedings in this Quarterly Report on Form 10-Q for more information.

Table of Contents

DELCATH SYSTEMS, INC.

Notes to the Condensed Consolidated Financial Statements

(12)	Subsequent Events

Reverse Stock Split

On April 8, 2014, the Company effected a reverse stock split of its shares of common stock at a ratio of one-for-sixteen (1:16). Refer to Note 7 Stockholders’ Equity of these Condensed Consolidated Financial Statements for further information.

NASDAQ Listing Notification Letter

On April 24, 2014, the Company received a notification letter from The NASDAQ Stock Market advising the Company that the closing bid price of the Company’s common stock had been at $1.00 per share or greater for 10 consecutive business days, and accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and the matter was now closed.

The Company completed an evaluation of the impact of any subsequent events through the date financial statements were issued and determined there were no other subsequent events requiring disclosure in or adjustment to these financial statements.

Table of Contents

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited interim condensed consolidated financial statements and notes thereto contained in Item 1 of Part I of this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto as of and for the year ended December 31, 2013 included in the Company’s 2013 Annual Report on Form 10-K to provide an understanding of its results of operations, financial condition and cash flows.

Disclosure Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q for the period ended March 31, 2014 contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 with respect to our business, financial condition, liquidity and results of operations. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “could,” “would,” “will,” “may,” “can,” “continue,” “potential,” “should,” and the negative of these terms or other comparable terminology often identify forward-looking statements. Statements in this Quarterly Report on Form 10-Q for the period ending March 31, 2014 that are not historical facts are hereby identified as “forward-looking statements” for the purpose of the safe harbor provided by Section 21E of the Exchange Act and Section 27A of the Securities Act. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from the results contemplated by the forward-looking statements, including the risks discussed in this Quarterly Report on Form 10-Q for the period ended March 31, 2014 in Part II, Item 1A under “Risk Factors” as well as in Part I, Item 3 “Quantitative and Qualitative Disclosures About Market Risk,” our Annual Report on Form 10-K for the period ended December 31, 2013 in Item 1A under “Risk Factors” as well as in Item 7A “Quantitative and Qualitative Disclosures About Market Risk,” and the risks detailed from time to time in our future SEC reports. These forward-looking statements include, but are not limited to, statements about:

our estimates regarding sufficiency of our cash resources, anticipated capital requirements and our need for additional financing;

the commencement of future clinical trials and the results and timing of those clinical trials;

the progress and results of our research and development programs;

submission and timing of applications for regulatory approval and approval thereof;

our ability to successfully source certain components of the system and enter into supplier contracts;

our ability to successfully manufacture the CHEMOSAT/Delcath Hepatic Delivery System;

our ability to successfully commercialize the CHEMOSAT/Delcath Hepatic Delivery System, generate revenue and successfully obtain reimbursement for the procedure and System;

our ability to successfully negotiate and enter into agreements with distribution, strategic and corporate partners; and

our estimates of potential market opportunities and our ability to successfully realize these opportunities.

Many of the important factors that will determine these results are beyond our ability to control or predict. You are cautioned not to put undue reliance on any forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q. Except as otherwise required by law, we do not assume any obligation to publicly update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events.

Overview

The following section should be read in conjunction with Part I, Item 1: Condensed Consolidated Financial Statements of this report as well as Part I, Item 1: Business; and Part II, Item 8: Financial Statements and Supplementary Data of the Company’s 2013 Annual Report on Form 10-K.

Table of Contents

About the CHEMOSAT/Melphalan HDS

The CHEMOSAT/Melphalan HDS system administers concentrated regional chemotherapy to the liver. This “whole organ” therapy is performed by first isolating the circulatory system of the liver, infusing the liver with chemotherapeutic agent, and filtering the blood prior to returning it to the patient. During the procedure, known as percutaneous hepatic perfusion (PHP), three catheters are placed percutaneously through standard interventional radiology techniques. The catheters temporarily isolate the liver from the body’s circulatory system, allow administration of the chemotherapeutic agent melphalan hydrochloride directly to the liver, and collect blood exiting the liver for filtration by proprietary filters. The filters reduce the concentration of chemotherapeutic agent in the blood, thereby reducing systemic exposure to the drug, and related toxic side-effects, before the filtered blood is returned to the patient’s circulatory system.

Treatment with the CHEMOSAT/Melphalan HDS

Currently there are few effective treatment options for cancers in the liver. Traditional treatment options include surgery, chemotherapy, liver transplant, radiation therapy, interventional radiology techniques, and isolated hepatic perfusion. The most advanced application for which the CHEMOSAT/Melphalan HDS system was evaluated is for the treatment of metastatic melanoma in the liver. During the Company’s clinical trials, the procedure typically took approximately two to three hours. Patients remained in the intensive care unit overnight for observation after undergoing treatment with the CHEMOSAT/Melphalan HDS system. Treatment with the CHEMOSAT/Melphalan HDS system is a repeatable procedure, and during clinical trials patients received an average of three procedures at approximately four to eight week intervals. A new disposable CHEMOSAT/Melphalan HDS system is used for each treatment.

Risks associated with the CHEMOSAT/Melphalan HDS Procedure

As with many cancer therapies, treatment with CHEMOSAT/Melphalan HDS system is associated with toxic side-effects and certain risks, some of which are potentially life-threatening. In Phase 1, 2, and 3 clinical trials using early versions of the Melphalan HDS system, the integrated safety population of patients treated with early versions of the CHEMOSAT/Melphalan HDS system showed these risks to include: a 4.1% incidence of deaths due to adverse reactions; 4% incidence of stroke; 2% incidence of myocardial infarction in the setting of an incomplete cardiac risk assessment; a ≥ 70% incidence of grade 4 bone marrow suppression with a median time of recovery of greater than 1 week; and 8% incidence of febrile neutropenia, along with the additive risk of hepatic injury, severe hemorrhage, and gastrointestinal perforation. In this integrated safety population, deaths due to certain adverse reactions did not occur again during the clinical trials following the adoption of related protocol amendments. The trials that comprised this integrated safety population used early versions of the CHEMOSAT/Melphalan HDS system, including the Generation One filter, and did not include use of the Generation Two filter. The Company believes that through multidisciplinary training, the risks commonly associated with the procedure can be managed by experienced clinicians.

In clinical development, the Expanded Access Program and compassionate use in the United States, the Melphalan HDS system has been used to treat 175 patients. In the Phase 1, 2, and 3 trials early versions of the System were utilized, while the Expanded Access Program and compassionate use utilized the Generation Two filer.

Regulatory Status

United States

In August 2012, we submitted our NDA for the Melblez Kit under Section 505(b)(2) of the FFDCA seeking an indication for the percutaneous intra-arterial administration of melphalan for use in the treatment of patients with metastatic melanoma in the liver, and subsequently amended the indication we are seeking to ocular melanoma metastatic to the liver. The Company’s NDA was accepted for filing by the FDA on October 15, 2012, and was designated for standard review with an initial PDUFA goal date of June 15, 2013. On April 3, 2013, the FDA extended its PDUFA goal date to September 13, 2013. The FDA’s Oncologic Drugs Advisory Committee (ODAC) reviewed its NDA on May 2, 2013, and voted 16 to 0, with no abstentions, that the benefits of treatment with the Melblez Kit do not outweigh the risks associated with the procedure using the early clinical trial versions of the system. On September 12, 2013, the FDA issued a complete response letter (CRL) regarding the Company’s NDA for Melblez Kit.

Table of Contents

A CRL is issued by the FDA when the review of a file is completed and questions remain that precludes approval of the NDA in its current form. The FDA comments included, but were not limited to, a statement that Delcath must perform another "well-controlled randomized trial(s) to establish the safety and efficacy of Melblez Kit using overall survival as the primary efficacy outcome measure," and which "demonstrates that the clinical benefits of Melblez Kit outweigh its risks." The FDA also requires that the additional clinical trial(s) be conducted using the product the Company intends to market. The Company held a meeting with FDA to clarify components of the CRL, during which it confirmed its understanding of device and procedure safety requirements contained in the CRL. Delcath is incorporating the requirements contained in the CRL into its clinical development program. The Company is also evaluating the best path forward for an indication in ocular melanoma that is metastatic to the liver. We continue to believe that such an approval would meet a high unmet need in the United States.

In the United States, the Melphalan/HDS system is subject to regulation as a combination product, which means it is composed of both a drug product and device product. If marketed individually, each component would therefore be subject to different regulatory pathways and reviewed by different centers within the FDA. A combination product, however, is assigned to a center that will have primary jurisdiction over its pre-market review and regulation based on a determination of its primary mode of action, which is the single mode of action that provides the most important therapeutic action. In the case of the Melphalan/HDS System, the primary mode of action is attributable to the drug component of the product, which means that the Center for Drug Evaluation and Research (CDER) has primary jurisdiction over its pre-market development and review.

The process required by the FDA before drug product candidates may be marketed in the United States generally involves the following:

submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical trials may begin and must be updated annually;

completion of extensive preclinical laboratory tests and preclinical animal studies, all performed in accordance with the FDA’s Good Laboratory Practice, or GLP, regulations;

performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the product candidate for each proposed indication;

submission to the FDA of a New Drug Application, or NDA, after completion of all pivotal clinical trials;

a determination by the FDA within 60 days of its receipt of an NDA to file the NDA for review;

satisfactory completion of an FDA pre-approval inspection of the manufacturing facilities at which the product is produced and tested to assess compliance with current good manufacturing practice, or cGMP, regulations; and

FDA review and approval of an NDA prior to any commercial marketing or sale of the drug in the United States.

Drug development and Regulatory approval is an inherently uncertain process with a high risk of failure at every stage of development. The development and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product will be granted at all or on a timely basis.

Orphan Drug Exclusivity

Some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs. Pursuant to the Orphan Drug Act, the FDA grants orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States. The orphan designation is granted for a combination of a drug entity and an indication and therefore it can be granted for an existing drug with a new (orphan) indication. Applications are made to the Office of Orphan Products Development at the FDA and a decision or request for more information is rendered in 60 days. NDAs for designated orphan drugs are exempt from user fees, obtain additional clinical protocol assistance, are eligible for tax credits up to 50% of research and development costs, and are granted a seven-year period of exclusivity upon approval. The FDA cannot approve the same drug for the same condition during this period of exclusivity, except in certain circumstances where a new product demonstrates superiority to the original treatment. Exclusivity begins on the date that the marketing application is approved by the FDA for the designated orphan drug, and an orphan designation does not limit the use of that drug in other applications outside the approved designation in either a commercial or investigational setting.

Table of Contents

The FDA has granted Delcath five orphan drug designations. In November 2008, the FDA granted Delcath two orphan drug designations for the drug melphalan for the treatment of patients with cutaneous melanoma as well as patients with ocular melanoma. In May 2009, the FDA granted Delcath an additional orphan drug designation of the drug melphalan for the treatment of patients with neuroendocrine tumors. In August 2009, the FDA granted Delcath an orphan drug designation of the drug doxorubicin for the treatment of patients with primary liver cancer. In October 2013, the FDA granted Delcath orphan drug designation of the drug melphalan for the treatment of HCC.

The development and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product will be granted on a timely basis, if at all.

European Regulation

In the European Economic Area (EEA), the CHEMOSAT system is subject to regulation as a medical device. The EEA is composed of the 28 Member States of the European Union plus Norway, Iceland and Liechtenstein. Under the EU Medical Devices Directive (Directive No 93/42/ECC of 14 June 1993, as last amended), drug delivery products such as the CHEMOSAT system are governed by the EU laws on pharmaceutical products only if they are (i) placed on the market in such a way that the device and the pharmaceutical product form a single integral unit which is intended exclusively for use in the given combination, and (ii) the product is not reusable. In such cases, the drug delivery product is governed by the EU Code on Medicinal Products for Human Use (Directive 2001/83/EC, as last amended), while the essential requirements of the EU Medical Devices Directive apply to the safety and performance-related device features of the product. Because we do not intend to place the CHEMOSAT system on the EEA market as a single integral unit with melphalan, the product is governed solely by the EU Medical Devices Directive, while the separately marketed drug is governed by the EU Code relating to Medicinal Products for Human Use and other EU legislation applicable to drugs for human use.

CHEMOSAT is regulated as a Class IIb medical device. As a Class IIb medical device, the Notified Body is not required to carry out an examination of the product’s design dossier as part of its conformity assessment prior to commercialization. The Company must continue to comply with the essential requirements of the EU Medical Devices Directive (Directive 93/42 EC) and is subject to a conformity assessment procedure requiring the intervention of a Notified Body. The conformity assessment procedure for Class IIb medical devices requires the manufacturer to apply for the assessment of its quality system for the design, manufacture and inspection of its medical devices by a Notified Body. The Notified Body will audit the system to determine whether it conforms to the provisions of the Medical Devices Directive. If the Notified Body’s assessment is favorable it will issue a Full Quality Assurance Certificate, which enables the manufacturer to draw a Declaration of Conformity and affix the CE mark to the medical devices covered by the assessment. Thereafter, the Notified Body will carry out periodic audits to ensure that the approved quality system is applied by the manufacturer.

Under the regulatory scheme in the EEA, the Company has received authorization to affix the CE Mark to the CHEMOSAT system as a device only, and physicians must separately obtain melphalan for use with the CHEMOSAT system. Our ability to market and promote the CHEMOSAT system is limited to this approved indication. Melphalan is currently approved in 14 member states of the EEA, including the seven markets where procedures have been performed.

No melphalan labels in the EEA reference our product, and the labels vary from country to country with respect to the approved indication of the drug and its mode of administration. In the exercise of their professional judgment in the practice of medicine, physicians are generally allowed, under certain conditions, to use or prescribe a product in ways not approved by regulatory authorities. Physicians intending to use the CHEMOSAT system must obtain and use melphalan independently at their discretion.

Other International Regulations

The CHEMOSAT device has received registrations in the following countries: Australia, New Zealand, Argentina, Taiwan, and Singapore. With limited resources and our attention focused on European commercial and clinical adoption efforts, pursuing other markets at this time is not practical. The Company will continue to evaluate commercial opportunities in these and other markets when resources are available and at an appropriate time.

Clinical Development Program

The primary focus of the Company’s Clinical Development Program (CDP) is to obtain clinical data for the CHEMOSAT/Melphalan HDS system in various disease states to support regulatory approvals in various jurisdictions, including the U.S. and to support clinical adoption in Europe. Currently, the Company’s efforts are primarily directed towards initiating a global Phase 2 clinical program to study the CHEMOSAT/Melphalan HDS system for the treatment of HCC.

Table of Contents

Clinical trials are long, expensive and highly uncertain processes and failure can unexpectedly occur at any stage of clinical development. The start or end of a clinical trial is often delayed or halted due to changing regulatory requirements, manufacturing challenges, required clinical trial administrative actions, slower than anticipated patient enrollment, changing standards of care, availability or prevalence of use of a comparator treatment or required prior therapy.

Hepatocellular Carcinoma (HCC)

HCC is one of the most prevalent and lethal forms of cancer. According to the American Cancer Society’s (ACS) Cancer Facts & Figures 2013, an estimated 30,000 new cases of HCC (including intrahepatic bile duct cancers) were expected to occur in the U.S. during 2013, and the overall five-year survival rate for liver cancer patients in the U.S is approximately 15% compared to 68% for all cancer combined. Globally, with 782,000 new cases in 2012, HCC was the fifth most common cancer in men and the ninth in women according to GLOBOCAN. It has been estimated that over 40 percent of all cases of HCC occur in the People's Republic of China, which has an annual incidence of 137,000 cases. GLOBOCAN estimates indicate that HCC was responsible for 746,000 deaths in 2012 (9.1% of the total cancer deaths), making it the second most common cause of death from cancer worldwide.

The prognosis for liver cancer is very poor, as indicated by an overall ratio of mortality to incidence of 0.95. The American Cancer Society’s (ACS) Cancer Facts & Figures 2013 outlines the treatment options for HCC as follows: “Early stage HCC can sometimes be successfully treated with surgery in patients with sufficient healthy liver tissue; liver transplantation may also be an option. Surgical treatment of early stage HCC is often limited by pre-existing liver disease that has damaged the portion of the liver not affected by cancer. Patients whose tumors cannot be surgically removed may choose ablation (tumor destruction) or embolization, a procedure that cuts off blood flow to the tumor. Fewer treatment options exist for patients diagnosed at an advanced stage of the disease. Sorafenib (Nexavar) is a targeted drug approved for the treatment of HCC in patients who are not candidates for surgery.”

Phase 2 Multi-Histology Clinical Trial - HCC Cohort

In the Company’s multi-arm Phase 2 clinical trial, conducted between 2005 and 2010, five patients with HCC were treated with the CHEMOSAT/Melphalan HDS system in the primary hepatic malignancy cohort. Among these patients, one patient received four treatments, achieved a partial response lasting 12.22 months, and survived 20.47 months. Three other patients with stable disease received 3-4 treatments, with hepatic progression free survival (hPFS) ranging 3.45 to 8.15 months, and overall survival (OS) ranging 5.26 to 19.88 months. There was no evidence of extrahepatic disease progression. The observed duration of hPFS and OS in this limited number of patients exceeded that generally associated with this patient population, and we believe constitutes a promising signal that warrants further clinical investigation.

Phase 2 HCC Program

On the basis of these encouraging results, the Company intends to initiate a new global clinical trial program in the U.S., Europe, and potentially Asia, with the goal of obtaining an efficacy and safety signal for Melphalan HDS in the treatment of HCC. The Company intends to pursue a staged clinical strategy, initiating a Phase 2 clinical trial program followed by a Phase 3 trial if the initial responses are positive. The Company filed its amended Investigational New Drug (IND) application with the FDA on February 11, 2014 to include the trial protocol for its Phase 2 HCC program. This IND amendment became effective on March 13, 2014.

Due to differences in treatment practice patterns between Europe and the U.S., the Company is establishing separate European and U.S. trials for the HCC Phase 2 program with different inclusion and exclusion patient selection criteria. Clinical observations from the two trials are designed to be complementary, and data between the trials will be analyzed collectively to support the anticipated Phase 3 pivotal study design. The Company intends to begin enrolling patients in its Phase 2 HCC trial in the first half of 2014, subject to institutional review board (IRB) approval at participating hospitals, and anticipates data on the first eleven patients from both trials to be available in the first half of 2015, subject to timely enrollment of eligible patients. We anticipate enrolling the first patients in our European sites.

Table of Contents

EU Clinical Data Generation

In Europe, the Company has completed a retrospective data collection trial which collected data post hoc from two hospitals in Europe where therapy with the CHEMOSAT system was administered in a non-clinical trial setting. It provided a retrospective view of hematology results from 7 patients treated with the CHEMOSAT system in Europe. The data, while not part of a formal clinical trial design and limited in nature does provide supporting evidence that the safety of the Generation 2 CHEMOSAT system and related treatment appeared well tolerated and manageable. In addition, the Company is initiating a Patient Registry, which will prospectively collect data from EU commercial experience. The first hospital submitted the protocol to its Ethics Committee in January 2014 and we anticipate the first site to be enrolling patients by the end of the second quarter of 2014. We believe the Patient Registry will provide valuable data and information from a commercial setting which can be used to support our efforts for clinical adoption and commercialization in Europe. The Company also expects to help support investigator initiated trials (IITs) globally across multiple tumor types as suitable opportunities present in Europe. At present two IITs in HCC and CRC are near activation in Europe. The Company believes IITs will serve to build clinical experience at key cancer centers, and will support efforts to obtain compelling reimbursement in Europe.

Sales and Marketing

European Union

In April 2011 the Company obtained authorization to affix a CE Mark for the Generation One CHEMOSAT system. The Company began European commercialization with this version of the CHEMOSAT system in early 2012 when the first CHEMOSAT procedures performed outside of a clinical trial setting were performed in Italy. In April 2012, the Company obtained authorization to affix a CE Mark for the Generation Two CHEMOSAT system, and since this time all procedures in Europe have been performed with this version of the system.

With continued economic and reimbursement challenges in certain European markets, the Company’s immediate market access and clinical adoptions efforts are focused on the key target markets of Germany and the United Kingdom, which represent a majority of the total potential liver cancer market (primary and metastatic) in the EU and where progress in securing reimbursement for CHEMOSAT treatments offers the best near-term opportunities. The Company also continues to support clinical adoption of CHEMOSAT system in the Netherlands, Italy, Spain and France. The Company uses a combination of direct and indirect sales channels to market and distribute the CHEMOSAT system in Europe. In 2013, the Company utilized medical science liaisons through a contract organization to support our clinical adoption efforts. As part of the Company’s restructuring, the medical science liaison consultant program will be phased out throughout 2014 as we integrate these capabilities into existing resources. To support our commercialization efforts in the EU, we have established our European Headquarters in Galway, Ireland.

During the quarter ended March 31, 2014 CHEMOSAT treatments were performed in the United Kingdom, Germany, the Netherlands, and Spain. Since its February 2012 launch in Europe, CHEMOSAT has been used to perform 100 treatments on 70 patients. Since launching the CHEMOSAT system, treatments have been performed at 17 leading European cancer centers.

Germany

o	University of Heidelberg Hospital

o	Berlin Charité Hospital

o	University Medical Center Göttingen

o	Johann Wolfgang Goethe-University, Frankfurt

o	University of Bonn

o	Asklepios Clinic Barmbek, Hamburg

o	Jena University Hospital, Jena

United Kingdom

o	Southampton University Hospital

o	SPIRE Southampton Hospital

Italy

o	European Institute of Oncology

o	Varese University Hospital

Table of Contents

The Netherlands

o	Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital

o	Leiden University Medical Center

France

o	Cancer Institute Gustave Roussy

o	Hôpital Saint-André

Spain

o	Clinica Rotger Majorca Hospital

Ireland

o	University Hospital Galway

Physicians in Europe have used CHEMOSAT to treat patients with a variety of cancers in the liver primarily ocular melanoma liver metastases, and other tumor types, including hepatocellular carcinoma (HCC), cholangeocarcinoma, and liver metastases from colorectal cancer (CRC), breast, and cutaneous melanoma.

European Reimbursement

A critical driver of utilization growth for CHEMOSAT in Europe is the expansion of reimbursement mechanisms for the procedure in our priority markets. In Europe, there is no centralized pan-European medical device reimbursement body. Reimbursement is administered on a regional and national basis. In 2013 the Company engaged a third party reimbursement specialist to support efforts in filing for reimbursement coverage. Medical devices are typically reimbursed under diagnosis related groups (DRG) as part of a procedure. Prior to obtaining permanent DRG reimbursement codes, in certain jurisdictions, the Company is actively seeking interim reimbursement from existing mechanisms that include specific interim reimbursement schemes, new technology payment programs as well as existing DRG codes. In most EU countries, the government provides healthcare and controls reimbursement levels. Since the EU has no jurisdiction over patient reimbursement or pricing matters in its member states, the methodologies for determining reimbursement rates and the actual rates may vary by country.

Germany

In January 2014, the Company announced that the Institut fϋr das Entgeltsystem im Krankenhaus (InEk), the German federal reimbursement agency, again granted Value 4 coverage status for the treatment of patients with liver metastases with the CHEMOSAT system. Under the Neue Untersuchungs und Behandlungsmethoden (NUB) reimbursement scheme, Value 4 Status, while not mandating reimbursement, allows participating cancer centers to negotiate a budget to fund reimbursement coverage for the CHEMOSAT procedure with insurers serving their region.

The InEk determines three status levels for medical procedures submitted for its review: Value 1 (mandated reimbursement), Value 2 (declined for reimbursement), and Value 4 (negotiated reimbursement). The InEk may also decline to make a determination regarding an application. For 2014 reimbursement, a total of 618 medical procedures were submitted to the InEk for consideration under the NUB scheme, with 16% or 96 procedures receiving Value 1 Status, 6% or 36 procedures receiving Value 4, and the remaining 78% denied coverage or un-evaluated. The application for CHEMOSAT was submitted by 71 hospitals in Germany, which represents a significant increase in the level of institutional support the procedure received over 2013.

InEk first established NUB Value 4 status for CHEMOSAT procedures in 2013, though we have been advised that hospitals did not successfully negotiate reimbursement budgets for CHEMOSAT in 2013. In 2014, we believe that a number of hospitals performing the CHEMOSAT procedure in Germany intend to pursue reimbursement under Value 4 status. The NUB is an annual process, and participating centers in Germany are required to apply each year for subsequent coverage under the NUB scheme.

Table of Contents

Separately, in 2013, physicians and patients in Germany submitted Individual Funding Requests (IFRs) seeking reimbursement for the treatment of liver metastases with the CHEMOSAT system. IFRs are case-by-case appeals for reimbursement made to the patient’s insurance carrier. While each IFR is evaluated independently, we have been advised that the majority of these applications have been approved in recent months. We expect that IFRs will be the key reimbursement vehicle in the German market in 2014.

Additionally, the German Radiology Society resubmitted its application for ZE (Zusatzentgeld) in March 2013, which is a permanent reimbursement code until a CHEMOSAT specific DRG code can be created. A ZE code is dependent on having enough financial data to establish cost averages. The application was rejected in December 2013 for insufficient cost data. The German Radiology Society is expected to resubmit an application for a ZE code with more extensive cost data at the end of March 2014, with a decision expected by the end of 2014. With seven centers now active in Germany more data can now be made available to InEk. There will be a particular focus in 2014 on ensuring that treatments and cost data are increased at those specific hospitals providing the cost calculations to InEk.

United Kingdom

In April 2013, interim funding for oncological procedures in the United Kingdom moved away from local Primary Care Trusts (PCTs) to a centralized body of cancer care commissioners. Delcath and its partner centers have identified existing Healthcare Resource Groups (HRG) code(s), which may allow hospitals to be covered for CHEMOSAT procedure related costs. The Company is also working with the HRG organization that decides on new HRG codes with a view to gaining a dedicated and permanent reimbursement code in the future.

The Company is also supporting efforts seeking a block fund grant through the Commissioning Through Evaluation (CTE) process which may provide up to 50-75 ocular melanoma patients to be treated utilizing the CHEMOSAT system in three centers across the U.K. It is important to note that the CTE process has been driven by partner centers and their clinical community, with the centers applying for funding for a limited number of patients with ocular melanoma. The British healthcare system continues to evolve however, and ongoing changes to the CTE process and funding streams have resulted in delays and made the granting and timing of block funding difficult to predict. The current expectation is for the process to be completed by the end of the third quarter of 2014 with the funding, if any, becoming available in the fourth quarter of 2014. The entire CTE funding mechanism is a new process and these ongoing policy changes in the National Health Service (NHS) make it difficult to predict the likelihood of success in the near term.

In December 2013, the National Institute for Clinical Excellence (NICE), a non-departmental public body that provides guidance and advice to improve health and social care in the UK, initiated a clinical review of the CHEMOSAT procedure. NICE issued provisional draft recommendations for the use of CHEMOSAT in the UK, and invited the Company as well as physicians and other interested parties to comment. The NICE recommendations were open for public comment until January 22, 2014, and a decision on final clinical recommendations is expected in May 2014. NICE may decide to conduct a Technology Appraisal of the CHEMOSAT procedure thereafter, the outcome of which could influence the long-term reimbursement status.

Other EU Markets

Permanent reimbursement coverage in remaining EU markets will require additional time to secure. In the interim period, the Company is seeking payment through various avenues, including new technology programs. In France, the Company has revised its strategy and decided not to pursue a multi-center STIC application. STIC is a hybrid of interim funding and clinical study, allowing a new procedure to be assessed over a two-year period on a pre-set number of treatments. The Company believes that the STIC process would be too time consuming and costly, and that direct pursuit of a DRG code represented a better allocation of Company resources in this market. The Company will also present its Phase 3 trial data, once published, to the French healthcare authorities in order to assess the possibility of gaining a DRG code without going through the STIC process. In Ireland, the Company is postponing commercialization efforts until a clear reimbursement pathway is identified.

For France and the Netherlands, publication of the Phase 3 trial manuscript is a key component of the reimbursement process. The Company continues to work with the principal investigators on submission of its Phase 3 and Phase 2 clinical trials for publication. The timing of these submissions will be determined by the principal investigators and the Company looks forward to the submission of the publications.

Table of Contents

Distribution Partners

As a result of the Company’s strategy to prioritize resources on the key direct markets of Germany and the United Kingdom, the Company expects that its distribution strategy will play a lesser role in its current commercial activities. In Spain, the Company has determined that there was no benefit to continuing with an indirect model and therefore terminated its relationship with its distributor in Spain. Similar to our strategy in Germany and United Kingdom, the Company has decided to pursue a direct market approach in Spain as opportunities present.

Material Modifications to Rights of Security Holders

On February 25, 2014, at a Special Meeting of Stockholders of Delcath Systems, Inc. held on February 24, 2014, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a specific ratio within a range from one-for-eight (1:8) to one-for-sixteen (1:16), inclusive, on or prior to December 31, 2014 and granted authorization to the Company’s Board of Directors to determine, in its sole discretion, whether to implement the reverse stock split, as well as its specific timing and ratio.

Following the approval by our stockholders, the Board approved a reverse stock split and on April 8, 2014, the Company, filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which has effected a reverse stock split of its common stock at a ratio of 1-to-16 (the “Reverse Stock Split”). Trading of the Company’s common stock on The NASDAQ Capital Market on a split-adjusted basis began at the opening of trading on April 9, 2014.

As a result of the Reverse Stock Split, each sixteen shares of common stock was combined into one share of common stock and the total number of shares of common stock outstanding was reduced from approximately 150.9 million shares to approximately 9.4 million shares. No fractional shares were issued if, as a result of the Reverse Stock Split, a registered stockholder was otherwise entitled to a fractional share. Instead, stockholders who were otherwise entitled to receive fractional shares because they held a number of shares not evenly divisible by the ratio of the Reverse Stock Split automatically received an additional share of common stock. In other words, any fractional share was rounded up to the nearest whole number.

The Company believes the reverse stock split was necessary in order to maintain the Company’s listing on The NASDAQ Capital Market and to provide resources and flexibility with respect to capital sufficient to execute its business plans and strategy.

Results of Operations for the Three Months Ended March 31, 2014; Comparisons of Results of Operations for the Three Months Ended March 31, 2013

Revenue

The Company recorded approximately $0.3 million in revenue related to product sales during the three months ended March 31, 2014. During the same period in 2013, Delcath recorded $0.1 million in revenue related to product sales.

Cost of Goods Sold

During the three months ended March 31, 2014, the Company recognized cost of goods sold of approximately $0.1 million. During the same period in 2013, Delcath recorded cost of goods sold of approximately $0.03 million. As Delcath continues progress with clinical adoption in Europe and other parts of the world, the Company expects to see a certain amount of volatility in both the average selling price and gross margin for the next several years. This volatility will be related to several factors, including: adjustments to volume forecasts; the expected use of third party distributors, whose purchase prices will be lower than direct to end user customer prices; the gradual increase in cost of goods sold as the Company exhausts raw materials that were purchased and expensed in prior periods and begins to recognize the actual costs of materials, labor and overhead; and an improvement in efficiencies as the Company increases its production of the CHEMOSAT system.

Selling, General and Administrative Expenses

For the three months ended March 31, 2014, selling, general and administrative expenses decreased to $3.8 million from $6.1 million for the three months ended March 31, 2013. The decrease reflects the Company’s efforts to increase organizational efficiencies, including workforce restructurings that took place throughout 2013.

Table of Contents

Research and Development Expenses

For the three months ended March 31, 2014, research and development expenses decreased to $1.5 million from $4.5 million for the three months ended March 31, 2013. The decrease is primarily due to a significant reduction in expenses related to the Company’s NDA submission to the FDA, as well as the Company’s efforts to increase organization efficiencies, including workforce restructurings that took place throughout 2013.

Interest Income

Interest income is from a money market account and interest earned on operating accounts. For the three months ended March 31, 2014, the Company had interest income of $1,357 as compared to interest income of $10,036 for the same period in 2013.

Other Expense and Interest Expense

Other expense is primarily related to foreign currency exchange gains and losses. Interest expense is related to an ongoing Revolving Line Facility Fee as required by the Loan and Security Agreement signed with Silicon Valley Bank in 2012 and discussed in Note 9 to the Company’s audited financial statements contained in the 2013 Annual Report on Form 10-K.

Net Loss

The Company had a net loss for the three months ended March 31, 2014, of $5.3 million, a decrease of $7.6 million, or 60%, compared to the net loss from continuing operations for the same period in 2013. This decrease is primarily due to a $5.3 million decrease in operating expenses and a $2.1 million change in the fair value of the warrant liability, which is a non-cash expense. As detailed above, the decrease in operating expenses reflects a significant decrease in costs related to the Company’s NDA filing and overall operations.

Liquidity and Capital Resources

The Company’s future results are subject to substantial risks and uncertainties. Delcath has operated at a loss for its entire history and anticipates that losses will continue over the coming years. There can be no assurance that Delcath will ever generate significant revenues or achieve profitability. The Company expects to use cash, cash equivalents and investment proceeds to fund its clinical and operating activities. Delcath’s future liquidity and capital requirements will depend on numerous factors, including the initiation and progress of clinical trials and research and product development programs, obtaining approvals and complying with regulations; the timing and effectiveness of product commercialization activities, including marketing arrangements; the timing and costs involved in preparing, filing, prosecuting, defending and enforcing intellectual property rights; and the effect of competing technological and market developments.

At March 31, 2014, the Company had cash and cash equivalents totaling $31.3 million, as compared to cash, cash equivalents and certificates of deposit totaling $31.2 million and $42.8 million at December 31, 2013 and March 31, 2013, respectively. During the three months ended March 31, 2014, the Company used $4.5 million of cash in its operating activities, which compares to $10.9 million used for operating activities during the comparable three month period in 2013. The decrease of $6.4 million is primarily driven by a reduction in NDA submission related costs and improved efficiency in organization and operations. The Company believes that its capital resources are adequate to fund operations through the first half of 2015.

Because Delcath’s business does not generate positive cash flow from operating activities, the Company will need to raise additional capital in order to fund its clinical development program or to fully commercialize the product. The Company continues to believe it will be able to raise additional capital in the event it is in its best interest to do so. The Company anticipates raising such additional capital by either borrowing money, selling shares of Delcath’s capital stock, or entering into strategic alliances with appropriate partners. To the extent additional capital is not available when needed, the Company may be forced to abandon some or all of its development and commercialization efforts, which would have a material adverse effect on the prospects of our business. Further, the Company’s assumptions relating to its cash requirements may differ materially from its actual requirements because of a number of factors, including significant unforeseen delays in the regulatory approval process, changes in the focus and direction of clinical trials, lower revenue and increased costs related to commercializing the product.

The Company has funded its operations through a combination of private placements of its securities, public offerings in 2000, 2003, 2009, 2010, 2011, 2012 and 2013, registered direct offerings in 2007 and 2009, an “at the market” equity offering program initiated in 2012, and a committed equity financing facility program initiated in 2012. For a detailed discussion of the Company’s various sales of securities and the “at the market” equity offering program see Note 7 to the Company’s interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q.

Table of Contents

In March 2013, the Company entered into a sales agreement (the “March 2013 Sales Agreement”) with Cowen and Company, LLC to sell shares of the Company’s common stock, par value $.01 per share, having aggregate sales proceeds of $50.0 million, from time to time, through an “at the market” equity offering program under which Cowen and Company, LLC will act as sales agent. During the three months ended March 31, 2014, the Company sold approximately 1.0 million shares of its common stock under the March 2013 Sales Agreement with Cowen and Company, LLC for proceeds of approximately $4.4 million, with net cash proceeds after related expenses of approximately $4.4 million. The shares were issued pursuant to registration statement on Form S-3 (333-187230). The net proceeds will be used for general corporate purposes, including, but not limited to, commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures and working capital.

In December 2011, the Company filed a registration statement on Form S-3 with the SEC, which allowed the Company to offer and sell, from time to time in one or more offerings, up to $100 million of common stock, preferred stock, warrants, debt securities and stock purchase contracts as it deemed prudent or necessary to raise capital at a later date. The registration statement became effective on February 13, 2012. The Company used this registration statement for its May 2012 public offering detailed in Note 10 to the Company’s audited financial statements contained in the 2013 Annual Report on Form 10-K. The Company subsequently filed a new shelf registration statement on Form S-3 (333-183675) with the SEC which became effective on October 9, 2012. This new shelf replaces the shelf registration filed in December 2011 and allows the Company to offer and sell, from time to time in one or more offerings, up to $100 million of common stock, preferred stock, warrants, debt securities and stock purchase contracts as it deems prudent or necessary to raise capital at a later date. The Company used this registration statement for its Common Stock Purchase Agreement with Terrapin Opportunity, L.P. detailed in Note 10 to the Company’s audited financial statements contained in the 2013 Annual Report on Form 10-K. As of March 31, 2014, Delcath had approximately $80.4 million available under this registration statement, of which approximately $4.9 million is reserved for the potential issuance of shares upon the exercise of warrants.

The Company intends to use the net proceeds from any future offerings for general corporate purposes, including, but not limited to, funding of clinical trials, obtaining regulatory approvals, commercialization of its products, capital expenditures and working capital.

Application of Critical Accounting Policies

The Company’s financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP). Certain accounting policies have a significant impact on amounts reported in the financial statements. A summary of those significant accounting policies can be found in Note 3 to the Company’s audited financial statements contained in the 2013 Annual Report on Form 10-K. During 2012, Delcath transitioned from a development stage company to a commercial organization.

The Company considers the valuation allowance for the deferred tax assets to be a significant accounting estimate. In applying ASC 740 management estimates future taxable income from operations and tax planning strategies in determining if it is more likely than not that the Company will realize the benefits of its deferred tax assets. Management believes the Company does not have any uncertain tax positions.

The Company has adopted the provisions of ASC 718, which establishes accounting for equity instruments exchanged for employee services. Under the provisions of ASC 718, share-based compensation is measured at the grant date, based upon the fair value of the award, and is recognized as an expense over the option holders’ requisite service period (generally the vesting period of the equity grant). The Company expenses its share-based compensation under the ratable method, which treats each vesting tranche as if it were an individual grant.

The Company has adopted the provisions of ASC 820, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.

Table of Contents

ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability which are typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. See Note 8 to the Company’s Condensed Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q for assets and liabilities the Company has evaluated under ASC 820.

Table of Contents

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

The Company may be minimally exposed to market risk through changes in market interest rates that could affect the interest earned on its cash balances.

The Company measures all derivatives, including certain derivatives embedded in contracts, at fair value and recognizes them on the balance sheet as an asset or a liability, depending on the Company’s rights and obligations under the applicable derivative contract.

In June 2009, the Company completed the sale of 0.1 million shares of its common stock and the issuance of warrants to purchase 0.1 million common shares (the “2009 Warrants”) pursuant to a subscription agreement with a single investor. The Company received proceeds of $3.0 million, with net cash proceeds after related expenses from this transaction of approximately $2.7 million. Of those proceeds, the Company allocated an estimated fair value of $2.2 million to the warrant liability. The fair value of the 2009 Warrants on June 15, 2009 was determined by using an option pricing model assuming a risk free interest rate of 2.75%, volatility of 72.93% and an expected life equal to the contractual life of the 2009 Warrants (June 2014). As required by the 2009 Warrant agreement, the exercise price of the warrants was adjusted following the Company’s October 2013 sale of common stock. At March 31, 2014, the 2009 Warrants were exercisable at $2.56 per share with approximately 40,000 warrants outstanding. The 2009 Warrants have a five-year term. The shares and warrants were issued pursuant to an effective registration statement on Form S-3. During the three months ended March 31, 2014, 25,000 2009 Warrants were exercised for net proceeds of approximately $0.1 million.

In May 2012, the Company completed the sale of 1.0 million shares of its common stock and the issuance of warrants to purchase 0.3 million common shares (the “2012 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $21.5 million, with net cash proceeds after related expenses from this transaction of approximately $21.1 million. Of those proceeds, the Company allocated an estimated fair value of $3.4 million to the 2012 Warrants. The fair value of the 2012 Warrants on May 31, 2012 was determined by using an option pricing model assuming a risk free interest rate of 0.35%, volatility of 80.64% and an expected life equal to the contractual life of the 2012 Warrants (May 2015). As required by the 2012 Warrant agreement, the exercise price of the warrants was adjusted following the Company’s October 2013 sale of common stock. At March 31, 2014, the 2012 Warrants were exercisable at $2.56 per share with 0.3 million warrants outstanding. The 2012 Warrants have a three-year term. The shares and warrants were issued pursuant to an effective registration statement on Form S-3. During the three months ended March 31, 2014, approximately 13,000 2012 Warrants were exercised for net proceeds of approximately $34,000.

In October 2013, the Company completed the sale of 1.3 million shares of its common stock and the issuance of warrants to purchase 0.6 million common shares (the “2013 Warrants”) pursuant to a placement agency agreement. The Company received proceeds of $7.5 million, with net cash proceeds after related expenses from this transaction of approximately $6.9 million. Of those proceeds, the Company allocated an estimated fair value of $1.9 million to the 2013 Warrants. The fair value of the 2013 Warrants on October 28, 2013 was determined by using an option pricing model assuming a risk free interest rate of 1.31%, volatility of 89.27% and an expected life equal to the contractual life of the 2013 Warrants (October 2018). The 2013 Warrants will become exercisable at $7.04 per share on April 30, 2014. The 2013 Warrants have a five-year term. The shares and warrants were issued pursuant to an effective registration statement on Form S-3.

The $1.9 million in proceeds allocated to the 2013 Warrants, the $3.4 million in proceeds allocated to the 2012 Warrants and the $2.2 million in proceeds allocated to the 2009 Warrants are classified as derivative instrument liabilities that are subject to mark-to-market adjustment each period. As a result, for the three month period ended March 31, 2014, the Company recorded pre-tax derivative instrument expense of $0.2 million. The resulting derivative instrument liabilities totaled $2.4 million at March 31, 2014. Management expects that the warrants will either be exercised or expire worthless. The fair value of the Warrants at March 31, 2014 was determined by using an option pricing model assuming the following:

	2013 Warrants		2012 Warrants		2009 Warrants
Expected volatility		91.53%		114.33%		101.78%
Risk-free interest rates		1.52%		0.21%		0.05%
Expected life (in years)		4.58		1.17		0.21

Table of Contents

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Delcath’s management, with the participation of its Interim Co-Chief Executive Officers, evaluated the effectiveness of the design and operation of its disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) of the Exchange Act. Based on that evaluation, the Company’s Interim Co-Chief Executive Officers concluded that Delcath’s disclosure controls and procedures as of March 31, 2014 (the end of the period covered by this Quarterly Report on Form 10-Q), have been designed and are functioning effectively to provide reasonable assurance that the information required to be disclosed by us in the Company’s reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including the Company’s Interim Co-Chief Executive Officers, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Controls

There was no change in our internal control over financial reporting that occurred during the quarter ended March 31, 2014 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II: OTHER INFORMATION

Item 1.

Legal Proceedings

In re Delcath Systems, Inc. Securities Litigation, United States District Court for the Southern District of New York (Case No. 13-cv-3116)

On May 8, 2013, a purported stockholder of the Company filed a putative class action complaint in the United States District Court for the Southern District of New York, captioned Bryan Green, individually and on behalf of all others similar situated, v. Delcath Systems, Inc., et al. (“Green”), Case No. 1:13-cv-03116-LGS. On June 14, 2013, a substantially similar complaint was filed in the United States District Court for the Southern District of New York, captioned Joseph Connico, individually and on behalf of all others similarly situated, v. Delcath Systems, Inc., et al. (“Connico”), Case No. 1:13-cv-04131-LGS.

At a hearing on August 2, 2013, the Court consolidated the Green and Connico actions under the caption In re Delcath Systems, Inc. Securities Litigation, No. 13-cv-3116, appointed Lead Plaintiff, Delcath Investor Group, and approved Pomerantz Grossman Hufford Dahlstrom & Gross LLP as Lead Plaintiff’s choice of counsel.

On September 18, 2013, Lead Plaintiff filed a consolidated amended complaint, naming the Company and Eamonn P. Hobbs as defendants (the “Defendants”). The consolidated amended complaint asserts that Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by allegedly making false and misleading statements or omissions regarding the Company’s New Drug Application for its Melblez Kit (Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery System), for the treatment of patients with unresectable metastatic ocular melanoma in the liver. The putative class period alleged in the amended complaint is April 21, 2010 through and including September 13, 2013. Lead Plaintiff seeks compensatory damages, equitable relief, and reasonable attorneys’ fees, expert fees and other costs. On October 31, 2013, Defendants filed their motion to dismiss. The parties have fully briefed the motion, which is currently pending.

The Company believes that the In re Delcath Systems, Inc. Securities Litigation action lacks merit and intends to defend the case vigorously.

In re Delcath Systems, Inc. Derivative Shareholder Litigation, United States District Court for the Southern District of New York (Lead Case No. 1:13-cv-03494-LGS)

On May 23, 2013, purported stockholders of the Company filed a shareholder derivative lawsuit in the United States District Court for the Southern District of New York, captioned Vincent J. Orlando and Carol Orlando, derivatively on behalf of Delcath Systems, Inc. v. Harold S. Koplewicz, et al. (“Orlando”), Case No. 1:13-cv-03494-LGS. On June 11, 2013, a substantially similar complaint was filed in the United States District Court for the Southern District of New York, captioned Howard Warsett, derivatively on behalf of Delcath Systems, Inc. v. Harold S. Koplewicz, et al. (“Warsett”), Case No. 1:13-cv-04002-LGS. On July 19, 2013, another substantially similar complaint was filed in the United States District Court for the Southern District of New York, captioned Patricia Griesi, derivative on behalf of nominal defendant Delcath Systems, Inc. v. Harold S. Koplewicz, et al. (“Griesi”), Case No. 13 cv 5024. In all three cases, Harold S. Koplewicz, Laura A. Brege, Tasos G. Konidaris, Eamonn P. Hobbs, Douglas G. Watson, Laura A. Philips, Roger G. Stoll, and Gabriel Leung were named as defendants (the“Individual Defendants”), and the Company was named as a nominal defendant.

All three complaints assert claims for breach of fiduciary duty for disseminating false and misleading information, breach of fiduciary duty for failing to properly oversee and manage the company, and gross mismanagement for making false and misleading statements or failing to disclose material information regarding (i) the Company’s New Drug Application for its Melblez Kit (Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery System), for the treatment of patients with unresectable metastatic ocular melanoma, and (ii) the status of the Company’s manufacturing facilities. In addition, the Orlando complaint further asserts claims for contribution and indemnification, abuse of control, and waste of corporate assets, while the Warsett complaint asserts an additional claim for unjust enrichment. The Griesi complaint also asserts additional claims for breach of fiduciary duties for failing to maintain internal controls, unjust enrichment, abuse of control, and violations of Section 14(a) of the Securities Exchange Act of 1934. The relevant time period alleged in the Orlando action is April 21, 2010 through the present, and the relevant time period alleged in the Warsett action is April 10, 2010 through the present. The relevant time period alleged in Griesi is April 21, 2010 through May 2, 2013. The Orlando, Warsett, and Griesi plaintiffs seek damages as well as reasonable costs and attorneys’ fees. The Griesi plaintiffs also seek corporate governance reforms and improvements and restitution.

Table of Contents

On June 25, 2013, the Court consolidated the Orlando and Warsett actions with the caption In re Delcath Systems, Inc. Derivative Shareholder Litigation, Lead Case No. 1:13-cv-03494-LGS (“Consolidated Derivative Case”). On August 1, 2013, the Court consolidated the Griesi action under the caption In re Delcath Systems, Inc. Derivative Shareholder Litigation, Lead Case No. 1:13-cv-03494-LGS. At a hearing on August 2, 2013, the Court entered an order approving Federman & Sherwood as lead counsel. The Court stayed the Consolidated Derivative Case, pending resolution of an anticipated motion to dismiss in In re Delcath Systems, Inc. Securities Litigation, United States District Court for the Southern District of New York, No. 13-cv-3116.

The defendants in the Consolidated Derivative Case deny any wrongdoing, believe the claims are baseless, and will defend accordingly.

Howard D. Weinstein, derivatively on behalf of Delcath Systems, Inc. v. Harold S. Koplewicz, et al., Supreme Court of the State of New York County of New York (Case No. 652030/2013)

On June 7, 2013, a purported stockholder of the Company filed a shareholder derivative lawsuit in the Supreme Court of the State of New York County of New York, captioned Howard D. Weinstein, derivatively on behalf of Delcath Systems, Inc. v. Harold S. Koplewicz, et al., (“Weinstein”) Case No. 652030/2013. The action named Harold S. Koplewicz, Laura A. Brege, Tasos G. Konidaris, Eamonn P. Hobbs, Douglas G. Watson, Laura A. Philips, Roger G. Stoll, and Gabriel Leung as individual defendants (the “Individual Defendants”), as well as the Company, as a nominal defendant.

The complaint asserts claims for breach of fiduciary duty for disseminating false and misleading information, breach of fiduciary duty for failing to properly oversee and manage the company, gross mismanagement, contribution and indemnification, abuse of control, and waste of corporate assets in connection with allegations that the Individual Defendants made false and misleading statements or failed to disclose material information regarding (i) the Company’s New Drug Application for its Melblez Kit (Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery System), for the treatment of patients with unresectable metastatic ocular melanoma, and (ii) the status of the Company’s manufacturing facilities. The relevant time period alleged is April 21, 2010 through the present. The plaintiff seeks damages, as well as reasonable costs and attorneys’ fees.

On July 16, 2013, the parties in the Weinstein matter stipulated to stay the proceeding until the federal district court rules on the anticipated motion to dismiss in In re Delcath Systems, Inc. Securities Litigation, No. 13-cv-3116.

The defendants in the Weinstein matter deny any wrongdoing, believe the claims are baseless, and will defend accordingly.

Table of Contents

Item 1A.

Risk Factors

Delcath’s 2013 Annual Report on Form 10-K, in Part 1 – Item 1A. "Risk Factors," contains a detailed discussion of factors that could materially adversely affect our business, operating results and/or financial condition. There have been no material changes in these risk factors since such disclosure.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

Not Applicable.

Item 3.

Defaults upon Senior Securities

Not Applicable.

Item 4.

Mine Safety Disclosures

Not Applicable.

Item 5.

Other Information

Not Applicable.

Table of Contents

Item 6.

Exhibits

Exhibit No.		Description

31.1	**	Certification by Co-Principal executive officer Pursuant to Rule 13a 14.

31.2	**	Certification by Co-Principal executive officer Pursuant to Rule 13a 14.

31.3	**	Certification by Principal financial officer Pursuant to Rule 13a 14.

32.1	***	Certification of Interim Co-Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2	***	Certification of Interim Co-Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.3	***	Certification of Principal financial officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

**	Filed herewith.

***	Furnished herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

May 7, 2014	DELCATH SYSTEMS, INC.
	(Registrant)

	/s/Graham G. Miao	/s/Jennifer K. Simpson
	Graham G. Miao	Jennifer K. Simpson
	Interim Co-President and	Interim Co-President and
	Co-Chief Executive Officer, Chief Financial Officer	Co-Chief Executive Officer,
	(Co-Principal executive officer and	Global Head of Business Operations
	Principal financial officer)	(Co-Principal executive officer)

Table of Contents

Exhibit Index

Exhibit No.		Description

31.1	**	Certification by Co-Principal executive officer Pursuant to Rule 13a 14.

31.2	**	Certification by Co-Principal executive officer Pursuant to Rule 13a 14.

31.3	**	Certification by Principal financial officer Pursuant to Rule 13a 14.

32.1	***	Certification of Interim Co-Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2	***	Certification of Interim Co-Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.3	***	Certification of Principal financial officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

**	Filed herewith.

***	Furnished herewith.

EX-31.1 2 ex31_1.htm EXHIBIT 31.1

EXHIBIT 31.1

Certification

of Principal Executive Officer

Pursuant to Rule 13a-14(a) and 15d-14(a) of the Exchange Act

I, Graham G. Miao, certify that:

1)	I have reviewed this Quarterly Report on Form 10-Q of Delcath Systems, Inc;

2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5)	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

May 7, 2014
	/s/Graham G. Miao
	Graham G. Miao
	Interim Co-President and Co-Chief Executive Officer,
	Chief Financial Officer
	(Co-Principal executive officer)

EX-31 3 ex31_2.htm EXHIBIT 31.2

EXHIBIT 31.2

Certification

of Principal Executive Officer

Pursuant to Rule 13a-14(a) and 15d-14(a) of the Exchange Act

I, Jennifer K. Simpson, certify that:

1)	I have reviewed this Quarterly Report on Form 10-Q of Delcath Systems, Inc;

2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

5)	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

May 7, 2014
	/s/Jennifer K. Simpson
	Jennifer K. Simpson
	Interim Co-President and Co-Chief Executive Officer,
	Global Head of Business Operations
	(Co-Principal executive officer)

EX-31.3 4 ex31_3.htm EXHIBIT 31.3

EXHIBIT 31.3

Certification

of Principal Financial Officer

Pursuant to Rule 13a-14(a) and 15d-14(a) of the Exchange Act

I, Graham G. Miao, certify that:

1)	I have reviewed this Quarterly Report on Form 10-Q of Delcath Systems, Inc;

2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

5)	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

May 7, 2014
	/s/Graham G. Miao
	Graham G. Miao
	Interim Co-President and Co-Chief Executive Officer,
	Chief Financial Officer
	(Principal financial officer)

EX-32.1 5 ex32_1.htm EXHIBIT 32.1

EXHIBIT 32.1

Certification Pursuant to

18 U.S.C. Section 1350,

as Adopted Pursuant to

Section 906 of the Sarbanes –Oxley Act of 2002

In connection with the Quarterly Report of DELCATH SYSTEMS, INC. (the “Company”) on Form 10-Q for the fiscal quarter ended March 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Graham G. Miao, the Interim Co-President and Co-Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 7, 2014
	/s/Graham G. Miao
	Graham G. Miao
	Interim Co-President and Co-Chief Executive Officer,
	Chief Financial Officer
	(Co-Principal executive officer)

EX-32.2 6 ex32_2.htm EXHIBIT 32.2

EXHIBIT 32.2

Certification Pursuant to

18 U.S.C. Section 1350,

as Adopted Pursuant to

Section 906 of the Sarbanes –Oxley Act of 2002

In connection with the Quarterly Report of DELCATH SYSTEMS, INC. (the “Company”) on Form 10-Q for the fiscal quarter ended March 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jennifer K. Simpson, the Interim Co-President and Co-Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 7, 2014
	/s/Jennifer K. Simpson
	Jennifer K. Simpson
	Interim Co-President and Co-Chief Executive Officer,
	Global Head of Business Operations
	(Co-Principal executive officer)

EX-32.3 7 ex32_3.htm EXHIBIT 32.3

EXHIBIT 32.3

Certification Pursuant to

18 U.S.C. Section 1350,

as Adopted Pursuant to

Section 906 of the Sarbanes –Oxley Act of 2002

In connection with the Quarterly Report of DELCATH SYSTEMS, INC. (the “Company”) on Form 10-Q for the fiscal quarter ended March 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Graham G. Miao, the Interim Co-President and Co-Chief Executive Officer, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) The report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 7, 2014
	/s/Graham G. Miao
	Graham G. Miao
	Interim Co-President and Co-Chief Executive Officer,
	Chief Financial Officer
	(Principal financial officer)

EX-101.INS 8 dcth-20140331.xml XBRL INSTANCE DOCUMENT 0000872912 2014-01-01 2014-03-31 0000872912 2014-05-06 0000872912 2014-03-31 0000872912 2013-12-31 0000872912 2013-01-01 2013-12-31 0000872912 2013-01-01 2013-03-31 0000872912 2012-12-31 0000872912 2013-03-31 0000872912 us-gaap:MaximumMember 2014-01-01 2014-03-31 0000872912 us-gaap:MinimumMember 2014-01-01 2014-03-31 0000872912 us-gaap:EquipmentMember 2014-03-31 0000872912 us-gaap:FurnitureAndFixturesMember 2013-12-31 0000872912 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2014-03-31 0000872912 us-gaap:EquipmentMember 2013-12-31 0000872912 us-gaap:LandBuildingsAndImprovementsMember 2013-12-31 0000872912 us-gaap:ComputerEquipmentMember 2014-03-31 0000872912 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2013-12-31 0000872912 us-gaap:FurnitureAndFixturesMember 2014-03-31 0000872912 us-gaap:ComputerEquipmentMember 2013-12-31 0000872912 us-gaap:LandBuildingsAndImprovementsMember 2014-03-31 0000872912 us-gaap:OperatingExpenseMember 2013-01-01 2013-12-31 0000872912 us-gaap:OperatingExpenseMember 2013-12-31 0000872912 us-gaap:OperatingExpenseMember 2014-01-01 2014-03-31 0000872912 us-gaap:OperatingExpenseMember 2014-03-31 0000872912 dcth:OtherNonCurrentLiabilitiesMember 2014-03-31 0000872912 dcth:CurrentAccruedExpensesMember 2014-03-31 0000872912 dcth:CowenAndCompanyLlcMember dcth:SalesAgreementDecember2011Member 2014-03-31 0000872912 dcth:CowenAndCompanyLlcMember dcth:SalesAgreementMarch2013Member 2014-03-31 0000872912 dcth:TerrapinOpportunityLPMember dcth:CommittedEquityFinancingFacilityMember 2014-01-01 2014-03-31 0000872912 dcth:CowenAndCompanyLlcMember dcth:SalesAgreementDecember2011Member 2013-01-01 2013-03-31 0000872912 dcth:SalesAgreementMarch2013Member dcth:CowenAndCompanyLlcMember 2014-01-01 2014-03-31 0000872912 dcth:CowenAndCompanyLlcMember dcth:SalesAgreementMarch2013Member 2013-01-01 2013-12-31 0000872912 2013-10-01 2013-10-31 0000872912 2012-05-01 2012-05-31 0000872912 2009-06-01 2009-06-30 0000872912 dcth:CommittedEquityFinancingFacilityMember dcth:TerrapinOpportunityLPMember 2014-03-31 0000872912 dcth:Warrants2013Member 2013-10-01 2013-10-31 0000872912 dcth:Warrants2009Member 2009-06-01 2009-06-30 0000872912 dcth:Warrants2012Member 2012-05-01 2012-05-31 0000872912 dcth:Warrants2012Member 2012-05-31 0000872912 dcth:Warrants2009Member 2009-06-30 0000872912 dcth:Warrants2013Member 2013-10-31 0000872912 dcth:Warrants2012Member 2014-03-31 0000872912 dcth:Warrants2013Member us-gaap:SubsequentEventMember 2014-04-30 0000872912 dcth:Warrants2009Member 2014-03-31 0000872912 dcth:Warrants2009Member 2014-01-01 2014-03-31 0000872912 dcth:Warrants2012Member 2014-01-01 2014-03-31 0000872912 dcth:Warrants2013Member 2014-01-01 2014-03-31 0000872912 dcth:StockIncentivePlan2009Member 2014-03-31 0000872912 dcth:StockIncentivePlan2004Member 2014-03-31 0000872912 us-gaap:StockOptionsMember 2014-01-01 2014-03-31 0000872912 us-gaap:StockOptionsMember 2013-01-01 2013-03-31 0000872912 us-gaap:RestrictedStockMember 2013-01-01 2013-03-31 0000872912 us-gaap:RestrictedStockMember 2014-01-01 2014-03-31 0000872912 us-gaap:StockOptionsMember 2013-12-31 0000872912 us-gaap:StockOptionsMember 2014-03-31 0000872912 us-gaap:MaximumMember us-gaap:StockOptionsMember 2013-12-31 0000872912 us-gaap:StockOptionsMember us-gaap:MinimumMember 2013-12-31 0000872912 us-gaap:MinimumMember us-gaap:StockOptionsMember 2014-01-01 2014-03-31 0000872912 us-gaap:MaximumMember us-gaap:StockOptionsMember 2014-01-01 2014-03-31 0000872912 us-gaap:StockOptionsMember us-gaap:MaximumMember 2014-03-31 0000872912 us-gaap:StockOptionsMember us-gaap:MinimumMember 2014-03-31 0000872912 us-gaap:MinimumMember us-gaap:StockOptionsMember 2013-01-01 2013-03-31 0000872912 us-gaap:MaximumMember us-gaap:StockOptionsMember 2013-01-01 2013-03-31 0000872912 us-gaap:RestrictedStockMember 2013-12-31 0000872912 us-gaap:RestrictedStockMember 2014-03-31 0000872912 dcth:Warrants2012Member 2014-01-01 2014-03-31 0000872912 dcth:Warrants2013Member 2014-01-01 2014-03-31 0000872912 dcth:Warrants2009Member 2014-01-01 2014-03-31 0000872912 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2014-03-31 0000872912 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2014-03-31 0000872912 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2014-03-31 0000872912 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2014-03-31 0000872912 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2014-03-31 0000872912 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2014-03-31 0000872912 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2014-03-31 0000872912 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2014-03-31 0000872912 us-gaap:StockOptionsMember 2014-01-01 2014-03-31 0000872912 us-gaap:RestrictedStockMember 2013-01-01 2013-03-31 0000872912 us-gaap:RestrictedStockMember 2014-01-01 2014-03-31 0000872912 us-gaap:WarrantMember 2013-01-01 2013-03-31 0000872912 us-gaap:StockOptionsMember 2013-01-01 2013-03-31 0000872912 us-gaap:WarrantMember 2014-01-01 2014-03-31 0000872912 us-gaap:SubsequentEventMember 2014-01-01 2014-03-31 0000872912 us-gaap:SubsequentEventMember 2014-04-24 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure dcth:Employee dcth:Input false --12-31 2014-03-31 No No Yes Non-accelerated Filer DELCATH SYSTEMS, INC. 0000872912 9442197 2014 Q1 10-Q

349000

181000

334000

582000

323000

360000

1853000

1866000

3476000

3740000

3935000

4066000

96000

94000

259102000

263923000

237829

715565

1147860

25676

18663

340254

349635

891368

1945000

34028000

33346000

36084000

37097000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-style: italic; text-indent: -9pt; font-family: ''Times New Roman'', Times, serif; margin-left: 27pt; font-size: 10pt; font-weight: bold;">Basis of Presentation</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">These interim Condensed Consolidated Financial Statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all entities controlled by Delcath and all significant inter-company accounts and transactions have been eliminated in consolidation.</div><div> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">The preparation of interim financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim Condensed Consolidated Financial Statements, in the opinion of management, reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended March 31, 2014 and 2013; however, certain information and footnote disclosures normally included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year.</div></div>

31254000

31249000

23726000

42804000

5000

19078000

40000

300000

2.56

7.04

2.56

9431907

8392641

84000

94000

9433703

8394397

0.01

170000000

-12481000

-5280000

31000

93000

10552000

5276000

485000

483000

249000

298000

2399000

2310000

-0.57

-2.40

-3000

31000

1.1433

0.9153

1.0178

2310000

2399000

116000

0.0005

0.0152

0.0021

P4Y6M29D

P0Y2M16D

P1Y2M1D

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">The fair value of the warrants at March 31, 2014 was determined by using an option pricing model with the following assumptions:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; margin-left: 18pt; font-size: 10pt;"><tr><td style="width: 45%; vertical-align: bottom;"><div> </div></td><td style="width: 1.23%; vertical-align: bottom;"><div> </div></td><td colspan="2" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013 </div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Warrants</div></td><td style="width: 1.44%; vertical-align: bottom;"><div> </div></td><td style="width: 1.44%; vertical-align: bottom;"><div> </div></td><td colspan="2" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2012 </div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Warrants</div></td><td style="width: 1.44%; vertical-align: bottom;"><div style="text-align: left;"> </div></td><td style="width: 1.44%; vertical-align: bottom;"><div> </div></td><td colspan="2" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2009</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;"> Warrants</div></td><td style="width: 1.67%; vertical-align: bottom;"><div style="text-align: left;"> </div></td></tr><tr><td style="background-color: #cceeff; width: 45%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Expected volatility</div></td><td style="background-color: #cceeff; width: 1.23%; vertical-align: top;"><div> </div></td><td style="background-color: #cceeff; width: 1%; vertical-align: top;"><div> </div></td><td style="background-color: #cceeff; width: 10.8%; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">91.53%</div></td><td style="background-color: #cceeff; width: 1.44%; vertical-align: top;"><div> </div></td><td style="background-color: #cceeff; width: 1.44%; vertical-align: bottom;"><div> </div></td><td style="background-color: #cceeff; width: 1%; vertical-align: bottom;"><div> </div></td><td style="background-color: #cceeff; width: 10.8%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">114.33%</div></td><td style="background-color: #cceeff; width: 1.44%; vertical-align: bottom;"><div> </div></td><td style="background-color: #cceeff; width: 1.44%; vertical-align: bottom;"><div> </div></td><td style="background-color: #cceeff; width: 1%; vertical-align: bottom;"><div> </div></td><td style="background-color: #cceeff; width: 10.8%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">101.78%</div></td><td style="background-color: #cceeff; width: 1.67%; vertical-align: bottom;"><div> </div></td></tr><tr><td style="background-color: #ffffff; width: 45%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Risk-free interest rates</div></td><td style="background-color: #ffffff; width: 1.23%; vertical-align: top;"><div> </div></td><td style="background-color: #ffffff; width: 1%; vertical-align: top;"><div> </div></td><td style="background-color: #ffffff; width: 10.8%; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1.52%</div></td><td style="background-color: #ffffff; width: 1.44%; vertical-align: top;"><div> </div></td><td style="background-color: #ffffff; width: 1.44%; vertical-align: bottom;"><div> </div></td><td style="background-color: #ffffff; width: 1%; vertical-align: bottom;"><div> </div></td><td style="background-color: #ffffff; width: 10.8%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">0.21%</div></td><td style="background-color: #ffffff; width: 1.44%; vertical-align: bottom;"><div> </div></td><td style="background-color: #ffffff; width: 1.44%; vertical-align: bottom;"><div> </div></td><td style="background-color: #ffffff; width: 1%; vertical-align: bottom;"><div> </div></td><td style="background-color: #ffffff; width: 10.8%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">0.05%</div></td><td style="background-color: #ffffff; width: 1.67%; vertical-align: bottom;"><div> </div></td></tr><tr><td style="background-color: #cceeff; width: 45%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Expected life (in years)</div></td><td style="background-color: #cceeff; width: 1.23%; vertical-align: top;"><div> </div></td><td style="background-color: #cceeff; width: 1%; vertical-align: top;"><div> </div></td><td style="background-color: #cceeff; width: 10.8%; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">4.58</div></td><td style="background-color: #cceeff; width: 1.44%; vertical-align: top;"><div> </div></td><td style="background-color: #cceeff; width: 1.44%; vertical-align: bottom;"><div> </div></td><td style="background-color: #cceeff; width: 1%; vertical-align: bottom;"><div> </div></td><td style="background-color: #cceeff; width: 10.8%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1.17</div></td><td style="background-color: #cceeff; width: 1.44%; vertical-align: bottom;"><div> </div></td><td style="background-color: #cceeff; width: 1.44%; vertical-align: bottom;"><div> </div></td><td style="background-color: #cceeff; width: 1%; vertical-align: bottom;"><div> </div></td><td style="background-color: #cceeff; width: 10.8%; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">0.21</div></td><td style="background-color: #cceeff; width: 1.67%; vertical-align: bottom;"><div> </div></td></tr></table></div>

205000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">The table below presents the activity within Level 3 of the fair value hierarchy for the three months ended March 31, 2014:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; margin-left: 18pt; font-size: 10pt;"><tr><td colspan="4" valign="bottom" style="vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 78%; vertical-align: bottom;"><div style="text-align: left; font-style: italic; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">(in thousands)</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Warrant Liability</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 78%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Beginning balance as of December 31, 2013</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2,310</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 78%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 16.2pt; font-size: 10pt;">Total change in the liability included in earnings</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">205</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 78%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 16.2pt; font-size: 10pt;">Fair value of warrants exercised</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(116</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 78%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Ending balance as of March 31, 2014</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2,399</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr></table></div>

217000

350000

297000

326000

-300000

-140000

-85000

-169000

-764000

-512000

-419000

248000

-99000

97000

106000

119000

619000

719000

232000

249000

268000

364000

10000

1000

6632000

6209000

2399000

366000

225000

6434000

6638000

37097000

36084000

-34000

4495000

30018000

-12845000

-5278000

-4487000

-10937000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-style: italic; text-indent: 18pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Recently Adopted Accounting Pronouncements</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">In March 2013, the FASB issued ASU 2013-05, which permits an entity to release cumulative translation adjustments into net income when a reporting entity (parent) ceases to have a controlling financial interest in a subsidiary or group of assets that is a business within a foreign entity.  Accordingly, the cumulative translation adjustment should be released into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided, or, if a controlling financial interest is no longer held. The revised standard became effective for fiscal years beginning after December 15, 2013. The Company adopted this guidance effective January 1, 2014.  The Company’s adoption of this standard did not have a material impact on its consolidated financial statements.</div></div>

-5059000

-10202000

315000

314000

-2000

364000

300000

2000

817000

1029000

34000

10000000

0.01

1711000

1292000

407000

310000

3000000

7500000

21500000

11100000

20900000

4400000

5000000

4495000

30018000

2738000

3069000

1487000

957000

1748000

7004000

1552000

603000

6804000

2009000

1749000

957000

2143000

603000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">Property, plant, and equipment consist of the following:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; margin-left: 18pt; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 66%; vertical-align: bottom;"><div style="text-align: left; font-style: italic; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">(in thousands)</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">March 31,</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2014</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Leaseholds</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,748</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,749</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Furniture</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">957</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">957</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Equipment</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,487</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,552</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Enterprise hardware and software</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2,009</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2,143</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Buildings and land</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">603</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">603</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 14.4pt; font-size: 10pt;">Property, plant and equipment, gross</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">6,804</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">7,004</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Accumulated depreciation</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(4,066</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(3,935</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 14.4pt; font-size: 10pt;">Property, plant and equipment, net</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2,738</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">3,069</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr></table></div>

4469000

1457000

42000

197000

42000

2606000

1368000

200000

1200000

-229132000

-234410000

P6Y9M18D

P7Y1M17D

P7Y4M10D

81000

310000

381000

310000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">Prepaid expenses and other current assets consist of the following:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; margin-left: 18pt; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 66%; vertical-align: bottom;"><div style="text-align: left; font-style: italic; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">(in thousands)</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">March 31,</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2014</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Insurance premiums</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">310</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">407</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Professional fees</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">75</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">377</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Income tax credits receivable</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">297</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">326</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Kits for clinical use</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">295</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">287</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Other<sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">1</sup></div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">315</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">314</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 14.4pt; font-size: 10pt;">Total prepaid expenses and other current assets</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,292</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,711</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr></table><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;"><sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">1</sup> Other consists of various prepaid expenses and other current assets with no individual item accounting for more than 5% of the total balance at March 31, 2014 and December 31, 2013.</div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2014, aggregated by the level in the fair value hierarchy within which those measurements fall.</div><div><br /></div><table align="left" border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; margin-left: 18pt; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 42%; vertical-align: bottom;"></td><td colspan="15" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Assets and Liabilities Measured at Fair Value on a Recurring Basis</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 42%; vertical-align: bottom;"><div style="text-align: left; font-style: italic; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">(in thousands)</div></td><td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Level 1</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Level 2</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="3" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Level 3</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="3" style="border-bottom: #000000 2px solid; white-space: nowrap; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Balance at</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2014</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="width: 42%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;">Assets</div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 42%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Money market funds</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,945</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">—</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">—</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,945</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 42%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt; font-weight: bold;">Liabilities</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 42%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Warrant liability</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">—</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">—</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2,399</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2,399</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">A stock option grant allows the holder of the option to purchase a share of the Company’s common stock in the future at a stated price. Options granted under the Plans vest as determined by the Company’s Compensation and Stock Option Committee and expire over varying terms, but not more than ten years from the date of grant. Stock option activity for the three months ended March 31, 2014 is as follows:</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><table border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; margin-left: 18pt; font-size: 10pt;"><tr><td valign="bottom" style="width: 42%; vertical-align: bottom;"></td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="14" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Stock Option Activity under the Plans</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 42%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Stock </div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Options</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Exercise</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Price</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">per Share</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Weighted Average</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Exercise </div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Price</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Weighted Average Remaining</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Life (Years)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr style="height: 12px;"><td valign="bottom" style="background-color: #cceeff; width: 42%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Outstanding at December 31, 2013</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">252,133</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td style="text-align: right; background-color: #cceeff; width: 9%; white-space: nowrap; vertical-align: bottom;"><div style="text-align: right; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">4.80—$248.64</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">57.90</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">7.36</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 42%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Granted</div></td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">—</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">—</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">—</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 42%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Forfeited</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(14,304</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="text-align: right; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">7.36—$248.64</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">109.54</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 42%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Expired</div></td><td valign="bottom" style="text-align: right; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">—</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 2px; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">—</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 2px; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">—</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 2px; background-color: #ffffff; width: 9%; vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 42%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Outstanding at March 31, 2014</div></td><td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">237,829</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="text-align: right; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">4.80—$248.64</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">54.79</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">7.13</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">Restricted stock activity for the three months ended March 31, 2014 is as follows:</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><table border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; margin-left: 18pt; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 66%; vertical-align: bottom;"></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Restricted Stock Activity</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">under the Plans</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 66%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Restricted Stock</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Weighted Average Grant Date Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Non-vested at December 31, 2013</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">20,358</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">16.88</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Granted</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">—</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">—</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Vested</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(1,624</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">75.32</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Forfeited</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(71</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">39.26</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Non-vested at March 31, 2014</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">18,663</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">11.71</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">There were no options granted during the three months ended March 31, 2014. The estimated fair value of each option award granted during the three month period ended March 31, 2013 was determined on the date of grant using an option pricing model with the following assumptions: </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;"> </div><table border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; margin-left: 18pt; font-size: 10pt;"><tr><td style="width: 64%; vertical-align: top;"><div> </div></td><td style="width: 1.85%; vertical-align: top;"><div> </div></td><td style="border-bottom: #000000 2px solid; width: 22%; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Three months ended </div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2013</div></td><td style="width: 2.05%; vertical-align: top;"><div> </div></td></tr><tr><td style="background-color: #cceeff; width: 64%; vertical-align: middle;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Dividend yield</div></td><td style="background-color: #cceeff; width: 1.85%; vertical-align: top;"><div> </div></td><td style="background-color: #cceeff; width: 22%; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">None</div></td><td style="background-color: #cceeff; width: 2.05%; vertical-align: top;"><div> </div></td></tr><tr><td style="background-color: #ffffff; width: 64%; vertical-align: middle;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Expected volatility</div></td><td style="background-color: #ffffff; width: 1.85%; vertical-align: top;"><div> </div></td><td style="background-color: #ffffff; width: 22%; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">86.16% — 86.51%</div></td><td style="background-color: #ffffff; width: 2.05%; vertical-align: top;"><div> </div></td></tr><tr><td style="background-color: #cceeff; width: 64%; vertical-align: middle;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Weighted average volatility</div></td><td style="background-color: #cceeff; width: 1.85%; vertical-align: top;"><div> </div></td><td style="background-color: #cceeff; width: 22%; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">86.20%</div></td><td style="background-color: #cceeff; width: 2.05%; vertical-align: top;"><div> </div></td></tr><tr><td style="background-color: #ffffff; width: 64%; vertical-align: middle;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Risk-free interest rates</div></td><td style="background-color: #ffffff; width: 1.85%; vertical-align: top;"><div> </div></td><td style="background-color: #ffffff; width: 22%; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1.16% — 1.36%</div></td><td style="background-color: #ffffff; width: 2.05%; vertical-align: top;"><div> </div></td></tr><tr><td style="background-color: #cceeff; width: 64%; vertical-align: middle;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Expected life (in years)</div></td><td style="background-color: #cceeff; width: 1.85%; vertical-align: top;"><div> </div></td><td style="background-color: #cceeff; width: 22%; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">6.8</div></td><td style="background-color: #cceeff; width: 2.05%; vertical-align: top;"><div> </div></td></tr></table></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">Inventories consist of the following:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; margin-left: 18pt; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 66%; vertical-align: bottom;"><div style="text-align: left; font-style: italic; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">(in thousands)</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">March 31,</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2014</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Raw materials</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">232</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">249</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Work-in-process</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">268</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">364</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Finished goods</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">119</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">106</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 14.4pt; font-size: 10pt;">Total inventory</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">619</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">719</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">For the three month periods ended March 31, 2014 and 2013, the following potentially dilutive securities were excluded from the computation of earnings per share because their effects would be anti-dilutive:</div><div style="text-align: center; font-weight: bold;"> </div><div><br /></div><table align="left" border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; margin-left: 18pt; font-size: 10pt;"><tr><td valign="bottom" style="width: 66%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">March 31,</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 66%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2014</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Stock options</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">237,829</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">349,635</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Unvested restricted shares</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">18,663</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">25,676</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Warrants</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">891,368</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">340,254</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 14.4pt; font-size: 10pt;">Total</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,147,860</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">715,565</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">Accrued expenses consist of the following:</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;"> </div><table border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; margin-left: 18pt; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 66%; vertical-align: bottom;"><div style="text-align: left; font-style: italic; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">(in thousands)</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">March 31,</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2014</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Compensation, excluding taxes</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,853</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,866</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Deferred rent</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">483</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">485</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Professional fees</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">323</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">360</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Other<sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">1</sup></div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">817</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,029</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 14.4pt; font-size: 10pt;">Total accrued expenses</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">3,476</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">3,740</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr></table><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;"><sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">1</sup> Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at March 31, 2014 and December 31, 2013.</div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">The following table provides the total severance expense incurred and payments made by the Company through March 31, 2014 as a result of the workforce restructurings implemented in 2013:</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; margin-left: 18pt; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 78%; vertical-align: bottom;"><div style="text-align: left; font-style: italic; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">(in thousands)</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">March 31,</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">2014</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 78%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Restructuring reserve balance, gross</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">3,974</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 78%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Restructuring expenses paid</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(2,606</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 78%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 14.4pt; font-size: 10pt;">Restructuring reserve balance, net</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,368</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr></table></div>

3819000

6083000

4000000

109.54

16.88

11.71

20358

18663

1624

39.26

0.0116

0.0136

0.8616

0.8651

0.862

75.32

406250

187500

14304

57.90

54.79

252133

237829

900000

1300000

500000

1000000

100000

1000000

13000

25000

467000

178000

467000

178000

one-for-sixteen

one-for-sixteen (1:16)

one-for- sixteen (1:16)

one-for-eight (1:8)

30099000

29650000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td style="width: 18pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; font-weight: bold; align: right;">(7)</td><td style="text-align: justify; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; font-weight: bold;">Stockholders’ Equity</td></tr></table></div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt; font-weight: bold;">Stock Issuances</div><div><br /></div><div style="text-align: left; font-style: italic; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">Reverse Stock Split</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">On February 24, 2014, shareholders of the Company approved, through a shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Delcath’s common stock at a ratio within a range of one-for-eight (1:8) to one-for-sixteen (1:16). The reverse stock split became effective on April 8, 2014 at which time Delcath’s common stock began trading on the NASDAQ Stock Exchange on a one-for-sixteen (1:16) split-adjusted basis. All owners of record as of the close of the NASDAQ market on April 8, 2014 received one issued and outstanding share of Delcath common stock in exchange for sixteen issued and outstanding shares of Delcath common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-sixteen exchange were rounded up to the next whole share. The reverse stock split had no impact on the number of common shares authorized or the par value per share of Delcath common stock, which remain 170,000,000 and $0.01, respectively. All current and prior period amounts related to shares, share prices and earnings per share, presented in these Condensed Consolidated Financial Statements and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split.</div><div><br /></div><div style="text-align: left; font-style: italic; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">At-the-Market (“ATM”) Programs</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">In December 2011, the Company entered into an agreement with Cowen and Company, LLC (“Cowen”) to sell shares of its common stock, par value $.01 per share, from time to time, through an ATM equity offering program having aggregate sales proceeds of $39.8 million, under which Cowen would act as sales agent. During the three months ended March 31, 2013, the Company sold approximately 0.9 million shares of its common stock under this ATM program for proceeds of approximately $20.9 million, with net cash proceeds after related expenses of approximately $20.8 million, and successfully completed the program. As of March 31, 2014, there were no shares of common stock of the Company remaining for sale under this ATM program.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">In March 2013, the Company entered into a new agreement with Cowen to sell shares of the Company’s common stock, par value $.01 per share, from time to time, through an ATM equity offering program having aggregate sales proceeds of $50.0 million, under which Cowen will act as sales agent. During the year ended December 31, 2013, the Company sold approximately 1.0 million shares of its common stock under this ATM program for proceeds of approximately $5.0 million, with net cash proceeds after related expenses of approximately $4.8 million. During the three months ended March 31, 2014 the Company sold an additional 1.0 million shares of its common stock under this ATM program for proceeds of approximately $4.4 million, with net cash proceeds after related expenses of approximately $4.4 million. The shares were issued pursuant to an effective registration statement on Form S-3 (333-187230). The net proceeds will be used for general corporate purposes, including, but not limited to, commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures and working capital. As of March 31, 2014, the Company has approximately $40.4 million remaining under the program. </div><div><br /></div><div style="text-align: left; font-style: italic; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">Committed Equity Financing Facility (“CEFF”) Program</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">In December 2012, the Company entered into an agreement with Terrapin Opportunity, L.P. (“Terrapin”) for a CEFF program. Under the agreement Terrapin committed to purchase up to $35.0 million of Delcath common stock over a 24-month term. Since inception, the Company has sold approximately 0.5 million shares of its common stock through the program for total proceeds of approximately $11.1 million, with net cash proceeds after related expenses of approximately $10.8 million. As a result, there was approximately $23.9 million available under this CEFF program as of March 31, 2014. The shares were issued pursuant to an effective registration statement on Form S-3 (333-183675). The net proceeds will be used for general corporate purposes including, but not limited to, commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures and general working capital needs.</div><div><br /></div><div style="text-align: left; font-style: italic; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt; font-weight: bold;">Warrants</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">In June 2009, the Company completed the sale of 0.1 million shares of its common stock and the issuance of warrants to purchase 0.1 million common shares (the “2009 Warrants”) pursuant to a subscription agreement with a single investor. The Company received proceeds of $3.0 million, with net cash proceeds after related expenses from this transaction of approximately $2.7 million. Of those proceeds, the Company allocated an estimated fair value of $2.2 million to the 2009 Warrants. As required by the 2009 Warrant agreement, the exercise price of the warrants was adjusted following the Company’s October 2013 sale of common stock and warrants. At March 31, 2014, the 2009 Warrants were exercisable at $2.56 per share with approximately 40,000 warrants outstanding. The 2009 Warrants have a five-year term. The shares and warrants were issued pursuant to an effective registration statement on Form S-3. During the three months ended March 31, 2014, 25,000 2009 Warrants were exercised for net proceeds of approximately $0.1 million.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">In May 2012, the Company completed the sale of 1.0 million shares of its common stock and the issuance of warrants to purchase 0.3 million common shares (the “2012 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $21.5 million, with net cash proceeds after related expenses from this transaction of approximately $21.1 million. Of those proceeds, the Company allocated an estimated fair value of $3.4 million to the 2012 Warrants. As required by the 2012 Warrant agreement, the exercise price of the warrants was adjusted following the Company’s October 2013 sale of common stock and warrants. At March 31, 2014, the 2012 Warrants were exercisable at $2.56 per share with 0.3 million warrants outstanding. The 2012 Warrants have a three-year term. The shares and warrants were issued pursuant to an effective registration statement on Form S-3. During the three months ended March 31, 2014, approximately 13,000 2012 Warrants were exercised for net proceeds of approximately $34,000.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">In October 2013, the Company completed the sale of 1.3 million shares of its common stock and the issuance of warrants to purchase 0.6 million common shares (the “2013 Warrants”) pursuant to a placement agency agreement. The Company received proceeds of $7.5 million, with net cash proceeds after related expenses from this transaction of approximately $6.9 million. Of those proceeds, the Company allocated an estimated fair value of $1.9 million to the 2013 Warrants. The 2013 Warrants will become exercisable at $7.04 per share on April 30, 2014. The 2013 Warrants have a five-year term. The shares and warrants were issued pursuant to an effective registration statement on Form S-3.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt; font-weight: bold;">Stock Incentive Plans</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">The Company established the 2004 Stock Incentive Plan and the 2009 Stock Incentive Plan (collectively, the “Plans”) under which 187,500, and 406,250 shares, respectively, have been reserved for the issuance of stock options, stock appreciation rights, restricted stock, stock grants and other equity awards. The Plans are administered by the Compensation and Stock Option Committee of the Board of Directors which determines the individuals to whom awards shall be granted as well as the type, terms, conditions, option price and the duration of each award.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">A stock option grant allows the holder of the option to purchase a share of the Company’s common stock in the future at a stated price. Options granted under the Plans vest as determined by the Company’s Compensation and Stock Option Committee and expire over varying terms, but not more than ten years from the date of grant. Stock option activity for the three months ended March 31, 2014 is as follows:</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><table border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; margin-left: 18pt; font-size: 10pt;"><tr><td valign="bottom" style="width: 42%; vertical-align: bottom;"></td><td valign="bottom" style="width: 1%; vertical-align: top;"> </td><td colspan="14" valign="bottom" style="vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Stock Option Activity under the Plans</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 42%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Stock </div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Options</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Exercise</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Price</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">per Share</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Weighted Average</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Exercise </div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Price</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Weighted Average Remaining</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Life (Years)</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr style="height: 12px;"><td valign="bottom" style="background-color: #cceeff; width: 42%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Outstanding at December 31, 2013</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">252,133</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td style="text-align: right; background-color: #cceeff; width: 9%; white-space: nowrap; vertical-align: bottom;"><div style="text-align: right; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">4.80—$248.64</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">57.90</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">7.36</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 42%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Granted</div></td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">—</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">—</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">—</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 42%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Forfeited</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(14,304</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="text-align: right; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">7.36—$248.64</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">109.54</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 42%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Expired</div></td><td valign="bottom" style="text-align: right; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">—</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 2px; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">—</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 2px; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">—</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 2px; background-color: #ffffff; width: 9%; vertical-align: bottom;"> </td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 42%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Outstanding at March 31, 2014</div></td><td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">237,829</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="text-align: right; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">4.80—$248.64</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">54.79</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; padding-bottom: 4px; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">7.13</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr></table><div> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">For the three months ended March 31, 2014 and 2013, the Company recognized compensation expense of approximately $0.2 million and $0.5 million, respectively, relating to stock options granted to employees.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">There were no options granted during the three months ended March 31, 2014. The estimated fair value of each option award granted during the three month period ended March 31, 2013 was determined on the date of grant using an option pricing model with the following assumptions: </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;"> </div><table border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; margin-left: 18pt; font-size: 10pt;"><tr><td style="width: 64%; vertical-align: top;"><div> </div></td><td style="width: 1.85%; vertical-align: top;"><div> </div></td><td style="border-bottom: #000000 2px solid; width: 22%; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Three months ended </div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2013</div></td><td style="width: 2.05%; vertical-align: top;"><div> </div></td></tr><tr><td style="background-color: #cceeff; width: 64%; vertical-align: middle;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Dividend yield</div></td><td style="background-color: #cceeff; width: 1.85%; vertical-align: top;"><div> </div></td><td style="background-color: #cceeff; width: 22%; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">None</div></td><td style="background-color: #cceeff; width: 2.05%; vertical-align: top;"><div> </div></td></tr><tr><td style="background-color: #ffffff; width: 64%; vertical-align: middle;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Expected volatility</div></td><td style="background-color: #ffffff; width: 1.85%; vertical-align: top;"><div> </div></td><td style="background-color: #ffffff; width: 22%; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">86.16% — 86.51%</div></td><td style="background-color: #ffffff; width: 2.05%; vertical-align: top;"><div> </div></td></tr><tr><td style="background-color: #cceeff; width: 64%; vertical-align: middle;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Weighted average volatility</div></td><td style="background-color: #cceeff; width: 1.85%; vertical-align: top;"><div> </div></td><td style="background-color: #cceeff; width: 22%; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">86.20%</div></td><td style="background-color: #cceeff; width: 2.05%; vertical-align: top;"><div> </div></td></tr><tr><td style="background-color: #ffffff; width: 64%; vertical-align: middle;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Risk-free interest rates</div></td><td style="background-color: #ffffff; width: 1.85%; vertical-align: top;"><div> </div></td><td style="background-color: #ffffff; width: 22%; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1.16% — 1.36%</div></td><td style="background-color: #ffffff; width: 2.05%; vertical-align: top;"><div> </div></td></tr><tr><td style="background-color: #cceeff; width: 64%; vertical-align: middle;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Expected life (in years)</div></td><td style="background-color: #cceeff; width: 1.85%; vertical-align: top;"><div> </div></td><td style="background-color: #cceeff; width: 22%; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">6.8</div></td><td style="background-color: #cceeff; width: 2.05%; vertical-align: top;"><div> </div></td></tr></table><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;"> </div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">No dividend yield was assumed because the Company has never paid a cash dividend on its common stock and does not expect to pay dividends in the foreseeable future. Volatilities were developed using the Company’s historical volatility. The risk-free interest rate was developed using the U.S. Treasury yield for periods equal to the expected life of the stock options on the grant date. The expected option term for grants made during the second half of 2012 and thereafter is based on actual historical results. The expected option term for grants made prior to that was developed based on the mid-point between the vesting date and the expiration date of each respective grant as permitted under ASC 718. This method of determining the expected holding period was utilized at that time because the Company did not yet have sufficient historical experience from which to estimate the period.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">Restricted stock activity for the three months ended March 31, 2014 is as follows:</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;"> </div><table border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; margin-left: 18pt; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 66%; vertical-align: bottom;"></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Restricted Stock Activity</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">under the Plans</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; width: 66%; vertical-align: bottom;"><div> </div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Restricted Stock</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Weighted Average Grant Date Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Non-vested at December 31, 2013</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">20,358</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">16.88</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Granted</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">—</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">—</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Vested</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(1,624</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">75.32</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Forfeited</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(71</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">39.26</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"> </td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 66%; vertical-align: bottom;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Non-vested at March 31, 2014</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">18,663</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">11.71</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;"> </td></tr></table><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; margin-left: 18pt; font-size: 10pt;">For the three months ended March 31, 2014 and 2013, the Company recognized compensation expense of approximately $0.04 million and $0.2 million, respectively, related to restricted stock granted to employees.</div></div>

51000

1757

9300078

5342976

200000 6 0.1 300000 0.01 0.01 4800000 10800000 4400000 20800000 50000000 39800000 35000000 P24M 21100000 2700000 6900000 600000 100000 300000 3400000 2200000 1900000 P5Y P3Y P5Y 34000 100000 P10Y 23900000 40400000 214000 116000 2272000 205000 0 82000 -2272000 -205000 -381000 -15000 3974000 1.00 P10D 295000 287000 0.05 0.05 377000 75000 0.5 3740000 3476000 0.05 0.05 248.64 4.80 248.64 4.80 7.36 248.64 Reflects a one-for- sixteen (1:16) reverse stock split effected on April 8, 2014. Reflects a one-for-sixteen (1:16) reverse stock split effected on April 8, 2014. Other consists of various prepaid expenses and other current assets with no individual item accounting for more than 5% of the total balance at March 31, 2014 and December 31, 2013. Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at March 31, 2014 and December 31, 2013.

EX-101.SCH 9 dcth-20140331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 020100 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - General link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - Property, Plant, and Equipment link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - Restructuring Expenses link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - Stockholders Equity link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - Net Loss per Common Share link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - Taxes link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 061200 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 070100 - Disclosure - General (Policies) link:presentationLink link:calculationLink link:definitionLink 080200 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 080300 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 080400 - Disclosure - Property, Plant, and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 080500 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 080600 - Disclosure - Restructuring Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 080700 - Disclosure - Stockholders Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 080800 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 080900 - Disclosure - Net Loss per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - General (Details) link:presentationLink link:calculationLink link:definitionLink 090200 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - Property, Plant, and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - Restructuring Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - Stockholders Equity (Details) link:presentationLink link:calculationLink link:definitionLink 090702 - Disclosure - Stockholders Equity, Stock Incentive Plans (Details) link:presentationLink link:calculationLink link:definitionLink 090800 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 090900 - Disclosure - Net Loss per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 091200 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 dcth-20140331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 11 dcth-20140331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 dcth-20140331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Amendment Flag Current Fiscal Year End Date Document Period End Date Entity [Domain] Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Legal Entity [Axis] Document Type Award Type [Axis] Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts receivables, net Accounts payable Professional fees Compensation, excluding taxes Accrued expenses Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated other comprehensive income Additional paid-in capital Adjustments to reconcile net loss to net cash used in operating activities: Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Securities [Axis] Total Assets Current assets Assets: Total current assets Assets, Current Total assets Assets Assets [Abstract] Assets, Fair Value Disclosure [Abstract] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Basis of Presentation Cash and cash equivalents Beginning of period End of period Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents: Net increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Class of Warrant or Right [Table] Number of warrants outstanding (in shares) Class of Warrant or Right, Outstanding Class of Warrant or Right [Line Items] Class of Warrant or Right [Domain] Class of Warrant or Right [Axis] Warrants exercisable per share price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies [Abstract] Commitments and contingencies (Note 12) Common stock, shares outstanding (in shares) Common stock, $.01 par value; 170,000,000 shares authorized; 9,433,703 and 8,394,397 shares issued and 9,431,907 and 8,392,641 shares outstanding at March 31, 2014 and December 31, 2013, respectively Remaining value of common stock Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Common stock, shares authorized (in shares) Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Enterprise Hardware and Software [Member] Computer Equipment [Member] COSTS OF SALES Costs of goods sold OPERATING EXPENSES Total operating expenses Costs and Expenses Prepaid Expenses and Other Current Assets [Abstract] Deferred rent Depreciation expense Warrant liability [Member] Warrant liability Basic and diluted loss per common share (in dollars per share) Net Loss per Common Share Earnings Per Share [Text Block] Net Loss per Common Share [Abstract] LOSS PER COMMON SHARE Foreign currency effects on cash Equipment [Member] Measurement Frequency [Axis] Fair Value by Asset Class [Domain] Expected volatility (in hundredths) Fair Value Assumptions, Expected Volatility Rate Fair Value, Hierarchy [Axis] Liability Class [Axis] Recurring [Member] Ending balance as of March 31, 2014 Beginning balance as of December 31, 2013 Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Fair value of warrants exercised Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Fair Value, Measurement Frequency [Domain] Risk-free interest rates (in hundredths) Fair Value Assumptions, Risk Free Interest Rate Fair Value Measurements, Recurring and Nonrecurring [Table] Asset Class [Axis] Fair Value by Liability Class [Domain] Expected life (in years) Fair Value Assumptions, Expected Term Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Schedule of fair value of the warrants Level 3 [Member] Level 1 [Member] Level 2 [Member] Total change in the liability included in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Roll Forward] Fair value measurements using significant unobservable inputs Furniture [Member] Gross profit Gross Profit Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) [Abstract] Income Statement Location [Axis] Taxes Income Tax Disclosure [Text Block] Taxes [Abstract] Income Statement Location [Domain] Income tax credits receivable Income Taxes Receivable, Current Decrease in other non-current liabilities Decrease in accounts receivable Increase (Decrease) in Accounts Receivable Decrease in accounts payable and accrued expenses Changes in assets and liabilities: Decrease (increase) in prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Decrease (increase) in inventories Increase (Decrease) in Inventories Inventories Inventory Disclosure [Text Block] Finished goods Inventory, Finished Goods, Gross Inventories, net Total inventory Inventories [Abstract] Raw materials Inventory, Raw Materials, Gross Work-in-process Inventory, Work in Process, Gross Interest income Buildings and Land [Member] Leaseholds [Member] Total current liabilities Liabilities, Current Total Liabilities Other non-current liabilities Liabilities, Noncurrent Current liabilities Total liabilities Liabilities LIABILITIES AND STOCKHOLDERS EQUITY Liabilities [Abstract] Liabilities, Fair Value Disclosure [Abstract] Total liabilities and stockholders' equity Liabilities and Equity Maximum [Member] Minimum [Member] Money market funds [Member] Money Market Funds [Member] Cash flows from financing activities: Net cash used in by investing activities Net Cash Provided by (Used in) Investing Activities Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Cash flows from investing activities: Cash flows from operating activities: Net loss Net loss Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Recently Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Supplemental non-cash activities: Operating Expense [Member] Loss from operations Operating Income (Loss) General [Abstract] General Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Other Other Assets, Current Prepaid Expenses and Other Current Assets Other Current Assets [Text Block] Foreign currency translation adjustments OTHER COMPREHENSIVE INCOME (LOSS) Other Comprehensive Income (Loss), Net of Tax [Abstract] OTHER INCOME (EXPENSE) Other revenues Non-cash interest income Other Noncash Income Other Other Accrued Liabilities, Current Accrued Expenses [Abstract] Purchase of property, plant, and equipment Payments to Acquire Property, Plant, and Equipment Plan Name [Domain] Plan Name [Axis] Preferred stock, $.01 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2014 and December 31, 2013 Preferred stock, shares authorized (in shares) Preferred stock, shares issued (in shares) Preferred stock, par value (in dollars per share) Preferred stock, shares outstanding (in shares) Prepaid expenses and other current assets Total prepaid expenses and other current assets Prepaid Expense and Other Assets, Current EX-101.PRE 13 dcth-20140331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#FQ),IZ@$``%48```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F=%.VS`8A>^1]@Z1;Z?& MM3T8FYIRL;%+0((]@!?_;:(FMF4;:-\>)P6$4%=4K=+.3:,V]G^^^.*3\+SO.A]-:`T5-SJD*]UG#+[N^*,+JS_.KOOH`&]G[^/(Y>]-<#[F&CS0X:?PTG,/NR<^#Z*06GIMNGP"3N'[6-HR1`]_:$`X)*8]O1 M]N?//UO>[N9I5!\<8B].P[HH0;$S8GO7:GBMGU8/H&(B9VD4QQJ.'&%7W=YL M7WBDE)MBU_NHLHN+&KJ4_"-B-!U/%`OQ['*ED3!1RF%HT9,9J&7 M4"T\U<%J"`=[!ZH^^CSYLK$SO+=N5#9@NIS]NHFD++ M28,5\YS3$$X4UD^&'!Q0]47P```/__`P!02P,$%``&``@````A`.>YA;+V`0``6!<` M`!H`"`%X;"]?FE!^1 MLD%(;+GW[]M-\>I# M7'=M:6@R-85OJZY>MZO2_'VZ/[LT14RNK=VF:WUI=CZ:V\7IR:Q!1/NSZ_^N?#N^5R7?F[KGK9^C9]\0[[UH7GV'B?\J$NK'PJ MS;`5[?X)R20S&_L-3JZ'+LXEPN&Y,@[/$8YI<*--<(!A6AF$$0]I:(J@ESE:LZC0\1=7A4:4] M2"C_QF]\F*\0SFQ4D!W\YG.-5'VN;,#G"(:T:0CBL/98 MSG`L9^VQG.%8+MH>+-B$1Q72;_()CA*D/4H0'"5$.Z($1I1V0L&`TKXI>%&D M71J"M6'M\&88WJP=W@S#6[0]1Z#GB'9\"HQ/[;C"::4\Y\`D)VU5$505::N* MH*I8NXT9MK%H3X$">T>T926#KNS1_^&+#P```/__`P!02P,$%``&``@````A M`(86%K=X`P``O`L```\```!X;"]W;W)K8F]O:RYX;6R4EF]OVC`0QM]/VG>( M\G[-/V!M5:C6EFY(6X<&:U]:;F(:JXF=VDZ!;[]+*-DE#A5]!4[PX[OG?G?X MXG*39\XK4YI+,7:#$]]UF(AEPL73V/V[O/URZCK:4)'03`HV=K=,NY>3SY\N MUE(]/TKY[("`T&,W-:8X]SP=IRRG^D063,";E50Y-;!43YXN%*.)3ADS>>:% MOC_R,;N=QDYM"CN M:`YQ;S+7R:@VTX0;EHS=(2SEFK4>J+*X*GD&;\\B/W*]29/D7#D)6]$R,TM( M;Z\.?H6#,!Q5OZRLN.=LK?]OJI;.YH&+1*ZKGX*UVV8500#K^M4#3TP*[WW? M;Y[]8/PI-?N'(.\A_=I!.*?^=$2=WMX1`I4B4V&XV9*9V+G/)92P"*0HL-A8, M`(OFV*_=8V?B%3B7BD/;H3VXBJ?=/7/%"LH!@PWTH&:Z9N*W29DBUZ7",A!V M<_29+0,]K("C.53?[,!Z*7E1-1X6P34,_*[*MSA6)3"T#P;OQ'4++!C_0'.J M,C:E@EG4NQ\7++`H7!@9/ZH0;NHPZV)!"QMP#J9Y&YXA!BZPB%N4CYJ]E)`MF5;LX9R'F+O``N\-;C*' MR=$]%*,66*PAS,F2/F:MO(>8,)BBG:'U/NZM!L?`A19P+)$[`PQ>*$% M7A?YGHPP?*$%7S_Y/3(8P=!"L*C0P@Z'%X($^Z-'!<.[^$O'<.]@.M1+R M=H3I#"TZ]XC=,$-YAMD,6XE8;&+"[,TC#'9HX?D^8JWACSF/>EA]![$;9$.$ M`X)%AWD+,3NEJ!6)!>D!QFR=$>Z^R&*U#[(>$=QYT5&DUL)PAVG?.W#GP16J M8\LA6GW&B=O?_&>_`,``/__`P!02P,$%``&``@````A`'DQL;0U!@``E!D` M`!@```!X;"]W;W)K\O:\_KBF-9Y]VLN91G6-DW;9WW\+$]>-VE M+?.=5*I/GO#]I5?GU=DE"^MVBHUFOZ^*?WRY/15-?P,1K=:KZ;]*HZ]3%^K?#N6GSUQ/X_358Y(6R+3^,S-=5 MT39=L^]G8,XCHF.?8R_VP-++\ZX"#S#L3EON-^['8)V)E>N]/,L`_5N5[YWQ MM],=F_=?VFKW>W4N(=J0)\S`:]-\1NAO.Q2!LC?2_B0S\&?K[,I]_G;J_VK> M?RVKP[&'=(?@$3JVWGW;EET!$04S,Q&BI:(Y`0'X[=05E@9$)/\JG^_5KC]N MW/ER%D;^/`"X\UIV_:<*3;I.\=;U3?T?@8+!%!D1@Q%X#D9$-!.K,`B7:.6. MYGS0A.>@&VXP2@IBI0FC. M2G!U,UK85C,%P?U@>@'%8WIQGSV"-R[4C0YG%-KO20@"2=40QB15",U>"6ZJ M9`K!R0.3Z>01##O48!8M&7F"Q+*6YH%OKZ:T2HU`EHH)7['"R@RT%7`(S73. M"&:<(YM50I!0,)PVB0]WD`&O;T0$NT728KUIN3`7.O3C1$D]>2VY6B(2,7<#Y-KI6`IIG9 M!5>L'I(!LZ0VN`K83DB'=:,16AI+GUO,3`VK&08XEJ:3IR%FD6?3)9$6-RZ1 M#Q8A+YQAW21/5DECL5@R=S-3PR:/8VDZ>42SFN?#,R`,40D%GT_IL&Z2-S4" M/PQ9/6:FBLT>!]1T]C3.X&VZ_:WX]`P(0^R?0C]DD4P'@$G?4@E\X8_X$T+J MV/QQ6DWG3[,-C%WYL])(\.@/&;J[=17DNG65Y&J8E62F[8ZV+LXNPP4\!__X M"!G0Q+-2P2?L@*'N^21\5FBI7K_Z05:'Y`G!C]*9J6(G`H>8X<7]8170R+/8 MLSI)!@RQ9W,AU8M7ZFJ*8N_GI[;,Q-N\<9)-YTUSS^0=LRF3!&HV(I&G8!1T MM7QEKB1283XZVVB#H\K!@3:=.XT_BSL+:Q(01FU>$;&22@>`N7DME4"L%LSC MS-2Q8B\>FKL2;<_=F/6)9,##^ M\!3CT1^S/IT,&+K$>`H%_RZ8#@"CD=LJ@5B,!I&I8Q?30\-?T*2&KP,J<,E8 ME(Y%V[$HLT0V)YRJK"KP#/;@]2+4\;@SOQ2WXH_\C;0W7NG%.Y!WK^#*^A6[I5 MIP]]CA&M7&'*NLV^:7GW`(.C_I[S\#P``__\#`%!+ M`P04``8`"````"$`Q"V):;T#```.#@``&0```'AL+W=O]`>!^Q(C@:\69P,KLWV4TVF[UWGRM4;08H M:>LX\^WWM`<9*RX#/HC4'__^>TY[6M;?WLO">V-2<5$E/IE,?8]5FM5$*CLR$JJ M)J)F%?RS%[*D&F[E(5"U9#2W#Y5%,)M.XZ"DO/)1826':(C]GF?L662GDE4: M120KJ`;_ZLAK=5$KLR%R)96OI_HA$V4-$CM>ST!N0"-=L>\#)8!*&W6.8<1F+![DNT3_XFLMF3A!YNU M#=!/SL[JZK>GCN+\F^3Y'[QB$&W(D\G`3HA7@W[/31,\''2>?K$9^$MZ.=O3 M4Z'_%N??&3\<-:0[@A&9@:WRCV>F,H@HR$QFD5'*1`$&X-LKN9D:$!'Z;J]G MGNMCXH?Q)%I,0P*XMV-*OW`CZ7O926E1_HL0::109-:(P+41(=%D/HL6CV-4 MPD8%KA>5>+!*@..R87JFFF[64IP]F'O@7-74S&2R`N7[<8&`&/;)P(D/:P.& MK""9;YMPOE@';Y"`K&%29."[98A+;+M$/&V1`'RUYB!@P\T9V)@S231NTTO# MIY-9VXTEMDA<>PW_QPF$9K@3`SM.;ANVV.!T/']LS3DQF(_IV<`P1:^"'\Z7 MK2Z&!1F8O6V"YBZQ[2,<;R`R/"H&3GS0;OL-H\]HHS=D^KSU$8ZW>(PW`[MQ M(\O8C4J*S-).>P)E'#XNL47BOGO'VV*,-P.[WL+H9DFER-SO&:=Z'^%X,SO? MX()@X*]RBDR?MS["\;80KW^$,'XAS\819/X^O>FS4\>-N`@_*8`'8WCFX!M)*)W^QJ M8?QXQ]_76P<>O_%<63)Y8%M6%,K+Q,DPJMK6]MC_%)J3VDU[.ENEMCUH M_X#3>$T/[$\J#[Q27L'V(#F=+""M$L_S>*-%;4^S.Z'A'&Y_'N&]B\%)<#H! M>"^$OMR8-X;V36[S'P```/__`P!02P,$%``&``@````A`'WR:1L2!```?0T` M`!D```!X;"]W;W)K&ULE%==CYLZ$'V_4O\#XKT! M!_*I)-5"V'LKM5)U==L^$W`2M(`C3#:[__[.V-C!9IO-OBS+^,SQF?&,F:R^ MO%2E\TP;7K!Z[9*1[SJTSEA>U(>U^_._Q\]SU^%M6N=IR6JZ=E\I=[]L/OVU MNK#FB1\I;1U@J/G:/;;M:>EY/#O2*N4C=J(UK.Q94Z4MO#8'CY\:FN;"J2J] ML>]/O2HM:EM6DC2T3%O0SX_%B2NV*KN'KDJ;I_/I M<\:J$U#LBK)H7P6IZU39\NNA9DVZ*R'N%Q*FF>(6+P/ZJL@:QMF^'0&=)X4. M8UYX"P^8-JN\@`@P[4Y#]VOW@2P3,G:]S4HDZ%=!+[SWO\./[/)W4^3?BII" MMN&<\`1VC#TA]&N.)G#V!MZ/X@1^-$Y.]^FY;/]EEW]H<3BV<-P3B`@#6^:O M6\HSR"C0C,839,I8"0+@KU,56!J0D?1%/"]%WA[7;C`=369^0`#N["AO'PND M=)WLS%M6_98@TE%)DG%'`L\W2&XX!ITC/#M',AO-B+$9K#[#<>PX8Z>S)=(_S9MT\VJ81<':AHRPD\I=@A9`IG*NV30)_&G@X`3 M0)('9!%71"%L]2#E?O4(AB;M*2-S M2ULD,0M13V0^G5K2Y;*\#42UF/B)58!)#V]D'=)SOVX$V[HGIK!(8B9"=SBW M5F.UJC.N#-@VX=Q6K5;M;$\_HAK!ENHIL51+C%0=#%I3K6K5RB":?6RK5JNV MZIFI6EPW,[S2WVE5]#,#"`)KSTABIK)L'`AS.++NGA#=T+ M4S>>S_OW*#J9^H/0[F6)F%#]VL06G4<7U'Z8AJ:<'+M MN'22Y20J1Z&*-@<:T[+D3L;..&7B):*M<@*.R!+F$_"W[%NPO=_R/-`D.A-)@(N$`)JUV0P_)[2`_V>-H>BYDY)]R#;'^&\VP5_Q[A9PZ%`O%'`-XSUJH7W$#_<-K\#P``__\#`%!+`P04``8` M"````"$`IDW*RJT$```[%```&0```'AL+W=O+CPSE5117MU;>//+/>62E27JQM,G%MBQ4)WZ?%<6W_\_?KR]RV M1!47^SCC!5O;GTS8WS:__K*Z\O)-G!BK+&`HQ-H^5=5YZ3@B.;$\%A-^9@6L M''B9QQ5>9XKCMU\C@M;&18EF,X^.&0)HSRY)*SHD*2DF5Q M!?K%*3V+&UN>C*'+X_+M'X&BEV:I=5G36I;>;+\<2QX&>\R\/U!@CBY M<=<7/?H\34HN^*&:`)V#0ON>%\["`:;-:I^"`QEVJV2'M?V=+*GGVMO2YSX];D.P9$TMMQ_4B82B"C03+Q0,B4\`P'P:>6I+`V(2/Q1?U_3 M?75:V_YT$LYK7M/DP2*!+[O M)-X$.%T6(J#MNHHT;B*-ZN27RTH/1`NSK$L9+($YEMXT$P3L*_B!8&2)-\E M2\T%H1"0Y/>-[T]7SCLD)E&8+6+@N6HP1$=$-X3,@J2E-UJ98-#;B(9X=D7[ M4!F/-T2W-7=+7#$3&O=+X$[[:Q'N`Z?7V6%:@S^PK]'1E,^ M?4:Y!.O*>^6"$!3NS?RYGH$ETVZVP2^.[T_5IKLV3.R)5B73=QNF2,FK`/N M!?>[U@]!I*TN.J;H;?51,C35\D6@U2#-Y2W!NFJ_&\XM8@SAC`81U(30U"]T M];*]#W=*N6FHQ2#&Y&(004T(S06!YCX^"35:ST*_R2@0%CV9!9WZB-2ZP2#M M4MP+4!"4[!=C8>E!*"L`\MPDZ7BA2'4?Y7#+IT M.=?&2\JR1<-UBD1*,(0Z^9Y;IX.?Y:XD?F`8=F MVX0?=%[BM\0T67$R#T.H$:);D;/P>2LX0:&V3;W)-&:5E4$()2:(;D4.Q):5 M@=Z$X[.=C0ZG4D2$=,,KBU2!5$4)/`?EY3WU(RNT?J,]H-[L6)W M4B!#O4?#$&J$:/'W.I-ZW%-1[QKJ3@IDM(*3WP"A1A;=2F=BFTL)#F"Z[ZW] M4E(@]7^9>R\#?!+4LE$^WJ;/@-+Q#`=/)W)6'EG$LDQ8";_(\QD"K_G-KWAV MM"5+.#.0AP/-`AS=G.,C^QF7Q[005L8.L-6=S$!6B8<_>%'Q&ULE%??;Z,X M$'X_:?\'Q/L"AB0D49)5^=&[E>ZDU6KO]IF`DZ`"CC!IVO_^9FS,8M--FY>Z MC+\9?]_,&":;+R]U93W3EI>LV=K$\6R+-CDKRN:XM?_]\?AY:5N\RYHBJUA# MM_8KY?:7W:<_-E?6/O$3I9T%$1J^M4]==UZ[+L]/M,ZXP\ZT@9T#:^NL@\?V MZ/)S2[-".-65ZWO>PJVSLK%EA'7[D1CL<"ASFK#\4M.FDT%:6F4=\.>G\LQ5 MM#K_2+@Z:Y\NY\\YJ\\08E]69?NU++K3U@X6SCST M`@)P:T]Y]UAB2-O*+[QC]4$(GTH&<3O@\#Z1I`;CD'O"&OO2!;.S)^'2W'\ M#<]9[PGK?4>"*B$85G7DW`F)MPI",$U/=&7"1/Z3K,MVFY9=+6AJ2`D_9WA% MR!H\,?$!E._MQ$/&T>G(H%&$ M[KB?(CIM;6B/(8M!8.0QDA@HWH"9Z2IBA1@RK0R_=4D5PDPT4!FKN-TG"(9^ M&C$C"Z.BD<2L9!<18S>6N_+*BQX9PV=>J`M-1W`M]Y"01K!)VFP4B9&D_95!(U:[`VME$*S]A2XR M5;LFZ_`>U@@V60?Z09'$*-9FKM7NP%H9D+6_-$2F:M=DC8.$\1HD(7YKWGD3 MHI\N(`A,`1(C!03$%"!W";QSA^L[-[HMT2,8MSN]'4&[!ZNIS/??]NBD:R0+ M0T4D,?(6$W]E=%XLMT?76,.'Q!"2*@"ZZ#KP.S;JM]NO42*_>K"H+H^FIGAJ2J:F5#/I MG/##->*D1@$Y3`Q3V7LW`L9$LUW,?HYZ#"Y#TP?!).$RDIP[^PEA8L*Q%,^3 M*"E(CIERS*EI>Z0QK2INY>R"(^0,"CQ8Y7@;D35\V"&YACV!L?5B4 MP_``:6I2=H=3"CBG]/ M\)N$PMSA.0`^,-:I!^RHX5?.[G\```#__P,`4$L#!!0`!@`(````(0"Q/.^R MT@(``,H'```9````>&PO=V]R:W-H965THV:9.F:1_/CC%@%6-D.TW[[W=MIP3(U*4O@'V/C\\] MU[YL;Y]9ZSP1(2GO,C=8^*Y#.LQ+VM69^^OGP\W:=:1"78E:WI',?2'2O=U] M_+`][`5!I5G$6B_T M_<1CB':N94C%-1R\JB@F]QP?&.F4)1&D10KTRX;V\I6-X6OH&!*/A_X&<]8# MQ9ZV5+T84M=A./U2=UR@?0MY/P=+A%^YS>""GE$LN.256@"=9X5>YKSQ-AXP M[;8EA0RT[8X@5>;>!6FQ7+/9$8#`6:11AK M)LQ;$`!/AU%],L`0]&S>1UJJ)G.C9!&O_"@`N+,G4CU03>DZ^"`59W\L*#A1 M69+P1`+O$TD0OILD.I'`^TP2KN,@3OXOQ;-I&9?ND4*[K>!'!TX>")<]TN>U$4_(>31H\UQ1/=\TMQFH*@K,3YHX4 MDZB?#&LGFE;OT:3!!R^@L`5YRKUX%N]\-?>/<7``#__P,`4$L#!!0` M!@`(````(0#%W[1SAP,``,`,```9````>&PO=V]R:W-H965TF'01#[%::UJQEF_!H.MMG0G&0LWU>DEIJ$DQ)+T"]V MM!$GMBJ_AJ["_&G?W.2L:H!B34LJ7UM2UZGRV9=MS3A>E^#[!4UP?N)N;T;T M%0N=:/8NTV" M"`'<61,A'ZFB=)U\+R2K_F@0.E)IDO!(`M]'DA!Y"0JF47(]270DF?1)T"2( M+POQM:DV1AF6>#'G[.!`X8%LT6!5QF@&O*?@:"M=N,Y%"\*D2!X42^K"BH%` M"$CQ\R(*)W/_&=*2'S'+,0:9B-4)H7*@:#/]`*X=;1QT8WQPT-F`N/9MO)_; MDUH%5FI/\RSU@_X\83=-JV0U1B0#?]D8$IT1"WF\7JP"IRZDIHM!%-Z:ZI8: M`X7480;B5A<1F0UAA!JD7*]>@6'!])0E;T%I0[O4D+[X9%@8ER&9%6+HAYGZ M^E7%1["IV$M)]Q/$@"1H2M]6/DD!_3,Q*8^!Z+E&9G<4P$O^/$35H8&18 M31J"HM9)X`7#;.CW-A/G&0P#B6G`G@$%-H5'X3`%&F-1MKJ(R&P(0[WJ#WH[ MIUV]`E]:Q1IC4W\1D=D0AOKIOZA78#/VHU6L(7WQ49@,JG^,&6Q3F0UAR$>P M8J^/?HLV#43AG:EN>03U+0SDK2Y#,BO$M*!.MZL+".FS$+:Y;NL8GP-'D-6" MYK%`,BN+:4&=>==;T">D]3"`1E"56E]>%$[-3*W>`0TRI1K*(<\;1'O0#:-N MABK"MV1%RE(X.=NK9C"$W:][VC6J#VV?.GB^1#-H750+VKV`_K'!6_(-\RVM MA5.2#5`&GNKUN.Y`]8UD3=N"K9F$SK']N8-_"@2:G\`#\(8Q>;I1$W3_/19_ M`0``__\#`%!+`P04``8`"````"$`_ALZVDT%``!O$P``&0```'AL+W=OJ.BS3DDG?BMK`FX#>O$5N"1 MTB<6FAX8@F0+9F:X_\>93UX9PXY&T75PR2=,HGMN. M5O_P(%M(<1%'B,#G'9%W$EV1"-4H$FWX]YV$A4B`3YDPFP2>-_.#.8SWG4P; MK.4S91Z+6=R]F,4MZAV/\BY?+QOZ:D`9@PGM-6DUO^K@_G^9#ZXS ME0)#E(=9".@ M&`$E_15&,)F5.1L5B1-,U1+8\!@;EF2HI)D:LAU"!G<0V2$2([)')$$D120; M$\4DF-=7F,1DX&:$I1@,RZ+5N7/BS8)W MH:/@?08340WA9&2(#B(.G'G?ECA36SM/=L/O@Q>]PIS_MP5C,JHWO3(@9K'LRYQ`F__V%B7'&DGD M#SO*3B#7YC:Z\\!9J*=2++-NKHMOZ)!+=M%-5VYTM?-=3M3.9U6NK]H$S MBGUW"@CZ?EE!K+70;1((5FADDS:"K4Q<#)Y$`CG]XTQ?*#N!7*>WR0Y\7ZN, M6"8Y@\X>2R75DUBK1WN\S]Y][&N1/=.(*7$IG-U M8%N9>"N#2""G?XX4WG$MS^^]"Q:VZP>J4"R%QB4VC$"6;X*U4X&$MCN;.IYV M'V2*MNH>:_J0>_!,*;8N>8-^?!^#QV?DI$!J%6I+O)6)XRKDB>)1F!T*.Q'E M+'@5VK-YX&M'0"QCQG4X#.%F)1)/92(7G]N>YVOW"GL[P*8W+D3^M,^?/2O2 MG,B67"ZM4=!G]B0/WJ^7`^:O&39^")T$C$3G\Q`.7LRC((3SZ`Y?A+#'8YXL M0MBF,8?7&P^]*?IUV6N/._$;)X0G)ZRS<4-X6L#\818^@$'XA\TLA,;Y#O=" MZ!V!6\.(X'7'-3^1W_/F5-:M<2%','':W\X-?V'"OW3BZ'BD';SHZ$^1,[S8 M(E`D4U:^1TH[^85=8'A5MOX7``#__P,`4$L#!!0`!@`(````(0"'I\Z+Q0L` M`+LX```9````>&PO=V]R:W-H965T_OA]>.U_SXVE?O-UUK=Z@V\G?=L7C_NWYKON?O_T/-]W.Z;Q] M>]R^%F_Y7?>?_-3]Z_[?__KXK3A^/KWD^;E#'MY.=]V7\_G=[?=/NY?\L#WU MBO?\C:X\%[S&1_'TM-_E M\V+WY9"_G2LGQ_QU>Z;VGU[V[R?V=MA=X^ZP/7[^\OYA5QS>R<6G_>O^_$_I MM-LY[-SH^:TX;C^]4K^_6Z/MCGV7_P'WA_WN6)R*IW./W/6KAF*?;_NW??)T M__%Q3ST0P]XYYD]WW0?+W0P'W?[]QW*`_KO/OYT:_^Z<7HIOP7'_F.S?SYOB6YCOGU_.)/>8>B0ZYC[^ M,\]/.QI13`T:D>WWNZY-%>\?SR]WW>&D-W8&0XO, M.Y_RT]G?"Y?=SN[+Z5P<_E<96=)5Y60HG="O=&(->S?C\6ARXY"7"R5'LB3] M_;-V!K_K.1$EJ1?6?+*@HXL2+^JRJOZ2$NM M;"S]UE4ZUN!V^).QN97EZ)=KM'HC>^S?*86)5+26K M=;G!_6KIE2MYOCUO[S\>BV\=VAY)I-/[5FRVEBO<\1JN%*Y7]8\6-:UFX>5! MN+GK4GE:KR?:B;[>#RWG8_\K[1X[:3-%&TNWF+&%V"J$V[D)/!/X)@A,$)H@ M,L'"!+$)$A.D)LA,L#3!R@1K$VP:H$_RU!K18O@3&@DW0B,>W2D#)9IM",(6 M7&1N`L\$O@D"$X0FB$RP,$%L@L0$J0DR$RQ-L#+!V@2;!M`$H3WF3P@BW-QU M:?>I%XT]GN@*3"L;L9?61B/=9%:;U"H!\8#X0`(@(9`(R`)(#"0!D@+)@"R! MK("L@6R:1!.-QOE/B";U$1>; M`_&`^$`"("&0",@"2`PD`9("R8`L@:R`K(%LFD03BW/AG0.9`/"`^D`!(""0"L@`2`TF`I$`R($L@*R!K()LFT0:>CH[:P/_F MZ4VXT161I*$(D'E-Q''/'EA#??%X]75>/#Z0`$A8$^G5.))$]77VNJC(6+4U M!IND)I77@;'0T_HZ>\V:7K4QIT-NRYCW1$!U?MGO/D\+NC'0MM*R"(9T,J[. MR\*)/N*2J%[,@,PK8E/3ZGN//3".V5YMQ%WQP5$`)*Q+77`=U4;L>E&1YMB# MZZ0NU7`]&>B3):V-V'76=*T)0#'I10'^+MY_)`"%]JR`\*(K((G0D8,8>VB, M[JPR&MGU*7H.Q)-$U/7U?M"[M<;&TO"A3%`1BD"Y_R&02):Z*?U:E*L8&GX7 M4"8&D@!)#;\#RS'.,UFSC*:%B/8U,5IF?6/02W-]U!E1%6K81\;TF$FKT:@> MGSDBC]&M'*&Q[7TP]@^?;92G0"+KMG8>(HHD&@]*YW9O<*O_\3Z8:J"3&%&" M*-6K&O<&^A_+^V#$`)GF1%>(MJ)?44B8&PI)I"V,D3&N,Q&B4,'FRD#D*236 MQJ@W-F::KPQX(002-=<&HD@AX9E6A[%R%\J`/<>($D2I0M5ZMHVT1:8,R+,^ M^"*"_!/IE2H2U:,.VU@D4W%9:$=*U$O)F"@S9<.C,$?D(?(1!8A"1!&B!:(8 M48(H190A6B):(5HCVFA(%U*$E::0E%N7B>+K\V0R/%7WCZG(6)JJV1-C+YDI M*Z5;79"1AU8^H@!1B"A"M$`4(TH0I8@R1$M$*T1K1!L-Z;J)P+*IVT_N3S(. M;.%=6:@%5KJ@@(Q^M`D0AH@C1`E&, M*$&4(LH0+1&M$*T1;20B[:C;NF@B]KPDVG6G;?%XQ%2MCFK5W8A\1L-:W("1[MY(PH;*BMU'B!:,E/N8D>[>.)DDRHK= MIX@R1LK]DA'M1_4-WYX81ZJ5LF+W:T0;B>SR^8`^!40H?&D*7!7QBL=8A\B:IMJ+S7!F@5(HH0+=!7C%8)HA11AKZ6:+5"M$:TT7SIJHDH MNZG:3\XJ,BA7HSRE"+9<8YH\CA$FS)05RSIG1%MRK2MD+3QI-;2J\/IV9&S# M/KM1DSU@I.9MR.AB91%;T;ROFV3;QLZ\8"M58\Q(U9@PNEACRE87:\S82M6X M9*1J7#&Z6.-:6OUP0#?LIJQ,FRSVKR5>2G,]K&>D)5X<([:=*:MZLDA$/XP\ M1FHG]QFIZ1E(1)WB@B%;*5\1(^5KP4CYBM%7PE;*5\I(^GRB&S(]6O9EBD6U:@IH^9:AJ2+,N(1G3.Z./,\MKHXUWVV4G,] M8*3F>LCH8HT16UVL<<%6JL:8D:HQ872QQE1:R=5E#V^-^U3&;E1E2T:JLA6C MBY6M?U;9AMVT+&61MFG.E=]\BF,+/^4:5SOFT$Q63=GJ4I)(V:AI)9VKV>^A ME8\H0!0BBA`M$,6($D0IH@S1$M$*T1K11D/ZHF]+$HG0ZA=?IK(Q2<2HJ9KM MF#E89:5TPR016OF(`D0AH@C1`E&,*$&4(LH0+1&M$*T1;32DZR;R./G@ M96^[;;5&V>";PD^T#HVI*NI3= MUH_B1JPS4U8LR%PB.HQ)I*2_'R*CY[(O&M9XTS:?:VI8C),-^TY<(5%B\ MT,%3]_JW.TJ/^E)E1,VO6V2;S]EGRHH[/)=(["YU00S-V:IZ\HUG79\-&K)7 MWW54;X,?\N-S/LM?7T^=7?%%?+,QFE"47V/^H,1V'^@@2XTSKM"S1U<\/FN[ M,J0KI8)09D17RKW$N/)@4SW4XA9O=$6H*+39I2+UH[,78W M;5V83MQ-6P(-5`.F/K0=H52>JY(V&$92M"Y(OV&5RC=YHID&EZA MY!FUH.U*YKCTW@^6H`M-VA;+[ MKD@,8QE*\E,_VZY0RMX5"6`L0YE[ZD^;.J'CTBMN6"*D86X;F87CTDM8:!\[ M;MS&$\>EE]W0/B&QVNRGCCMMXS/'I1?4T,_<<>G%OQ9.$ZC-WG=<>C\-[0/' MI;?4B/?KU4R?CKUOG_-T>WS>OYTZK_D3;5/5$>-8?7PFSQOR_:]/Q9D^&J-M MF+YJH8\$B./-_1`7U9X?W_P<``/__`P!02P,$%``&``@````A M`#A1F4;5$@``@Y$``!D```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`6<8H/QU0\'E/1__`S7%2')+]1 M.W/[T9V191;OS''P?J8+J.%;/#XS_M7'2[FHGYOC&#Y]=R[C!G?HE\%JO_KZ M9;OYA<08W/U:R=07[B(*T)/=FDIIKBJ8(E5#[%JG`<=]NK\QMZB[Q[8I21*5MQ@%QHO0X MM?:DA:*-HH.BBZ+G"OL)Z+O$.IB!*^PDPY@4L\[OR$UA/\W,JH>3M0C0.BP%6-!#:IV8'0#D1VH&X'&G:@&0?> M'[A?M%Z]6VG&:E#M%&/WJ$Z:L=IN-\T<3\5A8M`[P?33C&]VKL$)9IAFK`XX M.L&,T\RUN3^3$\PTS5CG:W:"F9]@%FG&ZBC+$TRYG()NK1-?KJ0AZXR).P>' M0C*&Z^T1&94J+@",2LVO4*F-"K4#U3CPOD)M4K,#H1V([$#=#C3L0#,.Q/<7 MY+RX90?:=J!C![IVH&<'^G9@8`>&=F!D!\9V8&('IG9@9@?F*G"<&?@W5J]9 MI)A;:\JQ/,&4RVG(:C;E2AJR'JV<#`YS7!Z1,2[%M>4'QJ74#^=B'_1,R;=? MO2JQ$7]K8W6H*HH`10U%J(1Z"8M4('/'ZB@:2JBD317(3-I"T4;10=%%T4/1 M1S%`,40Q0C%&,4$Q13%#,4>Q0+%$42XSX9HJYQ:54?'B)M('*EYJ,:=\5\WB MWJ`Y4ZC$1AQ&9L6C"%#47&&_:H>*J.J,5."X9_8V=28-153:I@H4#95!I6RJ0&;*%HHVB@Z*+HH>BCZ*`8HABA&*,8H) MBBF*&8HYB@6*)8IRF4F%236/&$4OWD;]1-'+KC2(-=I5ZIBS8>LTH?S.(WG>2EYQ*J/]ZA8N$]#U02EUZ39 M&<1;`I_I#'(SNS-8;X-4O!BE[\7AG=(JDX!)C4FHB:K@2$HKM([0UPE";E+ MJ^>RD<8KI")5;G&B8CK*+SBS,\B5*_;R2UY)(M?^.IW!NLM=25!RY\Y/.>:J M20[B^'YELOXR?J@D2TJ26I(DIP.%FJ@"CG0DLX#K3!J:J+Q-'Y(Q78A)>IF834&N;[&;PI78,'_QBKA2R2$C<%9*K!*M,EIQ&M`6L$]$7V%2-_?'OK7F'V1GD,J1/=(9X]9+8%[U2 MP+^S;N57Y,\!B3E%3ME7F01,:DQ"350%1SIR/`3['44F#4U4WJ:.9.9M,6DS MZ3#I,NDQZ3,9,!DR&3$9,YDPF3*9,9DS620D[@Q7A?0K"2P3T1G8G%!NXD=- M\O*8C4&4K=,8O%OYPZTT:Y!;6C<9[JSECQ7YHX'4&Y`$G*66D/@,W,L38,ZT MP@3(>R^ZEUU;K2SB!ZH;#W3G/E#CE`=J\@.UF+29=)ATF?28])D,F`R9C)B, MF4R83)G,F,R9+)@LF8CF@84DIA5LJKG&;!YR*9,]JSCA)D2\`LJ<51R7X1\N M)BKRYX*IO6/=.383)Q9!>Y=0V=1>9LZDIFWQ:3-I,.DRZ3' MI,]DP&3(9,1DS&3"9,IDQF3.9,%DR43TA7@@QB^-?OJ[&R>4FYA5Y(UHLS'( M94[O&P/<@(A719D-P:JGBOQ\`&H(2`+.4F,2:J(*-]*1S,*M,VEHHO(V=20S M;XM)FTF'29=)CTF?R8#)D,F(R9C)A,F4R8S)G,F"R9*):`ANF?AWUC)!,55P ME562HB/D&;,CR#50[SO":8N9O7CIE-D9[+5-"1)3&SVSM_:TRB1@4F,2:J(J M.-*1S+VK,VEHHO(V=20S;XM)FTF'29=)CTF?R8#)D,F(R9C)A,F4R8S)G,F" MR9*)Z`QQN<53A:*?^GY$Y81$^?5F-@:Y2.I]8X"I0KRF2MS?T+7NWSF+GG!M M5M5#$C"I,0DU484;ZI(9MX6DS:3#I,NDQZ3/I,!DR&3 M$9,QDPF3*9,9DSF3!9,E$]$0L$S$1(%-?KD9_:!H+X;,[P<';M^%M)W)A31N+3NMAUI"5M,VDPZ3+I,>DSZ3`9,ADQ&3,9,)DRF3&9,YDP63)9, M1&/`I<2B,;!1]99>*&9CD&NBWE\UG'8[H1@OI3)N)]Q;Y5I)4-P8;M*N@:H& M*::N!0],$__\L_F>9"TAZ<=[>!LDU$05<*0CF05<9]+01.5MZDAFWA:3-I,. MDRZ3'I,^DP&3(9,1DS&3"9,IDQF3.9,%DR43T1CREBX>!KAH#&Q4O:47BMD8 M1&U_IC'(S:S+B'MK=4!%?K8PO`/!)&!28Q)JHNHWTI',^JTS:6BB\C9U)#-O MBTF;28=)ETF/29_)@,DP(7N0D/RR<^@*2 M@+/4F(2:J/J-=.1X"/;M1B8-353>IHYDYFTQ:3/I,.DRZ3'I,QDP&3(9)42L MWY6?=UZ\L#_P?,PY)I1CRCEF3.;FP]Q>%*RQL^`<2R:B(V"!B([`IIIKS(X@ M9A.?Z0AR,WNF8"]>DJLGJ2,@"3A+C4FHB:K<2$R8+)D(IH"UHAH M"FRJN<9L"G*)T_MI`KS[$*^(,J<'5H>L%/.63<4_.<4D8%)C$FJBBC;2D)(7X]];B MF6D*LO+,4HB39YZ"K#P+)DLFHBM@/8FNP*:::\RN()_N09KU/.8<$R-'VDJ&*2>9,9DS63!9 M,A%-`6]1W,8Q6WHE03DS M@"J3@$F-2:B)JM](1S+KM\ZDH8G*V]21S+PM)NV$)'/H.[GJRWQV.X8X_,9B M2W3Y87I,^DP&3(9,1DS&3"9,IDQF3.9,%DR63,1O%>.5BB?4FOB=8GEYS*Y@ MKV;,O[GHNZL8K^S/4:\D*+<;X,JK@+/4F(2:J*J-="2S:NM,&IJHO$T=RPES%"1W"7+UX5[/<>?5Q/5642,*DE)'DQO94?/V4.Z5`G484; M&=M8V=;U-9FDW-%%IFSJ2N5&+29M)ATDW(=E/2\\0:4]"GQ]FP&3( M9,1DS&3"9,IDQF3.9,%DR43T`JPBT0O8Y)>:V0OD>J?W]Q!.O&:0FYG7#.+W M>YM%5?%CE#M+0!)PEEI"DL_:ELO9S#T)=0Y5NY&QB7>?UA)PUQI.VJ:.Y+0$ MS-OF+!TF728])OV$9#ZW`P.D/9-#?I01DS&3"9,IDQF3.9,%DR43T1%PM(B. MP*:::\R.(-<[O>\(,#N(ET>)3Z-6M57QG5#5#05NJ.:&0C<4N:&Z&VJXH:8; M:KFAMAOJN*&N&^JYH;X;&KBAH1L:N:&Q&YJXH:D;FKFAN1M:N*&E&Q+CT3FW M8ORY,?.$F^-+O!X8XTN^XLA/_WK\O=MO7NOKYQ^'"'T2H"_SF"]!]B?K51(C M/^Y8W_.^MM[_JAZ1&L&!&ZJYH=`-16ZH[H8:;JCIAEINJ.V&.FZHZX9Z;JCO MA@9N:.B&1FYH[(8F;FCJAF9N:.Z&%FYHZ8;$V(Q'A#C;ZD2*L>G&S!,>C\W+ MW<_U>A^L]JNO7U[7VQ_KZOKE97?VN/G])D>GG%;K\-EV_?WA7%1"25QT7I%HL5=/B0;$4I,5K MQ9+XS>[NSD;%DO@%[VZ\7BR)7^ONQN6.IL4K7BE(V_^:5XK2XG6OU$B+-[U2 M*RW>]DJ=0_Q2/W6[KU]^K7ZL.ZOMC^>WW=G+^KLX5X6+6W'*MW$3B?^QW_P2 MY_#\[-MF+QK,X=N?Z]736OQ>^L*%P-\WF[WZASC@RS^;[5^'\?#U?P(```#_ M_P,`4$L#!!0`!@`(````(0".*J,GX@8``&HB```9````>&PO=V]R:W-H965T M??WIZR_*OQ3%)2@LB7(J- M?2S+Z^-L5FR/R3DNG.R:7&#//LO/<0EO\\.LN.9)O*L..I]FGNLN9NUK&K-[WPYW2;9T6V+QT(-T.B_36O M9^L91'I^VJ6P`BV[E2?[C?U1/4;!RIX]/U4"_9LF;T7G?ZLX9F^_YNGN]_22 M@-J0)YV!ERS[JJ%?=OHC.'C6._ISE8$_[.@](!X<8UU(:M'B%S+@XMI!'M/+Q!*!_FHHVQLZ!F0HH`D M?WL.W.!I]@T2LR5,V,>*\?<2R)<^8@$+CF6@PE$OGQ/Y"G#I$#%120ZX]V+!M MS^O.N2PA8DS<3`C)T==-5YD,KFS.I#^+Z!>Y"<$3,HBHY;^XIW^>`"`&P M;1?:(!C%!:=HIJ;!DMJRB8MUAYAY1 MH.38JT*#Y?A5=\R7CA23`,,+X2PGN8/"6<_9B9D1$HC8*7?MS.54)L@8?GJ` M3U<1QS[G*4B$0%#7;:UBX"Q[,B)B#$T]RZ?31`>`;3M>E?019;()*DH3A*<; MUM+E:1X[^DJOU]G20PC$1%)BFD>#H':X24)!#3DH_YJ(:LA#-R:L)=1DHX8#->;T::O(0D)`A1=%8+M69_ MS9(X:6$^-VISP'6\WJ`TN0J1'8!X[4AC#+V[K*/ M(0F8.TCJH^0EFYSH^C8"@(9)4*I-$%Z/PGENI!J=@HGHB4R&GLE.B!]!.N-R MX7;^VNKA9"?9CS=D/\*E0P(9Q<0XP?/=FJ&\R&N)' MD':&SMWN8&I'!B<+:YY`5J-%TCTY0WT$&<4D2#U#_;$SU)_D3Q6:T_47O5ZZ M[4\49WA%7,Y)EN2CE4#F.C-3^CN!AD].N2=+ZL9IQBKG=Y<'^0,>U+N32B"Z MP>7Z\[;BB.5H!_*%`]WH('0,UD%NKRAK6]'/%L27SJ@ZWWN74$R_0'B.F5F% MYO4'-TR;S%2RA`2J[Z@NY!>CB`##!<#937*:8,!I7)&TD$!X4_5A*;X+1\WN M3@4WZ^/<[G*98.B;3D]!!*&":K60+1Y1E#$*:B/HS.YQUSX!V@?K8U](%1)H MF`1VB!'"U=33?CI/]`C6*;UKGP!!Y-EJX:Q$342$&%X)IPF8+LT;[:+1LEW: MBVEJ%P2MQ7I\`S^UZRE;Q^)%!=B\KI#Z#;IH*/ M]O&A]3G)#TF4G$Z%M]6-[#PJI^;3Y2<%'3S__%9^'\%.#ZKG\K-D!3_JO M\2'Y(\X/Z:6P3LD>0KK.$F3+\;<"^*;,KM6C\I>LA&?\U;]'^$U'`L^770?` M^RPKZS?ZZ77S*Y'G_P$``/__`P!02P,$%``&``@````A`%L\@T++!0``^AP` M`!D```!X;"]W;W)K&ULG%E=;^HX$'U?:?]#E'<( ML1TH"+AJM^WNE7:EU6H_GM-@("J)49*6WG^_8X^;Q`XD3GF@0(_GS!R/3YQX M_>TC.WGOO"A3D6_\<#KS/9XG8I?FAXW_S]_/DSO?*ZLXW\4GD?.-_X.7_K?M MSS^M+Z)X+8^<5QY$R,N-?ZRJ\RH(RN3(L[B"Q[O MU*#L%)#9;!YD<9K[&&%5N,00^WV:\$>1O&4\KS!(P4]Q!?F7Q_1)70[SOY$PP..J.?U0S\67@[OH_?3M5?XO(;3P_' M"J8[@HID8:O=CT=>)J`HA)F22$9*Q`D2@'/3^31: MS&@(<.^%E]5S*D/Z7O)65B+[#T&A#H5!B`X"?W400J>,1(L[AR@!9J0*?(RK M>+LNQ,6#K@'.\AS+'@Q7$/EZ15"*Q-Y+\,:'KH9D2YB&]RVC;!V\@W2)QCP@ M!MYK3%@C`B"MF8'-G5F");/45J;R@#^T:KQ_+N4@P+6CTT4='S-`3*1F MNLG.X)Z;W/V<$FQSWEF-4`@WAA$KL5+0?9"2SK^%@T8J([E<%L M>J-[I;6WUHVD9R!7?_URD$7/FO*0'C%SQ4Y[ZE]^)0$YR&H[UA2("2`&:AEJ MNQ!ZS-9@N._4*%,$LFB6%.:@0:@"H>'M-@BEWU@3X9"$'&4GT72X3@)!.HE9 M=+,5PU%6IM`F=TCM+M`@Y)Z$X?PV^2B#"]'0VLN>+.PEJ$&?ZB^7M\DMTW-; MA2$Z6SL)QAK[UNH[VY^\$K=;H'\-*K2]!JCE`1KDL@A&&6!XQ0%9YPJ*(!?Y MOV2"X1479)T5J&W0P08L*QR0'_T-)K>Q%]:1'T$N\ELV.$".WF8V7D?^3P.4 M^YMF71H7'_(EZU.CS)7/F.TZ&N10.[&LK[]VA1[J>PUR(1_E>02W:_W":Q!N M-VX)#R'::]W-<(@<90MO;W8TR*5VR_4&A$S+SHJ],9W4T]'W%V.S+*[13:DC]J M6ANO=!J$\H=+=GNC02RW77((>YIZ,\ M3Z&'Y-<@!_FIY7EN\JM1=A+V;D>#7!2P'+"_^RDZ7W_W:Y`+N;2IUFY[@!Q- M#5)HKO6=[J<(ZG5]"JFU:1V%EZ-LX>VMA@KMUO>6]PW4CIXW(#R"7(0?Y7D4 M[6Q`>`3AG7;C2<8^AXYR.X4V!:=S>V.I02XU6VXW(#BZG"%XYY$*19`#.1OE M<@IM5LZ(O;/3(/UD`1X7AZT[+T-V-LKE%-HFMWC1SJW=AIDS$)TBWZ4W3&TNW;CTWD3&:^W&F30U_=_9NW2FYSM MCJ&3]7>@!KF0`V8$N43;3=#I0`35'1@RVOBA6?DHLV/H8VW9&>ETH#8[?+!& MIK.E^7J:W,IEE/>QKO==Z4`$&;,0-4YE2C'*`QG>NK:EH//./"#(H+_1@:,\ MD+EXH`8YD$>C/%"AASI0@^JGJ\LPNC'KT2@/5&B;W.Y`#:K;/R)/DV8C9DPZ MG":-6'P*;;)W>TZ##-VCIC.0'H^@$0FX\6!_$/I])+Q)L\7@KAJ7#]:WWT M=4_5X57]#SAY.L<'_D=<'-*\]$Y\#T-GTP4P%WAVA5\J<5;G/R^B@C,G]?$( M9XPX4Y"U.E10YC=D6:EU6HOSS0A"9H0(J"G9_Y^JRC;L8N^D)=.QSY5 MG"J7ZQCG_M./YF1]K[J^;L\;VUNXME6=RW97GP\;^Y^_/]^M;*L?BO.N.+7G M:F/_K'K[T\.OO]R_M-VW_EA5@P4>SOW&/@[#9>TX?7FLFJ)?M)?J##/[MFN* M`;YV!Z>_=%6Q&XV:D^.[;NPT17VVR<.ZF^.CW>_KLMJVY7-3G0=RTE6G8@#^ M_;&^]-);4\YQUQ3=M^?+7=DV%W#Q5)_JX>?HU+::?:W/%60;U@E7X*EMOR'TRPZ'P-B96'\>5^#/SMI5 M^^+Y-/S5OOQ>U8?C`,L=0408V'KWP*VGJA\^U^C2MLKG?FB;_PCD"5?DQ!=.X%,X\9<+ M?Q5Y48Q>WK$,A"5\"LO5/,-0&,*G?&2\"/UHN1J)O_-((#1&#)^S'NE0QL8% MV!9#\7#?M2\65#7DI+\4N$>\-3C#S`>P?J]G'E*.-H]H-)H"NH=R^?[@K^Z= M[[#"I8"D!($->H68B$PB<#G1ZU8.7$T"U[3))02+"0)04<":W1X%&K$H$O-Y M*4%68YT@QXP/;/E`K@T8%*$X=(KO)QC!&QO*0F4O\!@U@L"2*4AH(C*)4`F6 M`V^:Y!+!\PM,YI-',%21QBSP36HI09*Q='"3CRAIIK!@;QY!;B"&;$ MEXPX08BXOPQ87\]H6N.MXP,W9M65:WB#M@*1;T*14LPY8HE*!@9Z@,),`R(T>@!QYTRA7 M?OF&]5"IYH=`NJ9W]9"I3WUAL62)R/7+(90;!\I0(# M!7%MFJR'9PIS702II6];Y;J5N1*H:%HP[Y\4/-(_V&Y7@A/ADAJI87CKE)!K M#'+D3:-1C^B25>CE%[)'IZ%D*6,(V>R9F\4R@%C-B0K(U7/`C2/Z!"S/, MF_39G^ISQ'5"8(1.Q$'BLV:<"836;$V;*/%@3D6!KYB3=1#-W(#`%U4MOL\SJ73^IJE!HKIE1@:*?< M\3+*Q/0'M4;/><-'_H$/,U#4U-L#)24V`N4Z@W=GL*Y$+3`#T4B.W9!*X+C^)Y;J)F7_4UMOS M3XILY)_)7^H31MRUO/):)`!Z&(;)*Z]%NHD9!E/Z]\71)QV&-Q2Y^NET*)L. M;:=#N3%D]*?6/-/!0;?6ZX*P>0^NX)DU-OI M$%ZWX^/`E:ITNCZGV]NFZ@Y55IU.O56VSW@U'L(-B1JE:_O46\.%)=BS\2U> MY[\R_NBO8&*\[606$)G\!"S@DI(E"JD+5;=(F3=,NSPZ88!4PLIVF_?8[ MQH3$SJ5-^Y`&_/?Q[UQR?!9W+W7E/!,N*&MB%WF!ZY`F8SEMUK'[Y_?CS:WK M"(F;'%>L(;'[2H1[M_S\:;%E_$F4A$@'+#0B=DLIV[GOBZPD-18>:TD#*P7C M-9;PR->^:#G!>;>IKOQ1$$1^C6GC:@MS_AX;K"AH1AY8MJE)([413BHL@5^4 MM!4[:W7V'G,UYD^;]B9C=0LF5K2B\K4SZCIU-O^V;AC'JPK\?D%CG.UL=P]' MYFN:<298(3TPYVO08Y]G_LP'2\M%3L$#%7:'DR)V[]$\1:'K+Q==@/Y2LA4' MWQU1LNT73O/OM"$0;1- MID&(0.ZLB)"/5)ETG6PC)*O_:1'J36DCH]Y("/1Z?80\-`ZBMVWXFJ=S[P%+ MO%QPMG6@9N!$T6)5@6@.=G=^:8K!TW..@H?*R+VR$KM0[."#@.P\+R>SA?\, M`3L&-38L6FDJ)@$_WBD&0T'-,I MTF-%>(8$0O9^$B6.W?%!",:WYLF)ED!)#%$:FXKTDL(($IQSB*8R&T+=7PZ6 MV@2Z@_,C*TV)EL"/3:4Y\`)K/3V_;N"!C]?CJ4T6GI6[1$NBC@X%^L\*X46) M`1E]!%)MLB!#DR#1DHD.H;F6GEXSL*8?P5*;+"RKMA(M.8UU>LW`4I>=U4O> MKCBUR<*:F!%)M.1\Q9U?-_!F'\%3FRR\R,+3DK[BIJ=+[K+&P$3P([T^C-TN M"W1J@?8:33H;AR'RLFIFK75V<;Z29O-!B[!_::`1/-@CV# M;M"&!#!'T7C?ADS,J^X*I#N_@7=TD6G-+M^3([:SZR:8:N0'\;OE#YRV$FO`U24E5"2=C&S7@(&A:P]MA M^+H?=>/3L`"S3XO7Y`?F:]H(IR(%;`V\*1S,]?2D'R1KNQEDQ21,/=W7$J9< M`O=TX(&X8$SN'M1\-LS-R_\```#__P,`4$L#!!0`!@`(````(0"OJ3(P+C4` M`)"S```4````>&POMN(T>6Y[\OL.^0*%2C M5(`DBU+=W+9K($LJ5TW7S9)L3\.8#Q29*K%-D6HF62HU]D,_Q'P98!?P$^Q# M^%'Z2?;W/R(_/)?/EV.LX_YK!A-)U_= MZVWOW,ORR6`Z'$T^?'7ON],76\_N9<6\/QGVQ]-)_M6]F[RX]R_/_^?_^+(H MYAGO3HJO[EW,YU>__^RS8G"17_:+[>E5/N')^71VV9_SS]F'SXJK6=X?%A=Y M/K\(RG\PSYI$=3>:C^4WV:N(#,.\O/YL___(S-?7F>]F;Z61^4=!T MF`^;3]_T9]O97F\SV]WI/6H^7#-2]N/^63&?]0?S?V^^^:#Y0YCG8 M_=O^9=YL]>#PZ/7!_NG+[.2/)Z=';TXVLU=O#[:;K4)?!]!@UA^S]F'^*?M# M?M-L]V"'_WOV=/?SWF[ST<%B-N/U[,6H&-#%'_/^3/3)#OOS]J2VMGJ[6WN] M9A]A&C_DX_'63Y/I]20[R?L%?#',7A7%(I\U7WCP=MK\*?3Q_72\F,S[LQLF M-(;]EC2+LS[.KZ:S.4R9GXM[.UK?-^>XC9$,3M!?C?FLU#\[[ MXZ+543E*F-TRGCJ8PK23`@KS5S$=CX9&[J_[X_YDD$-,=$.1;7PWZ2^&(S;B M(7^?'&;W'S8G^6J2G5Y,%P6ZH-A$9XSSHLBF\XM\=CTJ\JRXR@>C\U%;[@_S M02GW>\U.(Y_UBX)IM)[VBPO3/0/]D?]Y,?K8'^>3=L/]@2FT(IOE@YQ&9TQN M,YOD\V:/KR8?>7\Z&RUY_GZ67_5'PRS_A#(MX#)I/EMD-@B"W#W5T^D-0_&XU'ALX^UTGF>]W18'/_CEYU]^;J[1E,K%=#Q$&3XP'INWE@E7 MG.>H\2$FV530_>V=7G:%)H5XO+YO1TY:0^WWRTM[?Y M=&?/QGJVN??Y(_[WM&.F:MG;_'SG:=ER=_/)HUYL.;W[0C:14^F+^>AC/FY1 M^\=>R\CO#]%-(`Y$3.*Y-9ID@_[5")%K;B75++]`G;#:;`3(:Z,1YWB;SQI6 M;,F&;0'(G)0`Y;H+BMK!A]FN?Y)-OH_;[WY"&[(D2*+A>7H]'1 M*EE^?LY;,"T&>/]J-AIGSQS"M<#2K[`T[['D(,9\/@(;+;4\O=V5P+(EG:5@ M9ALPRG`Z'O=G18;J=99MZ856!RT9MH[\UUN_'61=4[CCFZE$K7A=6I!-"5Q\ MUT77W[[3BCM?7;_R_WH*8KHSTLH_#?*KN:/>#/#6OPOX2IVNEOTX/OK^ MZ.UW1R?-E8)3AHO!W-3!9-&&%6[,I2RZGKJ&6O;TX-W)Z4GV[D5VLO^Z/?(! M>AA0>9Y]F$Z'109<;;F1W\Q$Q:O9]+RMV=^]/SK>/WWU]IOLZ-_>'[T]:0]P M@@L%4MC,``OLU-BT9W]X.9J8LRB#U*3&<5[@LV&-=-V-:)+5]-YCEF>+[$)/DF+UO$VWR>C=F(YL1?OSLYR=B%C)F_>?GAX=9OO?L_O? M'-6&;O%V>^SK?/3A0I/H8_SZT#.=`\R8P)L5RMAWC%6_/SYZ">N]^OZHW#\1 MI;5Y+Z8S!@;'F%LQN,D4JR@`+BB/K#_\TZ)P@-LD7EVE=.U!AZ&O:S83[-_< MSO]=BK`.!-IK[O1A_YX1EP>4;J7G#^20OAA/KV^ET*WUN;5.!1\E041K]-%\ MM]\W%[U?\4`VG[)G>#D#8C9R:UU@^%5_FW.\D(>/)JCTSXJN3PS?3:^,UV!W M^;K.>$'>FW-!!\YG(X.!C@UO\])ACNT;C%9VW/(P4U5624%S/J9#D9/K&2&+ MK2$1,;>WPU%Q-2U0ZVC!TK-NOJS(D]%LM%H#NGHM1%7WP$UE)6YI:\OPV.1; MF.;ROQ[J;2]](!PC!`C>-@\'*"$$Y M)!VXNW-+'U\&9"WC-J?;E".MK#!CNX+9WR\PWMH4>`+8D$9@-FV-RQFE.<>S M&[:S/>2Z:9Z/)L3:A`E63%,$87J#/`?XF):`CVW2+G%"'_FG?#90L(VE^*\N MP\[\P>RW;')):KK_.!JB)UA'UYR:ZVB9*/<%L8EROXN+9GL-%#E/?&_[JWG; M'RO"=[:O70U;$O8U4?W)1*34;EI.*YN3^B;`S>5FY_1"2`Y(-KI4I+8K9OO"^8B9URW?83X>].<7 MV__I]L.LMPM#-^%(+H3V[X\6%&%,!^GE_, M\CS#G53ZAF`T3-(1D2)8OH$V;;^8.NJ/:XMY$;Y%5\` MNJD>/]O,KB]&`'FT`=,G['&..1U64S[)`6-FC+.C3^@,@6N(=8EKJZ6)H"=' M!S:<,RM:>5Q,18ISDF<6(FDNY#H_*[!1V<;U]?7VT#=J&^OY<)M=TK*1Y@GQ MRL*W(9]=%MJC1<$PF_KK.N,UFQ&.$QM1T;Q8,/)P MU%>LNQ6K>0=%\[/90HF@W4<>T-GT.$4(0$F&DL5D_2NICWRXR:^SZ>(#4I.V MSSZR".G3C&1;2&8PPZ2'O_U5^ZJ'T%PS%JBP.-T!07%2!_"P:3:X=SHC[12@ M<`BD2N;5V]?3_LP$_'`$NB"4#^6F(4K%E+I"6*RD%`3F`/7+N(E"K[RDH8P/ M8$7]4SO/6S$P8!Z"@F3/'FJP^',=56^3'I%,M$-H9_D`HH0Y*@@(,]5":9J% ML^9\1,.EDSW+/T!@'(6A:4`7F[?[)X?[WWIRK.);AJCB?/6)>F!OR]$5>W&& M.U9L9_MC8-,U7K$YX(*;T!E)"7PPP-4PHF@3PIB7_=E/Z/S6OVIKZMK`/Q#UDE"0_-[?(0M2#^4[<6**1XV(&+-];JE1#:HQ4);.`_2LW??@RBF:SRX^:4*`P[P8S$;N8NV/*<*X8GPT36VR01 M5AE,Q],/-]NDSMD2H#"FP4H!^%L!O[_]]3_>Y&/Z)CN9O;P9@D8OQB2QAK)O M,^S5GX)\Z%_T6EG.R#TO<728DK@)RF%;'))D&TF_ARB?X50N9Q8O\:82`HBR]981,\VMC``Q/BXL5-2/+F_ MI;X([,!Y+E4'3IL'"B,"0D97D,WHA#:(`C67."NL*^&@&:KN)M!YWA>#,(K- M!7!+'GW6-+$SU<^\')YG/6Z/+@D-OI1K[VL,S M()^II.%L@?L``X?]#5OF'@POSO(/(>N%RNYGUCRHHMKP`"E*&=31H7K<3T*? MJ)*-%X?[()/393,4<@*MN*!$1&#,8-%5NN&1T2RQ3K+2Z4&-(N%1*7*Z#8Y\^#ET9MW)_NG M+G;LDO[_/?^!7>?[8T7DR.E^=:]8H+-<8.]]1H'37_SGI]N/]4\)D@UU26E6 M3[_,7L"+WN:@/QZ=S4;Z];Q_.1K?^,^[UH]X.O\)<*2^9)KLXU(1\>QCF9P#W8138S? MV1R#H>T)X,UY6')^?C[Z!'\>',F_^,E81_+@_I%Q^NGU-(N]!\G8_N5G!U>* MU)JZL&[T(AV)&0#B%EZSGX+J8SCG$V.J@LB_B5ZC;YD29\^:&_J)L6K]*ERM`S#/,+IG;8H'W(XBYF8T(D,'R MTD:`3_*\J+&0%&%E4LR&R.%I23:*\TU_@@XUC7B&K/*R7!9[%[7ER7BT4(&( MFPE'^2*$?UX8H8!?2&<,3J+C>-6="-'P?#0C#8'9`7&?JSSP\69VMIBS;=7B M;*AD7=?3V4]::ASYLG\C/VRF*(.(Q^;+.HS(4"7#0CPW(Z`MZ?:DP]@1VD4: MKO^Q/QJK9@90AJ$@MD*E'>;!'8%K<[(-E?1A8\4%L%+]H7L7'HB)M@I;8/"D MQ.IG`5M(;MZAQVR$\FED-J58)-?Y'-\\'%Q(#*%Q1[ M:)M\-G2!3#E@F4D1T!8RHK)B;<4'_-/9Q%@TF$/`/*W&(ZJ%V***Z%!TLC@' M/^/O3SY\$?2$B0YL:APO#`'1J2FBOL<-+V%RL";"R![_E(/"6+VAWW!F]G&-_O[[Q_Z M'&+HQX(D_ZEWR1J`*[4+XK`7(8;SK37?Q^D?(%^]'?5W[/A%WM?)UK^9DE.P MU2)$-H,P/:.J!`N^\%!-!(&^[FCOM6-JEFHR(_66>$;(N.Q032WYY@YB@2:* MO@"*#BL-$YK'(7#F!91,L[7GTN.^`R[0DOP0SPO!5@387`MQJ!";J2J!F5*S MFLGZ"H7A8R-8 M034W.7I60&1DK5(SR+_H0OIZX'FLFI*XFF507.M9`1CQ=CZ$77(;G%<)LQ@,U(0'TX@?EJ(RW4'%)MC*'. MXBY(G%55("E>&M[\(KN87KME#,J/]YDMU(]#G$^G M>Q6\HK0M`3I)0,>^9[O$/N\1.=5U-M7G/L:DYE&+VJFXIPHM]&&HSKQ\K(GG M0N#YM]K,O>QD<0E>O!&CK9F*=L#I'A4"#+4VQMWBAA8%CI&/R1RZ[P])[-!G M2H;9=$+TA)"VM$>3&*\F(5ZO$+V[F"_V3[Z.X:W]D^^$J_:V=H!6#C"0!OA, MZL55J7G86&S+7X8:2NW[DK($296GGV%XX1V#28J_BDNU;TQ3YT4V9)(F\X?9 M0#V;'0BH)BIN-:XTI+$E^HX!T!!E$)MMF64?P(Q7VI^0CW7\R1J`BQY-J8*X M,)W55_@TA(1$S)DBIV,JL+5]:U=)=*K*=1AE)-;U=4\GDA,7#G."I754RG&. M,QJE)2A6F9YQ#K/11BN3-`/KZ*!\,N8HCDKT@_[5-.LK$5U"K)AGJ^FC4"%3 M4,X/WQNPSSP55JBB)EUTES*CP(`8.,&8?.PFA7X^DGE4!31J5B'XLV946V*> MR+=R+#%9US^70U\F9`3PQ8X-7R8P_?P";?=!5!#67$\>K3B_E+8*AE0< M[ALOIQ:&;:5!58A$?;D?QFB5%N%9X^=1L]W4$N4&=#P[[E]C[=W/:*F7^\V> M?L#]H@I["S4JD]Y\C"X<<>ILZ'5\S:=>*2=/6DM9OUJL)$,%X^8I(^FAQV2+7>ZH9H2*, M"YPYS]NV[I7KV'G_4T:>@5KX]*1+DWY_T&,)XX!21XL)$ZNM-R(",7]N)/7? M%03[YXF#A1-5C3")';"!@K^FE,;66W4;U_K?%UUS=@[R;MCV(XE:!-I=B-N< M0/+HNS)!@#2PC/+EN+F7T;$QLPH77&((41;8^<>_B\PZ-V*>A3-@!'%*E6&G M,PW/IA,TWM"9)QB$@@_BH>:ZEPW?[ZZ]4JQC,/8T2D? M1@Z4E>+>7A9?"X0HP]V2P1<+\DW$`QJ2,G^^=#%'\NYPE?&V2,<,*;_!'6/U MQ?1\KG\T%__U8C06_'"7#FJUBD$`/^M%4MJ"8Y\()\A(J[YN@;CS9W MGCQI_MJR'1M[FY_O/6XVZRKE*V.W=Z@=N2:^2=IP-R,L/H[^%#_LQ1\:Z<3F M/%BLE:-%T[#N^0J.BEV5BO[6QE>`(Q9,;BI-316+A`WMW-;[(W1K M)"LC^$4^LTRVAVU,LY:%6VF0I27(;%1PSD.`Y:",VX%(&P>?I;`!TV?$LK-; M'`ZQ:1P3L.HZ$1+C\8S7-?*)R@H\]@?`K^+R+9^"_BUN:L%I2GH$PEYE%LKPE]JAW0H4&N0VA;K7XBX=UJ( ML-X!LS:>*`>=M.]4.-%IDE@U*K3_=,W5M[[WLU5J]-7DRJ(Q981B4JT MAR*>5KEC(4)T4_\#1=5FE0T''9!8\"1%X*/-[/7K`QO7'MG(:`VK5`@UBLBB MZ<.D9)4RN'CQ0.;W$*"3K3E)$1TKM!I2:1]+]$=>93ZL+EQP(`A"-@05$)4J M<3$SRQ^8LQ4W>!*4QWXB04IA[_/M9U$K*.L[9&`/1?K2/&>MJD1@OK]O95?; M63`])GUK*LWWZC0EX48B[XIYE"IP9_OS.(M0/BB5U213F)^A#RT\+E3J)5U5 MO>_[NTGO$;_"'(:YRM<\G!FU;REDS*+=6T(Q*4I*,!0P.R<94D5]R3^B*\(, MS4:)-$QQ,2_2"J"O^D`7$;!9^IJM>M%VI>BW;PM.^;4VRM#`(G.X3 M:,.%.IN3+[KNYO0V*R?"8J8VG?I_'UL_IHXU,E0G6PN-K^'JU<<.DG7;F>8& MFW#[5QP_V=??B*$?5YW__?S\J%(`=Q+J1S4]Z3*-*JS*E/ZA)'A4@9G?@@0E M,G*7)TBB"68H3[]:S(I%R-2B=ZL4!KHUG#,WB0W^@/#1"]5&G&SM91M[>WM; M/>X2V]L)E9B8W$IC1==PH5R,A#I4<@"$_F3!7Z3:$F?4ZZDFY#]B+O)+/L:(5F-:*=3`XJ!,]#2^6$6=.BUK&/U95F8XD M;FVY5(`>AB4&.,]4 M#=F!@_M[B5;0WL6JF50ANTO>YWC0EIT+HS!K=KE-:EQ9.?W',FWU!HPN1_44K!W^,+* MNP(6N8SSE%Y1A%>JA@OA11W8J<3L_MZO!P_NBB@"D]36B>N;DK/]-(HN!U,$ M7W5<(\ZBO@^42DQU2A"/`*L::N(P@[4SNO=WD]B!W"!662.=!]K4)_E'BJI41ZF.^Y"5`[%*>C MN,\&WLTN!LY@DMW1FW2BX0Q;F)]%.@B30X#'3Q3Y=:[T('R=ZH_\KKIR"

I(;@L;;F& MF#@TTK49PDFEBKB-+MCM;9=6_*Y&]M;*(#'DOY$VV$L08JD-$B(MT095BXI* M_Y3:H)KH';1!DG&M]%B'$D@[#TH`D);_,VN!NJ*C&%*7!+-YW*5L%>NO0,T4&K@1:4PNN=I M8MCR-EJ!`W%Q_'^44GA20>O?2"?TJAZ%P!PA8)6CXHPV,/DIYF39554VZ^Q. M41K?V59.:675<73 M0L8R]-'2`;M8MU?W.>%8>U8NN3F7H'I"J'&66^D+M_N:2PK"`<'<7&!35Y06G9#$4Y_=B/\0[J6H`VE#PH%^9P<`T?]-*2R,1;O8H(NLP4NH;X;T(Z,06@1E;0606;NL_7RC2I)H1 M7E3:77X-V!W]83.@OEA;Q\_10P^77(44&YJD2/HHY,"#M<`:6]I!C,Y;F;4K12CC7VVX^]-XC4J4.:/P9"-W\^USZGA";'!9D^O1^=:X3B\T'&SWNZ-YI]?QT>^_) M\G&/C/]:?3465\\V-0=F1B97Z]E+'"]#5\="J-0I)XJY#5T@I1*=D#KK"`MT M%`DF0(.T='E]N-3S&"4DL2(OEHA')>4\**LP6LKIM)98<^53O8J&LZYO(URN M\9<%)DP_!MUF:K)40MUC"%'HNQ,Y8=YA/1VX!VJOZ2@@1TM7<$6'.7FZ%-)T MM%2@?KF<93;EULB2FL MZ2?$/DZU@XJZ-U][]F2[]^1W!+_^(^//Q[W?-1N4JB!>W[J\KV-.-F^=X[Y@ M)M#`TO0J1&K!'9S0,&0/R6J-6,YZ;+H#DV,:NZ4^WG*K18TDMFE&8_;SC.,S M)'%LVX(YLPS'1'4+5J^![;*T<]D)F]SI*`RGF/T)=D3B1/9=AI/C\/$]E>_8 M,.00*.?(#;:ZA=S.OH^4YX2=.T:AY$JVT?A'+)+:6T)Z^H#&H,_WB^++5FQ% MR5@W@0.SVLW)M6Z_VSY!9+AIA0,2-\XV9LF<\3FI&8L9-0=?'.\;V4,0KB[N M00H<7LAN!H&,;!;D0-;7QK&&H<0GD<%"5ZT.V8WR0H+="&:9JQUEPHIR;1:3 M84B,L&HN$[I`9AU9OPJ*H$LM-$8+3CT%G:044NW*[`31B17Y4E8*43KZ/A[-NR'1:F*%8A+)! M_EVQFP;S$_E>Z!*.P:';6;W.+ADM?`8M+7],([A6F,^9YC?'3LD()V:%(GYJ MJJPU<*K93_/U4N,%\),9LK`/2I&\I+KW>WV4I/D6^G=+;.+[L1;+?&]-FYUL M]#:?[+;PQ\;3UC>0ZJ/]\X$+?-;&$80EY84!74`UA!/)J?.0*1!_MAQ?5'O" M;3%2==U'>)S!6YUY?NK> M1*C=P[,)I7;!S<(Z+2EEYGP?J2S=2%(5-=<17Y6JH5K-+M&2GHII'0UPM2", M,.`OKT0S*Z78O85,7.%:Q"1H^M0$@2&KDB?V!<_6/?%0?\'ZT."-V_R45DI2 M44$[ZP,^I0>K*99]-1#62C`5]:0!*ZRZ%G.%]Z!R+WQB]ZQ-[,?F_PF)E"N3"V=B;M&$33QCMJI4S*FU]`LY5)'HIBG%'8G# MZ\HZI45U#GHP!L#8=[ZTK-H!#3.9>)=^=!\V4\T"*R'T(*Q:\FHU"]MSM4^O M)I'I>=;C/,%^61X4@T.WG&\Z6)PA7_LISW(G:U!J%&YY#>@:X78AS'H%;L'-F26V3XS*[47;_`S4I`$WM:&>WY&O!(Z.^[5J% MN$@BHFRRL4V,:?E0@9/LQLYRW*3;N#+=V2!DHIN9B+#Y5K!.HRTECHI'*C[" M_[A9,S#K[SDPRE4:,N*1/6-=2(!9T9NJ M1,/715L1PIXH42]?FN/YB`YL:_5 MQ384*%*I44 MM,^RN4OH:[`OU7X)(KJR2TU=E4QP`,P>&1`,CD<89\W&>N'NN0*#CDU<'GHK MY0'FXMHP)MK/_KS`FH00FXQ+WT"Q[-)EJ*T.C+?5BT5M2_;$^_/A=RNFUY>\ M=)]95VWH*!J$M( M4%>SNB'>AZUKZ?!N&+*?7=Q<*:[./5$@C=[.[]A__ZZ!&$%$#^Q5ZBL5+T9P MX(EQM&!P$VA>QZ%&65>4LO4F;TXC)SE3T!@)7>*J;BA?U!WHYJO$.5F@.#W+ M6KLSS^VQ@(!Y0Y5B],02X3[E#\XJ-8J[13[!8\?4-\0*^TXBRG4'>=27?-C"4K MICK8'$3%-B8A0P0O)9)3G`2(R`0"BZA0%56%EB[U:JJU^(P+%ZK9%U?T"51< M:!)-4FW.YW"B48 M7!NA;P5V$UJG[FGVG4'!]":L[R8)LGGE#LY&H&8K^AG4PG*/].OR=J!PN$P" M!U^N#4WXJ?E!^?$S-&IO]'JMGTM=1IK=Z'LG MK^.7RY!1^:2=Z:JE#51`RM[>;"_AY84H^ M)OAB5#_.IQJ?\L`UC<.%A:Y#K6=!4C^-P>$($,:$>GN6",I`U_I-7&6[N&[# M$63\@R]KF9Q>2?K,/PO/QR6<8` M@I,3.WIG4&J7Q.Z%_L)^=P+#`!3\?D[:F_?/,&.#+A;?=]2Z-9]N!=M1W:49 M9UQR5%*2YU%TB,H^U1?&]F.K@O-_` MC0<0#85JD9K]]/--+A/AL>4X^XGKA6:;7MNYB%JH3)>%^MVVXG;!>2E&7'?. M3(F#<5@="7,-8+@=/HX@J(@ZQ\$FW*R4M'"\7+H0%&L-V-$K6@QH[_$-J\X9 MCWZ2RVZJ:D*DQ;BX$!&DK11L0U2DI<-L._O405*]?&:Q(DN.N4<7IZ[S4VH@ MO13J)70X8S%)?M#2R]LFT&&B340MW+F7SUOB=(I"BR.@`I([O_%=M01U24]2 M?$K)FNL3:\+BO6161F7ZQ9+G?NT%"O=/R%+!+;&B0?!/XUAQ->8F];DD25H] M``Y+_;Y2&EY:6X?U=5/["7$S(N,ZN6A/U*F4NG;;/R7@5Y&+UM#%YF1!Y&:X MOUJ8[JY/"&#L^98CRW_D`*)G+ZQ[#PFF=S\G9`IA.CCI)ZG:4Y!K;2K5CY;S0--H"OB`T&1"V+CEKSUUD<(+Q,*A)YC2 M0Y%"#>PAV=!/?'4B7$NB$+RX\ISKZV?]L0H7E2?5$#RR"U+5(\E3Z!T_$Q"E MK0Y#""7/9C>\A74:NBM=97B#V:%ZDIR.13XU$%#.(+T=.G7I,X)Y6"-<+!JF M9G/RV36VFX'CIPET:-XN;V$)'4@IVX@5=0H3*1_<_Q3"L.)S_]Q=/P("&5>T M@[%]F*VDMYJL<9;P@67F*XMI`&&*DAG,$QW5!FZ!1\)W`DS1P22(.-]G*6^@ MB5HO<*QM6)QA\/\T7O<$6Z*.Z)''=^=;FTS^3B$ZZKH[;E!>V7BEN:C>M&U; M.4HB?(Z\E!"TVX;]"I8Q(/`#0AYR@\P6B>4;QD[U]\H>OGK%-PUUM6&/3(W: MOO=#:FKKB@NU]NV"IOD,#CDV!%F>JN:K@=^:?VR*/+G-NT6]$^[D!>0J_GBD M*&0KT-!JL))*K=9-\_HN%HH_\SKQNJ5T5"&.D=*QRTS#C:*GR$7+*1JX@>OB7W.MP@STS\ M6X"RJ:_MQJFE9*N^7"@1@2FO9!602__Z'"HB[8R;E^$/+QT14]8^G(>GKS@E M']@8-:N>W-9KA)A&.>-^SC+FG`QMQF60)J=U`[.;/\[E<1QLIT+7`@R/=S;Z#S=V+<9IJL]UOWEC$P*/6B.?$6C27`2+!+81*#AG1ISHJY`5 MC"9BQ"N5S;^V,ZE!IBRR+W>O^O3+4%I:GIM7$YC^=^UET#SD\[7X4OV:@Y.X M%EYYC[6.HAN&\1.>4`L/)][3+V4ABUA^6CM89:QPUR1:5/@F?,9U(UY*WPI[ MI=S+GU-^XS&4/29&:*70R><%$(S:C/84+]YM M^9'I8Y7=+,+'6LK[$9./^W:G*CR54T]XJ\!^;BV?I=G5K_*:ODPB1=7%N*W MZ)%\R*/M>DM:ZO&%6G2IV9G1H:N$K=EP64CW-IM1GX]F&*,1S5&D$I:W_J]/ M125YA11.WR$STERAT5'ZK9'6\.A>"O07:6C< M_[1NJX\^5W[=I@_5L,R5BG-8T^RGII+7+?<.2O>V7>'M5/K;K54(4800Q@H0 M:>J^N:`W@3"H95VFR?D7U].WO!H]T]<#+LB'XDGQN>_6CKN)$18!DMG6QQC` M5;!(ZU=DR./N%_]*W?CUC#&B`8ZM)V',_K1R1"U+O<[TK=^\:/5T@,^MWE&T M>MDJUJ^N&%_*_>5=XTM;)$,MD:`C14@`H4"7E^GMXR?A]O&E7=>O(7\MF[A, M2MO6?!W9NEDSLGNJEJ/17\.,[VL\'CL*`1DR!+JW&(^Z\T[D-5TOY_,XM\CG M\63SG>_:C_.M+?Q76M2Z42>MSE3MP>,ZW:DEU$[@.;-R#FW#_EQH\"V/MYBQ^B:T^&"(A[: ML?*=SYL/J9Y>VQY&JO["L M8?UBAN6M=JI[CY9.K7Z^?EE?G,R/%.RU3C(T(S9+QSJQW.1^O"DAV"B;P;*! MEUS_NK2YKGI;]O"4+,B2F^.6O=*<<6E"F71OZ4"!-\+55:MR2`KA-^[;S8X5 M?VIR:8"^A=RG]-)/``F1$%2Z\C4E8:7#AV@:'8E&.WBXJP590CPPG)I.#_D/ MDFA,RL\@/H[\D'6,M[8TYR$W$V;P6YOO_OI1.$I'?JBJ M,E7JPN]=8Z^P]^EAF^;XY2K32U)*R65J.OER.ZFN+'4Y9EH0H4Z6")2Q!H/J M^+1BJ_']YF0?['DRK?7[X^[?R\7%:PR&JW:QO17EV0(D8]F<@LJMF>-5BM?< M>_O.P9*K3E;0*<+U>1`E/R#;"HL](#9M2<27#JKY;)T(C>Y(HD[BMP>JWH[OH_6 MPBL+9!=[K%#&L<`P'J*MO]GDW`=/0]:=>V9E2++>4PY;W[0E);:+!D=IG:Z& M!"L7\0O/=PX,KP@8'=9O'!"WK0CUE/2+99;)X9DUK\I#L]/4.F#8(M>30"YN MZG=7I_>LDPP-*0ZQCNQ_9>L"B+47-_$7[48NG!=C>-D;TXMK6+]JVI.]65ZW&E05J"&,E%'3@FDMJ+`=6SWJBQ%56RU=J#J MMB.0AQ]61"R)UYS]LFV[XSF"-7P'XB#WJ1!1='01H0#+THU=$C5]G1PX66X< M_(1!TK:YUCO.@BF&(RKEK'^K'G=_\Q[W[M8CH:SF*:NX,\TUA@3=.KI[L^;+ MG21?,?BOI?EMNKPCT6_3Y7*J/PC8.^.&BF!+GW3:T@<],[I).S5KTO'!HV": MN3?4N]O]O+.[%?G*B,V;?2MA&8NZJ>5$4KWD^\B^D0F(-G\4Y[HS5_F^,MHK MPK>U,9)2;O\.9QQ#WDB2#^VHX%Z!P\L2[+;I7:)62K]P&>LW`XLU!Z?YL!3` MS:P[)VLQS%C\U-R$=F\KJ!FC=H45,UAA6;._,E4;LJS-YP<4#$D?5T510E^A MN(J+0BV>/^DHQ-(.K$<#U!9VUT298]]9D<7FP]I^S4]SMG)EZWC\LZ*8/_]_ M`@```/__`P!02P,$%``&``@````A`+L?P[R9"P``>&4```T```!X;"]S='EL M97,N>&ULS%W_;^+(%?^]4O\'R]M6=U(3P)@`N9#30N)VI>WVU$W52KVJ]\;?YDWV,9C&)@]=!MLF/<^[_.^S!>/SS66$K-SX9;N^F$>KM9OXCW[@)V],EFFLYM*4D7[R83$QKTPC-7D6+0#$'_Z[C9+O?I?^>??'=^^Z__GVNW_]S5O\ M^\=ORI_]^*W9R=40F>"#_3(ONWO%PL>IY$YFP>W-,@J)(>!U1M#U2QC]'#KX M&00#F(=?N[W9_&)\<0,XTT-X\RB(8B,!+X-][$SHKKST&S,W\!]C'[^V=%=^ M\):>MO`$"XSL>RL?W(0G.ZF&\^IY1#2Y32.$(=C4QS/4IA68Y.+)_3:Y/U78 M).@:-.LZAC]!%[-BOUW*=)7CHL3A,;H*7Q$]\=/CQ'01_X3V':W6ZV:QC1S6-_G2!S5?2> MPEHY%,/+'#IP8&3O'][6 M,(H)86R+3'72[S5\^REVWWH6LT*NP28*_`6B>)JQL5/6=\VN[IW9/=-+D,FB MJ!'J.+/A"83>3\/9S^**.IC&``",;]T?C*`B!= M>\14G15!'P`,!X/1H#>V;/B?U:W3(U#-Z<#4[56"0)-7"0)-7F7#[8Z"RI]E M"JP\:,Y5@D"35PD"35X=*J[`0^U>)0@T>94@T.15MDBD,%=A14]SKA($FKQ* M$&CRJK+!9U:!Q]J]2A!H\BI!<&ZOYM.JV?V]PY8,RB,S9>/C3!<.XMOK8K-& MF*<^1O$")NKY]82>#7/$]-SM3>`M$YB1QO[3,_Y-HC7\^Q@E"5RHN+U9^.Y3 M%+H!O.WD+?*_>UK"I1RX:C,QDV=__@+*A.7AE)M4Q:DT%%7/QMF$/;2[0WM@ M7:43-D6J5]["WZ[*UA6Z*^,2:$1NFPTG'(:%DBP<^&I5![V0N4^R!7,U\[1D M`XB)/"0D6ZBPD:_PXHVZ7 MS?I:QTNU0`*\(F(:VY3Y;&Q2P6AC&UE.<_*@OI1R8VKABXV.*RQM:%&VLZ%! MA94-+61M%..FTN)BZ0++4N&S\H1K]^GJO73TBM:6 MU.Q8HDJ/K!45W(*73V#X`8"`JZI>.NNNH?>?>T'P&?OC?RZ+(0"LJMW>O"[) MM7^X-(\7QW%K`;Z%I>OL;=K=IP>@JZZ15=O(<-?KX.W3=O7HQ0[;I<%4L+.X M1,Z/IFR/.$[2)AES;J\/1K\/0R03)XCM%OU^@' MGJ3Y.$8_K#M5.A%XT:H?@DM:O\IXP/TR65"#"VA0[\.C$@&L+N0(P`DZ$.#^ MGHP#"$\="EB.``.4(`,Z>J#@F#WJDFD$,<)6@_U0JH<;D5@HJ3VAE7?D% M_7NL=(3R>Q3-I-Y"H'.:X6`/@*-4UI58726&N!TRC5,`!WLH<*#75=/E]>IJ MOC9"2-$%#)P1*`/[&%$7E:3F@DX.8#\C4X7C$!(46(IT0P`X6B`01_0T];\] MBD%3#TRC05,73"$(??`9D*/<48:"`1=%9)$@Z6K M1%(,NFHD=X6EJT02"+HJ)/6$KA)),>BJD<05NDHD@0",:*F0U!.Z2B3%H*M& MZ)^X1';HLFFZB$K63Z^Z!ZV?&J_+QH747MVD"?R>-T]G M3^G,$7S!YE)D*HUW5+FX31O73HWG*/9_@4DFWEDUAQ->;.*=>(D_IV=^CMWU M@_<*4]'TLM/KME\TNLQ5B>8SB,FN.];S(@;CFI>T=;FO9Y,S!10'3:*2- M*)=G39*?([`@K&PI$-X*I5T,LEHB&BW'%:'&*PH[M%>'R^$8:-!*FZP:Q"E# M0%%R8\W1[2M*$W3UG.6+U2Q?(\VY+M'4#MP=7]?>$RSBPJ-Q42=QTZ/3Z4+X:D/7QN! M0HB=!-]Q!$+(\:%[.0"E0^Z\PZ-2@,.VHDZIOZZ>/O0;7%(]=A>[<6E:*-`# M'-6#Q:+SCF)K.!/J0*E,R5!6._(YA*(:E()G]:,$!!7#Y)WX*\%4$&FL&SIX M#">P6"X)"O#)9H*,F\L`9:+Q7`F,(9`MDHACXY-T!9)^KZ%5R/$ROJ^45F"8 M=V"E9)*J.BEMXB2XLD-!;Y;GO:)C2Q#$?)$"E.9')029Y2C9E)!.`I&:@PN+ M$&"'\L2QY"O1!PX]U+B-PVF]F(O1E-<&H>;JIT8Q'#EJ,&S;IY=,6:I-.D7> M$P*[7#G%"B"==8<,C*HIA+.\1N+F*7&6*8VH,=,TN/!@3/MC_*QA54?;"2$V MTB812?`5,9!J\XR&LN0@14)_#_).!*`NDD^KOL1'95]_)`:0*=S:2W.]65#'B+,\E0*]Y<8W[9D?*=2N*=`'K'(A@_D+2I\U!?9M279G;J+O.J*`8/] MC`P,>'[Z?!O`<^TC?"H^VY2(,U]B$&Y!EY+T[,U?C!G<8UX($O,!NU$90?>O MZ\`-W22*WPSS(3!%/VK1_\+U'"1$Q,_OXC/O(*LACFP%!N/F[@,4KPU]C&_L3\ M]7XZ'-_=.];%J#L=7=A];W`Q'DSO+@;V;'IWYXR[5G?V/Z`,?Y+D&G[3XHB? M_&`_30*S_9Y]O0G@AT'BS-@,_&=^;F*2@Q0^V^L&L.$*>FY$9U/\9,KM_P$` M`/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL``!,```!X;"]T:&5M92]T M:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z''FF9EEA3 MHD#227T;VN.``<.Z89UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7,;5B;6%= MW_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[66\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPXVRV%;P!\ MHYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:"8LT`;Q)< MF+%#OEP:TKR0]`5-5-O[,,&0$0MZKYY__^KY4_3J^9/CA\^.'_YT_.C1\<,? M+2UGX2Z.@^+"E]]^]N?7'Z,_GG[S\O$7Y7A9Q/_ZPR>__/QY.1`R:"'1BR^? M_/;LR8NO/OW]N\*1R5D1SBB!4-?A.KL$S(P5SX15Q/*O!T M0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DWQ%%2AAW0 M."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2(GIF)$E]> M)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q7H7[#Y;H M'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;:YO..UK9>$\H8P,U M9^2F-+VWA`UHW(=!O-29#`P<7""P68,$5Q]1%0Y"G$#?7O,T MD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY&2-58,ZT M&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8GB]%1VVLU MUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<):G#[8>V^ MI+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*])`79T74LF M$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^@>LY;6TS MY1;G-.F*EV(&9\F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI9/G>:W/@ MG^Y\;#*#4FX=-@U-9O]2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WYGC"VENPL_CZG ML?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F\=%]18U>F)*<]ED.`XBC%A#9,&00.CA;,0 MG):+G,,,;.Q(L2+#M_%\/<7AC+[O"O!-H9P59%N;[W+WF?&R,E#M"4S(SFN>O]PQ32%0L`E& M$^M$90T`<$2"VY4!@9#G[KSCN:DR/$Z#R30:QR!'&Z;-/;>6&-&M-E+\=J)X M;^5,1GL3..]-XLF[3<9[$SCW)J,@3J+TWR"AFU27T1TQ9+E0)Q>#[Z.SFE@(0VI)+YB?4[AL27O8;/B#,/Q];OIT9=73G..[9S"8P.3 MRW.S8C^W))WXJ:RSFV`,?>;\0K.#CBFG@[^KKM-X ME+YB[12S;L^\[@>/;OH_=';0,=WQVG,:CRZ='?&]H1D4CM(U7M=4!%,E6[.Z MUHC*K6VJ,#KT^]M1U[*'%]!O6U*RKT25O-&H9@4,C8(IL"G7L=V-D6W7 MLC;20*?M+BOXL3+8YU$`XD)*T]_8+C+\JI=_````__\#`%!+`P04``8`"``` M`"$`@2T<3FT#``"D"P``&0```'AL+W=OS/7MFB5\HQ5A[7]X_O]A[EM246JC!2\ MHFO[A4K[9O/^W>K,Q:,\4JHL8*CDVCXJ52\=1Z9'6A(YXS6MX$G.14D47(J# M(VM!2=8L*@O'=]W8*0FK;,VP%%,X>)ZSE-[Q]%322FD200NB0+\\LEI>VFE(;:M,EP^'B@NR+Z#N9R\DZ96[N1C0ERP57/)< MS8#.T4*'-2^P^KY)X*NP,IJ34Z&^\?,GR@Y'!7%'4!$6 MMLQ>[JA,P5&@F?D1,J6\``'P:94,MP8X0IZ;[S/+U'%M!_$L2MS``[BUIU+= M,Z2TK?0D%2]_:9!WH=(D_H4D`/67Y_Y4$D<+:NJ[(XIL5H*?+=@T\$I9$]R" MWA*(KX5I&6VI;U4*)2+)+;*L;=CM4(2$>)XV892LG">P-+U@MD.,9R)V5P0F M`?):C5!X5^.?3;]*03!*P1!0VU;?`.Y6F]][[Q"1A"W$4`(.=96@6^&;V^"J M"!#TO M3.:Q:R)V743B15$*()-:4'<2W"K,6/VC2$,;;&I;5K$N.AO M$6O,F,8QA*$Q^1^-N,CT,1Q$K#$Z8C](YGYO#^RZ@"!LO[6V&C/FWAC"<&]A:IN6,"[Z6\(:,Z9Q#&%H]*!%=0V<)K)9U7-RD/$% M=/D?S^,X:/^D^J0Q`'X4)W$+,#7B>3TY9$^?[L81$_M1/#BN/0T:U3D&,77BT=[Q<:).W1`,/X=9:Y#.>K[P@KC7>'!J MPHVM$4'H^M%KX]$J]5"DAX:2B@/=T:*05LI/./#XT`[:N^TP=NMC_^W=W^*0 MAO>=]@',2#4YT"]$'%@EK8+F0.G.$C!6Z"E+7RA>-Z/*GBN8CIJ?1YB&*?1W M=P;@G'-UO<`7M//UYC<```#__P,`4$L#!!0`!@`(````(0#*2G+3PP,``)8- M```8````>&PO=V]R:W-H965T&ULE)?;CN(X$(;O5YIWB'+? M!(=3@PBC)JW>'6E'6NT<]MHD!JQ.XHQMFNZWGZHX)+$#+-P`2?[\];GLLHOE MY_<\\]Z85%P4D4\&0]]C12)27NPB_\?WEX='WU.:%BG-1,$B_X,I__/JTQ_+ MHY"O:L^8]L"A4)&_U[I!>%P M.`URR@O?."SD+1YBN^4)>Q;)(6>%-B:2950#O]KS4IW<\N06NYS*UT/YD(B\ M!(L-S[C^J$Q]+T\67W:%D'23P;C?R9@F)^_JHF>?\T0*);9Z`':!`>V/>1[, M`W!:+5,.(\"T>Y)M(_^)+&(R]8/5LDK03\Z.JO/;4WMQ_%/R]&]>,,@VS).F MFV\L8XEF*_P*TA!%&5`(.H7Z\E!Z5%_I\1D=K*F(2U"7P?S?,PO-MD M5)O`=VTR'X2/$S*9_C])8$95)>R9:KI:2G'T8+D"MRHI+GZR`./S68%TH/8) MQ9$/Y00#5C`U;ZOA,GB#Y">U8FT4\-DHB*V(3PJCTO^%+DCSNC'C7NAL\H8,$T M>1G;BOB:PB*$,%W"ZV0HAA%TXK;C-F1&T26;.F1]10X9BFVQNQUT;19>,.(40]R47T&;WH*'81B-.?:V-Q&)S M2Z$ON<"&!^?-FP.*'3:W"HSD*EM?:+F?+ M4"4ZKB73:B>>C\*%;N6#V_-Y\7V(;=D3]4 M._ES*G1=.4:^Q>>44GQ&TP[!GM^[C@WH?'M\[<(VFTRMF9VZD-!9H-@^HTEW M`"Z*`72P!Z^9NTY;7_7+S`!KQK;P MZG`P@[C2M,CF0HNR:A$W0D-K6_W&PO=V]R:W-H965T MTYYYHA M9$)-""E@/O;?GY:MEJQ^O4S8S5XLD\>M5[):+;5D^]/O/__;XVEW>+VK M>XV;>FW[NCD\[EZ_W-7_\T?\6[]>.YW7KX_KE\/K]J[^Y_94__W^W__Z].-P M_'IZWF[/-5)X/=W5G\_GMZ#9/&V>M_OUJ7%XV[[2E:?#<;\^TY_'+\W3VW&[ M?LP+[5^:_LU-M[E?[U[KA4)P?(_&X>EIM]F&A\VW_?;U7(@N?WZ^/7;VV^;P_Z-)#[O7G;G/W/1>FV_"=(OKX?C^O,+W?=/K[W> ML';^!\CO=YOCX71X.C=(KEDT%._YMGG;)*7[3X\[N@/5[;7C]NFN_N`%JU:W MWKS_E'?0?W?;'Z?2OVNGY\./T7'W.-F];JFWR4_*`Y\/AZ_*-'U4B`HWH72< M>V!QK#UNG];?7LZKPX]DN_OR?"9W=^B.U(T%CW^&V].&>I1D&GY'*6T.+]0` M^G]MOU-#@WID_3/__;%[/#_?U5O=1J=WT_+(O/9Y>SK'.R59KVV^GJ[.J2],M5OJ^M/5V0?J^\2XK2O+'TJTNVWU?EK2Y(O]Q6 M_WUWZ=$0+$8$^?S*YGH\$-0_3(/-:+K0MQZ/!/4/7=*CCKY4A(>`LKNVH>P2 MS_K$\QIMO]/KYP/_4KWL%,]ZY1>CMED$71[#X?J\OO]T//RHT<1(77QZ6ZMI MU@N4'$=O4;V)Y[\*9XICI?*@9.[J5)XB]41ST/?[EM?ZU/Q.\\9&VPS0QG,M MAFRA)@DE&TH021!+,)(@D2"5()-@+,%$@JD$,PGF$BPD6$JP*H$FN\.&%BG^<(A;,%%0@DB"6()1A(D$J029!*,)9A(,)5@)L%<@H4$ M2PE6)>`XA&:(CW"(DKFKTR1B@L:[[;L>&!0V'@T-8]1V38;&Q'@)2`0D!C(" MD@!)@61`QD`F0*9`9D#F0!9`ED!69>(XC?KY(YRF9&BRI*%A'-+RA$L&VNB2 MUXR)\1J0"$@,9`0D`9("R8",@4R`3(',@,R!+(`L@:S*Q/$:)43@M18E"%>N M3THF]QKW]D"3LHM\N60-C1$7"X%$0&(@(R`)D!1(!F0,9`)D"F0&9`YD`60) M9%4FCI,H_7&<5)WZE(SKD8(4V[7<(05HF>0A-&7L/.C+>3`R M1AP_,9`1D`1("B0#,@8R`3(%,@,R![(`L@2R*D@KSZX<%U%._!$N4C*NBS0I M!0V0T)"RDSIN_A`9(^.D@O@V51R!36)(6;KG2J?&B*4SD!Z#S<20DK1_XTI/ MC1%+ST!Z#C8+0\K28ANR-$8LO2I+.]ZEW>U'>%?)N-[5I.1=(*$AI9OQNFX_ M1<:(;R8N2-F[8),84I86N6EJC%@Z`^DQV$P,*4N+@3,U1BP]`^DYV"P,*4G[ M8D^S-$8LO2I+.]Y5)Q$5[FVHDZ'S\V[S=7"@))!2B(H%KT6[8+TW5BJN=W-A M0B7W(@HU\GMFUHT0Q8Q*T8I:"5O1/&7R5M^[=0=+:JVXBB(_\XO/V5(^E,SGA2R0A/:J1& M!!]]^+XX^ABJ_9LJ:-L?,LI/9O.!$FG4\O(#%+]#^:@0BKF4[:X1(ZN=,**\ MP33*ZPBME*NCX6^L?%]L93+6LC6.&=D:)XPNUCAEJUY^@YU>0XR_&1O8RN:, M;&4+1K;KEHP*Y5ZC):;!%1M4C`VURR\?@54$(NXFYH&W$B)&53QA9^9311?F,K:S\F)&5 MGS"R\E-&%^5G;&7EYXRL_(*1E5\RLE8K1KF6&_/J).`*O^J#`]NH@3H)5GYU M8ULL54.VL@,T9&0':,3(F2!],4'&;$7YA@E)KR>L1FQE:TP878R_E*W<1H@@ MS-C*!N&8D:UQPNABC5.V*N+2N[EM=,0$,V,36]V,;/BDC"Y&9\965G[,R,;=A)&5GS*Z*#]C*RL_9V3E%XRL_)*1M5HQ MRK7!N>JY(/:L2-U[OK\CBE*)8^S52HF;M;XG=Q%!-'W+M+U#Q5%;/ M^QH5@>*W>GU?Q&7,0C901HQL""2,+L9ERE;N3"!",V,K6^.8D:UQPNABC5.V MTFM_N]$3]S=C"UO;G)&M;<&H/!&8'E8/GGH->8RWXC(5TP(U&L=)QTX+/%!^ MD10HF7QPV)'0\D0&,%"/"955.4!$EP^M#:<7(:((48QHA"A!E"+*$(T131!- M$0'98QT.@^3<57&V`:_&2OK-T`1R]N\,D8T M0I0@2A%EB,:()HBFB&:(YH@6B):(5@YR_79=QDB/N<`]F#&RE>WE$%&$*$8T M0I0@2A%EB,:()HBFB&:(YH@6B):(5@YR?2$SQK_Y_H$/2>*`D?7($%%H47D) M$FE/9*TXTF)$(T0)HA11IA%U$\D[_:->5')6.)GOO>OY8:[BIJJ,2KV#*-1( MQ5)I@19K3&2M3.\@&B%*$*6(,D85O5.9#?^3,SIZT,!EG1/E/ M:D;LR M8E1.^O`I`%O9K':$\@E;6?F4T47YC*UR>7=24VF_2=M_W5G%+J&\XU#/-]3^ MU1ED';GCL%;<,R&C\B#36D[L=L0F).:"M/(;]^!S-;8JCSTM;VM,V:H8:+U. MH^7LW<13]HS-*T:=VF24.U)&\?M6AV*KXO2O1NY@%//9L&6L;/\6B'S/*-)6 MZBY,S]&;">[^--96:J]MK"KZ%VI,6-[6F#)JY]-&Z[8A'X!EMC9JICLVG=T9 MCNA.*M3HBMH35EVA>BA3JKI"]13)G:B',K]`Y3=8AE**0"4,>(72 M@4`M]GB%OM-\R&=;4LX`_MX(&F7*QXT`[H_?L* MW@E6E?;>;3`H%BS15#KM#=29*6K1>6X055ZA3#\85'8B)?S!L/(*Y?V!RL2Q M'LIYJ7NK6C#K!^IE,RPR[P?JE3.\L.@'RZKAM;@-EE5UTUMJ@7HM#956:J16 M7:#7\@+UTAT6R?J!>O4.+XS[@7H!#R],^@&]%%O!;P-ZG;*"4]WJC3R\$O:" M964D](-!98%A/QA67@C[`;U>7%$#C8:J-M$KCX%ZQQ%+Q/U`O>F(%T;]8%1Y M(>D']/XQ%DAH[.1U-\WHI<^1W]9?MM/U\7ROFY?V6!2=!@KG=JT?N^[B M&D:;'XLJ:V?UI3C#FWW=5%D'?S8'H[TT1;;K&U4GPYS/ET:5E6=]4'";>S3J M_;[,BZ#.7ZOBW`TB37'*.AA_>RPO+5>K\GODJJQY>;U\RNOJ`A+/Y:GLOO6B MNE;E;G(XUTWV?(*\OQ([R[EV_P>2K\J\J=MZW\U`SA@&BG-^,!X,4-H\[DK( M@-JN-<5^K3\1-R4+W=@\]@;]71;O[>3_6GNLW[=-N?NM/!?@-GPG^@6>Z_J% MAB8[BJ"Q@5I'_1?XH]%VQ3Y[/75_UN]Q41Z.'7SN!61$$W-WWX*BS<%1D)F9 M_3#R^@0#@'^UJJ2E`8YD7_OG>[GKCFO=7,V(/5]"M/9 MI#%405]40=9EF\>F?M=@IL*';B\9G??$I;J\G`:'1(%]K[Z@**C*$Y59ZY`Y MU$X+D^)M8\T?'HTW*.2D$&&"+ M\`;*^R.\H3+4&YZ5Q\%HEJD8P2-XDT`%H0HB%6Q5$*L@44$Z`9(1,%T_P@@J ML]9A!HLB(2LE?.R+!) MTX731R1`)$0D0F2+2(Q(@D@Z)5*BL*E*B?['W8;*R`XP(GU]6]F`?!$DOKX@ MXV0C"V6RA2*(-XL&8HY+^A;%Q(),I94-+Q%!7#J=2DO6T?,[WJAG#A15=RSS M%Z^&]0+ROU([%FS(PS9-163C&)F4#B+!0$RGW]?-.5$6Y%"\YUE$C$P,0JJQ M:$5/"Z"JS-5$O.>JZ515\@9.3C>]^5)?ON<-'%BY.51%-H<1:C$_UI"5DKTO M@O@X`T9@%HS-%DIZX1!DD=Y4LE+?1TQD8B'J*+ZGHT3I:+F4U\1TVI'D*CT. M2K9>*:V)?7VX[!]'T,7HQ&HA#\`?HX2##)G]3Z&^=$..!L-L=6F/^'M3G+.V M6#CF4:-PPA$75H:7\O>]L&P03+>?,8B&*P8Q)%784EDE?'H:H@V'GW/#P9BA MI<@VY%'#-+5,I>`B_GY241R-PC%'HW#"$1->*NMCRM_WPK)!]$#YOQA92 M?6-(*JRE.C-YPP=A4L"090D4G!:6Z)Y7;,Q51N&$([K" MO&W(W%3VHU12EHVCITQD'/S&9HL]7]#N7_D).[>.67@<2<6W4I8'?XSBN08, M6;<7.![%RL9V%.6(*T\+DHUR6I`#NMU9HG3FV*A(F?*5(J5G5>3U8MQ9N=D_ M6/[8D7=J\/04W*]B/D$HP"C$*,)HBU&,48)1*B&Y[J`6D!<6[`,_>QU`=92E M;D!4;+(7*)/-IS=9T!"BQFI#*,11$49;C&*,$HSH]=TXB,&?X3INN#FIBN90 M^,7IU&IY_4JOVL@#3'&!AWM`;^G".1BR4#FQX8+0OOIFP:\.E3:QX\)1$6O% M*Q>.29BGC@N')'9KA]'?[HV!GSN>[@VA1J`N[2X):\@%]C<[IN M[^NZXW]`QX:X=]_\"P``__\#`%!+`P04``8`"````"$`HDBI.=<$``!C$0`` M&0```'AL+W=OZ16JJIS3I\)F21H@8F`W>S^^]IS`8;AI-EJ7Y;EP_;XLSWV3%9? MWO+,>J5EE;)B;9/1V+9HD;!C6IS7]O=OT=/"MJHZ+HYQQ@JZMM]I97_9_/K+ MZL;*Y^I":6V!A:):VY>ZOOJ.4R47FL?5B%UI`5].K,SC&E[+LU-=2QH?N5*> M.>YX/'/R."UL8<$O'['!3J<1<'I?/ M+]>GA.57,'%(L[1^YT9M*T_\K^>"E?$A`]YO9!(GRC9_,UL5CQ`/U)ZJSK_6]6%W7XKT^,? M:4$AVI`GS,"!L6<4_7I$")0=0SOB&?BKM([T%+]D]=_L]CM-SY<:TCT%1DC, M/[X'M$H@HF!FY'(W$I:!`_#7RE,L#8A(_,:?M_187]:V1T83=SI?$)"W#K2J MHQ1MVE;R4M4L_T=($?2JL>)**QZX+ZW,1M/YV.-&[BA.I"(\E>)#>N`:=QN> M4H^0$9F,9^CTG?5F4@^>:KTA>4=$B0<]B.MXLRK9S8)*AC!4UQCW!?'!AHJV M6+&)_\_"#Q%#(UNTLK9A"T)@*ZB9UPU9+%?.*^0YD3*[`1E=8J\D,!%H-N@# M81^(.H`#C!I:D+]/H(56D)9R:*>`EJ?;XZ`DE$K0!\(^$'4`C0/4WB=P0"MK M&\JQ3Z1:T0:<@82&DC4131RL&.[Y(8[E]HZ*,PYJ+5W`IGR;?0TZ^5!?1QFK+D! MV_EQ-U!8=T,BHB_B=MP;2&`@H8%$743S;Z[[QUN/"_/B@[T'S>B>2Z2;<;(D MO4`V0BKN@8&$!A)U$8T,'C\Z??1^SE%8=UDBG6`;2&`@H8%$743S;ZG[A\'V M/AYKM*([+A$]UOVFV`@UL3:0T$"B+J)Q(>#XX\'FTKK3"NJ$VX0"$PI-*-(@ MW4T(2M?-_SM;T4S/?PEI49_T!NX>^SDJMBR#%NKTCVEO'(2ME,I7)"&7ST*= M)8ZO3N4+EJ,Y-*KZDB;/.P:E!IX,[`@/6IP\/X@9")UA0$+N MG'=+=TQZW>'RC5U_Q@6.:0T9.?6Z9"2$06E.2$NOUY)( M(Z5\#10$3;15G/840RGE$1X%;SGO12%29@8HXQ2[0_FQ],E1V&4L(=C$K>/+ MGE][TDBUC`7D>4TIA%+*@R\=6U,]>I&4"-BLR@?AI87/=V$Q\..I"=/C[S8;(/X',?AN0` MOO!A.`W@2Q\:_0!.QG#/Y%?%_LJ$^-@=3!WH>#XV"?,+-#X?V]K0%Q>^#.E` MSP,/AKYLB;\=PG>H,+#&SO7AD&^NO?-\."&;^';B;T4].`UWN.)>XS/],R[/ M:5%9&3U!PL:\S9;BDBQ>:MFB#JR&NRWO5A?X,8/"^6V,Y7UBK%8OL++3_#RR M^1<``/__`P!02P,$%``&``@````A`.=^S4:U!@``@QL``!D```!X;"]W;W)K M&ULK)E=CYLX%(;O5]K_$''?$$,^49)J"-_:E5:K M[NXU0\@$30@1,)WVW_<8VV#[T&Q3]:;I/!R_V*^/[0-L/WXI+Y//>=T4U75G MD.G,F.37K#H6UY>=\<^GX,/:F#1M>CVFE^J:[XRO>6-\W/_^V_:]JE^;Y5V5N97ULF4N>7M(7^-^?BU@BU,OL1N3*M7]]N'[*J MO('$6-N3%#:;X\%C(#:/JGST\YX(DY"-H:YWW8&_5OD[XWT_TESKM[#NCC^45QS MWF3@*,A,K055RJH+=`#^G90%30UP)/W2_;X7Q_:\,ZSE=+&:V03")\]Y MTP8%E30FV5O35N5_+(AP*29B<1$;>L^NVY+(G89SWA!^>&F;[K=U]3Z!!0C3U]Q2NIR)0V5%EC"C^KSY7MI` MOE"5)RJS,\`!R(@&(2;*6*2^.G MD=A6:'1GAAB$R\BBVV(^++3,$!?'K5/Z`;O]`_V@T6H_.&&G'=VK#HAXB/B( M!(B$B$2(Q(@D,E$&"L>9,M"?W."IC.H`)W(.DK6MS4@?)";00\1')$`D1"1" M)$8DD8EB"JUQY5/O?A;2:'7LG$BSCXB'B(](@$B(2(1(C$@B$V6@4%LH`_W) MV:RM&(=K89&O)O2:K`]%]FK6\$.#0:,)(\-^Q,OC*B*:ETG#$C*'HP\CJQ5 MM]59,Z(=@_X0(,82""3YA)4C$=4K:XLV'@*$E3=?N>35"1 M]SY1&R)0\.%-DJ?-[1)9S!9ZP&!4);= M1#>+1-3=F\7ZS99+-><3(3-B,*W*?GRSHI6#;B1'D.J#'VO]\!0-NT=27GZS MAE;WH-DAGT=9S+6YON$'XKK5E[LA%HY$U"`<"R2$M>XEXGHGK&8@+,(A7 M<$,/7<*1DFE+;>\X#%%B67@"+?O1^@*QU65;6MH%XKJ<5?WMA7`DH@;A6"`N MO-1VS41<'\D@6HW)!K%3X-&=C-=TLF\<*8FU1"NTCQ+#\PA#MBWYQM&\6XYK MLE(72,";6,/M0X[82Y0N/2,L'`O$:D8RL[13*E&4U0.$[%/+JP@79K!HH;*2?6Z@9\&*)$0P\C'Z,`HQ"C M"*,8(_K"G'<5.L'\82_`V4O-,J]?\D-^N323K'JC+[?AO-AO>\S>O+LK!QX- M04#G:P>>I$8X6<*K^NXHUEL0D((\'6L#8C";8UF#_-G2>8"WS!G3OP M\F>$@X6C#FX<=W0$AXUS&+W@;1QX0L1W@"R_; MR\MF&S:_?;]>)M^*NBFKV]:PIY8Q*6YY=2QO+UOC[Z_AEY4Q:=KL=LPNU:W8 M&C^*QOAM]^LOF_>J?FW.1=%.@.'6;(USV]X]TVSR+Z5C6PKQFYR_=&1&I-K[B4OMZK.GB\P[N_V/,LY M=_<#T5_+O*Z:ZM1.@;"]U+,/<;3J! M_BF+]T;Z?]*H+H^_E[<"U(9Y(C/P7%6O)#0Y$@B2390==C/P9STY%J?L M[=+^5;W'1?ER;F&Z71@1&9AW_.$730Z*`LW4<0E37EV@`_!W6X$R=E6N["]+=D42XVXT3KBQQ.9T[[G+5C7,D<<$2X+ARN)M:[IRW?EBM1SO(BS)KHMP99D@RTC/UBP>KJ*ET00;W$4GF]B, M3B1,&6["I";I/.=G;;;;U-7[!!8RV*"Y9V1;L#W"QMU&*83_/K(?^(ZP/!&: MK0'C!&S%ZIS$VS(`(FJLA!Q$BQ$!(@)`0(1%"8H0D M"$EE1-$$QH4T(=OT@PN'T,#:`^6%`'CEL*`QE42(4`DA`4)"A$0(B1&2("25 M$44E$$11:=PQ)+H3@P]B3Q&WVU&^Z,[@-X>E4_H!>_T#_2#1:C\80A^29&LZ M(,1'2("0$"$10F*$)`A)9409*#RDE('^Y'Y.:%0%&")[T%ZLM;4J@O@$^@@) M$!(B)$)(C)`$(:F,***0TEA^R(V[D$2K8V>(-/L(\1$2("1$2(20&"$)0E(9 M408*A8,RT)^+TC\P(Q<0" MD:EME3H109PZE:D5Z4CQ,Z#=E)1X[;G,7_<5[-`@P(!Y9K`_L3J(L*C2=<0` M2>[!D,\@9]EM=8YE:YM=T`?PL804T`P*3(NSSFQ6I''0A&016[_58:DOC MP!/7HB[U&40/MYV?`PY1U=:N5M.'_+XC6"),'/.H[N#;$2<<^H`XY?<[8M6! MI"1[0"!6P?4]W-L,4IVFU^!]%%\6/H<68K0!@[BMYBND$&M,MI5HGS/'F#G1 MF%U7ZV#*9BT+Q3;F%IPPLYB^PM1!RS*(DXX=`'Q*E"K*X^4GF.Z?;)_9\5L/V4 M[VT&J99SU8?5H8_J+4<3%DG.NC%E63D@(9*0UO0:&[I)3C'GV@KF,E MMZPZ@V2_SC2A#K8(XA+X#")O-WOM<+E"$YTUW327,TW#A$;;2!DDU\T(\FT$!1@*,11A M*,90@J%4@13;P0XTI,7#[X0Z'E4,#D%!VIMFI1?'?91P&X8"#(48BC`48RC! M$/DVTDUE-V]4'_JM@[YWOA;U2W$H+I=FDE=OY#L&).PV`J8?6?9+#X[S,`H= M7WEP^AW`[;5'9F;@CF/Q[S4:5[SVX("(,^#$Y"5P`L)W4M+(T`WX)O34K0VM MB3U\*^ITT'$'^C30P'[FP1M'W/#3'/B'&M[//7CYAA/V"P_>$0W@:V\_.(+# MVCL,WO#7'IS0,1.<6#UR*,5WPK5'CJ;X1K3V(GK#%'K`EZM[]E+\D=4OY:V9 M7(H3.,+JMH^:?ONB/UIVK'RN6OAF!8L#/E7`-\H"7L599%\_557+?T#+IOCJ MN?L/``#__P,`4$L#!!0`!@`(````(0`MOMX1DP8```H:```8````>&PO=V]R M:W-H965T&ULK%G;CIM($'U?:?\!\1YC\!5D.QILKMJ55JOL M[C.#L8W&&`N83/+WJ:*[@>XB3B;:E[%]NNITU^GJHNC9?/Q27+7/657GY6VK MFY.IKF6WM#SFM_-6_^>3_V&M:W63W([)M;QE6_UK5NL?=[__MGDKJY?ZDF6- M!@RW>JM?FN;N&$:=7K(BJ2?E/;O!R*FLBJ2!G]79J.]5EAQ;I^)J6-/ITBB2 M_*8S!J?Z&8[R=,K3[%"FKT5V:QA)E5V3!M9?7_)[+=B*]&?HBJ1Z>;U_2,OB M#A3/^35OOK:DNE:D3G2^E57R?(6XOYCS)!7<[0]"7^1I5=;EJ9D`G<$62F.V M#=L`IMWFF$,$*+M69:>M_F0ZL;G6C=VF%>C?/'NK!]^U^E*^!55^_"._9:`V M[!/NP'-9OJ!I=$0(G`WB[;<[\%>E';-3\GIM_B[?PBP_7QK8[@5$A($YQZ^' MK$Y!4:"96`MD2LLK+`#^:D6.J0&*)%^V^@PFSH_-!;XM)XO5=&:"N?:!3TYB3=:+Q7RY7@')`T<8;6>'3^X(>?G`?LGM M5YV].9N8\^D2%_O`#UC;>>!31#F96XO5NHWR@:/-'>&3.]J].@_\3-C(=D;\ MPCT?+M5@^])N\R%IDMVF*M\T.#N@?'U/\"2:#I*)#6:3=UO^O1V'K4:6)Z39 MZA`_;&8-:?IY9RY6&^,SI%;*;=P1&]EB+RPPCY#VH`*>"O@J$*A`J`*1"L0# MP`!9.FVL_T<;I$%M1%2N`'JQ+$4(82%<#BK@J8"O`H$*A"H0J4`\`"0AX/22 M))E!LHQ7`9$3Z+75X=`.07R"!`0)"1(1 M)!XBDB80%]$$*^,[#P[2P-D#Y3L!Z,GA1H]4ZDPZE0CB$<0G2$"0D"`10>(A M(JD$@A"5?IPYZ-6*(H)Q&;)H*\N'F9(A8G!<0FD]4.&E]3S.8+26U\$1]GS" M$K4GR($@'D%\@@0$"0D2$20>(E*@\`B3`OW%NHXTL@(<&>:BN;"5'>F,Q`8> M".(1Q"=(0)"0(!%!XB$BB0+/)TF4Q[N/UG+L'!GL/D$.!/$(XA,D($A(D(@@ M\1"1`H5^0@KT%W"C3I_+^/9F@F^YT0AI%)PZAWETSN52298\M`SJREP[6+'((:F+ON%"B](0C MDV%F*L2^&!^*2>8*A=7#N2)AQ>::3Y6..!;C(_)B*S;LRT>R;2@CZ]R@C1!; MYV)+@0)!HO=J+)6#L>^MA..!0U;[8MAFLR<@LTW*U4(^7;X8[F M2$",=[8B^K`8K)983C_LR]ZA#V_C^A6Z)H?D-%,;\=ZJUX<[+CNM/6'%CY:M MQ.&+\6%.==,+XE!8]<21@'BR6DM9^5B,CR00MF3O$(AW<$.!."0GD'*<]F9G M)>(X<$A*(&9EL8VV;))!?+R?/J#$(26.!,2)UXKRL1@?R2#L&H<"L6?D>^L\ MLBCUBT-R8BEE?(^O"FK]8I`U&R06A^;MP9N91#?.,DPL0ASRN0;$D8`$L;*\ M6"QO)+&PY51UFYD3F+9]/(JZ_XYG)6]B^\UW30[)N:=$O^^M^MQCCGA?TU<] M^@S@5G8KJVG9RK'W.3,K/&T-#.ADH;!Z.%DDK/AD*U.IP;$P&,E1[&15KY-`ATHY%'(IU!`H9!"$85B"9(K/C:[JA;X*OG. M%VZX+24GED%(UB?-4JFU>^X(5GVV=8X"\JB53Z&`0B&%(@KA72^NGBV"Z"\+57BWZ6!V:>RN''A'@B6K^-J!5XH1W`0'V)FQ M$7"!-=&1T':@ZQ[!S:F#G28=B6V@&AN`.^ZG-G75Y>+=]PB1:SEPDT4G<&<. M7.=0_&GN/(W&X,X=N-F@#N[2@1?O$=QVW-$(]K:S'QTXV`Z\]E`F>`UPL-.G M([[M8+]/!P+;"=B`T>D$-_'WY)S]F53G_%9KU^P$&3%MRT?%[O+9CX;WZL]E M`W?P\#B#>V#XGTL&]QM3+.RGLFS$#YC9Z/Z+L_L&``#__P,`4$L#!!0`!@`( M````(0#'I1_MFP4``(45```8````>&PO=V]R:W-H965T&UL MK)C9CJ,X%(;O1YIW0-Q7"&0%)6E5%C;-2*-1S\PU19P$58@CH)9^^SD&V[%] MZ*BJ53=%Y?/QC_W[>,&+;^_EV7HE55W0R])V!T/;(I><[HO+<6G_\SU\F-M6 MW627?7:F%[*T?Y#:_K;Z_;?%&ZV>ZQ,AC04*EWIIGYKF&CA.G9](F=4#>B47 M*#G0JLP:^%D=G?I:D6S?5BK/CC<<3ITR*RYVIQ!4']&@AT.1DRW-7TIR:3J1 MBIRS!MI?GXIK+=3*_"-R958]OUP?0>*I.!?-CU;4MLH\2(X76F5/9^CW MNSO.V MLUJT!OU;D+=:^=^J3_0MJHK]'\6%@-LP3FP$GBA]9J')GB&H[*#:83L"?U76 MGARREW/S-WV+27$\-3#<$^@1ZUBP_[$E=0Z.@LS`FS"EG)ZA`?#7*@N6&N!( M]MX^WXI]T_*\+P]/'C^5K[Q3#29/ M6PV>O-IXX,TG[J1MZYV*/J\(3UYQ?O,)UW.ZP6K'?ILUV6I1T3<+)A0,1WW- MV/1T`Q=R1HQZ)R'SX&=I`.//5!Z9S-*&7L`(UY"[KRMW/%TXKY!O.8]9]\3H M$1L1P9*+R6Y-L#-!:(+(!+$)$A.D"G#`%ND-).%7>,-DF#>B5VL!;F9YAA$B M0E39FF!G@M`$D0EB$R0F2!6@&0&I_Q5&,)FE#3-*29*9WO-U%^/"D,B@L1ZR MD2'2'41VB(2(1(C$B"2(I"K13()^?85)3`8F(PR%-`!/)1YTSR49(EU"9(=( MB$B$2(Q(@DBJ$LTE6!\UE_IW%[&LL.C6#-&)=4K2B0P2TJDJK5G'3D,]W@W80;0Y%?GSFL(*#0;T),\(UB=^ M,&(JNG6M,"`E>S#:#`79N^T^O/;(+SN/2)R1@^<<3\EJ?*B;GFLZ,"J]A]DG2G1HY@350J M&KW8^][$SV\:6*G1M,&SF" M1%?<,+)I(RKZ\IBZYU(EPL*QB+H))P)UPJ.I MT;Q4E+?">OZQ`YEJ4+?$?7::\F/=K>%KER,]_2;Z7-GK#+5)?`5PO/;9M-U_-KIUZA-9>`-^+ M^`7K40#?2)@_CH-'\`@7K,[@?KWAYL_$[#U`SA38"78 M8P.VC>*2T`_89HH+(C^(N@)'^@278-?L2/[,JF-QJ:TS.<#H#ML%J.JNT;H? M#=\(GV@#UU_MGGB"ZTX"'P]P469;!TH;\0/>[,@+U-7_````__\#`%!+`P04 M``8`"````"$`6/<&\DL%```/%P``&````'AL+W=OZ6]TFJU'\]I,!`UB5&2EMY_ MO\=.'/S5JJGZ4LK,>'QR9N;$>/7MM6)'4 M(WYF)3P'7A5)@Z_5,:K/%4OV-,!?G[)SK;(5Z4?2%4GU]'R^27EQ1HK'+,^:GS)I&!3I\ONQY%7R MF..Y7\DD255N^<5)7V1IQ6M^:$9(%[5`W6=>1(L(F3:K?88G$+0'%3NLPSNR MW,4DC#8K2="_&;O4VO]!?>*7WZIL_T=6,K"-.HD*/'+^)$*_[X4)BR-G]8.L MP)]5L&>'Y#EO_N*7WUEV/#4H]Q1/)!YLN?]YS^H4C"+-B$Y%II3G`("_09&) MU@`CR:O\O&3[YH3_YJ/I?!P3A`>/K&X>,I$R#-+GNN'%?UU0EZI-0KLD^%1) M)J,Y&2_B.9*\LS#N%N*S6QC/KKN["Z,6O23C/FF2S:KBEP`=!GSU.1']2I9( MIEAH,_2\O$4+^!!)[D26=8C1P!/7J.7+AL1D%;V`_[2+V7IBS(B=BA!E`[P> M(]CY`HPBB\`H2BE`;Y7A"II:@%2$#0A$?0$@D64=3@S2+`3;-H:`F9[9B06R M#[%1(O,7H!19T!R@HD?@UK8+>@]F'V+#1*/K,/WSIQI-!$LT?15;RU0VW8W5 M+%I2O!^'42PN7EGT0C0+08!"W,G04"\&$Z`2&-BZ"PF`?:\]$$V M`000/LZ`C#:W5R:-`\-DD"!F6M_ML\HKTE@P.I-)P]3J`[D_%DJP)C(A>Q_N M!*$,-H#.I/.@F\S=?&(:8W`'C@/I=)!>!5Z93")F-A%O"BBQ%/3]D9#15B5T MT6M5045Y:!=BI=$N&H**L\10(EK10UUZC13G&E$CDXBY340?Y4S&('$DKCHJ MD]X1;^HC\0@DO?T$$:Y"RM0.$;V$4=,H9=([0I=/LR.$5-D=,7PRA+I:[RYE,GFPCN6[:Y3#PR"II*Y4 M*I/.PYM223U2.?M$/[A**3,[@V$?)J]1#@^#E))V&JCW@RZ+W6#H)K,?OD8I MJ:N4RF3V@WVFO$;9/,2#E%)&FP*A3%H_&":#!UR8.'/Q&8&0>2P<(K73$/:I M4BW4M*N]@6DO'0I6'=F.Y7D=I/Q9W*[$%+_<>G-[];.EM\L=6@)<.IX%/`N? M)Q[CODA>^=AKXOXFR?90BFRRYQQ/#$_LVX=.X)EX/5-XY%61DVT&S\R[9@[/ MW.U/"IL#`J[;,ZGC`=<(VCD.O!M>&=MZ("F"=^*UK`9PYNO`56+U34T5M&5-%;1-306T)44!8PZOG#=>0Y.;(?277,RCK( MV0$#-1Z)J\.JO=!LOS3\C,'%I21O&PO=V]R M:W-H965T&ULG%A=;ZLX$'U?:?\#XIV`#?D@2G)U0]7=*^V5 M5JO]>";$25`#CH`V[;_?,>/@#Q*:]*5M.L?#\1G[3)C%M_?BZ+RQJLYYN73) M*'`=5F9\FY?[I?O/W\_>S'7J)BVWZ9&7;.E^L-K]MOKUE\695R_U@;'&@0QE MO70/37.:^WZ='5B1UB-^8B5$=KPJT@8^5GN_/E4LW;:+BJ-/@V#B%VE>NIAA M7MV3@^]V><:>>/9:L++!)!4[I@WPKP_YJ;YD*[)[TA5I]?)Z\C)>G"#%)C_F MS4>;U'6*;/YC7_(JW1QAW^\D2K-+[O9#+WV19Q6O^:X903H?B?;W'/NQ#YE6 MBVT..Q"R.Q7;+=WO9)Z$Q/57BU:@?W-VKK6_G?K`S[]5^?:/O&2@-M1)5&## M^8N`_MB*?\%BO[?ZN:W`GY6S9;OT]=C\Q<^_LWQ_:*#<8]B1V-A\^_'$Z@P4 MA30C.A:9,GX$`O#3*7)Q-$"1]+W]?!J$!.#.AM7-\^`]![8ZZ)%0F"8&]C--[D_A(J-W?4]JDJT7%SPX<&GAD?4K%$21S2'S9 M&-+HMGIKI[!%D>2[R-+F@DW44)ZW%0GHPG\#23.)62,&;H3"F(CD@A"5`'H= M1]BXS3&$$EX7_T))+#(IT=A\WOH*Q$0D?<0TZB`&1]!.YSC,38"7;J1+$81= MWE;2-6+@='1RJ2>WB&0(87"#!]W/38#A>&K/C8E%#2%Q6V=O3*"U!-U@A1GDB;S) MZJ$>0:_T"&KW"`FZ7C"IV%`;,6LJG%KSNOM,A:*_&YY'+=-82Q!>C"B*+=-) MC#C<6*(.KTE1>/;C%-'I38IVMZ`(NDU1CP]1%`:N41QN9.(-V_Y*1]6IQILK M09?CU7TMD@7&%!@-U0DQA?M2PZ!7&@:U:K>6('R^%4QD$%4E<:"]4YC\K';Q MB6KH\%"1SJ<(M=L$O;0!!;*$308A)K^'F@6]TBRH0;$-F)=!73?)#4$=MW%/.1T0T5F@``8W\[K:'=*20()Q#$_O8B)H$B!X8IL77#*1].P0I6[5G" MCL?:R?BKF.`1>''K_HO3Q35,%]M1G-\%8+AW2O?L9UKM\[)VCFP'2X/1%"2K M<#R('QI^:H=0&][`6*_]\P!C7`9#LV`$X!WGS>6#&'MU@^'5_P```/__`P!0 M2P,$%``&``@````A`$P'Q&&3`@``8+ M1L;2)J>U:GB*7[G!=XO/G^8[I9]-Q;E%P-"8%%?6M@DAAE5<4A.HEC?PI5!: M4@M#71+3:D[S;I&L21R&4R*I:+!G2/1'.%11",8SQ3:2-]:3:%Y3"_I-)5K3 MLTGV$3I)]?.FO6%*MD"Q%K6PKQTI1I(ECV6C-%W7X/LE&E/6#,WHIF%9& M%38`.N*%GGN^);<$F!;S7(`#%SO2O$CQ?91D8TP6\RZ?/X+OS,$[,I7:?=4B M_RX:#F%#F5P!UDH].^AC[J9@,3E;_=`5X(=&.2_HIK8_U>X;%V5EH=H3,.1\ M)?EKQ@V#0($FB">.B:D:!,`32>$Z`P*A+]WO3N2V2O%H&DQFX2@".%IS8Q^$ MH\2(;8Q5\J\'17LJ3Q+O2<:@WG^/HR`:A]/K',3KZ>QEU-+%7*L=@I:!'4U+ M70-&"?`Z7R-(QZL8G%XR"@X=R;UC23'T.BPW4)SM(@K#.=E"HFR/6;Z#.4:L M>H2+S]%F?@*>`^WTC96`@\$&1'-HX_VR]&H=V*GM]UGZB<-]XA-IYXC9^!B2 MG4-&%\2.CL6ZS,<7>ZD7[18![B"+*(R.)2P]!JB&O$Y$KJXBLO\ACB('*1^/ MW(&ALPZ4S=["Z8J]])!#\;,3?ZOK$+@#W$876+Q^?\C]*9!B,7'`+ MOQQ)UQ0]O'8GAUXZ7!RX4U,[[GR^<)JB:FW!$'4?X2#'8U7BE)37!K>](.EP M7?00/SU7%SJP->5'Z)JB>[E>OI2DN0#%OJJK_IV3VE931M].+>F*?0VZWY!? ME`,W?S'HFZKL""7'?@9TC@C4U+QR5@XP;=>'"A2PM%L=/F[L'8IRA&QGN^8) M^K/"-SKZWZ)G<4H;:N\TIXT?PDCKDB1N)($G@](GCAZTA&>TM%U M[U]_XNA+1WA*1W^V#`)_L0PA[">.\"O7"T_IB(*9[P;AD@M^XKF0GO!4GT3^ M?,'R9+HY(L^\;&G1%]MU1VX6K`7()+T4;&6A"*B&>@D&5<%_*B!4CI'L&,O& MAD4,M:'0=:];#Z&U\PJ=4DJ;V+296"2#!6L+1IM.@6P*Y"/``45*%I3^$V0Q M%B9K""@>@+M.5U>9#!:#2SH%LBF0CP!-`W3A)VA@+!L;&E.5!JWF>M"QL(&Y M<#?R=9-$F2AA!I(92#Y&-&T0SR=H8RS0N)!`)0X&A1YY+(V>B5,F2IR!9`:2 MCQ%-'*S`J3A?K<8VE?Y.)@,A4[\K$1(Q1:R>B_A.+A#>OVTQC$17(1&6BV'7 M02MO4B)E-(292@0ZZNX63-PR8>0AL9>MPHGZ7)*86A$3L)*[E9(K(<]3NU@V0##`1ER!GKE<6KGCZ8K"I;+2^I3M'89L.+G!%UB? M#B7^>--RPDD*V#<`T@N^4`'Q;D\&1W&Z%,<(X>@]+[ET]$3'(V]QE\J9V;F9 M?W]4='$.%@>J!G*!Q$,X0?X(H+A M]P`/HY@',N%)PBAYA*=A!'/'Y$F7$2QE$\_#*'^$PP5BYSZPC]G%XA'N1G#` M,?EC+X+3@8GO_&@'B88?'*4,+@B7XH1_+;I3U5*KQD=([IQ/P4Y<,<1++P?) MGO1P-8#\PWD6KH(8MITY:\4C(?WPPCZ@+I?;OP$``/__`P!02P,$%``&``@` M```A`'R/Z`OK%```9GL``!D```!X;"]W;W)K&UL MK-U;<]M&EL#Q]ZW:[Z#2>R3QI@O+]E1$W.]`S>X^*S)MJV*)+DF)DV^_IPDT M^O)')%/C>9@D/YQN@'W00'<3H-[]ZZ_[KT=_;A^?[G8/[X]G)V?'1]N'V]W' MNX?/[X__Y]_1+Y?'1T_/-P\?;[[N'K;OC__>/AW_Z\-__]>[[[O'WY^^;+?/ M1U+#P]/[XR_/S]_6IZ=/MU^V]S=/)[MOVP?9\FGW>'_S+/_Y^/GTZ=OC]N;C MOM#]U]/YV=GYZ?W-W<-Q7\/Z\4?JV'WZ='>[#7:W?]QO'Y[[2AZW7V^>Y?B? MOMQ]>]*UW=_^2'7W-X^___'ME]O=_3>IXK>[KW?/?^\K/3ZZOUVGGQ]VCS>_ M?97/_==L>7.KZ][_!ZJ_O[M]W#WM/CV?2'6G_8'R,U^=7IU*31_>?;R33Z": M_>AQ^^G]\:^S=7YCPE=:6/*D, M_+;;_:Y"TX^*I/`I2D?[##2/1Q^WGV[^^/K<[;XGV[O/7YXEW2OY1.J#K3_^ M'6R?;J5%I9J3^4K5=+O[*@<@_W]T?Z=.#6F1F[_V__Q^]_'YR_OC^>7);'EV M+M%'OVV?GJ,[5>/QT>T?3\^[^__K8V9#37T=\Z&.I1Q\OWUQ?K*Z.%O,5"4O M%)2M^YW+/X>"LZL?*G@^%)1_#@67)\OYZN+RM3U>#`7EGT/!^>*']BC]97^H M\L^AX&ILIA<^X=503/XY%%LL3^:7J]EJW\`OE)S)J=!G1AK_L&.=Z82H?SGD M:&<+O4_YEZ'@3#[Q2X\/T^3B!YMTII.A_D7O;7YRN5HMSR\O7CYSU%'U MNS4)>7FWI_V)O^]'PNLN37`?^_#"[NGAW^J?TW=LAYGHBQHW8Z`C5456U@0^A M#Y$/L0^)#ZD/F0^Y#X4/I0^5#[4/C0^M#YT%IY*>,4=R'O^,'*EJ5(YTZUYK M,$F;>PG1$;I(X$/H0^1#[$/B0^I#YD/N0^%#Z4/E0^U#XT/K0V>!DQ"Y/OR, MA*AJWA_+)<3J-)=N!J[[F)F<&F/0T@W9C"%CEB`A)(+$D`220C)(#BD@):2" MU)`&TD(Z6YRD23O_C*2I:N1B*:?&F!!>ZH:@E[(VAHQ9@X20"!)#$D@*R2`Y MI("4D`I20QI("^EL<;(F-T(G:],C.WT;4M'[Y.A&O>YEM;\E_>+=D39ZHYW* MJ[%W.<V#22`A)`($D,22`K)(#FD@)20"E)#&D@+ MZ6QQ&EY&1T[#OW&`HJIQ,S*(W4=E]C9F?S\`V8Q!^H0*("$D@L20!))",D@. M*2`EI(+4D`;20CI;G"3)P,])TLN]5$6[N1C$ZAV0`!)"(D@,22`I)(/DD`)2 M0BI(#6D@+:2SQ6EXF5DY#?_&WJ&J<3,RB-L[9E[O&(/&W@$)(1$DAB20%))! M(D24UFG2R]W#WVX6XV-%D=A!200E)$BDD)*25EI)Q4 MD$I21:I)#:DE=0ZYN9`SVLF%ZC'GDJ!#)[RJ'B])`]E]9K;P1^MJ**\*FE0& MI)`4D6)20DI)&2DG%:225)%J4D-J29U#;M[47,Q>J'BE#_53-QFFZTO3M1JR MNPV_(06DD!218E)"2DD9*2<5I))4D6I20VI)G4-N+M0=G_K*$+FCWH;&@3GC(J(@4DQ)22LI(.:D@E:2*5),:4DOJ''+SIF99 M=MY>Z4/#I,SN0_8\K1\AST`!*21%I)B4D%)21LI)!:DD5:2:U)!:4N>0FPM_ M8JOZT.(-]R%.>=47(/V%SNY#"V_L9J)TAPE((2DBQ:2$E)(R4DXJ2"6I(M6D MAM22.H?H+'G?@$9%B M4D)*21DI)Q6DDE21:E)#:DF=0V[>U'36SMLK]Z%A]FNGQYX0#WT(%*COL]R& M#TD1*28EI)24D7)202I)%:DF-:26U#GDYD+-6NUM*3ML36'.-05-=A_BF@*C M0E)$BDD)*25EI)Q4D$I21:I)#:DE=0ZYN9A:4WC+?8AK"NI11JXI>`^K;$R4 MZ4-C04TAHR)23$I(*2DCY:2"5)(J4DUJ2"VI<\C-FYKKV^.'E^=#\V%IP!XF M8+5@HZ-,MPI((2DBQ:2$E)(R4DXJ2"6I(M6DAM22.H?<7*C)NIV+-ZXIS(=) MOYVD<1W`G@^9YTWZ>:PN:.=M+&CZ$"ABP9B4D%)21LI)!:DD5:2:U)!:4N>0 MFSVY\.DWT[2N`Y@]:&9_]2.+FCWH;&@Z4.@B`5C4D)*21DI)Q6D MDE21:E)#:DF=0T[>U-[D/[<'=-09-I^`TI((6DB!23$E)*RD@YJ2"5 MI(I4DQI22^H<3F[;`UA077%#39?8AK"HP*21$I)B6DE)213F0LW?_;'<6^Y#PSJ`-99;C$L#=A_RGU,P4;K#!*20%)%B M4D)*21DI)Q6DDE21:E)#:DF=0V[>#EM36'!-09/=A[#,$#`J)$6DF)204E)& MRDD%J215I)K4D%I2YY";"S59_QE]:)CTVWVHI_[=YOUK)8M>%N.#C\$@ZGF^ M\96E^UR*IB=)U M90-9U>>,*@Q9U<^]F7IIHG3U%:NO&=48LJOW)C&MB=+5=T[U;L+5>L#/Z*;# MNH*=<"PU;!:@P)#UF6;>E[VAB=*?*1K(RDC,J,207;VWAI^:*%U]QNIS1A6& M[.J]\ZDT4;KZBM77C&H,6=7/O1%W:Z)T]9U3O9/PI;_>T??P$_7V_?.7N]O? MKW=RP91I\L0ZR$+>*-POV/ZZK\5=!M%D.O.&%`PD:YKZ6$-2I,GJS*PKT5%R M\;>N\=[:IK5M_H*-,2+:G3M*_+ M3>3T8HE)Y+]WW_XID?*US)A)KI4L!U)GA/YE@_G<'Z/J*'/\@:9S*[E]7;)V MH'X?8;Z:SQ9>19$N99HKUF3J3C3):&P\J-G*JRL=HM3I/T;-Y]YM/]-UF3WF MFLP>"TTO[K'441?[#[BZ./'.OTH'F)W5FLS.&DVFZ5I-?G=AS=#E#QMHD_^0-/^-VSV%XM0DYP*5E*\3Q/I*','B369 MZA--IOI4TXO59SK*5)]K,M47FDSUI:87JZ]TE*F^UF2J;S29ZEM-)JK3M*_+ M[?/^XL[$1=KNVUS#60[D]FWOAK714>8$#329$S34Y%P@Y]X%,M)1,CX;LS^[ M\*)B'67VF&AZL?^E.LH]"*\39CK*=,)G%/98ZJN^7LS/Y_2+O`E/I M$+.[6I/97:/)-&FKR41UFB9ZN;]D]+9;.5>2E@,YG7_A#6,W0Y33^?N"LLJE MKP?A$*466\;TS^?H_'U!>51*%XQ9?:+)=)]4TXN],]-1IOIHK'66JKS69ZAM-IOI6DXGJ-$UT?K5TA*&Z_.R6M*P:N.G[_0&C.%6C-XH; M2%4ZWOL7WA1CHYZO407-:1H,)`L".H.AIKZCS!<7EW.O7T:Z(M-18DVF[D33 MB_TRU5'NE<#KFIF.,GO,-9D]%II>W&.IHX9[__+DPOM\E8XP>ZLUF;TUFDS; MM9KTS7_FC70Z'3!Q69"#YGFR.GA@J*KQ3HZ!S.FZ68("4DB*2#$I(:6DC)23 M"E))JD@UJ2&UI,XA]T8N)^E$C@[^EF:IZO&2-)!SR5IX<\:-+FA2&9!"4D2* M20DI)66DG%202E)%JDD-J25U#KEY4ZM,]C7XE0'8L.9E;@S7RX%,PV](`2DD M1:28E)!24D;*206I)%6DFM206E+GD)L+M9ADY^*-:Y5+58_7AP9R^Y!W"=[H M@B:5`2DD1:28E)!24D;*206I)%6DFM206E+GD).WE;\"]7(?VH>[Z=%D&GY# M"D@A*2+%I(24DC)23BI():DBU:2&U)(ZA]Q+4YE5_UI%:!K$;UEVATE+D%!8;L@MZ4+#11,J!W/Y*:K-D7WE<.O9_; MR5=Q>F9PO>I)36VM0_=7(734HL)H8G"H:N)RP&'/LQS[$/OR6MU M;]R_60U1IF"@J?]9OK.3R_/9E?,_]_VV4,?OJW#;WQ_@O]+^',BO>G+;?^E/ M\'64W?Y#0W_9?^\%9'V>T_%)SO._'Y M"4Z:<3M.FL,&?2L.^C39-RR,`P-&A:2(%),24DK*2#FI()6DBE23&E)+ZAQR M3Z"I09^:"Q_X>-N*@SY-SO5TZ0_Z3)2^F@6DD!218E)"2DD9*2<5I))4D6I2 M0VI)G4-.WM2OC1UPX=V'NP,-358?(@6DD!218E)"2DD9*2<5I))4D6I20VI) MG4-N+M3XS+X)OG'B=(YQWK4FMP]YHZ6-B1K[$"DD1:28E)!24D;*206I)%6D MFM206E+GD)LW?Q3\\LWSW!Z3[K^)N]9D]Z$ARE#`J)`4D6)20DI)&2DG%:22 M5)%J4D-J29U#;BZFA_4'WX?..:[79#*R(06&[)&8-_H/393N:1$I)B6DE)0- MU#^#X[://T?PIST_])C).:<.FNS6&:(,!4.4>G7.&J?Z4QP395JGK\MZ/B5F M5$)*29DF+M&?J^D!KL#_R5DQR"C`2#J`5/JYV\B5AHHDP[ M]97+;[UIBE%[8LK9M7L#[]1$Z:JR@?K:W?/*G_OXY]6/3:?/.2?2)!_,:@I_ M8F>B],$&FLRW-^%`^JF7L\7*^]"1+F2^&(HUF?0DFN1HQV/B0R\Z:OA"6J8V MWMXR'3%Q)JI9CWTFOG)/Z2=)]ES^?"`94(_'.)][%Z*-B3+MUA>4GYC1%`Y1 MZM=+K+J\;AOI*#.YBUE]HJ-,]:FF%ZO/=!0GWN>'303WX5Z?'&9]SDFV\B?> MNJ`Y$P)-]DDVU"7-:!IKY$TUFCZFFX4O)UM>SC8G29UXPD/WD@B:Y(XPM)P^P MN^!.L M_87Q/[FE[&MT3U]-[NGKY7UCHO2'#0:RGP[0-%RU+L_/O7HB78]UC=1DG:>Z MGI>OD4.4?".[_SM-LY,+KZ-DNFJ>K1=JGF-?(]]VS]E7X[6GJEG(C%PV.LI0 M0`I)$2DF):24E)%R4D$J216I)C6DEM0YY)[^_MRHS]'!XW'YPWW^-QR:G+N& M_\C7QD29DQY3JY!1$2DF):24E)%R4D$J216I)C6DEJ3^'*(YS_N\]7_>L/^S M;/?;Q\_;S?;KUZ>CV]T?ZD\77JKGA4?N_ZZBS%[7:D8F[>MON5!_)\HLS]?J`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````#__P,` M4$L#!!0`!@`(````(0#/BK*."`8``&@7```9````>&PO=V]R:W-H965TKN7C.$)&A" MB("9:?]]CXT-V">=[51STVD>CE]\7G\=O/[\M;K,7HJF+>OK1B-S0YL5U[P^ ME-?31OOG2_AIJLDM]+3;:MZ+5/F]__VW]6C=/[;DHNADH7-N-=NZZ MFZ?K;7XNJJR=U[?B"D^.=5-E'?QL3GI[:XKLP!I5%]TT#$>OLO*J]0I>\S,: M]?%8YH5?Y\]5<>UZD::X9!WTOSV7MU:H5?G/R%59\_1\^Y37U0TD'LM+V7UC MHMJLRKWD=*V;[/$">7\EBRP7VNP'DJ_*O*G;^MC-04[O.XIS7NDK'92VZT,) M&5#;9TUQW&@/Q$N)J^G;-3/HW[)X;2?_G[7G^C5JRL,?Y;4`MV&$.8C;PA<>=D83C_TV[%V\%?T6[Q M,^T(^-NG2XWFJ;SU1KVWB[GO9UVV73?UZPRF-!C2WC*Z0(A'587OO4O#2/QH M(&`$J,H#E=EHD#YXW,+L>=F:[FJMO\"(YSQFAV.('+$7$71XJ:RO@D`%H0HB M%<0J2%203H`.M@S>P'3X"&^H#/5&9+438&*68H2($$U\%00J"%40J2!60:*" M=`(D(V`]?(015&:CP5H9)\G2D#/?]3$$AF0(6L@A^R%D<`>1`)$0D0B1&)$$ MD71*)),@KX\PB72$#*XA$B`2(A(A$B,2()(.B622["/ M2B[=W]_%MD*CF1DBB5U/;+;%?%)VF+UX.+%N.>XQ4C^<=_6#1LO]X*0_/^A> MM4?$1R1`)$0D0B1&)$$DG1(I45=)E&[P*]CHW[G!4QG9`4ZF<]!C\G=5AP?G+"W]>#YEC><$8,-K"7\5286^/ MD'`\MF,?(091]J1D#!#"*4?DCD>TCGG+HR_U[4<>P:??8!(OAZ8F<43-'CZ9 MEHH+>^@2FWFCE[Y`SF!XP)%%>C,M=VDJE5$H6HU?(9%`HW8LT*B=R-K68N58 MMKS+IZ(5TY87("W(IO;=F4I3F_KZ#::L&)H=O0*@2P_V\HE-2@_V8Y1HZ'-D MLEL'-ED"CBR3V426CJ/,C5`T&CL08>E81(W2B2QMVH[KJ";UB9A,6C:)EFY3 MD_I=ZKWKD!>`8]=WA"-X\^B=X[3&0^[!K0W?Q,0"?<>.QJO&J9,< MR;-0&>(]7(_QN2JR]3F".2Y0(-"JGX5DX2X=Y4P(1UZP/UMX,[UH+B& MG%2^]*`6O<-7'I1C=S@QX%J1+215B=`+1U98*$_@7/7H28?5X%3QZ,&!G\"Q M`&WN/8%[S8=[6COZ^CM*.].#:Q+\AIWEP=4`Y@\+[P$LQP]V"P^^DN]PQX./ M.>#ZD#?<<]ZR4_%GUIS*:SN[%$<8%H-M$$U_4]K_Z/AA]%AW<,/)SJ4SW&@7 M\'5JT`5QK.M._*`O&.[(M]\!``#__P,`4$L#!!0`!@`(````(0#MDF7:9@8` M`/\8```9````>&PO=V]R:W-H965T?#ROSK6_1E81I=GY]W^:DYEROS M>]F97Q]__>7AO6E?NF-9]@8PG+N5>>S[2V!977$LZ[R;-)?R#&_V35OG/?QL M#U9W:P]'L]]71;EIBM>Z//>4I"U/>0_][X[5 MI4.VNKB'KL[;E]?+EZ*I+T#Q7)VJ_OM`:AIU$:2'<]/FSR<8]X

XML 15 R33.htm IDEA: XBRL DOCUMENT

Restructuring Expenses (Details) (USD $)	3 Months Ended	12 Months Ended
Restructuring Expenses (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013 Employee
Accrued Expenses [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve balance, net	$ 1,200,000
Other non-current liabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve balance, net	200,000
Operating Expense [Member]
Restructuring Cost and Reserve [Line Items]
Number of positions eliminated		50
Severance costs		4,000,000
Restructuring Reserve [Roll Forward]
Restructuring reserve balance, gross		3,974,000
Restructuring expenses paid	(2,606,000)
Restructuring reserve balance, net	$ 1,368,000

- Definition

Amount of cash paid in the period to fully or partially settle a specified, previously accrued type of restructuring cost.

+ References+ Details

- Definition

The charge against earnings in the period for known and estimated costs of termination benefits provided to current employees that are involuntarily terminated under a benefit arrangement associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination or a discontinued operation as defined by generally accepted accounting principles and costs associated with one-time termination benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 146

-Paragraph 8-13, 20

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4(b))

-URI http://asc.fasb.org/extlink&oid=6394695&loc=d3e140904-122747

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 5.P.3)

-URI http://asc.fasb.org/extlink&oid=6394695&loc=d3e140864-122747

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS146-1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)(10)

-URI http://asc.fasb.org/extlink&oid=21915506&loc=d3e1928-114920

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 112

-Paragraph 7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 132R

-Paragraph 5-8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 R25.htm IDEA: XBRL DOCUMENT

Stockholders Equity (Tables)

3 Months Ended

Mar. 31, 2014

Stockholders Equity [Abstract]

Stock option activity

	Stock Option Activity under the Plans
	Stock Options			Exercise Price per Share		Weighted Average Exercise Price		Weighted Average Remaining Life (Years)
Outstanding at December 31, 2013		252,133		$	4.80—$248.64	$	57.90		7.36
Granted		—			—		—
Forfeited		(14,304	)	$	7.36—$248.64	$	109.54
Expired		—			—		—
Outstanding at March 31, 2014		237,829		$	4.80—$248.64	$	54.79		7.13

Assumptions used to determine the fair value of stock options

		Three months ended March 31, 2013
Dividend yield		None
Expected volatility		86.16% — 86.51%
Weighted average volatility		86.20%
Risk-free interest rates		1.16% — 1.36%
Expected life (in years)		6.8

Restricted stock activity

Restricted stock activity for the three months ended March 31, 2014 is as follows:

	Restricted Stock Activity under the Plans
	Restricted Stock			Weighted Average Grant Date Fair Value
Non-vested at December 31, 2013		20,358		$	16.88
Granted		—			—
Vested		(1,624	)		75.32
Forfeited		(71	)		39.26
Non-vested at March 31, 2014		18,663		$	11.71

XML 18 R37.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share (Details)	3 Months Ended
Net Loss per Common Share (Details)	Mar. 31, 2014	Mar. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,147,860	715,565
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	237,829	349,635
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	18,663	25,676
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	891,368	340,254

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

XML 19 R9.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets

3 Months Ended

Mar. 31, 2014

Prepaid Expenses and Other Current Assets [Abstract]

Prepaid Expenses and Other Current Assets

(3)	Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:

(in thousands)	March 31, 2014		December 31, 2013
Insurance premiums	$	310	$	407
Professional fees		75		377
Income tax credits receivable		297		326
Kits for clinical use		295		287
Other¹		315		314
Total prepaid expenses and other current assets	$	1,292	$	1,711

¹ Other consists of various prepaid expenses and other current assets with no individual item accounting for more than 5% of the total balance at March 31, 2014 and December 31, 2013.

EXCEL 20 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\X-3)E-S1D8E]F-CEF7S1C-35?.#9E-U\U,#4V M9#$P8S'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/DEN=F5N=&]R:65S/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O'!E;G-E#I% M>&-E;%=O#I% M>&-E;%=O#I.86UE/D%C8W)U961?17AP96YS97,\ M+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O3PO>#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/D9A:7)?5F%L=65?365A#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E1A>&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T M4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D=E;F5R86Q?4&]L:6-I97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I%>&-E M;%=O#I%>&-E;%=O'!E;G-E#I7;W)K#I%>&-E;%=O M#I.86UE/E-T;V-K:&]L9&5R#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O M#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E!R97!A:61?17AP96YS97-?86YD7T]T M:&5R7T-U#I7;W)K5]0;&%N=%]A;F1?17%U:7!M96YT7T0\+W@Z3F%M93X-"B`@ M("`\>#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O M#I! M8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E M;%=O7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA2!);F9O'0^)SQS<&%N M/CPO'0^)T1%3$-!5$@@4UE35$5-4RP@24Y#+CQS<&%N/CPO2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)S`P M,#`X-S(Y,3(\2!7 M96QL+6MN;W=N(%-E87-O;F5D($ES'0^)TYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQS<&%N/CPO2!&:6QE2!#=7)R M96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS M<&%N/CPO'0^36%R(#,Q+`T*"0DR,#$T/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-3)E-S1D M8E]F-CEF7S1C-35?.#9E-U\U,#4V9#$P8S'0O:'1M;#L@8VAA'1E96X@*#$Z,38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\X-3)E-S1D8E]F-CEF7S1C-35?.#9E-U\U,#4V9#$P8S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-3)E-S1D8E]F-CEF M7S1C-35?.#9E-U\U,#4V9#$P8S'0O M:'1M;#L@8VAA'0^ M)SQS<&%N/CPO'1E96X@*#$Z,38I/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)V]N92UF M;W(M7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XT,CQS<&%N/CPO6%B;&4@86YD(&%C8W)U960@97AP M96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA2P@<&QA;G0L(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@("`@ M("`\=&0@8VQA&5R8VES92!O9B!S=&]C:R!O<'1I;VYS(&%N9"!W87)R86YT2!F:6YA;F-I;F<@86-T:79I=&EE7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A3H@ M)U1I;65S($YE=R!2;VUA;B6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL M>3H@)U1I;65S($YE=R!2;VUA;B3L@9F]N="UF86UI;'DZ("3H@)R=4:6UEF4Z(#$P<'0[)SYW=W6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$P<'0[)SY/;B!&96)R=6%R>2`R-"P@,C`Q M-"P@FEN9R!T:&4@0F]A'1E96X@ M*#$Z,38I('-P;&ET+6%D:G5S=&5D(&)A&-H86YG M92!F;W(@2!T M:&4@;VYE+69O6EN9R!.;W1E6QE.B!I M=&%L:6,[('1E>'0M:6YD96YT.B`Q.'!T.R!F;VYT+69A;6EL>3H@)R=4:6UE MF4Z(#$P<'0[ M(&9O;G0M=V5I9VAT.B!B;VQD.R<^1&5S8W)I<'1I;VX@;V8@0G5S:6YE3L@9F]N="UF86UI;'DZ("2!P M:&%R;6%C975T:6-A;"!A;F0@;65D:6-A;"!D979I8V4@8V]M<&%N>2!F;V-U M3H@)R=4:6UE7-T96TN)B,Q-C`[(%1H92!R:6=H="!T M;R!A9F9I>"!T:&4@0T4@;6%R:R!A;&QO=W,@=&AE($-O;7!A;GD@=&\@;6%R M:V5T(&%N9"!S96QL('1H92!#2$5-3U-!5"!S>7-T96T@:6X@175R;W!E+B!4 M:&4@0V]M<&%N>2!H87,@:6YI=&EA=&5D('!L86YS('1O(&EN=F5S=&EG871E M('1H92!-96QP:&%L86XO2$13('-Y2!L:79E6QE/3-$)W1E M>'0M86QI9VXZ(&IUF4Z(#$P<'0[)SY4:&4@0V]M<&%N>2!H87,@:6YC=7)R960@;&]S2!B92!R97%U:7)E9"!T;R!C M;VYT:6YU92!O<&5R871I;VYS+B!4;R!T:&4@97AT96YT(&%D9&ET:6]N86P@ M8V%P:71A;"!I2!M87D@8F4@9F]R8V5D('1O(&%B86YD;VX@'!E6QE.B!I=&%L:6,[('1E>'0M:6YD96YT.B`M.7!T.R!F M;VYT+69A;6EL>3H@)R=4:6UE3H@)R=4:6UE2!A8V-E M<'1E9"!A8V-O=6YT:6YG('!R:6YC:7!L97,@:6X@=&AE(%5N:71E9"!3=&%T M97,@;V8@06UE3H@)R=4:6UE28C.#(Q-SMS(')E6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$ M)W1E>'0M86QI9VXZ(&IUF4Z(#$P<'0[)SY!(&1E3H@)R=4:6UE2!T;R!R96QE87-E M(&-U;75L871I=F4@=')A;G-L871I;VX@861J=7-T;65N=',@:6YT;R!N970@ M:6YC;VUE('=H96X@82!R97!O2P@=&AE(&-U;75L871I=F4@=')A;G-L871I;VX@861J=7-T;65N="!S M:&]U;&0@8F4@2`Q M+"`R,#$T+B8C,38P.R!4:&4@0V]M<&%N>28C.#(Q-SMS(&%D;W!T:6]N(&]F M('1H:7,@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\X-3)E-S1D8E]F-CEF7S1C-35?.#9E-U\U,#4V9#$P8S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO6QE/3-$)V9O;G0M9F%M M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$P<'0[)SX\='(^/'1D('-T>6QE/3-$)W=I9'1H.B`Q.'!T.R!F M;VYT+69A;6EL>3H@)R=4:6UEF4Z(#$P<'0[('9E6QE/3-$)W1E>'0M86QI9VXZ(&IU MF4Z(#$P<'0[ M)SY);G9E;G1O6QE/3-$)W=I9'1H.B`Y,"4[(&9O M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E#L@ M=VED=&@Z(#8V)3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@3H@)R=4:6UE6QE/3-$)W!A9&1I;F"!S;VQI9#L@=F5R=&EC86PM86QI M9VXZ(&)O='1O;3LG/CQD:78@3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^36%R M8V@@,S$L/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([ M(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F3H@)R=4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXR,S(\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C M8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)A M8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S M($YE=R!2;VUA;B6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A M8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXS-C0\+V1I M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UE6QE/3-$)W!A9&1I;F"!S;VQI9#L@=&5X="UA;&EG;CH@ M;&5F=#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[)SXQ,3D\+V1I=CX\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ M(&QE9G0[(&)A8VMG"!S;VQI9#L@=&5X="UA;&EG;CH@#L@8F%C M:V=R;W5N9"UC;VQO6QE/3-$)W!A9&1I;F"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K M9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I M;65S($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W!A9&1I;F"!D;W5B M;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD M+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE M=R!2;VUA;B#L@8F%C:V=R;W5N9"UC;VQO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\X-3)E-S1D8E]F-CEF7S1C-35?.#9E-U\U,#4V9#$P8S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'!E M;G-E'0^)SQS<&%N/CPO M'!E;G-E6QE/3-$)V9O;G0M9F%M M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$P<'0[)SX\='(^/'1D('-T>6QE/3-$)W=I9'1H.B`Q.'!T.R!F M;VYT+69A;6EL>3H@)R=4:6UEF4Z(#$P<'0[('9E6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$P<'0[)SY06QE/3-$ M)W=I9'1H.B`Y,"4[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@ M5&EM97,L('-E#L@=VED=&@Z(#8V)3L@=F5R=&EC86PM86QI9VXZ(&)O M='1O;3LG/CQD:78@6QE/3-$)W!A9&1I M;F"!S;VQI M9#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@#L@=VED=&@Z(#$E.R!V97)T:6-A M;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F3H@)R=4:6UE3H@)R=4:6UEF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R M.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA M;B6QE/3-$)V)A8VMG6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SY06QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C M9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXS-S<\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&)A8VMG3H@)R=4:6UE6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXS,C8\+V1I=CX\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UE6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[ M('9E6QE/3-$)V9O;G0M M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)A8VMG#L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P M<'0[)SY/=&AE'0M=&]P.R<^,3PO M'0M86QI9VXZ(&QE9G0[(&)A8VMG M"!S;VQI9#L@=&5X M="UA;&EG;CH@#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W M:61T:#H@.24[('9E6QE M/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC M;VQO6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W!A9&1I;F"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE M9G0[(&)A8VMG"!D;W5B;&4[('1E M>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W M:61T:#H@.24[('9E6QE M/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O3H@ M)R=4:6UEF4Z M(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)V)O6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F3L@9F]N="UF86UI;'DZ("'0M=&]P.R<^,3PO M3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\X-3)E-S1D8E]F-CEF7S1C-35?.#9E-U\U,#4V9#$P M8S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M2P@4&QA;G0L(&%N M9"!%<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@ M5&EM97,L('-EF4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&IUF4Z(#$P<'0[)SX\='(^/'1D('-T M>6QE/3-$)W=I9'1H.B`Q.'!T.R!F;VYT+69A;6EL>3H@)R=4:6UEF4Z(#$P<'0[('9E3H@)R=4:6UEF4Z(#$P M<'0[)SX\='(^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG M+6)O='1O;3H@,G!X.R!W:61T:#H@-C8E.R!V97)T:6-A;"UA;&EG;CH@8F]T M=&]M.R<^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T M>6QE.B!I=&%L:6,[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY M.B`G)U1I;65S($YE=R!2;VUA;B#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T M=&]M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@)R=4 M:6UEF4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^,C`Q,SPO9&EV/CPO=&0^/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!V M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT M.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B3H@)R=4 M:6UEF4Z(#$P M<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F M.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UE MF4Z(#$P<'0[ M)SXQ+#6QE/3-$)V)A8VMG6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)A8VMG M6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&)A8VMG3H@)R=4:6UE MF4Z(#$P<'0[ M)SXY-3<\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UE6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@ M.24[('9E6QE/3-$)V9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&)A8VMG3H@)R=4:6UE MF4Z(#$P<'0[ M)SXQ+#4U,CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)V)A8VMG6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXR M+#`P.3PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@6QE/3-$ M)V)A8VMG6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UE'0M86QI9VXZ(&QE9G0[ M(&)A8VMG"!S;VQI M9#L@=&5X="UA;&EG;CH@#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E M969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B#L@8F%C:V=R M;W5N9"UC;VQO6QE/3-$)V)A8VMG6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B M86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G M)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG M3H@)R=4:6UEF4Z(#$P<'0[)SXW+#`P-#PO9&EV M/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR M<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W!A9&1I;F"!S;VQI9#L@=&5X M="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[)SXH M-"PP-C8\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI M9VXZ(&QE9G0[(&)A8VMG"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0M9F%M M:6QY.B`G)U1I;65S($YE=R!2;VUA;B#L@8F%C:V=R M;W5N9"UC;VQO6QE/3-$)V9O;G0M9F%M:6QY.B`G M)U1I;65S($YE=R!2;VUA;B3H@)R=4:6UEF4Z(#$P<'0[)SXR+##L@8F%C:V=R;W5N9"UC;VQO M6QE/3-$)W!A M9&1I;F"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG M"!D;W5B;&4[('1E>'0M86QI9VXZ M(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[ M('9E6QE/3-$)V9O;G0M M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B'!E;G-E M(&9O7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'!E;G-E3H@)U1I;65S($YE=R!2 M;VUA;B6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@)U1I;65S($YE M=R!2;VUA;B3L@=VED=&@Z(&%U=&\[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE M=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$P<'0[)SY!8V-R=65D(&5X M<&5N6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$P<'0[)SXF(S$V,#L\+V1I=CX\=&%B;&4@8F]R M9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE M/3-$)W=I9'1H.B`Y,"4[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N M)RP@5&EM97,L('-E#L@=VED=&@Z(#8V)3L@=F5R=&EC86PM86QI9VXZ M(&)O='1O;3LG/CQD:78@6QE/3-$)W!A M9&1I;F"!S M;VQI9#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R<^36%R8V@@,S$L/"]D:78^/&1I=B!S='EL93TS1"=T M97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2 M;VUA;B#L@=VED=&@Z(#$E.R!V97)T M:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@)R=4:6UE&5S/"]D:78^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG M3H@)R=4:6UE MF4Z(#$P<'0[ M)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W M:61T:#H@.24[('9E6QE M/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SY$969E6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMGF4Z(#$P<'0[)SXT.#4\+V1I=CX\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UE6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG M3H@)R=4:6UEF4Z(#$P<'0[)SXS-C`\+V1I=CX\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UE6QE/3-$)W!A9&1I;F"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@8F%C:V=R;W5N9"UC M;VQO6QE/3-$ M)V)O3H@)R=4:6UEF4Z(#$P<'0[)SXX,3<\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0[(&)A8VMG"!S;VQI9#L@=&5X="UA;&EG M;CH@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F3H@)R=4:6UEF4Z(#$P M<'0[)SY4;W1A;"!A8V-R=65D(&5X<&5N6QE/3-$)W!A9&1I;F"!D;W5B;&4[ M('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O M;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2 M;VUA;B#L@8F%C:V=R M;W5N9"UC;VQO6QE/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3L@9F]N="UF86UI;'DZ("'0M=&]P.R<^,3PO3L@9F]N="UF86UI;'DZ(" XML 21 R29.htm IDEA: XBRL DOCUMENT

Inventories (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Inventories [Abstract]
Raw materials	$ 232	$ 249
Work-in-process	268	364
Finished goods	119	106
Total inventory	$ 619	$ 719

XML 22 R28.htm IDEA: XBRL DOCUMENT

General (Details) (USD $)	3 Months Ended		12 Months Ended
General (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Reverse stock split ratio	one-for-sixteen (1:16)	one-for-sixteen (1:16)	one-for-sixteen (1:16)
Common stock, shares authorized (in shares)	170,000,000		170,000,000
Common stock, par value (in dollars per share)	$ 0.01		$ 0.01
Minimum [Member]
Class of Warrant or Right [Line Items]
Reverse stock split ratio	one-for-eight (1:8)
Maximum [Member]
Class of Warrant or Right [Line Items]
Reverse stock split ratio	one-for- sixteen (1:16)

XML 23 R30.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets (Details) (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2014

Dec. 31, 2013

Prepaid expenses and other current assets [Abstract]

Insurance premiums

$ 310

$ 407

Professional fees

377

Income tax credits receivable

297

326

Kits for clinical use

295

287

Other

315

^[1]

314

^[1]

Total prepaid expenses and other current assets

$ 1,292

$ 1,711

Maximum percentage of prepaid expenses and other current assets (in hundredths)

5.00%

[1]	Other consists of various prepaid expenses and other current assets with no individual item accounting for more than 5% of the total balance at March 31, 2014 and December 31, 2013.

- Definition

Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.

+ References+ Details

- Definition

The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References+ Details

- Definition

Carrying amount as of the balance sheet date of unamortized costs of insurance coverage, which will be charged against earnings ratably over the period in which contractually agreed upon coverage's will be in effect; such periods expire within one year or the normal operating cycle, if longer.

+ References+ Details

XML 24 R31.htm IDEA: XBRL DOCUMENT

Property, Plant, and Equipment (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 6,804		$ 7,004
Accumulated depreciation	(4,066)		(3,935)
Property, plant and equipment, net	2,738		3,069
Depreciation expense	249	298
Leaseholds [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,748		1,749
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	957		957
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,487		1,552
Enterprise Hardware and Software [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,009		2,143
Buildings and Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 603		$ 603

- Definition

The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.

+ References+ Details

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References+ Details

- Definition

Gross amount of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References+ Details

- Definition

Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References+ Details

XML 25 R8.htm IDEA: XBRL DOCUMENT

Inventories

3 Months Ended

Mar. 31, 2014

Inventories [Abstract]

Inventories

(2)	Inventories

Inventories consist of the following:

(in thousands)	March 31, 2014		December 31, 2013
Raw materials	$	232	$	249
Work-in-process		268		364
Finished goods		119		106
Total inventory	$	619	$	719

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

XML 26 R32.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Details) (USD $)
In Thousands, unless otherwise specified

12 Months Ended

Dec. 31, 2013

Mar. 31, 2014

Accrued Expenses [Abstract]

Compensation, excluding taxes

$ 1,866

$ 1,853

Deferred rent

485

483

Professional fees

360

323

Other

1,029

^[1]

817

^[1]

Total accrued expenses

$ 3,740

$ 3,476

Maximum percentage of current liabilities accrued (in hundredths)

5.00%

Percentage of current annual salary as cash retention bonus (in hundredths)

50.00%

[1]	Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at March 31, 2014 and December 31, 2013.

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6911-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 8

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

+ Details

- Definition

For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.

+ References+ Details

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

XML 27 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2014

Dec. 31, 2013

Current assets

Cash and cash equivalents

$ 31,254

$ 31,249

Accounts receivables, net

181

349

Inventories, net

619

719

Prepaid expenses and other current assets

1,292

1,711

Total current assets

33,346

34,028

Property, plant and equipment, net

2,738

3,069

Total assets

36,084

37,097

Current liabilities

Accounts payable

334

582

Accrued expenses

3,476

3,740

Warrant liability

2,399

2,310

Total current liabilities

6,209

6,632

Other non-current liabilities

225

366

Total liabilities

6,434

6,638

Commitments and contingencies (Note 12)

Stockholders' equity

Preferred stock, $.01 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2014 and December 31, 2013

Common stock, $.01 par value; 170,000,000 shares authorized; 9,433,703 and 8,394,397 shares issued and 9,431,907 and 8,392,641 shares outstanding at March 31, 2014 and December 31, 2013, respectively

^[1]

Additional paid-in capital

263,923

259,102

Accumulated deficit

(234,410)

(229,132)

Treasury stock, at cost; 1,757 shares at March 31, 2014 and December 31, 2013

(51)

^[1]

(51)

^[1]

Accumulated other comprehensive income

Total stockholders' equity

29,650

30,099

Total liabilities and stockholders' equity

$ 36,084

$ 37,097

[1]	Reflects a one-for- sixteen (1:16) reverse stock split effected on April 8, 2014.

XML 28 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:
Net loss	$ (5,278)	$ (12,845)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	178	467
Restricted stock compensation expense	42	197
Depreciation expense	249	298
Warrant liability fair value adjustment	205	2,272
Loss on write-downs and disposal of equipment	82	0
Non-cash interest income	0	(2)
Changes in assets and liabilities:
Decrease (increase) in prepaid expenses and other current assets	419	(248)
Decrease in accounts receivable	169	85
Decrease (increase) in inventories	99	(97)
Decrease in accounts payable and accrued expenses	(512)	(764)
Decrease in other non-current liabilities	(140)	(300)
Net cash used in operating activities	(4,487)	(10,937)
Cash flows from investing activities:
Purchase of property, plant, and equipment	0	(34)
Net cash used in by investing activities	0	(34)
Cash flows from financing activities:
Net proceeds from sale of stock and exercise of stock options and warrants	4,495	30,018
Net cash provided by financing activities	4,495	30,018
Foreign currency effects on cash	(3)	31
Net increase in cash and cash equivalents	5	19,078
Cash and cash equivalents:
Beginning of period	31,249	23,726
End of period	31,254	42,804
Supplemental non-cash activities:
Fair value of warrants exercised	$ 116	$ 214

XML 29 R35.htm IDEA: XBRL DOCUMENT

Stockholders Equity, Stock Incentive Plans (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Stock Options [Member]
Stock Options [Roll Forward]
Outstanding at December 31, 2013 (in shares)	252,133
Granted (in shares)	0
Forfeited (in shares)	(14,304)
Expired (in shares)	0
Outstanding at March 31, 2014 (in shares)	237,829
Weighted Average Exercise Price [Roll Forward]
Outstanding at December 31, 2013 (in dollars per share)	$ 57.90
Forfeited (in dollars per share)	$ 109.54
Outstanding at March 31, 2014 (in dollars per share)	$ 54.79
Weighted Average Remaining Life [Abstract]
Weighted Average Remaining Life	7 years 1 month 17 days	7 years 4 months 10 days
Assumptions used to determine the fair value of stock options [Abstract]
Dividend yield (in hundredths)		0.00%
Weighted average volatility (in hundredths)		86.20%
Expected life		6 years 9 months 18 days
Stock Options [Member] \| Minimum [Member]
Stock Options, Exercise Price per Share [Roll Forward]
Outstanding at December 31, 2013 (in dollars per share)	$ 4.80
Forfeited (in dollars per share)	$ 7.36
Outstanding at March 31, 2014 (in dollars per share)	$ 4.80
Assumptions used to determine the fair value of stock options [Abstract]
Expected volatility (in hundredths)		86.16%
Risk-free interest rates (in hundredths)		1.16%
Stock Options [Member] \| Maximum [Member]
Stock Options, Exercise Price per Share [Roll Forward]
Outstanding at December 31, 2013 (in dollars per share)	$ 248.64
Forfeited (in dollars per share)	$ 248.64
Outstanding at March 31, 2014 (in dollars per share)	$ 248.64
Assumptions used to determine the fair value of stock options [Abstract]
Expected volatility (in hundredths)		86.51%
Risk-free interest rates (in hundredths)		1.36%
Restricted Stock [Member]
Restricted Stock [Roll Forward]
Outstanding at December 31, 2013 (in shares)	20,358
Granted (in shares)	0
Vested (in shares)	(1,624)
Forfeited (in shares)	(71)
Outstanding at March 31, 2014 (in shares)	18,663
Weighted Average Grant Date Fair Value [Roll Forward]
Outstanding at December 31, 2013 (in dollars per share)	$ 16.88
Granted (in dollars per share)	$ 0
Vested (in dollars per share)	$ 75.32
Forfeited (in dollars per share)	$ 39.26
Outstanding at March 31, 2014 (in dollars per share)	$ 11.71

XML 30 R22.htm IDEA: XBRL DOCUMENT

Property, Plant, and Equipment (Tables)

3 Months Ended

Mar. 31, 2014

Property, Plant, and Equipment [Abstract]

Components of property, plant and equipment

Property, plant, and equipment consist of the following:

(in thousands)	March 31, 2014			December 31, 2013
Leaseholds	$	1,748		$	1,749
Furniture		957			957
Equipment		1,487			1,552
Enterprise hardware and software		2,009			2,143
Buildings and land		603			603
Property, plant and equipment, gross		6,804			7,004
Accumulated depreciation		(4,066	)		(3,935	)
Property, plant and equipment, net	$	2,738		$	3,069

- Definition

Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.

+ References+ Details

XML 31 R36.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) (USD $)	3 Months Ended
Fair Value Measurements (Details) (USD $)	Mar. 31, 2014 Input
Derivative warrant liability [Abstract]
Number of inputs used for valuation of warrants	6
Pre-tax derivative instrument expense	$ 200,000
Hypothetical change in market price of common shares (in hundredths)	10.00%
Impact of the hypothetical change in market price of common shares on derivative liability	300,000
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Roll Forward]
Beginning balance as of December 31, 2013	2,310,000
Total change in the liability included in earnings	205,000
Fair value of warrants exercised	(116,000)
Ending balance as of March 31, 2014	2,399,000
Recurring [Member] \| Warrant liability [Member]
Liabilities [Abstract]
Total Liabilities	2,399,000
Recurring [Member] \| Warrant liability [Member] \| Level 1 [Member]
Liabilities [Abstract]
Total Liabilities	0
Recurring [Member] \| Warrant liability [Member] \| Level 2 [Member]
Liabilities [Abstract]
Total Liabilities	0
Recurring [Member] \| Warrant liability [Member] \| Level 3 [Member]
Liabilities [Abstract]
Total Liabilities	2,399,000
Recurring [Member] \| Money market funds [Member]
Assets [Abstract]
Total Assets	1,945,000
Recurring [Member] \| Money market funds [Member] \| Level 1 [Member]
Assets [Abstract]
Total Assets	1,945,000
Recurring [Member] \| Money market funds [Member] \| Level 2 [Member]
Assets [Abstract]
Total Assets	0
Recurring [Member] \| Money market funds [Member] \| Level 3 [Member]
Assets [Abstract]
Total Assets	$ 0
2009 Warrants [Member]
Derivative warrant liability [Abstract]
Expected volatility (in hundredths)	101.78%
Risk-free interest rates (in hundredths)	0.05%
Expected life (in years)	0 years 2 months 16 days
2012 Warrants [Member]
Derivative warrant liability [Abstract]
Expected volatility (in hundredths)	114.33%
Risk-free interest rates (in hundredths)	0.21%
Expected life (in years)	1 year 2 months 1 day
2013 Warrants [Member]
Derivative warrant liability [Abstract]
Expected volatility (in hundredths)	91.53%
Risk-free interest rates (in hundredths)	1.52%
Expected life (in years)	4 years 6 months 29 days

XML 32 R24.htm IDEA: XBRL DOCUMENT

Restructuring Expenses (Tables)

3 Months Ended

Mar. 31, 2014

Restructuring Expenses [Abstract]

Schedule of restructuring and related costs

The following table provides the total severance expense incurred and payments made by the Company through March 31, 2014 as a result of the workforce restructurings implemented in 2013:

(in thousands)	March 31, 2014
Restructuring reserve balance, gross	$	3,974
Restructuring expenses paid		(2,606	)
Restructuring reserve balance, net	$	1,368

- Definition

Tabular disclosure of restructuring and related costs by type of restructuring including the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost.

+ References+ Details

XML 33 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 34 R7.htm IDEA: XBRL DOCUMENT

General

3 Months Ended

Mar. 31, 2014

General [Abstract]

General

(1)

General

Description of Business

Basis of Presentation

Significant Accounting Policies

A description of our significant accounting policies has been provided in Note 3 Summary of Significant Accounting Policies to the Consolidated Financial Statements included in our Annual Report.

Recently Adopted Accounting Pronouncements

XML 35 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	170,000,000	170,000,000
Common stock, shares issued (in shares)	9,433,703	8,394,397
Common stock, shares outstanding (in shares)	9,431,907	8,392,641
Treasury stock, at cost (in shares)	1,757	1,757
Reverse stock split ratio	one-for-sixteen (1:16)	one-for-sixteen (1:16)

XML 36 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2014

Commitments and Contingencies [Abstract]

Commitments and Contingencies

(11)	Commitment and Contingencies

The Company is a party to several legal proceedings. Refer to Part II, Item 1 Legal Proceedings in this Quarterly Report on Form 10-Q for more information.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

XML 37 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2014	May 06, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	DELCATH SYSTEMS, INC.
Entity Central Index Key	0000872912
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		9,442,197
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2014

ZIP 38 0001140361-14-019389-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-14-019389-xbrl.zip M4$L#!!0````(`!J%IT27C-M'.GX``$#8!@`1`!P`9&-T:"TR,#$T,#,S,2YX M;6Q55`D``U2::E-4FFI3=7@+``$$)0X```0Y`0``[%UY<^,VLO__5;WO@/5N MLI,JR29UV?(<6QX?NZYXQHX]V:.V7J5@$I*PPT,!2-O:3_^ZP4,414F494FD MQ%0ED8D&T.C^H=$`&L"'O[S8%GEB0G+7^7B@'VH'A#F&:W*G__'`EW4J#K?;)G72T/0F^39P;>DZY)[Y'M1-S@R#6;X\)&>6112Y M)()))IZ8>5BO8^TOC\(BP*PC3_$G_W@P\+SAZ='1\_/S(7XY=$7_J*%IS2/N M2(\Z!CL(Z2WN?)]#CLF/5,;D+U/TSTU%#2WH'JG4F%3R+$(H5C_ZYY>;!V/` M;%I/\X/5F^.,26XZ1T%B1,JEVVKHQ_,:&U#$&9PG)KW)LB4S#OONTU&0!MGT M1EW3ZTT]R@1Z[E,ZC'/UJ'Q4-80)&5E,QK,K@82L&CPQLPW=(TB-"!W?SB8T M/7'DC8;L""B8X$:BJ?X?J.)T;9C0@3,QIB^$)`!YF5+TS-R.A0 M;LCL7"H)L^B3620WLC-`0A:Y-Q0SZ"$E(P-[,0;9&3`E2^F&-\Y@,LN@WN#0 M<&TD;6G-F#!/WX0^3<@'[$RG4G63>]8CJG.=HLH^'DAN#RWL,^K;0+#>QP-D MH!Y5=O@BS0-R%!2D;`(HU?'8BT>X^?'`4'2ZIGMNS)ZBC:F9XW%O%'Z+OW(3 MO_EC--2F9AC)K(T06?CBLU$ANAKHNKH4RB[^>)L:YU2"#&` MF1?*HUW7.G'A8Q?KVRQN;IQ@`ALO0XL;W`MX)"8'NF".&\YI M3N/F''R*/DVTZ\-19E%C%HZR>-@Q?V\F`KBSFPA(MJM"0*CW.^%"=F]T9X%M M.7/,R]]]/L0F?QY]@[F:0D3\K=R8R-'4,5I2;=X47C;HS.=2_94O'.[Y@D'Z M%7_!7W*/4#"[^5L`Q!IG,_EMP0VCD@U644ZDF(R?IMH6@6-&"QPS2+]080S0S:X0 M6AB$IG2R:_"Q]0JES>ZX@Z,0N!@7E$#_8O1#,1^8U#2D#NW MPZ$K/-^![S=WNP;:.8W<)&[SJ:B:,J8/-E0^1+DM]/9\B`*?-LEOV??3!=F( M,["=GK9?%ESM%U3H+J_YWI*#7>@],"U&MU:2,W(I<>K:\N+4UG7P4FN'XH1? M911G0QVI7TJ<*LM:Q*EUM4X@3OS5U$HG3JU;USK+B3/(TM36MW]53;R+,O_= MVE)`N5:.4F/4'`"'G^1XB-]5`$ZW=$O.3(%&W_1PD0LH6G=?@!*U=!M`*=A` MF'+3\EF4QKX`)6KI5BQ*H1S0"AX%@,?$%3$3FGY#)Z,:,0HP8HPUG3;^;^Q. M5D[DEIW(R3A?;4L1$97UWI4I8DMKY;3>\7K\@_\HV>\^M.3R"?X3'R)*?=\; M7+SA/E-4^PP1CV.',V6]'62VUC3:Y+=!E5]1=AN4=QN\TOE>[RB_!BB5@U(! MI9JS%&?ANVA`44?D+>I\I7;HQGJN\?W:,;!]3PR3RC_:)!L8Q7?,:>:NN1?Y M=-S:#QVW=E/'DP;_[)D*H(;'C.5\'82%IEMK)"Q8`2ID+''XXB*7J]&CZWL<*WW;K1* MJ3LU"\C74ZM'6UZ_,55D8*W]^NYE@+4+;\&\F;)71?,V'J#9SH5J^P:Q5;5= M:MM58)]W%5Q68VJ%R_7NU^P;&@LS$"_3!9.[;W$F*5 MAU?,]>Y5<+D+8VKEX144EQE++=7NRXXL=E0;:]M4[0;C;R:BK78G&#C"_*??P,5XM5THQOVQ"R5.TZ[=H:^)U5"<[J(+XQ*7ZC+ M[:Z$.DIGC";S)RCD/3-\(;C3+S="<[0_\6)B#D&\Y2QI)B`2,[1,9*R)B3D@ MRQ#2--IVSNT58\K<(^KH+W)\:A1]8XW M,_DYETH*T2\*;3E*WFG?P">,7L\;C?O^!3#W1/',8WB_++6NH17"5Q*>>FZO MZM&%=^(*/0Q/(W#,UI)0K+K[HB&WZNY[X]X6U+NHNONZNGO&,FW5W=^RNV\0 MN@5=="VTG2QY=Z_ZZG[UU:I3Y#@X`_R9W/)15P_8<*66RQ?#\DUF7@G7QD>^ M?$\]$7[;NZ3"`!E3@6D9F`;MV7GE]4BI-VD M+U!9U?)8U6*-_6F4[L4C*L5^QJ30:&DU6A5&MH^1]%,WC=9;+!KBD\-*U[]J M6OJIGOSYPL_7*J0]HV1U#.G2'EKNB+VZ\,Z\PM4F7+Z2_U"OGT%_-+%/DBN+]NOU M(`$?ZXY3,(&$W>:>]3('T(-//6I):-!4SKBF!)5_,0CTZ*SVOF)B?"]=0^S/D3AF)3%XBFH`D-R/)T6AF,3$C ME\K\D7\PRZI_=]QGASR`UER'F>1:2I^))$KC]"SCW#!^+!^24/X`W[&7R$E#%A M0+>8G7^AW5E43)HMQ2PY!U7V73&:9D:E1\EY1.+4J6$P"XTIZ%YE3W(U45Z: MF7O6Y])#'Y_@F<=I;L8$F+Z8G8O+F_.S;W\C#_]Z^';YY:%&KK^>'R;9F2QP M2F<@/P'=_-HQV0OYF67()R11%$"PF*6D#S2SF"E&7-MVH4OA7+U&U)1)DEO? M0W?!!-UF\*5RJ`P!>8(Z@\DVF&."-E5]4RX$,9G!;3"('P^T@T_=%HRFW>,) MGN=4,6V@DA;S"C[*+!,U-G2*))^1FC1/J2)F,A(:S`6L!%0YF?E%SV(E4<0T M,^B:9M6.WQ=7J&OU7R:KQ'SC8=$P7#!)DMS1$7VT&`'=$/@H?.B9B0U]<@&, M6BZ.L>3?WW#.\-D"I?Y?Q%@\R0_+"XL[<\RPL$19XZ*P(%7.XG;\:'GOP>DA MTAM9,'WH`7V]1VUNC4[)G[^!?R_)5_9,[EV;.G^N$?6E1B0(MO>>*&K)_\M. MB:X-O?<'/_:]]ZD2L?HZM7C?.27_\27,.$9C.D_)!FR6-:0F@A#BX>[JQLP&=\PTT%4_C,WP6F!^K4?0H969]\3\2\S7<\)$*;JF:IH M84WDB<'```B-)..YPY#JF>%#7Z?DT;7,]R1,%O@MX.]=^R=D[,@SIWG,DC4) M&:>^YVZ.<<5JA/?+ER%,$YE,\7TT%O.1`D+\%\`G@:3HYZ,@1S-(Y@I@V3;; M5/2Y4[=8SYO0=QHI4?-8V#SL;!+P2=P>\08,,EF6^PP@/BT*QS]2>_C^CWI' MFY)AT!$?76$R$??!>7URLE=TE^]\N7E.]\$\4%7=P&>64U(\/&Z^Q#!-B2):1 MEL,[[@"J7%_"2")_2NMOTAR\0D3Z(@E-0F>B.L-%:$!]C8-950?(BFO^HZ;^ M00Z(="UNOEH]^!@:$V]@V&;8L"\8M$J:>BUG'UXW/SARSU<^S,<$'7X\"/X_ M4R/3&%\7/"HTOIGV+Y@1K+P6"I#-,@$RX77D&58>J?&]+\#W-NL`+%<`6F". MS7J]-QQ<-CN0X&X@^"MJ.[`&S@ON$^+,U*,OH8NV[+BR6$9K,!_38GP#-N9- MAI;O,JK,/[U*I,G6!?4AK:?^ M*>V0=L%Z3`B8BN.J^UL-82F9;*O7;Y:-V=TSQ<-&1GAJ(6+U)S:QRM=8Y, MU#P\BJ"5&$+[1`5W?3GE0-1`V]X`L$7`E<'C>CYX&=QC-E)BD#P&L_1<06Q7 M,.(-J$/:/V"!1G@,R$J$WU./Q!%^!&/K5*!^,LP*OS8/,[00_2Q:6/*U0[ZZ M3P'_R'M-!2-_=JDP40H77###@BHPL(@ZHP"Z)PW]^+T$I3%#72P`5?@G?X.6K4L\@A)(">.T2X!5AD24&%0.X,^(N4?7`6@,Z4@=Y6"_(P:` MOL=[WH@,F<"H-_*NK?WP4QB-S46L?^HX2"ZIA4?2N$H>0=DVMC!LG4D>1\E& MP6^P//W!)%K:46,4,J$(2YV\`D:\`0?V0@G"ST>&4HJ@+"@:F1$!Z0M5"UZW MR'$#&W3]!.(@P<%C!<8!Q>S,":4-1,#F5.RYZX3LHGLO(05^J3FAXN@SM-6! M8A\&C$'OPF(Y"A'ZT0.SH"_W:Z3/'(8GKC"1FC9WU.DLI2/\=,\D4VW'/TR\ MHM4=*N'/KQF/O@7W1*(B;H=X.`WO.YGJ4='O#T/+`5B-Y8*O>//C4;'5A6)]N258%:V8W..8SGUW] M1%^!W6&@G@4GEE;AK]EL9?(W6?1;V3QC*<36U+9K"&`$_270'92L)K M--,LSJEB;:SFZC8=[36LS@UHG<'V`QI_OIID]9-VIFA39:^5SSQBU4\ZG67X M3(\M,UA+6.&5\`E3\"SNIHM?`X.Y4'GO1'\@M':JRF22W`,U#B;T1-N=D.$>7#?TJ9[Y?I$Z(;3*QL*'N"=/>#5@3_IVEFC M8Y1+SUT#3Y%XP M!`\I-^O@LQMTB.Z MNH:!A/0@)KU>1& M5):ZD'6^#(_U=KO3KF2XX!J+N3+4]=;Q24K-SLB[U!<%#5\G3K1NZW48N?*FBFH(HHLQ0#,C7PRS!!YB?"=\4QV86Q.0%&+ M[M3-%NMJ>^=:XR0#*%-[+*LPDF_7N=GJY&8DN_[75=S13EH9%;^NQGQ;7%KW M>%Z-GZGD*H#C#OPN:+SR&=(,**+;WEDU9\4/S@;3)2"/U\WZ&^R3T6!$$],_@T M%&Q(Q71L%LP(,/1/F"K&244'AL%,U@A3V%`5,XX.'()M-/C0@G;R('KI5X?' MT4I*YF:C_4\6/C:+(+E4XC:)7@!@:0-3C%CRX7=03KF4% M[;]@ED&](!H+R23HE/>`8[!V2N1U(Y1.7""2XGW;DH:L#BA,Q51H&;.X>@\A M""XS8@4!V/X8@:\7HTR.418&W4FHP*%]]1&U9]/OH`4I M?3M<(4"Y,>#=5MCP!A0D#*(UO$!?=A2UA9>],U.I]'6XKT5H=(?<"5LPYJT& M5?0L!M6BOJF)\@RSA6&S"&W(X@#\H%P1^T`J[!",/4:3&4Q*#'O$J$Y*>C#2 MH\QB\Q+=79L5RPEDOA4`TXWC^&H)V0Y=R>.->16PV;/<9ZGJPD(CD03!C3#U M=W#>GQ%_B\/6>S)PG\$;$K4X^I0[/6Q:7$7/=3W']1@Q8S]%AJVW1A/ADJXO MR%D0]AEXI8Z&6',(_H+NA%3@DUQ[&-,J&/AX&S8>AHCN*!T<<@3E4M0H?*]P%'O>!*]A&C M(D=(9KXA?ASQA!P@*^H'1B@\42N`+`CLG`HQ0GPJ7S/M36"6,\?$_R4RGGE1 M+I7I=?Z5WFA/^E>YZMIBJW+Y<'HC%75:]%8U\L0B-(\;G5*U*F-3=SKV!V8X M:T)@^+;"M6,(F!`R\NZ"!;^F=F:SJPSR1]FCS,MMP$Z'R>9H:W;%!6KRW'W[ MC.4.[?CD#9J-RPQHVZ.E;K#<]SA1J$V\01*F2A@YM>[,-0]5V&TO)+X5JJ#Y MCY/@TD=FMN3JM,1:\RQ1IP(I%_&S@A3TQC:DH#<62J'>!E.MO;T<+E^8,#C` M]D[@^9$QC8R)Y"H"BLI7Q<>),DR=L="Q@M":2:$U8"`X;'<62&P!BVN18F)3 M8_RP(5$O&ZY;OJVFED^^T1;&J)H^::Z)XSF)CE?V0H40@.5,DBJK>%]N)M(5TOS>-"X_6G,6RGH9_WG'=Y MEE3'JY[0T\F0"F^$TWN)2R4PD;=8'U=BA&LPAJ"7A^0>;T=&FCL@)M?7-7*- MIZ5U@BW!:B8Z:&H)_$VN"KA13-V-F5+R1%)U]ENM>D%S?O&!02:L4;1(XSJ) MM=3X2'=B&2C'DL5R1FVF034F#.J[K[CLHS>F9QBS:\NY5O$B^:G#+0"6\,$2 M'6V2H^QUAKD<@8ID\#1B$)1#W(0G/2,E'$A<&^79;39QR3>I]X1.)&VM! MAF2GXG>:W4:GI:_4@C\=:CK:!+QIPV?OB7ZLU6"J@?]&K0-3/7`%=%`8`;JU M5K-9.]::"E`GM6:W!?\>1Z0<7W,-]E^04J^!@&/*1@V8S1)9SBL5<#E;XGHD M?V+6:(YP7[TDIEX[1E-7!U\DM:.:+G_OY9EC&6<\IP4Q#*=ZSK( M\CK+T`25S.E70=F;8CF?*6@UN_.,V5R68\`J=DW7LJA(A%#.XQQ9D*&6B.=?_W]Z[/[>-)`G"OU_$_0\X7_=W M=@3))L"GNJ<=(3_4XUO;TEKN[IN8V.B`P**(-0AP\)"L^>N_S*S"DP`)D@`) M4+6QXZ9(H"HS*S,K*RL?GZ^J0VA-<^S$5I?Q:WM(@SKA-:?R93<[P[$1*"$; M^R.0R`SE.9?*2\RZ?-4!>Y::=G[5OW>42]]WS;N`GQZYT9P37I23P5F<$;N3 MX[BK:L-,/8X-DS4!O]WN`KHC"N_:&3U1%>K>P:M1#XZ!ZR![\-(7.`?9N=\%Q1'H"2>HS\::6N`)2>H$K8= MKYVT3&F)0M!2#82R4(4_?H'?WL)_S8-J`PVGZ=NPPM&K!JY448+I8&?@XE(% M84&.=1@3SQRVI-D[[N30U<&TFPAH%]/M,(7>[;#XW)J%_HZYY@-%=E146$4; M7&1I53Q#37"6*C=`RG97.#$2Q>"UR##'!:3#@KV.K$)#V"I1NM!VDW$M)P=' M!T7Q3HR]$]-F[.#XV(2[7[\W2MCU6^9M"+8;Q:$0VR%@J_6&_=VQ#9_#FWV% MV^N;KBVRP\H;BC.^H;AHX04%FM\?0WD5)RGBU#.[G>!:R@9L(^W$U9+I@8[P M,9[2YN&45+<5G5O1PR*DFY,1G61XG7'/(H?8/%)TE+V;=)#-`CBY MI(+'-0FP!J<7TB$1H_P8WH0#@QJB+%+@A:3Q74H0>A(O+ADXP,?'A6GP>'T6QA&LPC@"8K40VD>@IL4\C]<* MQI]`X_HQ)3P=$P6B=T7D?2K&-TT2/@C&15L8<,^95'\*)T[4=L5B4(S?Y-TC M^&`W8H7PF;(*7"\0(<;XC@&@W>/5%P_9YNZP-")`\=!NBJTW7OQ7A*OC415F M\=*%:AG*][>N[W27/)AR.2 MR6CQUW._>W@;R(=;N`S@!B6T*!=-WA&DICP2VTDFH!,[TO;;)7$L;3!>[VV6[%&0OTVYFQ_8Q MF\E7JLM!!0TD#`>)"D./"[L&[-D*)\4YA]B"!:P725M-K1&:T`;P^"RU"8Q* M^$PK7(+M3;<:RHFH[8_4GZ.JY9"K7^7JU]48MY;E>/8]JV^3YZG]N@N=NFFO M[!V\W<.F#2:=:6VM#V7/:LEW!>VZAA>=\6#4/KX[?&-H>8OJW^T'YOET_QN5 M$>7>P*IVB?H[US:D@6Y[VN-..^-Q7?;;:7H7GWJ])=N5,$Y&G7%M'5&;VX&Y MJ$%TRT\48;9@=1Z7)G6-W;4]>],`;;2U.+U0.X/Q])@.A$;T1I9<_IRX?##L M=[3149VDS3DHE>VQW(+3DSKL#8MS9K&*;"5;8$D*-;AQ>N,@;;0UK';4X:0S M'9^ZRWG]J]8<2"2GGX+3)^JH,QK7Y1P\-G=MC:,L#DE>+P1PY;@,IA;=PXVG M*(`%\P9T;[$6C4P_7\_??^PCV[_RL M+UFIJEC#)(V&+UZK/74X2*0VEX>K&@H5]_0X`H4&92C4[UVHH]-1:$-)JOHI ME%^%:IV'^NID6A&%.DJB#P&/*/[==NY@[Z$^\@KO\7T_NF7&'$\P<,HV*> M?ZCJQ1%QP'"\^A5OOP?4'&U6O'E054&<'7?N*HE3=M_NJR/M1,39S?"KE#BE MS#[D'$VM@3B12?.5N7TS_,?XDW;QKIR-@G/NC^B>!MLAB$;: MXO5-_Q_:)W5\%$3W/-TX.=F_;5=_EF"H\.-!*6H'UO\LD;U41(RX[D-4"SJR#>O"MH:$O$LO[$?# M>\]08<[)\8JM4ASY`JC*7"^1I$H]$P0AH\JK/''38[MU*4KVWM(MT*+T+):B MC3)!>:E7RMM>!7>`''R:,Y>:T;HN(?,K_Q6^6SHQ9.);I M\<^8PHI(T1$PS,[&D0,@J6L]B89C<>)QNJ+@XX+9J31>TXL2EF<=Y2'RN'1` MQX'I.D?3U0Q-5Q=M36I0%>[SECF/9N*-R7#5./+AHBW2J$;MBR):>(LP.Y-V M%G-N\IY(5ER0A6;%@41_,=%6"(99*C1\),PQ%%Y>J[;+V[?*5!WUE$O8WY#4 MF(&:9K(M\.9F/N?C@#,"#&%'8D$GS*GN\ISJ1=BB$ZL`,,$ML(),AX6E18[: M6>4QAJ)3AK5?/*SAFMCF22?ZQ>GYEO.(ZVD18-2Y#*<2G'1'G0##>1/#AI@9 MHBD6Y?Y;8BD`3Z*MUJ?5%\GSGOE=,.O/"BJI%'N&7>52B>PB=9U%HO-+B:SZ M7T1SJB60@W!$NS'WF9C#B[+K!30/6,6:EA[&@HV?]_,B"8`7J8P#LV?>+U'2 M.W\'FA%CG&Y4;AQ9;A=WC;%1N(!R1S[=EH7DN M]AR+.Y#24L+.T9OD`YC-]'GM@G\%#NT`-#J*.$HYB:,H*?!2,&)7[;_B$!6L M#1\O[/4;"<&,S4GR8Y:&D3I8XL'B71,3-$GP4V*PP:;!>LJMB?IH31#Y.\EA M.A'I4@IIBRZBO0)&U5>P,P*9`&?@EU)Z2%HY\!59^H#QC]AND/>-$J(O.#^2.&Q!F"KE@B(> MURC)%&F(S10T2T@E"GZU94=TC//!Q5GWJ?.<;WM$'U&P?BZJ8XXSXR+M>7!188#8EI(]DK\.XZ_^6K+YB4")R;\?HXTG1V.T MHECZTAGO93?HIN2*1?=$\?&IU.*4R&?(-R30+7[@'K-?+L5Q)N[WIB7FKE,* M:9X+M3<:_%C92N8JV^,0M$YCI8*DG./STI'W%YX1`8?A0=W\=#2Z2I9J`DOU MU=YD6AU+E342:C0%,GD,;3,%,'*HNW[-5,Y8*Y'6<4Q[H$1*R7$F;H@]`.:` MMK>LK2WD$YI:,S<=C:J2H1K!4/U1=0S5`%/@ M7+P"%%6"W66>F.YZKZ1KH/VN@6%OM*6^BW0,R%-<:;M2G9S)@DI^:@`_H679 M"I=`.B"[_4'8GQR;/6&@!@:O7`%9UX[]#8XW*A/C*@)U=<]SL$>CB+W*AEN% M;T:APJ:/(5Q(&Q'8,T?:4/A?%+"7#(/SE)>!S3OIL-DKC![L8.R9+F*31%\> MJNS*(V,I8.>.,;LP+$P]E[`P7"81><,LYQ'#O#RB05'$(]"#B1#,9/36DJ=, MS#"T*!EX9!.9P]Q;'CRK4RQZ-NI,O[]WV3UQ@6A`%L;]%1(Z7),P=`O#2)>) MW`T*H]QG-"T++03(L)CNTGB+F'ZMR@>B0N)4U[ATB>RH4O[6NM-G7C,XBL$:'A*# M=8H`UH+&.,KO5"#Z%F"@K@=PTLQKQ/A2,,F6;(JVA(YM"K2=')"QV\8,F#U( M5$D4HW9^R01;FRR=49SX]FWX<$$ZKM"\8?"H!*^8C<3Q5CH]GW4AB31@\8VK&#&^][` MH0!5APR;:,8M5QU"W#]BD-.)KL]R#8MV[O0;Y?HJU50G:J@3M>.ISF(^C>MM MJP'=%!_A3H`V>H]_J:KC8YK[S33D-ITU#]1%PP*L6V!C;"P(:<_6CQR[9!M7 M2[[C"3D`I,R&W!.V9$`S;:":O3L'YMEMW8!_]M/I3K>O_Z? M_T-1_O:_NMU;8\%F@45&17'?OFZ7O[`V]ILG4?;@=L&8_QL@O0)R1--@1V8D MVA2O&OE+=C_;Y\#V?WPG%H9N3E%Z MV?U0LI3L?K@-IFR=@9:9`K+[H>Q^6&XA9??#4\S='-TMNQ]*AI+=#Y^#5T!V M/SP[UX#L?BA/<;+[8>.FE_P46I:M<`F4#D39$BP2Q:3$>7^=9.(?#W[(2_7[ MP@S'-DS+I$Y]G6Q?K(X293=UE-]TV,)??G0\[Q6\'D?#OQ?1\(6A+@E(_@1` MDG!P,-)01#`0"!$`.#U.'D[]P0XGWAHKHP2VR7_]O=_77B@S9IA+W?)^?=$= MO'BM]4?]?C^'ZG7#G5XV'OB2ZH7'(UH\,T[7#))KR'LQ%I(]4=\Q;(5VG0%R M#:4T1L\Z&DFF5,N4:IE2O4/V@TRIEBG5,J6ZK`BU,]%*IE0W,A-'IE3+E.H3 M:0294BU3JF5*M4RIEBG5C0>TT7N\3*G&,65*M4RIEBG5,J7Z;%.J*[R4B*Y/ M?G,=SU-N7&=N^MG;$/J-_W3H-9$Z25T3)48^&))!!,F@!"0#O*_:`LD'VW"6 M3/FJ?U?B+';EGT@\A:CW7UGX^!OP0OQ\T^]_XCL&\K5ON_8P+-T#$KZ[O;GZ M:'K^5WPI>QFB]G>_#=DG!SMQ:7*((S4O:B;'NZJD5*.PM_JO"B_&*[ELVQ?8 MK-*)/@%OBD#R'710R3NT4]TT7GK*#.0M\#SN!_GL^$P1J>'X0DJ@,GV'>B6\H6M'-?O)!]3%F"!Z70V M)&T-G&%\P&,!334Y:.BUZJ;PQ&]!>Z M#1LR`JW#6B"E$&4Q M%8["WWNWO0X:](\,F<6#-75-)X"W?!V$1+=G/,?$IG4&=OSOP#6]F6E018]\ M0M\Q6&8]F)D^KQD2SJ-\X",A3S\P.V#*+5@@IL$ZF3EH>0-_X;ADPW2(#6`" M@HG6![9*FQ$,/.PF1HRE@4I)%-+V'X[[3;DEY'`:E_F!:WL`^P/C@"?(I7,) M!&;_!@\^F.P1>=B$4P\][C(OL'RN4H#G$[?3^@P7F=]=PSA(`)=9.CX[=X&I M%J;'I[=B2XUH;0!W`^\5HX`O482O<@_LZH)P/,'02XP:M2%'`@"X,`P<_"RTN0W?=)WCK M47=G`"W(;X!IR%R>9CQJ8[4"I4EV`DX4X&J![%KF$M0I`42$8]]7IAN*J0"- MQO"B=4DL/TQLI["=!:AG\D!\>1?XQ()`1S&2".)!]GC%R:'`.Z8S4YS`]T"1 M$>`"VC2PQ&ET+$*R1G5PZ`7#`44$7!*KUQQP.*\L]2=43J0BD5:H.6>(!->< M0E\*#DY!*&)?B@%.(),=WM4-F%IP['-'Q)>1F^]@J1OC0, MU`!)=MR.:OC2)J;<;3&GHRT8KD]Y*LQV7;SQQ?ZH)=E3#_%9Z4\$&.XX\*4; M@%:&+8G97ADV#6>[X:--\!;<%ZH*A!=)JD\ER25@7:\^';9T5VRNS]]JV3UR9MNDM MV$RY=YS9?MN$3-5[SJEZJGJL#);3\55S()$@A;1XF.?[_A\:^C4/9P801;^#0]O%=Z`MA2F9B[O*'KAK1,@*.Z%LA:"E)* M`[-93H:'>/TSR\L]WP[/N`@>&+`:*,JLWV07*\!;U4WB+NFW1X.'HV?V2 M=`;90.RL%LPP1M6$!$;>!B4Y]'OY,3OUM@.+C&&1,#^]'T'$VA#EOZ-I! M+97XM):*L`54T9",Y[/E`<83(WD"5?3X81'':C:_)W^6RJ'<+;9;W0W(1`Y# M88);XAGQQ%Z+/!YG)'Q]W*K!*J6;M?Y%6;#X83/Q0)=7@U:5?WZBH*7_ZL9U M]Z.OPF*X<;W$Z*=BE*(Z*XE(]5ST_DKT%H@^_CVL5T[P77XWO?@Q7LB:?E`Y M',DAHHJ];S$PG-Y\!TKM0??-!P;;IVX;H.$^V)[O!I1[G*H#DQTM46#[RF7_ M"IAM/*6A29;@CFC'!]JR:) MEV_0YN73!A>%:K.R1:Q_SFN\Q/B9KO_Q6`L&P`Y=*>W?J.\6WA6#/F>OSY M_?AHTL\D^6V;IFZHRZSJ8-R?%B[K9JCQ7/]6]Q9X[L+J1U37YN7OO)[4*X7; M\J@,+WG?FAR>@"%PA'"`-T_X-L^%I%?C-P\\9B3P*S]G0S#=M81%>CFK1U=L M,_N@&[U:V<(.AQ>C,OCFS-P0?'EC';FA.C5RCB_.QQ.)V4X(6?JAB"\ M*T?U+P858/P85G%!O.!5&SX;W,3M*#>.91I@THO_;LBUAX'B<=+#\)?YOTW/ MO]^>1UM1FGM!LAH6J*$:BI[+OS8O)QP40D<69N7J;RZO'VC MF)Z')64N;W^G7[K]44<41%MA'34?S3\%<$5KSG>P/AY5L#""96#1$4_QX>SI M6:+`9**BGFG#\UAN3=1,H[*2.HQ`52.!EF+4ERL=#PRO%`-'IDI\5'Y.)_9T M'1>87C&"^X\,=I/7%*;<56\19.8,UX=4NBT&P-?\<&EC)Y&KZG M6PSAI='FS!5%"KVPWB.\L+*83\\@ACX<[TVJJQ?]8IE@^\XX(%%R?Q(C'(NO M),VXD4X+?88@H,;",HX=A',[_;&.)&R4]CT@L&"6J!2()1@1?P1ZIKM(%$,' M_-E\CK4@'WCUO#FPD)YRCU3` M`J#Q^/]7MP-$5-2\3RYM4<%&&C(BI>G%T,_,&=4J%#P9)D4J)@QB^+"J5(@1 MRRQ@8!\O'AG1BBHEDCB4J`&XJ_J.-I!X3Q25]WAGVNSV$#U6H1'3'Z5=*CES MU`'FSMNTUM?*P^G>Z[;Y;]$&^&VTLO0GE65'+KGA?5##KT/U\HYYAFMR7L*# M+K>7+:<-+$G+RV5LA#8L*F;_BRX,XAM(GH;;4KB)T"YH+E$]S+!LV2RA*."/R/'-BQASBX@:0%J&[B^4VRO''<)5.W^1PK_U&.Y"*+-(!!;ZZ?9B2H_ M>[Q.]-RTV"Q&Y19O#/C1[_UWT8P/@%V"&8PH)P&Y??\V-3T5?M:QB+KG(,GF M&.V&>!0A_,C`Y`)+[27RZEH!^T,#_!X?'WLSSBL]V,*X%@@+UF,1;X0++'6P M71AOUHV%D;TD%P5>`L%.\I='EN&_Q&].X"9_=+%\'QKM(6M3,?*L2129GT#Y M-A5IOP8V97 MU.EEG#(^4;DD3O"V8[,N2&N7]@/EI?KS]!5.&G[MF=]]E$WX01V_BDX-:W"L M'1Q@]LN5:UK*--1D?GC$@=7=#C2<,X#P<.BB/EE"=#]?WKZ[_$^%KA5BI8"4 M+`"80]?EIS_T3Z%EUE,NL0/"HRU8`KL6N#/1@XN.=);CL?`/,2=PX3?FKZ/E M4HE>"JYI:0PQ3:B(2JH-T,,-@WF%8W64SX[6!'? M$(7_Q=./<`P,!\PI]N_GKRHGU/IHO!9\U(D@2_H(&YJ5(HWA83C$"N&QT:1^ M!!EC?,!BKL*S+IQ;X_,;O1[0-@($"!'G4(72A&O!=Y^5'K9[A"/$YE4(-R-1 M^5^=]#MP",'_T0+\T._U8=N":5:5[&WHNZ%`#N M'$ZADO!I0]S8A5UD8S`[\#,='J)]VF,[V2]1_P##X*H*60>[M,#\<6<&-U13 M`-V]20T8?-<)<0QAB!L?%/%)=;M$R>I\]7H5DP=#X)?P[-:BO3#?=B7O&JXN M,(O_I*R`TY:ZP0(Z(Q#++-F,/L\8=A%1!._`'$;@D8Z#_\>D@7M@_^O`Q=8U MP,?,QST7/F,+ADBE:[]\8A;,88$>__O3S'6,A07R.>-:[H/]WT(#X5\P>JR) M0N#_SE;`>@;^#=P(,W!LE)>)<=_=ODI,:&)'&VP;PEE:GRTQ!![=5`M88V6& M:MU8L"75U==73Z%&HO%)!8CJZJ$KC=QQ-"O`P;ZO>*`-O85CZ??D+TJZJOZ/ MAY(-\K@",A+=D.Q"=?FH.,F.`+:"QY9(-TYW7T=1A%D(%K1>#1"SGM(BIOL@ M&N#8U*:&E)''G;+1@OT$"R8(BF2ABJ=@:>$VA\QV%W99F;G!/1%&,*+@K0ZW M6%&KW@=309<34BY2P8&LGLCWB M3B=$$MQ5Q2D2C"38%O7ENNB\_?O[3]>WEU^1+3S8@05;`&^S[D+H/36UG-Y2 MMRRL+[CF.T!60@=",@5H,N3^ M\V'K12S%1LX7">5X/C>_`^9OW^/Q^%NT%7&7!3WU]=&)D!5TSOJ2R1,3#T=F M_'NB+>\DXZ7.!O"<,/FHC0[VX]VB*&[B MGCKI%'$=8A?JAJ0R:--9;)T69"C-Z*X>IH`-U:`F0HQVV),03#J/TKH/4#.YN\"BO!@UYTBJ0+'M/UT("U MYJCK@#TZ[C=$-9Q9]#G"X$K3Y5L:;DXF-OJ*IP7B\5T, M%IA,T7C`<""3ZS']039Q M8`<[JV5H_Z(]C9W4@SN@S;E"*&M8%*LKV/:9X_V+DOV'0/Q0>4".L#[QHUCO*^A[W@P)O>*`?$[:+GCB1-- M!/@A]1R]R<=(V/5B]Q[6)UF)H1/L7WKN*)8D/E+6#.1R8`I2;7X0:(Q%"38:< M3VU)8#[`[1>QS:[0>8%""?3_QI[P*.+A*=&J3>ULK+Y]<7`A!6V2IYV*3/[< MNZ)V*5QO/T\WM9VSP^:"R`QT;%]AQP\W/N1'[0]YPQN77^22S1YWDH-?&%WW MZO%5FK"&+>;E&DQ(\TO@7-#+RLO?+B]ON/M$GNG_ MY%=X:+.`?E/[..Z72%"4V^[_HTWF*?1_1Z?C0+C[4;'1;7P8:X1G`(Y_TEV* MCR5W$B)Y-SPH10/2^1LC!G0!:GSH9BBRMNY'KICXXK!0UM()U\W@-\$B45A# MR'QY5^KA'H:V;+3EDHGUC6%@0[!<<3*1.P1@7\8;I/#^T'I%3A6\<1#]#O?C M^T[(CB;+D02V( M)E*X:"8AA"]]7B>%]NG+"'=;PQ7%1YYV#$X$TQ]I5:Y#_HBWT-J$5 MD!1)9.=:--;&]AI$ATC;D*@V'#OMA';(M]&RSIW`@P;UD. M)74)&5UK[7)[O";H)S$598"I##"5`:8RP/2\`DQKC2V,PR<3G2@+2T\D6CP> M4'I",6>_OO@`!.B.7KP>J.GQ1!)F#.(801SN!F(XL>C(N3%P%%\0 MS_/'9=CG&8=]#EK39S'3K=9+M*M-L_>918F&>+,DWKSY>A3@$37:E3T:98_& M`RMRRZYXLD>C[-'8$FZ4/1H;T.2JYX-+)=.6RI1DL9:/&AA22;DUS MAX':KTGD9:-&R(_<$O`&`_#,FU*+0V\RC8&:<4US8K3 M+N3)0?+OXGAV?2XYU"31"F2G.552*X2%'>:^^1;;6?N.!TKRO&Z$NF4'!OCJ2C3-3_5*UG))^YB(,9\*X;\&I<+N;1G7^/Q+Z/A M/S/_>OX5+UNW9(EM:;*0:;!0"XQM(=V.'=3&.6F!]=&.2QR67+6#]>99].LM M%G3ZPI_`AEP'=XA;QR\S1970[=V(L01@V.$4RW)\R&U)3\^(1T08PV&DRQ&J MU/!50W<8Z3:!=HDU;-A,*=.8GN?%\A>J:5(?I^%.7KR>JI-ULA9.=SP\=DHG MGKYXK?:UBWT0N=&?>`4%WP%TJ(82UIU8P:[]U%%N8"L415&QO2J5GLLB%H[P MU1'OAZ_3RZ")HCJ%8%&!?>JQO5=;X"1QUH<\!RJ4:>F\+Q76 MR]EC&BK_=JT#5WKD6WKH,GZS!-QJ$NX^:JI^Q@;8/,=I$,EAP]H1$6RV(Q(? M^%M[(+`%DE)C'XJ M)`X7G`(DDO4Z$N4ZMA3,$2^*]\!&J::"SFMUHJI9E;MMHM-@4\:.4;4+[6!L MHM3?`JCCU.!]"#[L3_(@C`:M$)PR%!NH:SMN$3B.P=C,4^:NLZ0]BN;D;3$> ML+[ZRM)Y9;UU0/FK5_#F!_$B%L2BUV["M[+@]R_Z8V[?XZ=!?Q,BH]`/DL*D MS*RGPT]%THO#FMK?O%"`WV34-ORT_DC@!Y^VXJ>IE2+X(8'@6]XVBE1S]RNH M:7T%^\3U"DL9(DQP5/W8N^DI__Q$YXS_ZE+30BINBR=!_RFLK`G;Q)5NX,'_ M*7ZX%+$X"+P-VI9S[%]OL1;7]?Q/'0"U_6OW"UX'7'XWO;\BN#A8$50A4!RD MOSZR>]UZ3V4$Z;40Y03&'V_XLUL615754HN20&_7]7CK/#)>L%A4]H/%^/@V M)B]Y#)7+>Y=Q+HM.@T`OM<)5R+A.-JP"010!%,*#X!30GU"$O4<@^-$R2A%? MZU_43?PL<>,BHTEAV+Q`1^3_-.4)6(2U6K(/ATUC^;Q5J9+?T6HY-=5'Y;;O M/*KC+<4J17E>H'4N.MY1A?KOV&K#2WSK).K7/W*DURY$YO`QZ(\O*@?\-]?QO&[LI]^@H_+GH@'R%^*OPI?>/'U]6C%2.=%WVS4- MGA&'T^P);!-/CUA- M&YLS>\=GBWAN>"#ZX\.2N@+2!5`Y?ID,2PK['O2I@#FV@`]K.ZP-_,J%OCR[ M[RCTHU'6,50=%=X$IC6C=L#X\T?\Y^CDP%DC.."9G=E\W!\TE,O+[,CC:8U< MCJ9L@)7M3[C'A3#LQO;D.VN/;M^!W2O3[?71IW);H#RW--(6J$^,RO/-GF*D M#NM3CO7M'CN82B?:/7`Y')N)AGZKB%RKB%RL,'"H:(:F=V:HL29^BGR=-/UD M(?SMZ;.R$'Y9$LG2X[(0OBR$WW1NE(7P&U`/K.457N*35E5%P%I:J:\QZ:ZM M*5*A=B;#Z?$J/H.0Y MR7,-KV%Y?H>9R$G\S,\R9UQU7.T,CUE>5AXZ)-<1UXU&==4\DZ>#&C<$]':N M7`R17>CN[!'S,_':S'/F/OXA#PWG:L!IG7[_B.=Y>6R07$=HEATL.E\>E/PH]QC= M*<],YVJ]CCO3?EWA9/+,)+FNH+&$2P#"VN5*3.V7)J(J"-MBM?#CO]<5TM9NMBK1KH4&%T?PM84LI.);(SZ%P,VM8D[\BR M(SN3[7,$M-E^P16RGU(-["W[*6F=R:"N&/3FL&QS()'";GM0>YUY39OBV='`#BPW^ M^N+=[UMFS.ZI><)$@E)??B M'/MJ7:XV%1`0@.N![QP/\(SME]?;95>)$WP5?BPJ-B#K*PO/,8)?U M%&0]A>9PHZRGT(`0BI9?@,EZ"DT[L;?&:2_K*4AF/BMFEO44VK=_R7H*9Q]P MU@IGQ7%)UE.0UFN1),MZ"I+K9#T%>6:2 M]12D77ERNU+64_A%UE-H+J#-EAU93T'64Y#U%'81;^^Z`Y>O!X.QQ<@CS$F&R>K&?1L+8S-H*O#T60_T'W7--#AXOF\ M(L<2GTAQ50X>XJ5;?*<:!(9:%OR<.8X"]VX\HUZLT?UPP!-/T2C*/S]1KNY: MM97]4/KK\E%W9U^?5NSRN^G]E1F$3[4![7Y+L,XPX.%8[\&C@>$'+FQEI!N^ M,.[;O$1=:OHF;`0EJ^JDQ@*1%B/%`\GJ.L^BNLZX-=5UTMPO9,,K:W>UI*K. M.XX=ZM4.V5UO0:_I]I-B+E<6PPT7I/W1<;^!768PM*-BFGA`/N6.^3YS87`C M\!33]Q3'O==M\]^D&'5+"9]G'<6T#1?3[14VGYN&R6SCB90*2#G697!!'RAS MT]9ML`DMG,H)8$X8T::!#V2!HJRZ>E%%? M84`EYXDQKZ=<>C`4'YB*$#%W";C0@'?,9G-$`:!],-&4!<+!%$B*<(`T\6TC M<`&@!'!)7C06L+H,9]%7,.1WT.\^&+;*#\->/S*"7:&J82H/".8"65FX42&X M?L:>YLOOLJ4.9(9)TE/"7\Q]H#E_4'O#:!8@)@!K!3-.S$O#<`/X&,Y#ZW(- M`[MPE+*[A!6LFF7J=Z;%]P\GI#:Z^#QX%SZ1OYF@?Z-;!/CM@C$@()X.8/XU M4U\K:>KO+XF)RD\K@EDX9W`V6%O(!*<`(5;Z$PJ%!]/.B$.3 M/`4'*B>X7ZR=HC)L"V\4BGM2)\!BH]*0Y;6RM5@F4UE>2Q8TDN6U]KA$.WT` M8^;.[G!9/J[ZF<< M]NW6$)&9OM+->K-[3G8UMVN<3=,`;?0-VDNM,^Z?.D:M`7>I)XBS:8&ELC'. M9HNI4G>@JS3/**LEGW>L5B"J[\EZPY+.$`'QE[E+=,4R&P!70"FY\?3/^Q\4G=?HNID9] MX$94_)-,1Z"H&O@Y\S]=M-+Y"@`0\$3AO';R7!NG3 M+<1`VS%")Y?@DW^HG]1)%03?'X\S7(D]6'_RC^$GM=^0E;AQ'0Q`@&WL@=D! M\]9HK%O,^\)__,UQ9MYGEJ.Z=XK\FZHI-9@W0[7@[190.\[<+1; MVTJ2+QY.M<$&LE4%476$2J\A0T=O.CK#(5,Q-!-USV/^^N(:"S8++'8])_/N MDAZB0+:FQ^K5V(ZL)"UE9[+2<0&R,YD,G9"A$R<)G9#<*#N3-8HAGWTQ_P^V M%_!8SY7+EF:PE)$[#;G8:LVM%9P+VA>W(UE9LO(Z>L-^"[M>/(N"FIOVL!O7 MF3//XYE`<\9D\3.13:Y@597;+H\--2W0?R'*1*]HX3_P).= MRL[6BM,NY,E!\MR1>>Z8/51EQ?TZ=PL*2$&8O&`5P@3[!NLNQ!68FGK16^J6 MA?=L:Y6`$&HL!\3S/8C@,&1$?%F`O&&`-MOR5-M6?5RV/6LZVHX#M8SZ8 MLP#,$M-G2T4W#.`:2NY&=_'2<;%M@&XKHQ_#9`M>-E-D!"MZMN8IS9D,UJ6: MEB4:!)1(B(ES73D6U$0]D82]9#K639@A5'/==%&*`H;E4+$>)Y(`$;O3@7#% MZ3C)E$N8Y-*>I1*N^0S7]I=PO#O M'Q99!8;,UMO5[^]==D\YT*)6JX65C4GD@7X_7%APE#^PO%8 M"`BO_#H'&=VGZBVGB-#C2,,79YME--1*[*H%N0KJZ/R2%1+Z*:$\E$\)_D8U MH_P1\W>D3Q12*,=T!#3!B[X+(YU1NEHD!8/S$X*/I'F/9?=6GD-UMBMRK&.\ M7)&R*]*J+++,BI1>`;"O?-9%$P>(PE%I[+*\B4XW)<^41\O%5=J6!;NC<5"9 M'7"T/7^S#7CP]E^""-LOU/=FB>.H;XFCQ/'T.%:>1M`B)<8W&<=F3_CX-^8K M,384YF4()FY/O0BE[56UY8E65JRM&1IR=*2I9^= MR5%Y3EJ+3AN%WM#XKJRJDX=,%#HH&&H#'$W,YY&L(5E#LH9D#E*45I5."IFUE!3KBYUY5*2G;LZ2JI_64<1G6N?E'_2J`H.J]"XZSW- M(JAI]#?9KF#)CF+AL,\[L^H29D6T'2**U+>. M0(&O01```'SGQM+A^P?F89:A,F,^'S"7!F<`ZAZ%_@@T7XB7]%GMO+$=-=3YJZSI/EG@`;2@2#O MB9D$R?20B3'KD;(<%RY,"W3Q%Y["`,=9-L^1YZ#QUE->7N.I2AEFQ]37]C>U MVC^S;/.`>=HY2K0M%?^H#DL'0,8#%[-$W:'C*8F*E'5&;&O:+`^B^0G2RC8+ MU?XEG&1OIQ(L6E*%U@V,V.!JD@C9::SQW/C^.W,-<[T^[HG`N4&[JR&PK&#/ M(--=2L=SE8YL=^N&<&8HM$W917*E5DK)0,*`7A MV=]TCB:]B[-J2'S6_'W&-L>D-Y"-P=IW;OB-W^+6J"1EO'S3JE&?)'JQH?27 M["C9L4'TE^PHV;%!])?L*)/;SMEK?N6X%XO7<S](O:O]^ MRD)#536J;X!W2QM,.E.MKM(YS>&N1K/^\0C79/?OGC@WY%[DJ(D(S61=*5?/ M6*ZJ26X8]B9R+VH,<.=+N-,D3&S+RFT-;^]5MW#?"H!1L<(OS/-=T\`D>UZZ M+JSAMFO5P7@@FOUWV_2]RT?=G>0`A@G#R8YNP3:&@3S3/.Y3[[H MDO?.G/>>_5E<-V_/, MH6G;MIJ^:ZH@A:8YP9`R7^8D7O]I9SP^ES!.R>8MN!`[*^E1>T>S55L4`[UC M//+6[NTW^M,2]E>%QEAKWXX1,[S]]J7G!4O1W7N_7NYB)IHH&SBQOIH'RF&[K[MCK;=65P*,$93N<%+O&XS=+9\8LD#*8 M@OK+4R@X/1JSQ,]EFS?6OCQG$2R>GGD\S%%MV?[DFW%/J^;T\&IO.JIG@NTG M3`&"EI?1WX0.[%_79;@DH]<-65K`=UEOK=>O=+V+#JSE;Q?S^'MISF9@$C7Q M+/H.MG*8:J8\F\;?$_Y9'Z.0LGKW%:!F+O_^^ M8A2U_^!88/Y9.6DO997K:E\M3<82XW?$/Z/S!W+G#/EI6DK3TQWO2U7T5+=E^;_<6]+AD43 M=/T^WM_]_::YSM\/]@.,YKA/'>5MX+KH^]W%GQN]+EY^WI[:D!HF#`>H>R9L M:T#CE!,SKZ)%^/'.57[*%?ODVR(CW1[<$BS,LHE-U:Y^LF$].8PY+%"3F2)@TH.QOJC@I>S MKJE;6T[#9Y^!LI-2X#0QD>L8")+)$B>@S$'Q^P6W)#LFJ+DGY8?>DT.R?@-<`\5-5C5?L_'5\U!Q+)X2?@\/ZI$TP; M4K>A*!VG!4'VUW M/1W#-@<2*3IG)#J3LQ&=O0*5-@<$Y88@7=J^.3.MP#?_= ML`),@)J[SE+!K-?`Y]FG\-)[W;6!&)YRPUR>P;I3W%)RSGC*<,8KF#`QW_4\ MG`TFH[F>;833U7H;'Y$&6M#-1[=GE"_6R:1RKAP?N,/4+>M)B1;?BQ>?TEU9 MB@-P`"/-!2SD`H!!\8@+[IBA!QY"R$Q7`?N5&3X,YP36#'X#>'RS&TY8MKM0 MZI9^_9*]..RO=&R7T`%(_Q>M#O0Z?I>4XW05:FC(26$`5$5[3A.\G[+Q3AN" MGV3HVS-??1EGUC3OTZ8+&%[91103V>_0=C;!.6=TT5&= MI,TY*#VKH*Y*ML#G%X]RPOX`#;"&U8XZG'2FX_Z1%(2,O)*L]V1&J(Z*FJ6&/_KVZ M:]N6!EG4<'XY\\H[:F#*):S\@*G,J2\?%RGZZK8Q^ MQ`$-T;+6B@.8%=W/JT&8#+.B@H2]-3[?%*Z])4XZ-PS["Q90"`P_;#SRG6`>6!\*E%) MMJK'@&5UVV`ALP&+$=?,:$56O)NR!]/.F'+W1&]B.)5NXV=03?>+-78"'L/J M&($5Q84_.NXWX$^8Q4TNE*>8RY7%<`:8S[2)\60#X&S@WV0J8[EE]*R,Y3Z' MT-G#9?FXI$%[,_V&G7%:N!#IM,Y.-9//L)3++G8<,LN"Y^#$P6SFXB6K/5/T MV1+[I/JNCG4BUKR#_)7?^`LPPV7J\??"W[7-*:@$MLE__;W?UUXH,V:82]WR M?GW1';QX/9BJ%\"#"01+S7H"O`817H,2>(W[T\%A>(5^10,7M'N]8O@@*.80 MOG]^(H?SNE,W?)-[@3>@H6H#]:\/MN$LV:T/O(-^Q(^.06F>E]]-[Z]H4C$G MGW$3YJ,7KX=P%AZ4<$&F$FD'=DGAA!PF\K__1?O.[OP#K'POH$/"6X MGE^\<#";P"X16"'MJF<(-<,0$_48'+&&V`G6_+,CJM>W28%$0.^N.[B)<)C& MP!UGW)M.C\$CY5&5S%,[\U2QW2#SJ+WC*)C3,,\&&^4WO!RJRD;=8L.E]UN: MN6(S-+MK5&%&%`-_6OG^'"#^C9)?#E)5&CZ[F%I_,#JNAN?XR&4NM\P567KJ M=#P>/(]E_H-W*6J4;<]A.IYAKXZU7?P$%>%UNK,<>C#:9)PEP#ZU7P`,M<%% M3QL?\218"NT&.)N:P"EI"ZE^S7$"'U&TTE],[UMWCOWC30S&`^`5%UC"4S"& M_8AS'LBLV.,F*X840 M*;0'QX))+-2+312O$,X_(C!/*F#3<6T"EH_I;@O6`.DZPH+M(E_3\:@*W],> M"_8.\Y28/5.>3&;-UM;JA$L30E;)PFQ8@(K,B+*H1)2/[']=V/\;1.8$RY`Q M>2L6E`WK,>`"H=6T)AOQJL7C"EQ@NCI?NMA:/XZ_-3'WGE;Y"?VM.<`WP$/3 MII-[VN/1@,/[9-0;5"'956.>YBLO#$N=4;HNID::H$$H3@I5,V\D'JKE#S:F M8YD/3+FQ=$R.[%]4O]3<07D]Y_!=!O["<]L?:J`J)+@*_6KH/6T#W83D'^&34/Q[=*]KH![OF[/*)KU2(&+6U!/@+13O&+>I>*N48JC2>^B0I.E)"IR M9;=%HAX>?SH:]B879[BRXC;XZ`NXP\W^KJI4&VGJH(H+WR*HG]VJ5+'!:8/) M5*M'@K*KPNTY,/6`W.]X8EAXV.*62X<2=^@)K_O6>60V96"($B<=Y>/'MPE_ MHFZ!!7)Y[S*^GE'1'"",6KPH9*T1#!P$#@&?'V;GDV_U?+RU=,^[GO^I(UW\ M:_<+Z@I.?P0K@BH$"F$2SL./[%ZWWH.QZ#_1"X3GI3T36'ZTC*W+AID1%]G$ MB%*([;L8%5%1[4?I(OULULL:ANK@J"A^9;"6*Q-]`BO']1$T9+G>32]F)EBC MI>GCABO<"E>F#><6'/E*-[A7KV+.RYJSQ9P7`<=ABT`+(2O@OQ#O!-H?;TJQ MX*B%+*CU1X*<\&D["ZZE'S4?Q?Y%?\Q1Q$^#?BD4CX7AKDJ=E\Q!A5&C1B?; MIJQ&)XCPK6K5^9$YK0R=MZW5L?5;.]:ATBL%?N1(^ED$73Q<*VV_M4A:B.$4 MV]THQ>L2@H00E7*I#,H3.!?64Q![D[?W-,0NY]O51I41FS2,0S\#`@EJBS(S MN73APZ%7M)I4Z.%XLH[0VB2U`[U;7KHZF58+=,D#Z%X+L.-Y4LM>)E2]0)7B M>IAS.(OK/NNZ<*P9<[W_$YX@/CL^ZXBKP]L5V.G=V^#.8_\*4$F]?\!_-^(L MQN.CX6#T+8VT%?MX)IHHID/Z>T&*UX[-NG/'[7KF=Y\Q.X/W!D#BV#S,WH=E M2:"K?,'EWHZ:>'4#=AF+;@U>Y:7ZLSI^M0GLM4F.`_E:Z=O60)Y5WD>"?"VX MK/I%*`SRBE!4:L8Q&_%8+XZIR,,(1_*!(X+3/?'+U7F7ON^:=P$O%.P[8)-A M8>SM".:[I;<5A0%+Z6)=3:<&/A*X96P%[6(\RCF![``NZE[EG>D9EN,%+E/^ MN:EH=Z[FCE]N:KGNL-Q\7-:9%F=;I6D#[>I?7[R[O;GZ:'H^U33/UI^&$^#. M!:C+59O.S#/=IP+;6FW?M2+WSBJOX*^2*L/%J_M-7JV7N=I4VE\`K@>^-=0P'YC30A?PY&SJS5_=T?P>(J MY765Q\_9!.M:KQJ@O[:5*W;G!KK[I&A#7G>_PZ.8!,N&E?>%+TK15UC\'Y-^ MPZK]>O)YY8'.!+JMZ$MFS\A=`=M.8H2$#'C*)3XD6@1@L![OVH#2-0?Y\JF] M`Q;F`4A(^],UUF^`Y`#/.Q^1S^H/8!?'D\6AZ/ M+`M\F%DP_"(%"YS@EC`!?U*GEW%*:IEAVO0G6!SX=HZ%@9/FVX\]!3LHY,%Q MQPP@DH`5H\30^[-R34N9AAT0?.5Q81H+Q8?5W0[T';L'PONNCIL(CH8$^GQY M^^[R/P5_OO]N+#@6B%`^P!RZKCY#[H/EN-,]T^LIEY:E.(^V8`F@M0-TUR/^ MP$V7A7^(.8$+OS%_'2UXF9D80P<`4/RO*B?4^FB&RXBY M1>N++.DC;&A6JJX(#P>K4'ALM(,>0<88'["8JQ;ZC!J\@+`9?L@$-K^$QTXN M`G$.E1Z'"XIPQI7N8GW(`#[!"QM7H2.8TV5+'0BD3OH=,/[P?[0`/V!65@<# M)E>$_Y\#LL(`%H]>9+IK M4^>/",P._,P\%K8``60\5#I8-I8[66VJ84PCBPM&6)ZHX!\?%DF`O7!(52'K MH$T)\R]T+`&+*^6&:@J@NT>I=9GO.B&.(0Q<684QHGE\TN9-[]+O`EIPE"7Y M?AEJ)*W_R^773]%?ZB^OE!O7N7?U985;?.U[X@<['8_12>U_C+(`D<-@_7&; MB^ZA2"L47#PE242/I(B$?`[6?D)-F;Z7$;58+G\`L4IR_=QUEGR#0%T!_TUL MS:!YOWY2&#]<.;#1T.7:BB\*,C5U3+H''.YQM_7H:@U^-AB;$2`_#"YZ4P5H M;`$_=Q142ZX0>X[JHQ-8(+FXV7KB??T>R-$+;_*H1=`"X1XB"C*81*K]-@_:(G1PQ99 MP->&[BWBU_0Y+'RDFJ+R]+FC)2B&K.`%!J@M;QY8UA,YBBU&"F3!0@A!,=)0 MZ0Y(1!57[`FVDT`\A73&0N/J..SDA4M20)8*5=`QA#*^Y]TDD;!RC_E"N2YE M159I,R1O!/OG1LF#G[8)WA-LDT+@UAJS;94Y-9Z_>ID;)9$[5.2&L<3MI'>& M.20`[3V;F<)XJY4$P]ZP2A(,8Q*@;9ACQ:X"%T_<="(#/..#!S"A*,!,*`F+ M"(W'*\==*K?=@?)R,!ATU>E$&_3%D0:!C>`D9KP#3>.)U)BP#'5X=F,X^\JA M)H2F;5@!CTJ]"WS0;-A8<&ERHZI#I,4;7-`M_^8@X9DK(%K.`L.'$9P[7^@X M`#T`XCAN>#35+?A]'G##7[QH6/"P`=#XKDF_&_H*;21.T)G("$%5C0WF\$7Q MP`:]'+'-`OO491:C'Z]&0A^';))0^VVV`LM$%*8,G_=75WG&8;NVH:1MJ.UD M&VZ(TDR2*7PL12H4*5U!"L:\\WO$3O%$T1Q&M#@`"X@>'"_A`,(/E#\,$MJW M\(SMP)D%YM2&75*@"N`&D]Z:F.N&_]!=\;HHY!IOHS):--P[$P+"3U#48'*# M(E75GEJ=)E7[R=WD,FY"&9ECZP*O#1+VJ?Z@FQ;Y]!/[0G+IA-LDK53JU-J# M\61TH-9NLM(.HAOR;*P(6''L.PMZ362XZ7]G^]Q/<3NI>"Y2(*)Q5P2@KA1'?G&:[) M0W\R:AY^!2:T4$EBZ4;'Y8(7'\^$\S-]S-[?'.:G$-0QH`MLCSL>\\ZEO4FL MUJ[Q](,>VW#T]+KHEH7]+\B5J@`2-`BH"*P=P,]""+36TR*Z"C]EBH"D/5T\ M`[FQYS/Y1$PZ/CT+4P#)T1#%/6'W"\:H9+P3G/V2,]"[D9=F6/7 M%CK#\2>,HQ`_.56LFC MY`Y*;5!:J:E:":5F!&GB*F`R`T2YLVT,L4'W"JD,Y^Y/00 M,7%B`<13R>U/CR-LREQ&BK@691Z@\XL'J8EH%")M+\HU"A"5RM M:,U3W)2=NRR'44`.UD)DW&O\H+L4/",X(?07+AV7\=J%/L@7[A+1K@G<(,+] M"/*>DDJNPKWT`84C%,7M%WNP#0.:W,;V?JZ;8?*#J--M;A/3\XAOWH4X"O;> M%/R=#K^^V#W*NRQ'E^T%+B`9:B4Z'I=JR;RA=3!&5V]M=0V[`Q`,QE6'A0V. MBPPE?0N7!2B7RA4>S5A M3X)Q2*?UB/VT0OH7-!T'"!0*3-RI=?CQ6;2D"JT;&+'!':GA>57L(;FQ,@8( ML_L;PH]44Z\AL."1G"<.Z%0$_%*5YLY^@[W?AV3RE076!"QP7.,@S& MYO.=#PS%V-,W)N8&`6#=24_;)Z$Y=:A.CK&69IG(1=/]]5#LO8XR2:1X:K2R MG7(U**!UXIX'.UXQY$`RI_]K[;GA-WZ+6Z.2S!#H5*)Z7#!*D^,4 MHIHPD(XGL0VEOV1'R8X-HK]D1\F.#:*_9,?=V'$#'$WDEL.MWY9[S47#R5KM M7WE4;=I1]:4Z[`SZ#?8*UH#SECN^Y\CAS\K96)?#G=P^TN$N9:`%,E`)>FK_ MHC>2#-X6!F^*&7.DD\&)_.*YD3[GYRQ_3PE(E1T6]J1:#3R_/1!.LGA;5DJRN&3Q,U\IR>)UL7@=YXQC$_+`P\>P`+R6WU5D M(OS3Q0CJ.I*4I.7Q+'T`2)DYP9W%2IY)&@=IH[U;VF#2F6H71]K*3L==C6;] MXQ&NR>[?/7%NR+W(41,1FLFZ4JZ>L5Q5D]PP[$WD7M08X,Z7<*=)F-B6E=L: MWB[L*;RUHM*IRNI=E:[RAH7GUDO78G/2>YNZ6AK)"G:B5&MN"?*XDKWH79FH M`YNN$$F%7ZFZG:.DRD!&1?>P`>UR93E/C%79?N(8I3L3W>:R6,UV*+',RU<6 M%:RE8H]A:3^L^;AECK`_:%[G0*JIG:AF*!J>IJH)*H%'YW([68<2OUDZ,V;% M[5SCBMRZYP5+CO_/96N6U+X\9U%/,#WS>+BQ]EP9)96;.AWJS-YT5,\$VZ\Z M!0A:GB.K"84'OZ[+<$E&KQNRM(#OLMY:KU_I>A?Y.DN'7.?R]]*T MY4#;/3AHQV&7PGV7)GNEDFV%&\-U@TB&/G-T.;.0`P M]D!A)(_4!$9_BM[SHLXN#K8=8N3/XUU>>LH?H8UFAIVA9P"`Y:RPOXNWJ8'@ MPL3^L]1$.3;TN&_6S=\7A3MU??C?>[?PHLMT+W"?!*VP&PMWS7K8O0A;-3NB M#6)2Z8CF-FE?N?#3FN%RSA\,VR6PUS>!%RT2UKJ,Y;T$GL,VPS!JEAS MG(=Z^(G^0@`K-6HS/>5.][AK6#=\!#-!%][:V]MA]A4@['),=3]#KV@BA`UV MA>[*`?("(_F/V%(*O\4./`@]>:C#5DC4/(=?4H2>:W*2QSLC71Z:X2]BB(/AY7U:^H]K+KX_,KNYX0'MY3)NQWU)"+A^-T7:J_ M\/H19&1'FU[V+JA-B-K$I9(3:NUB0>5"E7=H75UAP,4?&'#1)OZHO.1565W6 M%&_-9\?NX@&!6^+5](DX>?3?V96+2/-,-:D=_7;W2&@2S_H3XTQ2>.?6B2]X[<]Y[]B>3 M/^A4(@\@YWH`>:EVQEJ#*R?6@/)^57=/SD:2FTND[XUZ`ZVYS'S:PHYMVWH. MJP/?G$)#LH[C";:UB7I,!W@%R]68C4X*SG,6G,%%3ZNK9>!YEBQKV[::OFNJ MH&)9^W\%IO_TV?'9 M.],S+,<+7/85R/_&@F=>_\__H2A_^U_=[FUPY[%_!1CK_?Z!843\/_$AA9[Z MKVZ7/QB-'SW-'X[&`P+9N+9?V/S7%P;2M*_V5=^A3X.!^N+U1@';%E!<&#V\ MA;7B*&.*@=X6^&Q8NN?]^N+=[-A9-4I;Z*XM->JAH_>>+O^1IMDZ`+U/3`=RJ(H%J.#8N5H>."P!\]S'= MYZ7ZLSI^U5-`SS'*&$+]JDR47`$\<'5S,4]J^$1BF,*UO9(23IZEY2%A\`2* M>4SPB=P6M/%V!E;\"4$@L%4K08SK!!I_5/AH8'C,"2IR[PR1&YGG*3'\"4J&AI1L& MG!P`$+2LLMF=+KO7J90B!7S_?;41X%N^1Y>@J9J$&&!4)Z-)`8A\T+IAS*'J_C"N MY85\#BB+`(153)_H5M%1WNB>:9#XO3.M`-[+(A".)X;CHUW/::S$2#3.I3T3 MHVP]Y&W"-L%"O M-?+L_>VGK%Z_'`JNR\T7(_?UIA?LB'6L58Z';][3W+;DA%IE7 MH1E%G)W",#G`6WK_@\W-N!M\^7K^EEXMU*L;T!PFT001[O=4@>9.DT:X?HCL M#;0H%GM@CE499C$_@V%W1^4P4A3ATUS/=P+RVHY9\6,X[('\/DCR>W501?1\ MF["M.\I*#ZLS\Q1H3[>`8#H8U60CP=./C+LHA7G843Y^?*O\\Q.EI_U7]Y:> MOPR?CQ/7`%LU?BQ):0$JSG^C$YNSWW%N&BH>*7G^E7P_A0#`X$']]!.O>>F_[0`QZ@5`#%2@0^V@9_,'T^@R2ZZ,A._=#?BZ' MR)$(SSW55!?[=%0G(!"&AI#\QG4,QF8>/[A^@.,&G>E`08C%$";Q9]`=UW/E MB_"TB[W$JWP10GBN`)P0FDAV$10`Y'HNP`BAV&0MH/%XY-594UC#:7J'W@/% MRA;L*P,:K&!#N%ZM'-='N''->C>]>$%P)%Y%1SC#A'\+CI)7NL%5>(VKE]D- M-JQ>!"B',P(SA+)@&4,:)$CP\:;42JK]!BUE&=G:)I^G7+WCR-ZP.0M6@ZE0 MN;X\C0V1Y?FA/K%U:<%.#<;7GS.>,'&CPXKVK+RN7 M.`%8$CN<(H49[=Y&XX.(TP1;2,*V;$XTS"A3L,P^I7L`81/.DBUB>! M@XMI#0MYN70"[G6^8\HJ``ZDJH!W3PI8J[!@?/7"'Q+6?JUV"X?JJ_.&W80@ MO7DB@`BE\,M-AX#&FBR#44H@=T4U]NYBO4<0MF.O#MK3(MF_Z(\YDOAIT-^&Y*2%.,*)MA^=;?M;%W)\<1B.D2-7W$2* M\K*\.&DG=)Q&3Q4?[,-'/M`X[VB8&QJE\-HGA><&>0Z'CFV9#=<#1)0D3;8! MMC\I^A?5D"++UJ5(T;\H10KU.*10M8JX(J/&RG&%5HH4@[U(\4?8N.\Q39,R MV-.[\>4%GRL/Y8,07;<(4D?B7"!V0J^(STNA=S!+KZMUK5KTBC1:N=4[5'FM MNZ`NRJ-'-ILH98T7>^%C958/W^4_S=EO'US>C?R2,IK79=L*C2,CJ MPR,2M]G^DF,7D49]^9:YA>2I;*K$[&(GDOABE_@UR5 M8NP+O9AO*:W#=0`MBB3N.+0HJ44WV?\;J$&[HRCU_S:9ZG&)#]YSDQ9.^_1< MES]WHS_1UY?8[K:C(.MU>=SDM6B(D$LN&N(-CI"<*#'/FZ?X$3$'34%2N(V4 M_,FG%>-.%P1'0!,)B]H/I>4@4+*^DKT4S;L MH4A&"QF7AL8C?*1WOS!*:#+G)DC85T<(68K.^&;&&$N^]=41@KE38%LV>O2U MIB;VJ))3GA"Y'>)Z`#E5'>^/G'A(B8.,$NA>1O'.>:?/Z)5HSOCY0]=+FVAK MA\I-\QT=G]V6"(_?>Z$#ZM7US7]'4877[KUNAW^_=3S@0]1YOX$8*R\_.I[W M"F/2WIG>RO',\"605C">,[R9'/EZGAR7A@7=@H/BD-=V8CST>?'1#ESBQ`9R M&!RMI-5N[#/54AMN1?3BX7[*!UO)U7`)$0KC;3_8L".G@W3#F,%UO1.]+M[F M+Q_(-=VT9MAU]H;AOAL7=%-:9&_4KRGOY;-C(SOHE'TDP/L0=FW+B\:FUY)O M\9?"=XI"LG=!];J!A0$I_)QWIBS=#BSGU\R8*@-_\ID9L5GV?3W6^-+*1`?LPI# M@=T`2B*4MR#)D/Q>N:F.^U`EGN6-F.0=S''EN#O2*WWVWXURZ`AX%T7?[@-0 M1+7_,/V00'"@2]AQ%PDQ7A^S6H!*I,6]UJ:34@"% M@4`WS,460IB@1'>MC#J.1@%N:!]Q-?HV<%UR+GD>RR2QA"$MT5!H6]!`X3A@ MA-`H8A`^1AF"IU(\>(#V*!-(L^.LC:9`S@K72`$P`.<@6*#'@1_G#&\)^7/9 MR,CHJ2MX*"3#/MPYF"2XLV#@FL`K(\V3T0[0Q6R#.E?,JMLV]G[U=$MWG[`# M)W7N=9D//^*!XLZQ@S3K)%P@A?P@'>X/O;PO2W94F%_+/' MU/$-C.,#GKIAN'A9Q\+(W-1%"SYRR9\HCI@MQ37#A(\J;]C*P2K#+8/A9%P2 MK"CL,I=IPC0Q;+TL0-^F7<1R?8S?%%-7KU0+IVH"=@O2UT2<#XP>80EEWWW8(Q]N.`26\P+LL!5:':!%:HPU)K)"O4I?*K90;+ MM+_]/'<?'A\?>]_O7*OGN/<_:8#`3_CS M3_C@"_&\#T3Y]070C@KSOJ#!L\.+1RW]CEF_OK@2WW9YL9P7.TP<#IB>'!!V M`CBDP+=+"V;!:K#,[OY^^^(U4-YB!EY=1J4@E70MR-P2DU$%2B=3J++WMY]2 MF*70M1Q#P+5P<<7_=QI!@3[_\B_KSDIC8>$M@0,<\U,N#2]=0Z':VK^^4'O] M\%7=-;;033SQTUPW_&Z6?A@NE`N14[A,'%@8-0MH/O9:'O9:X[#7ZL'^(@_[ MB\9A?U$/]FH_E_7[C<,_`](>!"BCZ;1C:[HC*[I!WFH/&K?8@\UKK>W)[,,\ M[(>-PWY8#_9J_B[7P&UNRSZW-P%R-SJU>3N=NF6KVTZ`,KIN4*NNXS>,6%'8 MQ+`T9ZX\Z&#N!IZR$A>2+'DAR4O51I=._#*1Z@?;CF+"`?K!G.$]E`F04R'B MP*:8$+R!7CHN-J#0;67T8UCKSJ=KDSO=HJ3;M4Y-O"YE6,%!?#O80Z&.\EAJ MU#B.&FUFJ,&>$C7.PW[<..S'AV)?1IR&)Q*G[-5@9U^QR;W>JDUP)GFL,VD< MZTPVL\YP3\&9YF$_;1SVTWVQS_##1_@#OO_;3P@&?/C_`5!+`P04````"``: MA:=$QAU^<:8+``!WD```%0`<`&1C=&@M,C`Q-#`S,S%?8V%L+GAM;%54"0`# M5)IJ4U2::E-U>`L``00E#@``!#D!``#M75ESX[@1?D]5_@.C?9;D8R?)3(VS MY?4QY5KOR"5[LGG;@DE(0H8"%("RI?SZ`!0HD2`N4K();>7%A]#=P-?=:%P- MZ/-/JWD:O4#*$,$7O=/!22^"."8)PM.+WI+U`8L1ZOWTCS__Z?-?^OTO$$,* M,IA$S^OH&K$X)6Q)8?1(TF7&);#H83RZO;N_B.'J!^=G9R>1T\S,F<$1V.XS'C=T64?#;5U&"O%?OR#KBX_ZIV?] M\]/!BB4]V411[%%)0;ZJT4M,7'L?AWGIEI0+0A;16]A<>U&TT1\E*1S#221^ M?QO?;;D3F')]S`8QF0]%V?"!D@6DV?HA!3B[Q,G-?Y9H,8K6X@OA6`._S")1&*X#[MU$EIU9PK@A,!->%_,)*B M1/3WQXS_%+9BH\D58+/;E+RR;Q@L$\1+V[2W535O`VBT$$%-A"]NW2LR7U`X MXPSH!=X3]L8HO>L^'/2?02KBPN,,PYCZY\5)P"L.!1]O1L"-., M%9$Y9SU3T[E$/"#_/CW>P2>48HRE(>/QXS$WVG-`!2".HXM06=P^/R*+'F\>0!K$Q"/20[ MD81E(JI"*_7O2UI%"6AH M4G,_175Y448BDQQ">4^3$^=7*&:N\I\N;4V7,'%ZL)-N9W$373 M*&GZ\W!,?PTI>N%P^.3!97T?4JDE.VFH/M``H(<;V*5)3SAS>$)'RBEKI;4N MA!(LT$_"Z02E5GXE.':-WG6:^@!>I@G9I$8LGE8M\WL.;!TIP#XQ)K8)IDD7 M6I&*@D+T=^=ZPKF""&K-,!:;%Q@F-X!BA*>,#\#+N;`73*[A!,5([(6I6*JE7ARJQ1U` M/.Q;EQ#>S/6!RX)\Y$F,!K502%5H*4(UJQN.AV6U0L);D3Y1"-B2KHVV-1-( M7>@(0K6L$XR'874RI%W_5K9KO^.MAB1!`@9('P!*[O`56*`,I.I&@YVJV&8P M485J9S]8'L8V"I(6_S&?36X0TPE;I,4 MO:#PUB=%=L6:-U.QMZY(ZJ!:%*`]+6VWVZ_*&-Y$122/B(0*_DO$[Q>0BG2+ MR^P*4+I&>*K=,FC"4^PC^/$$:/HV:.T^X2DQO'&TFN)59'C9AJP&'+O-"3=' M@&[2'*G=2;SD!7B>IDRKB'W:HM%!/NII80;5$PPIFO5ASX=TZ_LVTI!LV@"4 MP<1V"0['_CQ4=7#/_W^_O+DVB8D=[O^KBUK#MH,'Y>Y4P$S96:?D3=@MVA5L MVC*)1BEKT?YZQJ?XY/>K&R_B^J5^U1TOV MPDB-V;N+,'KSD+UU4`D^E4KRB5ACX>$=[XD%!LM$+-JT\0YGD/)/-(LO&UEI M(:8G"]`W/#'9?<`L)+S%M1QJ\-08YBP44AM:B@X/IUDFQLWBUDAM1-(7;XZ.E39,YV@"T.D3#F$! M+IUMP9LX@V%%(1I1FPP7582N1W1\6/Z%\M;RY>&DEL&F*9'@*R6=CF:CR9A[ M&];D66G*2N-8J:P[#]0IF-C;7G&[$G_A;B4^79?KV-<>00J9;&!]Z\906@S$ M:FD0*+X0DC`[%)5$@V='TF%R@$'[Q`M-]?B_*BJ?,FA%A#=!R+=][6YJ(REF M_5J2(&WK@<9E6[V(`$=\0[QM@%Z)N";0(=U.<$QSS(.\SPRGPAV@Q8V;&>Z5 MNWT?0\M_R'!FV./,^]I7@DFU_F(;1;^2:<94CF$>3"$:MPU>A[T]17JF'+SO M$M!]SD#L6_;*ZL\H3VA*D1/H$&_(/;PEE+<1;XY"X_43!9B!.#<33O+_I-&2 M?R\WVYB&PYVWK:3<1=^@DN!]]5VTV\3IWZI!1W0PJWD7)ZPLJP=($4FX7<0E M!G@--[^]DJWLK-:<*Q-K9^'O9C*!,?>OFU6-N0E'6-]X13EM6*5RFK%V M&(#:V)_LI9IJG&E0OP@\S>J5X>1#.(.Q2*_EK>1+B!?$8]'/ZV\\Q-SA6X0! MCODTZY('RA?=2SW-&7?I!]Z,728\Q1`F[)8[Y1UC2_%LU"A?8W-3ZRY3^S/L MDI^<#)U.[9M:E[10@CKG]ZQ3)E0YZPIP-Z!M?&O=W?:*;DUJ#2_9V]#Z30I$ MB]AF8;3'-BUC=[$-K/,IXQ.YC+D34&C,351C7&/&(M8U8`PNYMFL3O90BD_L MT]2=Q[X&=>H>)M&=0AUQ$'3WR[<(@MI:P]MM,;1^NW_:-`A:&.U!4,OXQTJ> M#2!:V(7^PG9IIRV$W)LGG80 M9>WADFWK/^AS&H9#I,LYH1GZ;XYK-!G1*<#ROR)CZ0M`6/2E$;Y&;$$8VI`6 MX[SBF`>35]P_WE_>L;GKH56XA^<>H"G2B3^&'(!+#],[XZR&UAA.*[3'YH9- MH!\T.%:J*6:QSD7#>S]G.%H(M&*58\@PMQ*5GS74$!V;KWB!W<-)3/+#6^., M^4*,HCB3#YX9T\DM1+L\H MN("N:/NM"^6B8S.[!=@>!J]*#>\BLSE6R:^-$5UL1Z_>WHKYJ!.::NU<,60 MKI,<^.#8?9;Y%@?'VEK#2336?&'H'^=US2X:/P:OOX*,>PE(ZP'20J/"J=)T MUPFUJB=^8"K]J2RH\GAH54"(I\FRH;\1^ET<+)(8UK(([$2J<16B@*UK@^-G M7D5">/O)VY;>BE=59C#);TR;[*LE4NVK$`5L7QL8@N/:M;$AEBM!5;=$]@!:V; M[&::W9)11W,TYO?!V,8'#'+#VR9S1CIG8`OK\>R&]F_V@K:G\2W/:!_D%IKA MD%8\2<$G=TA\>]$M-'W9L(-J=U-*3W4TEO7#V2Z^&R2_PT'\+R@3=ZNO."7B M;?]6R[@P$TC$.H*C,:H371M[ZH0Z3LG?=?YLN&;2_:2YZ_?I0P";/P;D"[=" M[`(LB;OLFQY6LSW4KX.K=%!S#=8'_*7D\.;5E>_KW1V0\K]3*%^_**<:^]X" M/+38^M?X[2DV?"]](Q4V\N?#M<'USJ5Q@)(%XLSN3&7V M*WMLYW.5K[(GR;ZE:`FV6$,1#@^/]?WZ!2A"XM$X"0B@XI?$(S;Z0!]H-)O` M+_]XGR<[;RC+8YQ^V3W:/]S=0>D$3^/TY]%^22.=__QO__^;[_\Q][> MKRA%652@Z<[38N<\SB<)SLL,[3SBI"P(AGSG_N'N\NKZ8N=X_^?]D_W#G:_X M=9'%+[-BY^C3IY]W]G:.#X].=K[-\#S'Z^=T,D%)F>_OG";)3@6> M[V0H1]D;FN[O[5'J29Q^_TS_\Q3E:(=PG>:?W_/XR^ZL*%X_'QS\^/%C_\?) M/LY>#HX/#X\._N_F^G$R0_-H+T[S(DHG:'>'P'_.JQ^O\20J*I$;P]^?LH0A M.#E8T>)"T'_M,;`]^M/>T?'>R='^>S[=K5FDCQ6(,/#W'GPM$YF]3P?5TQ4H M010+4#?$KN"+HQ5P$_#GZE_38I=,\L[._1TF);E!$G6@^<`+%^(Q8?"SPY/L,)U/BHQ=_E7&QJ'ZY(E:5%O$;ND^B M=)#.M?!;$L$JO\.8>T!YD963HLQ(N+UX?T5ICH;,IQB?$8LD,FHW@E-T%\5\Q('"FSC.`^S7,T MR.VUT!L)<)72@(RS>)#Z(2Q&["QSD&0`*UT,]E:8;]%3@NPM,`R=O?7%G$$A M.DNAV9P[/BY[@=F<.R$Z&V'9G#4.(KM!V9P]*4IG(7D(S^K8AP9D;`I^EF4T#+UXPR1F.%8Y4JT7(OF6!I#`<[QI*1&0!<=DF`6BZOT M&6?SRAA,.!;C:[(891/&9?UGD]'5NXHX+0ZF\?R@ACF($@6[X+P=82\]Z$N; MGRMV*VP6N")_4W_!Z=X4/4=EHI`%*/,(X+;+,9Y'L8*R31BN4=O@MT*U-T?S M)Y399+:-UP*G,\)4-BF?T-YJ(BSR"V)OXV2#JEV.FXJ$@P M(@F>M#`GM#439^"NJ-H1/4?Y4[4M*O.]ERAZ)=NCH^,#E!0Y^X56(H[W#H_J M7LS_K'_^\VL2Y22_^R/*,N(N=]D#[30EHJ$KDONMJLU)](22+[MJP&0[1`67 M`1_X$KEOS`^(MONBZL'C:Q(7';DU1M3"*XUHS\#:LDZS]ER0S3-#7^^C#4L" MSQF>*VL1F\B]%N+SCIC.3H%WE/#CC#RN^["]V4P=%2JV:&C(3\MB1A;3?ZW= MG?F(')(YB`@R>-M0EU//)H1X:ULX#L46R-[\+JOVR=-JO2+K1^L5?M\F9"/Z MML$?,28;493;V%;X^&N;.?%K,Y`L57ZALL2V`$7+:PWHTC`:[QBTS4%5-DTK M$*"ME?\357YQ])E^G(.F7W9)^HR6/Y!M),G;+I(JQ_RRFZ.79L7$@Z4\1&17 M>_H>=W.OWN_U7#5^=ZEV0>%>8`9MY6*^%%*-5YBHMAL8@L@,*GYN6F&RJ;'V MDZ;.;EIO51Q%<B:GKI,:ZB M&3HHB/3IAK`Z+^>@=L!GM9"=9YZ2'\@]L)CQGG:64%0_G6%!^,Y-],[7#_2, MZ:?]+##]"!@7Z:<]K.\_OQP`52''Y5OP(YV-UF]=[7#.?*HK>`96+7P)YBB8;ZL*;$S9@C)T-#D0Q]$&O'Z612 MSLN$[L+/T6N&)G'5X$#^3E"EL'1Z.L=9$?^K^EW:)UX;DVVTM1+LH1V%@3J: M17U3ML=($`DME[];U#5D%5!93*Q`1V%P&M):C(<5\B"*?DWC[A@"]*B>BO:C M42A:((V^8MO(F@4\?V\,)S,T+1-T]RQN+NB^-M0BL\4W0ANH$FN,D*TSS1%>*\O:IB1:>KCST+0\58K"=:A) M*8CDG"\+H7S>J@_+K*D_0F9-S1'^*MXZ9B&R(J[\2O%K34QH0$TBVVM`O6)V M2"8$5>?MVY"PGF_/BH)Y`W"-HAS1MA]:75S]XVK^FN&W9:\?6'S6'59/IOJP MT')M(,I@XVE0LJDU16I3ZI2""$^7948$+#-$N+V,W^E?L"')`>LY$P&.PUB4 M134P#Q'N(.+,BF_0"CA/Z_GH/1V'OL5"&2BYAS"(R@K]6HX>DRO6L`1JW6H' M0XU#XVI"&FB>BSB(DLQUE$[/RCBAIS+3Y4F>/2@/8'F#PH!QF(BVZ":Y@@*- M9@%FPZ_/54Y:=?M]CN^7URVFON*9YXKX#'>J4TAK`6*J4A_OK"FNQ5 MK%5OH2BCMR4UTKOG>YQ7-I!?)/$\3J.BU^$_#`DT41I(?+75Z)@"MC1'K<8< M!0:JCC=#PD'L8![IUR_T-`7*;M<;X8?LG4'GX4C,1"B3B?J["(/8A[28K[E^ MP$ERB;,?428,+WQH*(Y`T".Q!#VI!T<&B,+`G4W_O"?Z"ZA\J&%*"B=0N-\V M*1NJEO5(#5%RNT'*[[8%XN\1%43>Z1]Q,:/'K"C8!6>$P$)Z(T9L*V+I;5E- MCTI_]Q*(_2@8C(*%C-HD'-G`2NG_%4C[B2"[S<4=*,HC>TTH"B,WVH>BG6,: MSX%1`JI#K;:N_QY/1\I5.L%SM#H9C-T9!G2B*$#6TRR$#*3S1-UTL([H<-.) ME!@U-"&1(':S'`[!1@$E6+&]^.\N4=$[WSRD_20"]`*#"*J#Q)I)]%HFPC`* MJ%_$AE4(.T2&V$4P/2'U89BK>CGX#D<,5$\-#\A3>JOF[5A1.`6]K]_)\#`& M$0J:Y\8*T@@96#TO?+`Q)A"*0@_('O@4@H@&$'O@(B$'%!B(_XQ!JFB.,4AS M!1YBGNZ#RA(L:+^W8`:@?R@Y&&8`PK3`S`0L)`2<0CC[@KS])AYNW%$`9=T[ M0E!/:[Z"RV(M*65Z;73M")$.=&^.9JL#`FYQ6M.^CJ.G."'<)Z7U"SRTR>2Z$43\+!2 M+E#S?%(`*/@C!96D,SB%%$#I)EB>SG%)XO,;<0::C/]&?"I;'FU.DO2EJUS& M*6&%9.^7T82Z]**CX2$HV-$'1BB"MPX+,Z-G.V8$W218-9NGDR)^(V0XX4$" M5<\"%RIX$U"33T_+7)QN6D:6`8D$HY300[3Q5ASKA9"M@,^!#%ZIZG*:A'X. MWB`:1BH.[UZKW5"#YD!%ZAI`0#0.)0OD\Y`[P#*<'H\XDEU`Q-A$U:Y M&*C9YP$`!:]R)>GT5,Y#&4:'!SVJ^BRJ+N":4\:6U1HJS`M:?NR[!KF/%O2G M4]JUR'J:)8?2.\//8HM]_,';J.LYU8QH]KEI=J=83&Y,&?V&LKDMLV[B&FK" M2US;:Z[`7&W(-)>4:S/\'R>;I9SN^]'TO'I9=H^R&$^7C@#OFJ3@[>V3`#QX M>]&4V&A#)4!>:_V3[P-/)@A-\TLR=ZQ`1,\$BM^B@NX6)@@XK%)OT/K0$Z5! MP9N-D?1ZQJ-*@M7O#NU&CEM4&-F%]KAZ1&E]&@&%:L#P$46U@(?IS7Q M);9@.2WDS$I,B\J<]8;NE);Y\R7.F&UV="V$J<7EP`2O5179]%3)PV=&K7MG$6M7CW0&$&W?T`#0?!6-'A6#/L.-,@Q^S,M5ZOM:1C!]3HG MWLOPX>$]#`0?O'7HRCQHSP)A9[HW+(-`6^(-&9@Z*T@^Q"#X) M9A3>#Z0'JKP-&91>S0#PPKM02JEE\:@ MX"W,2'J+)98&"69#ELNR]?7!3<.F"VG+J*OE=;E]NWM^1A63&7[)HFZSDQUD M[BBYXD[0\8[KM MST.),[/TVRG=8+;:G?`WB*W'_:U@_3AXJY%(9+R]JY$QK5KN\EU^%_<-GZ'[ M,IO,:&?GV8+L*(M%96+L1]X^WW1XZ^M&G>'!F\'`&3'YJE&'&#,CRUVZ]"WL MW;/,6B10C7?;(%3PNE>33__]-HB3:=)SC1@2`#KA5`XHZEWQ<7[IP%X5V4&E MAETJ[1-)3P['L?&R452:JR]4E1$"XWA]NL*1U^DFBJ"]#3 MU!I@+)KBB&2DJ36N(`[DK!D3Z52DSE%ITI(2+5V8*H^))[*8>"*+B2>CT@]? M)+.8>-+1E.670.W6B1LR'3.NTI1@V7M`,6S8JM015$.K$K0#CW<1=#*)SOOB MW4VL,:A1OE89%+;NC437,`)5_`-/?E%R]W,TJ:@1N",%C^>#@TX/@8>M>TUQ MC5T?PCSP/!,[B=3R8`M"!:A0@<_8*XWVLQ%4HD32J%>?.EB"2(:E!YKDO!-- MUM*D4WKPV&TT1V"5PB4)U0-OC$CX*X[!]J9R\LWPN6S:F2,$T-)UD'=8,E[#>UUD30U%-0Z;&&IGHY5$#) MI)JRA%F@6%WN7AWW#W@_/CS\B9^924"YA^DW03VMK)(\2TTR2&>=7(F+R,TK M99`F_')9!52D0=\OG#4U*'_;K*C!L%XU/Y9/.?JK)!Q>O)'_<&JE$BBF9A[4 M"-(7-0G5,QDNOC#NN>AS!Y>#9'!\S?O/>F0JA;4NS84X:#E*#RI#&JSV?BG/ MN^*A%&J(YH6)E8GNPZF6M3F$%W41#*QSWR4.J0OWM2VO4_"0`IIV4,;*T63_ M!;\=3%&\5"_YHZM5\M.?U^@E2BY(42@ZVZMWA@GA8JT"^PLCQ-%351+7NP M>"C<5`F^(1)67^/T[O459T5)V%II2B;0FQ!)$QOA` M7\L`F47O=_;R:_W["+()GA3J>40#0Q`7VU7\P*\N^T^:.MN(GPD3BKXRL(CK MIHY60UO-LHI2>BNR#[5`&85,+\)4@J>98+;$-X35>3D'M0,^8P\ M:_+/Y1/@04MP]%Z@=+H^#+DE^A0E1,&S_0F>'U0B]X_"!FYV/D=%%"?Y;K#- MDKQ.D^ONX1!#K[_L(51M@U1`:/G-W[(SB]V\OCQ^1G8ANNJ8?L>=:$RH#5/J M2L9F\Z/5+B7EIM-S)^(BB(!O+/%E%"\/4#[-\W*^;#`D.^(;5,SP%"?X9<&S MX.3 MT@^BQ=)8UF7R>942:_BNF*'LVRQ*ZQ;S6YR^D2E`TP><))C##MZ\EKLP1AW7`HP&`48@3["CBOM;F>L">05K;NI MJ$3.K]+EI2OA1!E#OIR'&FV^/N*-0SV/*>AH2QK$64CNYN/W*@*'%WD,^7(> M>;3Y^H@\#O4\ILBC+6D=>?S>1^UN/LCF\1G%19FA/)RP8\*4\YBCQ]1'P'&E MX3%%&STQZU#C]R:;#>PT;TOHN[E-T]U<)8;1_8@)`_0T)K?O2<(Z@TSOI`_= MM=O[.4^%$4]UCP^_'J*E,;EU5Q#FU2-M^-/<*WDJ.GBJ*7QX]1`MCQ(/CLVEO*F]^X=[6]/5F#P[NQH5X"@OSD?5B+LPI4EA#\\>HBF`G=LB2C, MOT?:&@A)_!#GWR\SA*[2`F4H+UR[M8B>"V^&Z7TXL8%>`O==6`+FL@'TU#W) M!7W2R3Z^H6Q^!/FJ4T)-)W5$:'N\=1=0,6N(3"P8C+3Q2B]+\9.H^\G.M\G1-ZZC\-9T93F80P?>EI5+ MY&U\J2J<;[A:ON$2^=_% M/>UJ)>@UF",`EI'"NFQ%<#Z+>R$Y/L M'N,APV]_[?PXED-CWH->'3O';!R/NX6J?5\5?ORT[FX"")6<#*7PXF]+ M7I?N%"6)4R=R-+L.7,<>I\QAJ@Z?XN@S[0%"TR^[14:/-:4_X+1`[\5%4J'[ MLINC%_J'1^^B5[?>1O/6Q>RU@T"/:BVT'[DTTQD9F4W*)[2WNEZ^8[;6#0T+ M16\9H"W:U`[;-(.X0Y>Q=%XMO1SS:#_L&`A[Z#0Q8(:Q-VVQLK0/4)58PGY3 MR4T$33VQ@6/3U)_=CBI/ND+/49D4)LKJ2:"NKC\;K5>6WQ7U+JX_/CS\Z09! MM6$%T.8=YUQ03^DVQW6PEF20SI8(5S>-.?9]J4_(N&=Y3\=HD%8B+E8:VG2J7!Q=DEB M\&M]$0E_*1ULGH/>QRO/9=/\6WP,>XLNHA]$@CE23^BEBJ/V!2AEWJ@S"#/O MC;B#A03>DD/0_*:NGO)S1!"@F1EV`$(MH`\)G%AA+K3*>@;,K#+2#A-!Q-8' ME!=93(_`J5@$K4D(4T\B!V9+;4IE1C9A5AP^@@A2#U0V8'?3^YU9T/KW[=O5 M\(1VMJ-I$&1O!OQ;`QQ=^D^:%K&12"),^?NZPR*NFRI=#5VI)*S@KZ*47M[E M0RU0]BG3BS!AY&DFF!SOAK`Z+^>@=L!GM9"=9YX68,@]L)CQGG:64%0_G6%! M^,Y-],[7#_2,Z:?]+##]"!@7Z:<]K.\_OQQTQ+LF_UP^`1ZT!$?O!4JG:-7& MTA)]BA*BX-G^!,\/*I%79SS>H(@>@5$MEN>HB.(DW_5E*LV#)U&1DTSN.HZ> MZ,G-,3C_+K;Z%";FA/ND&A`EB!P#E,G_$Q:PG4]X6*G_HS-UREA:MB]R[ONN"1M=?[=+86A]U MJ(K-^*5=`8(H7YG*QA'M5V)=USC/K]))4D[II8@7448/Z^*F]YNB.]!G#>A^ M^+$=E07IVP9"U?[N]RPKR_(^HJ)8]MT[=G"`D!N/;A'Z<&%#I8S)9UM2U$[J M]RK!Y42MQ%P??"LL]"C`MTHY0OAMLWS=*=I`.4;(3&V'?J^\:XBI;HQZ@^KI M5AVT;69I-%E.;5.5H]I`_1XX)&96RS"U#/+O9HCA&.#*\/P>P\.-X*HKL^J* MO'V6ICHE?E;@E7WY/7G&AL#0]_G6\5I\H^KC^WSW.RW+$[V9C=5PIMD+P\/Q M?+6_DOYLT=A87F;HKQ*EDP70\:DQHNLGHA%>NT3M&RXVF2C;=K[J'U5B):S7 MW1"?X,<^&B,$Q;/>"'\=JCIVPREOB>4'S8Q/C%=]ZA'97@/J-9^&9$)0-ZU] M&Q+VW]JSHF`Z=L'>PU6T!1M%=88([*@_Q/=N2"&R<(Q((CYH0WQJ/!OJ4PDK M%)TMJD7\:Q+EN3BC@N'Z>507;JNS)^&D;")GZC(05H!:"FO8,]443KPZ.B(# M[Z4MD@DBD>.8<'_/[&I^.:MUFR]@.VR1G[!B\CB]AI^(CM5O)-GKYAU'-='= MG.L$DQ/?X!0M;J+L.RHNRW0*GU8@!F+?37&`?&>ZKH(P5IP7039CC:GJ&R\. M,V'%Z+/%JE]%(7?FP_;S9PAVJW-HZ>1L(H^&F`BK(7CX1PA=*<7I@6MZ]C^R MX=$+(LT66+G=[V:49IV3./29M/P=#(^YL(+[MK@:/R4?O;-)<_8Y018Y@MKM$;2L2["85!_6V%<-!6[R_4IVL3 M&PTA-\%^DI3WV59^82T=*WKAR!\;1%:O8EN\]X^*T\))'024N>\B^13#BHNN M#4^I9\*_Z4ER7!>VIYJXVK2^8++1%8/+C]4JB8[$[11\R*YE09"^,TJM:(1U MQ)9U3W#)M:P'(A-6I&IP>*QL*3#E1MI0394LY MV29+@<6V;BDG'4OQ6^BW=S7AT.M5>PB'WJ9Z[>)LOO7>_X^(LE"LB@2<#V'5 M!_0J1/P!H9X[KG6/I?;,V+^@4H4%-S=BW99T>N^>EX'A-\+D):Y"127'W7/- M3]>[=(?5,Z<^;"LLRW"6[-N7.B-N;LZ[S]"WZ'UMY>LRY<4[%:K[8:`R/+O? M4`Z_%0:E.R_V+4F!@X'Y!,>$_KEXQ<4,%?$D2K[.*,]7Z;)/YCZ+)^CNF4@U MQVDE0C=:&8VMIU!S[%:8V9#YLF]RFMP,K")SS.]J_DI6X;MG+6;NTK6CK%;T MCFW:1UPKPB;BK;!J9S-MW^1MLAK$&5+-]TGE?'E!$UTPZ)TZOV-Z-"QE]B$J M1$<$J`T$^J]E`[?"O(UGRK[YZK`2Q-%2$,,/O86!G6^C5O=376'MZ-'O%CU[I=S:Y]-[#(:?-(K'&K1]ES4*1'=V7V.;9A!OTX479@LO*@_GNG90E5C"?E/)301-/075H:6AJ5XG M44#7B:LI2]@+)5:7A98F3A6.O:KBD=P0U`?(">/HY\M_NHZ(,CA:H^CFRUY\CU`;?9\`'Z^O#=5*.D M#WFSC%`?@B:8C5VF>8L*>DG'/ID4\C9.2%I,?:5M_U?E_\;Z\ M2.22*(CF8&51OT!F]XH0(2KV>[L5=@*Q9;3LP&)K:/V=X3Q,A-,Y+M/>30PV M<=J9:H;34TRQ;G_8S2PW`Y@MGJN3INWP&D0ZOMX8#I1*7+>RB;Q7O+*#?*,5 M+!$XZEH#Y3Y;P`B`,MD&*-E9W\24`BGB676RX2N@AG;@ MPJ`->2RLCF(Y@E@S80:Y12U5<*'OA%&BW(2-W7LYD&\[WL8X$GW^^6+_3!6AL?@&T#`("@]L5P]4TJE]Q: MVO4X"&$0L>@!Y446TTZ-BD50RT*8>D(X,"/0M8ITNNKFX`S"J>O2L*AV+BJ; MCTBS(FET-=K!Y;&6_E@^Y=7-!,7%&VT(\%U&[_##*XO+P-B"P07SNPK.<$(T MGE_\5<;%XA87J/KU\36)NQ5I5?#F"BD$]]6D*%,8UI:UM;7EH%^MED*T;M[U M?DUP3H]VBJ?M;P\HX8Z654!KJ<6@`6M70T95S8I1NGEC_)7D7"2JT^A^5A+J M*,_/HT5^B3,=?0]"PBS!$$G(-F)C7I2MQY!8&,<_M`4#W\@(0.#UT4M_K\K" M()=$>3$`434_@1S'FX2N'(0>\!9``L6Q@A64W^J[2.F`4<"R">QB5<7F8@IB M3PUP!Q;VI'!\;?LO-LN4">M;6B'FH.4H/:BR[F"U]VJ2_A4/57"':%Y8=C71 M?3BUTC:'<+E4!`/KW'.Y1>["?6U+ZRUR8<)R:H)"1QBDEDDTQ9ZJ<_ M`'A)7G`E%TBDY!]5MI/K`A+?M[!P__?__;R.T1-.LX@D?_UN\>/[[Q!.5B2, MDH>_?K?-W@79*HJ^^]_+__O_^O?_Y]V[7W""TR#'(;I[01^C;!63;)MB=$/B M;4XM9.CJ^O+L_.(4'?[X;S\>_?@>G9#-2QH]/.9H\?//_X;>H\>\QU'R^Y_9_^Z"#"-: MZB3[\W,6_?6[QSS?_/FGG[Y^_?KCUZ,?2?KPT^'[]XN?_N/3Q1##E)/;ZY>UYV9\H3]#?5I5D3]#?F7* M4SS!5VZX&5_H*YQ&)#Q-0O<%[[J"*OQ-'J030*7O;/P+N"^UH*@Q^^F"_JWE M%S_G.`EQ6'EFMA6QD[OFP99;KFV35GH?_E9'#Q4YOB;_/4[X;,\RMD+=)[]U"XM MTV^5ES:I9)NN<,=#KP3_%=_%5E^J5=%%T61&US%URY(+G+S[[>8[%(4RV67] M$V*__?M/NS+WW_,X;5=-D*ZJ`M&_:EZBE/AI16A[N5B(U`I M,PH%4(U]&5:5:LOR*2H>(_8<40'$).8%L;8JB?EG;T-;IE&A7&UQ(L!_)*LM M8UK=5`O0KI0IWUDB,P+G0HM0(%<9ER%9]D6IT+P:61;:)3* MCH:GQ#(L7M5.U`!6Z5:(9C+O?F="J))"A9@/&-=5-+&L#Q$+)&IM6BAM3\J3 MOY-XF]"N],M9%.,T$_)#(M/B14]F-!\Z%F%Y(#:NQK](I\)]_0P5#WU`NZS: MB.%7%J&[(]Y&M=#6I&@N<_=KO"%I'B4/-WF0;\6@5HNVL"T3'0UQL6%8I"M] MJ`&O4*UP7W4@:QE4"/F`?TT-$[N:$+%!K-4FAH4,Z?H.J1#]@65Q4Q^K8B)+>$VP`6V)D4M]?X M(45;O)-0B&Q-"V>R7I/D)B>KWV\>`XJQRVW. M%G"PE3AB;!LHM(&N5!B/>H5Y8`KH/6GXH#-0DX,+(BYY@`I9U!#V@BLF."!# M:DK((H5NAU):+Q-/^^PFG\[H+]T.K$:J,_73DP*8_.G8A)[^$9O730")M'93 M0,TI3O[!?N&BACX/9L30?\"/P1QT>8 MEF_:>SH"W!U;4)`6FY4!622]Y#^6#3CZPGZ?>7945BE$^R7;".T(5K@4ZD\< MB&^I64GL;3[JA-OB$4"$98:@@VK#IBZ.UJ*[T,E^\B-6MKX_47\W<41D4MT@ MN-,&^;5E M4=[?K-&ATJAR*$DWPO*R%$6GSQN<9'CFW'HLU`AHO7<8/\Q@*S:,*=-\/%B` M-2?CRN"(!`O.`JZ-2G44)"&JJ-&PT-R!^8490=S*W&V:%ZQ9^$B;A0>M[S5> MX>B)E?PSSLMU%)(F5B7::4?%HD!!0F0<-*_4^S$ANU1]1^BT%LD.4()S/YBJ MK&46CX@WL6;MVE9)[G+$#(H+X#.-,"G\#X1T-E,+CZ:`P#TP+ MO2<-/70&ELV'Z!Y[T"TRJ6DRI#YZO%'H=?BC]3`WCVZ".$@C#7\D0FW>](1@ M^-(QZX`G8@\&_!`I+D_(F@T3\(-<#A!^7L7;8AE"\.P)1V2UV>>&XML+.=&1 M%W!!:'%N#C3Z2$H:R.7:3!#)P9"A;]D!'Z1.#"@AT:W'T+`O8VB:^NQS0?WI MA73HJP@8(;,[)RFVZVW,3C+YB#>TMVP:G M^#XSU33U2:P^?H/DMP[3XEQMVJG:4/!RO M\NB)#U`U]ZABYJ$+ER,9C!\H6#I[ZQ\ZMCAR.VR89D1+ZULLU4+ M**9VV:_L[RMJG?*2I@4T-I'*+`IJNW^>.U(Y9`R9#J'=&`GOK1U@7;W-?-$Y MR:,P8O<4/.$;O-JFO'"G?-8(AV<4+"S1VN:\UW5Y?QJD"7V-[`JG?/LJ[9-M M^R.MD#:K^`MCX\NYK/+R($GR>XW5O MGQ&P69BHV#`[;V"L"^)1;.R6R6%X;+MJ1\B=.73:BI`G[0A9V62[L(LS.=`7 M9A=QPW.O?H>&/UR4%$(/-%#6'@!C9:?4GH5+=O:5\`1N4W%E>&N*.PE;.P?N MPU'/EWV8Z9B0A8\#?B2;)P>!&P-!2W1Q99D0>*>I)V;7BV>$,XX;'U[$!D1; MH]U[@LEBU)[F36Q49?,HUS$HIL/T1^M=FA%YL5M]`I[`I3NF@`3-@%1.`9,B M_;O-%[:S#.?961"E?P_B+=[MA.P&79U<%3+EH5.B7;CD3/1($7-N!:G^O3O^I:$6UMHVPSK5CY&F.UL=4P MIDIC*DOZ*8JTV8# M>=UX"7!RK?``?UJAH<=!@RFBU!Q]J7Z=>\C5N/9-1EA,4WF%JM&(BS+A=P(W MX&!IX&TTUAII&)-$7+1UI-^KQZ`R=$."<,Z`_R&@.%GAFT>,\POFANWQZT]" MZL3*3R07&TDSF6'(P1.-#Q6EE*K+\BGBCU'UW(M),VV]$KLZ:%-%IM%DB-JJ M5[P0+J71"RJX`;1\1F[:-3^,E\QHE*4<\6*5C$$=:WBB6QDCU]%QQ8O5,!^" M+,HN[\MS`J/DX8K$T>JE^+_LK'0[I9I%9DJC&67B!I9=%A[53#,VM.2R;-7J M%?T>.,D].%3%$A5D3)UU.6BBW^:CN0'OXMMX57'3W,Z2R?"S4O@61KR3GI>>=L@@ M(RJN34XC]28W+?Q-!4FK88`-OZ_L)@_2'`29NE$!"T/+#_@A2MB2+]9T%`5] M[:B4#`:X@V5_4,`9+@_M<7F:*`^:LW(-@LI#=BMN^';P>#@U'@^GP^,15$YM MY1$$AD>-AIO_I2%^@((<51K%@.IK1^G1U"@]\CW1ELRC#=*U2;S!YM>LO$%V MD(BQ);1^?L[*C#6_/5FH)RYK<;WP>;)*<9#AC[CX MTXCE:E4ER66J3C@N=@:^`%5\IHN\KU9D/WAXS[D$ MX"0.LNSR_A^TK0V2_#*]CAX>\UMVT5.W^=(*5HV50G`LC:6F07--G1K)G6-J!*GRY\.6?-L/IU)!-6D@'#+D0GG9EX\(M*I2T[/%B[:6P9((E_%HY M%6U`%O%++3NGC.$R?K6NBBX>+.77UZ^.*NK%_%(5+4T\6,XO+-?I,TY748:O MTFB%ZX=9^=2(/X8F5-32FG#!.HW3:<8`S`IA35@3L\OJ5X0+:3[ZM#O4?,-T M^8A!2.(X2!L'GOLX>&`*0UT$L("%07#06-/&#:/2S,0.MP,4A@5P00WU0$9E M`'$+#9FL%II[6G1F?MB,A$Q`D%E'3,AZ'177M+"Y,,*W2.!D%>%LMQ%6MCMH MF'+5T%HJCPTB5N[@&]L&<#OV_!T<__Y'^]Z=*-,JR+0[Y M,R:Y./CY_9]JR<.#__7'A8AW08X^458\(JJ`:$W_D:M\Q"O,%S:6OQX=(*JX MP>P*8QR_>,-0^791!1JD3.SO`15:<0!4JU&,)YS>$?WPG,B'+6(7WRVO,5MP MP*#"4EE>I,'.0XY9:O+ MPN09K:[)ZDO*FJVF)'33M;/MM/GJN;%JPCK:XF9LUZ?PN"D35+JJ M.1/7CJ9)VRDIF[6N[3DYM$GQ(TXRV@L[3V@:CC_C_/+^-GCN.07'(\ MAV2VX8]PT/K2$$FIO6P)H)AD\Z\OT%8PL:Z)'E]D2AV^J&V[11'D`@"=GQ$0 M6G0Q5(B@[R\HEGXX0.P$$-JUIM('Z#C/T^ANFU?;DVF3/ON=5+"`D_>_`1`W M4/N<_Z/+X7T_%/CRCHF5A72YXE`HW7^`DG\J,,53)U-!7*C*:"P"IL!U'N M0$T"F=[RY/+F]@9=GJ&;XXO3F[E!KZHY8O&ANW@7B+?1+K7G!]15$%=!&Q;2 MSJ!L"^&J&Y;E?)O(`R%AAC(2SWWJLK!:9+@UQ*L4IQ[@DRWJ.7W>T-P;R^XU MUXDU4"L6`P"PR#`TEA4^=+"6JBXOKTZOCV_//_^"3O_CZO3SC0\!6EF9Q.[# M]V$OTN@R0&[5&S)H2*`!/SCH'0RP"1W8(+U`>''C,=G@-&!+`Q$NG_J%@+EG?*&!?3&SUWMTFZ67;W/V;'ZB.]QFN*0E^LD MV$24EFR2XRK%FR`*:4DO\T><%M>):G>5`%DK/^=H:R/I--(_9*8!4Q0552$\ M+$OAFM:M:PJH$_IG ME)?HDH0CJ5PGT`CD@$)(S[*+X"!S8D)[L>ZR>HSFGWO25Z:`@\KO+F973T7$ M&XG=&1FQ2?$JXM=H]DC0?U3COOEH--1WQF#1W;.K!G1'?-G\I>IGS`UE0940 M_:?L`K;Q7BV,=K5GA&4:/05LN\!9E`0)+51\GM`F9,MWAEU$P5T41WF$,^$$ MZ4#M&MR6VJ/Q;^4/EB)#7*M99&^Q.MH*Q>7C%T_FU(;BB(!4;I>T5H;:O!Y0 M!@^HWRB9+$W3B_9(+1(%8W#?N!NZ2OV8<5.BWB>B+_Q3U*^0;.IZD#&KKR6F MD6^)M*%T^96TTB/)H[$/R1\S5RH* MF5C@=]2O^`A&6/S,5WSR#0G5WC>^`M_'W0JFV""#*K!-/(UBDWM&/KRAG^R$ M.*VQY:X7%:?*70IHU.+C]]NOR,;GX]OCY]';`QC*RVN)DUKM[?XU5^>7_Z MO'JD%8ZO@QQ?)N([0;NQ=H!J%7^M5,>RRL(9:)RV]ZNDG:VYY1E)Y^/XLH]9>J]9-![R$;N'5/2 MS7J[F'B;F&?;>PRV]1CO_U+LXC'9[S4=9,^"*.6G4'QX^80#MHZ$%>TLQ?_< MLD`FN#+*0J/\)D8:(^%NX`.2`N;N5+0PM;)L/$7U8R\NF+)!`QE<76UR&2@W M"6?L:WX2%FNZRE*&E\DU9AD%S6;98&SV6T+N,IP^L5WGY\EFF]/'M&:BN%A/ M\.&%J_-+082W)+IVTZ4[N!NH&`%<,">!Q4T9C:*1"]=+9AT59_;=O10K38O[ M;SRY5M(Y.431SR$0)2$3V*,PSCIY*R^"\W:]867,V!KJ%3N_B\2TT&P6G_5* M%.'63%$00'6*@"%1[0K\\`EKUZ:QR\#8LGJ&GNJ'?*[X<9N$%+/YX]S';0T` MCR3`F%>K/&2H;/D!/T1)TB=^[X:U;]P'0N1K(7]_Q,\;]A^Z M[#B`E7`6RA^VA]V:2VN^4ONHZ0`5'E#'Q0':=6^XEP.T&US@=K_%"B#\OI98 M<;B'73;).]W@G-;)6K!.W;VCD9TW$T-ZS44R5E/ MPT%8[?AP/7TF=F<;YD16I.&JL?7#KS73!MC01`Y%Y>DC0$=91V6AK_DIV5AE M=AUEO]-2TB"38\J$W'!UL4I-L;98K.9@9:;(T23KBA6.;1=F2DTMV9-W]_01 MBLIG**4/,_\7%BMQHUF+J:M3_4),D07=,DRYUPEAZW0YL,D;!U:VMO*0P4^DR1M);RW+"]6-%,@ M=L6;#,?8A=U5.+PD#K<1CBZ4Q;[!D;Z:$:FY"JK9!V?G/C9-H"]>/C\W]B>JEVV*Y_K+MKAS'FV_.-+EV:W523+LD5VYZ>%FM5F&W_;"\[5HU&N_75I MZLX?%-U=E=!)V'!<6*/PX[0,G?,.>GM/_!J_<\XF48B<`K"24.O*M3!DNWW/ M^4._8'?L+4[7!N.5(G&#,Q`*<8<[QYF#2<\[:#@:K]SQ\#1HS@740)/L_Q6CI:!FD;<(:@ M8=N#68*Z-+[-%'0+YGJVH.VO%<,*JWR&H&&W"FTA.Y!;,8_`K:,OS#[B#GP) M=*#\`)Y6$,(2?FJA=@,]O=`I__R!=G>G=R:Y?,5$M!L&A:)044U@W$F0DOLQ MBCDR==FDHS?7L1A5N(C7FHJ1T%2@)62=U+I7))+=%62,);P`SLNX86_*B3RM,H5+7'FQI2'MTN M!P\QW3C3:(QY,<+TX>5#UO%D]XG`;\VV6]T%STV7^B.N-EY[0TA0PXD4=QI4I7>.AM"!9 M\F'@=7X"%QNB^'&;1^JS^.2279J*)*&8V;?MA(Q2-T;\DV@O^2_HR+?#]10U M*^*3N@HD%.HK"5DCL^T541;&1%D8$V7AD"B+:8BR&$6419\H"X^)TJU9#5$$ M5:`GRL*,*`MOB7)H3)1#8Z(<.B3*X31$.1Q%E,,^40X])DJW9C5$$52!GBB' M9D0Y](LH,-O4?PFBA%U*?9ZLXFV(P_.DNDK78&;?J5\WI_ZH_/IUZH>\I.Y6 MJ4U4\@F/!=&497E+\B!&Q26SB,W7T\YK7*_;C4HM]@27>I[$R,EHZ.[T#S.$ M.ST+1%X$AT>#Z-Y[G^*0KX<1Z4OM31!R?501\XZ^9_Y_0.>-@';Z+:#-0Y6W M%M&\F&H8OR'C)(A7V[CX#"2.STCZ-4A#69KLVA_\7C69/W_VJHE+Z.E>-65A M)]JKIBB#=/7+;QEK1FZBAR2ZCU8!;85$#=#WY6#T#^@+LXQ*T[Z,(#AGGYN] M;7J`.]O;)G;M:&^;ZCU?0U.AG<%VX`*^07`P,PY8*$_#_J`9=VBWS6.0U\W@ MON7!/6L$]VTSN$<\N+^:&&XVP>\(D\XBM7KA`/C;S!>/M[0+D=,7.$["L^B9 M_2T3SPAI!:O8J!`<&^&DID'CE,Z+,MJHE9?UM@G97>LE_0!O^ MR[PH%E4%T7[#-DX;0DU@]G1AZQ-L:%=@UZ(R%U5M7NU=;4I&_,RJ<\Y1L_-D M1=;X)@]RGC=*-B1II,J7EDJ-1*O$+F1SJW:APK!*YP6EQRQ#?L7A"UIL4/U*UZ`DC-M:*OO\M";9A1%5_\&;+D@X2 MQ*K^VK21*#0II+3I"YLNF"=:L8*#!`TDQ:QJ2\(RJVG;(;L$;BP8UM->%@([ M5J%*Q(L#!DUJ6DX6694H"=-44I"F;WMFXMP&S[M-++*1-1/1%G5DHB#<$1MW ML*?/P)V>1`KU)7V&9QX0,JK:'E?T52`BBUBKSQ:5=<<(`DO+31R-`<^BCL%4 MIK%QSZ-]>]#0DB3\4-B:OTO0*INR6Z"4E$=BX.Z!T#9\$J-R8TFA=E>!AU_/ MLGMUS:K98IKE"Y4T5/$[VQ<>EV8DJ\[X@8Y#4UJ?(.LW/NY,KZ_*_+TXR M>GH51W*:F:U2'$9YAM):Q`=ZR&I3U+[(/KZD96F*"]N4OCU7,(%/YD4>!F&D ME;YCON2X?'J`3K9I2@/%ON-$EZY;`V7F!#W%088_XN+/\^0R?\3I9_H!B]IJ MK`SHQT]KU5U8M5`=3R-C9\`YBZU?#>7LS"TK2;9LGS!9E)#D72E=[U>*/!BI ML<<1&5^_/?H:6^FPVM*[1UP_7JW(-LF5.9*QBI3;(A5P3O>=&'/YYX++"7Y@ M,VJ:E,K4K1V5)69:%`Y*&9]2+G-P*`FKKCP=4?O::H+*O$V$25\`\,FI5\(]U[W="4YX!.L.E7AEB5\2IX804\3D+Z2[K%H4VN:&-$ MV[*HC3CCMYI]]"P!:V*@[F085JNUB2FQH.IA*SQX1^BK%FR`* M/^)[3+O"X6G1$-!@Q+O(Q3G\6G+;&)$2W^ MCY)&UV%3&*BS!!XUBM&J:J2J"">^10\K7"HCB2U*=%'%Q)XZPIB7:#;*..Q% MVQ3!#5OD/>W2`BI5.5NX6&'?-IZ.)7]WW\^2)1E62FO32!;+2-K8E M"QX7&M8G:3'[_NRHWM67M7_13LXW[HHJ7TE121WIB-A04_.M9]\URAPV,@)/ MHP`F;S+.7R_"C&/]4(C-&[F+HKR8[&/0B]9Q6R4ZFE!RXT[V,6C=J3FE45]Z M1!V#"B;V%='EC5RK31N==<D=C(+388>C%U\T,L,B2AF08:'D1D,^B M),H>S%B14]O27]!Z^HG3V@@K#T1`60?6P+]IK@0]'U[KF`! MWW\1>1B$B7;OA>&C?NQ7YV4P3'1)@S5.O$@C_D'2W]D<+UGA3!H8A4+=R-@1 M@N)`RZR[V"AR8T2$ON*2_?0N2MYMBA\]`;ZX$D7(EWYR"?);\D+H"RPZPP=\ MD!2Z&`:.=IADCXOU+ES`KT`Y`B^Z4#D`,','RRQGQS\4NYO/$QI7Z"^"<*D2 M:P1,L1@`)42&H?M9"A\Z4DA5E]6_V+V"].'\'%#6)+'[ZGT:B#2Z1)!;G8T) M%T$2?MA&<.>BI-9A>?/FRN4W\A$821/]"X@&6/L3<4=0R/+ M6H8OF61:GAQ8;X$#,K2FVBS3ZS;Y9NII/N:QE3N/)`Y9Z>I_Z/EGJ5:QT%AM M+!<-'8$RTLZGDIY>7LHT$YSXX$G1VR-@8&D?SP$!W/VBQLEJN_8VLT`R2.>0K@?_83"<-@7 MF`?--4P\&3)"9J`,E!<>!DA538M9HJD/*6$$>A+R2#WXP*/=B5IR^O1E^JQI MRL"196<5?"!>Y<60'QV]Y:6_I\&I:U/,#/''EQ)B)R[A0=>>*YBX2"GZ'@9A MI)M8[)[N.SST&88E/CS),\K,1[+D22\H[5V!+7B2FW:45XB]V&79G4-./`Z7 MLGI5YMSZA4YR'74*[LDR)_F99/*#QB!/#QMQ))C-F((=MIO)L8]0UF#7"*P2 M=$*WZ*[:<)^%-3E:_LU%7FM*?_G,;Y2_ZUMA( MK1^7-&IP^%8ZU/+B_/C#^<7Y[?GI#3K^_!'=W%Z>_.W7RXN/ MI]<,D,+6*B&=>DE(1*"Q*&&GCU@;V"H0\]=PV4C$;M7/!6 MX<;E"(7>[?`AO0YM&XV#+QL/++%A/,YGQ5*%OOFXGY*A[F#I(I,R<`F#R>Z8 M"1-'7+ZU]?\-856?UX&#U>=LT#(+M,S^G&=]+ONO*H=C4CU)3Y=GVR04+\Q6"U5PE0B-Q:W0+/B`B=*-$LYRQ25_AM;\ M(;IG3WV!N+I"B*-]"O\*B,ZR`Y:AJ%\.`LJB04CQ%9Z\,*9($=`Q4 MYDPV/^/\),@>KU+R%(4X_/#R6X;#\^0L2H)D%24/QZL\>BIR9?%X]7`#Y0<< M8F`DM>Q=0N88@[VK"#G0Z)(IH?N8?,T0XPBZKQ104&O,?+/."(01J#IOD]W> M5C,0#"V);S&BV"G;*K!9;%`HJF."4-%-+!"X`A^?M'8](`#(C"W926LK1OXM ME6-'(=R]\$/EN'"#_%YR7X4@/>CWQVO&2N$6#L+ZQJI6]+VQ-E:"9M5N\,7`@'5'R_7@B\+E!(,O>N\PF:MZ\$74__)S\,4$88-2U\&# M+PI;PS)9OP=?ZDN:A\8(`P/J&*$TX"9&*%Q.$"/TW@?$")W17HP@E8+W,<($ M8?H885CG1C%"8,*`XKO""]HX2%SW;,;CX;3]J=-6`^]@QKJ-:1 MY]EW//L)K^*Z(`:?L`?OG5@'N5U]Z$J%O0]%:-ZJ;A?[6[GR7H]A[7K8=Q$$ MR<'YR.`\9,+\8ZJ!-KEKF*1#,BDDRC9FIYDM?`8E&1#)Q;"DPN4@F\2=ZT$V MA5LX^.H'V6I%WP?9G*#9;I`-%,[S-E1?CUM&RU9]-/'M'((O/AU8`'4<&&!R>8U75")^0<0T!.QLH+:1 MN6/`0(01F%KOA@,[2^V@,*04,P`>L+T;YAP:[;SM^RI'^`$JE-"7\D]O+@B? M"_W2UG!:^,_:,M):H6WX;NP[">M)LO,@#SH<(;(*/%LI]&,&^.TW"1YR;TXPDF;ESI*HZ$=1-ID\$ MPD*0`T^E2.R"]444]@>`8=&,@,4C]#U[^,,^`T*2]0]#Q)RY^V7Z$"31OSA% M3RA+:<\BY/^@:#VJP"*XS-L=2#*`5H MQ@)8("6YP?PL?\$)94'LS0%CL&@E#L'2B340YEO1":Z\_H6S#T$699?WS??X ML,VB!&?91YRMTFA3OFECY(6-LM!.KVQ$?Q)?NO`'X\M56(0HG6VX?,+I'5%/ M+4Q1WD'1%,Q_%64]#:V@##$)N=!`-`S%$&Z-0C3<^_D>"N"Z.5.4=-8HP+I> M#1\'J.7E`'$_B-RCIB?Z<^D+-9SQ\P";LT*E/_3%FPF@UQ=L9)W,5Q-M9NWX MLKO%CK,,YY(+7N4"54XF$!@;/7LFP9=52%TH0Y58J;B@;6;:RZN)F'[8#K]Z MLBU22"PYJ7FXQDYJWK[:%]7%?,433VYS'8,#6:`=`(390UIUK14OF+3KJI=L M!CF9)`3FQ;;=A#VE+RT1%-I+VA1N@BBLIOB*\Y,+EE30*?0\((FFWKMLT5>0 M@#5BI1Y]5+;=@@LVLJK]C$!6'6O;*/(I[0:%E"H2C\;4_+&9K#7];?`L#.NN MG+1:!'@G('R'+A;H7(W+$NICC!/'RU(?K4H#*-_IH*!6\J+=\I#C+\$1=_RN:\P0P:A%E3@PY#JED1'*7Q M`$4:&B\MG"PO;W\]O48GEY^NKD]_/?U\<_[W4W3^F?[[%'U_<7ES,_<*&#C( M&@9`>]"8!SLSVZ:!S::D7K`,N#\#41SW%-OUCIJ6VJO,#MC&1#;)P9HU;]:< M>$P]91?,+^[-WJ'[3!+27M-7#@"IL@1CI68F8*`$$8>T;L`[1*8>M='$S%#9 M*%?-\.E_7-&&^=2'EM@<%EW*6U6:@-5:_1YS#3W.2\Z;(,;9-7["R1;3F"*B MHD2D2;R>"`3-.D;!226VKZ602*UL8=/B5Q_Z\;)*Z])"\9$%).A(]R`OM#9[ MZU/L+&,$E+0T?8%.J](4`&I!=B:-@?US`>P$/P0Y#K4]0)$3DP:BH[3\7&UQ MC!+:]<193O_"GGJ`**1S-0Y*NP5$A53SUF6O5A/! M`DVYR@@&:7/&ZJO@);B+^5W8O(Q!+-L?:"!9?B*EY$A2*6Q#]L?T;E1DTFDO M*PK5"X]\&>(TJ61B71MMZBB4FKS1VIZ3,WQV_)8H`V M3/B`KPS$E?SL'+5%$1E;OST&&]KH$-K*\Z1`!DO%[-W"89BF:)4"^_"E"KJJ MP7RU`_/IVP.S))6;`LVSIGBT0)^#-?Y(UD&4=)LDX<.JV>D\',O(ECG0=$UD M64D.K7*,M8MYGE+V2;9SG]"[^= M($>?*&H?T='B`-&:_".7^(A7Q1%VY:]',W-&`11B7+,=!O6%6T22V?*$3S>\ M5H_KJE922R8L9%E?&)1P7?/NN"?Q9$Y#H8$^(WNT0]_33*'X=>9U-H8PD')( M55DJ.G7UY,P2>_"*9.<\K6D*A?,7H"%3HZ\C0M>T*B5SS4(D;*29/Z5/%3IB_GJMJC M)[PM`LKEKG]@T.H)I!5-7TO:0?O7L.^Z$>R[LFT)NQ:DS6&SQ^9UFR@"@Z9A ME-28OG5L*.J:R)Z/.?G&SLVH5H\GH?98)@N-'>_T&N.YI_/AX!Q+X34*7=(:>9K&EC"WL5KX10`EHOO MEK>L1&CS#9WRB4DG\.Q/13K"YR%@WF+J#P":A[USH1K'0GEU>)I;4!Y."TWS[`9NR:2Y+_`E[O:^1S*XO<[2./?Q9P'F`$C9<=M@@::Y$4NJ M@Q[!8.D/;H67O5]`4"\LFJ]QNDQJ/ M80A:&W35NG0=&+"MK;*L_\GZ(^MHN_:CN]&OJ3XIA%]7"/S=2_;1W;'BH.*A MPV_/N&VM-P)I_?M^UKHZWAE7^[R1BZPP#K,S^B'85"`K$SNJ/GH*8SQ7=3Z`R6KH3L-6(RO+SC[=]C;= M`\3$?=F::($.,KCZ>I34*7;+/U)*9QL-Y76$!)Q9U'B8A(Q6$X@F-KI$ M[&R8]VA6Q100)APTF1?4J!KQSY=#7&3EZQ\Z:R*JXQS$(;0JXT[6*6K=#>): M?4;MCF:;NKW#N_8NP?./&>KKW81:RG-L55I&A)*=:PL-+^CUAGIO8^"U>'OX MDH\Y@``,8N&@V@/@BD&]HS'@.M0FZY]?&[BDRP%AP#7O`D!)V2ZB!)_G>-T[ MC<1809<6-!1<<:MV,4DRWO4VB&5M(VJJH2],&G%Q7_/Q/BQ,B">L.$/VU;I& M'.QX\H^(OZ0D,R9A2UA'P%+8%?FX>1?SB'IW@YBW,Z#+GAZ8I*=\:R/`A&N] M>C+D&=NT%T[%@QF_WSX>Q'"VR8\%%< M>8:$W"D;,;+KRS]*?HRR54RR;8JMFTF%JHZD0E57;!4XFZZ')'<^B,0R]+X5C2!3K>F9HIX>^,$W$57UMGQRA MV[8;!PSO.;MXUQ1IHO2Q]WOY:1J_C^1D;0DRX>L:57&I+;OD__0B/>M_>Z+Y M;&WH'KH0[']``08+H1X*F[KSP1!GF!T;3UO9 MC_@)QX2WL^5&_RXP360KJ*IEQX)791T4S@:.E`#7ZB\K$9Y7ACNAF<%O5-=D M0)5T"*)2:U%&;W].$N5IM,K+HRK%45TELR.-2&8\6?I6@4DB=:`AAT1ON7M4 M;)%#7XJG`?],GNNT`&5@@M4X>87;8TZ_O4 M/>#M4(1U63VBQ@64M[36"PB#2C,3\&%;H($%<('Z11?V;/2D5$8[;3^GY^8F MAZI!G($='C:F)R3+/V]9I^GR_HID$3\-Y#2.UE'"'ILUIX9&U`VJUHB;R*)Q M"SY\-+0$`V*+B>%E(TUF!"QF%]I2D(*U:6LE/E:QH@NLENU?X`,-C+74O1 M`U0*HZ]4&C'QUXQ(DRP4#)(>YIB[O%ARV)&UGNG0#-CA1\:>)L@7I4Y'=3_; MAR*)1UJ\.0S)'C`VG4G]X4C&)JQZC9X$'@A+R0'D=BHB.@F58'DG,2),^*I_1FS3V6F0T$F6@["EER\\.5,$BN$ MR.AH4(,*3DJTI<14>O.#G679#-H]@\;.20OGNED;V):)V).6I+D+8G9PL@<' MLRDK4M-FV354NM9I=M#G`>5?>!JD"2U4=KQ:;==;GJ-^Q/?1*NIWVTP5:D+H M%4;30^<"EBR&WM34,3*R;/R.PN+!W,PQKG\RM(:ZK-+IMCEFYFE&QCWA9*L8 M%A$_KMG4?3R:.VV#L$P1VE;S0J"RO#[]^^GGWTYOYH:^I&J(V>?LPKHMV0:Q MR,ILD+UY#%)\%V1LIFJWA.Z871SQ@(M3%W8B5\$+/P2:];?.@BC]>Q!O\7&6 M;=?%K1-L7(DM.KO%Z7K1`:5[1V4=N'0TDI#NB@9);>>E5`4)Q\Z7U4\HCNYG M7B$Z`2/(U-AKQT%W/IL1U?6;[5]LOBS>Y7*;9WF0A#17^@>.'A[9X/033H,' M?(W9-E7>74]X*[0-8O;&AU!!>WP)QD;S,268*\P/+[,7\7]T\9TT#"-+M:RD M42F.:GETL;]M"`!!(1H7&,0#M3K#"P/2'(W]%O.U4T&,L[)?\PLA8=:_A44E M4D5ZHTQYB6W<29PXNJVHCY9^X05"#=8I#4 MFA<05Z-;#6QH3`^`L_9R%[%]4SC72+YE?CS$L0&$C=&K`"[4Q3X"FV"K!R6V M+:N:KPKD/WAP<\JPFI:LZ+.KZCE7ZMVL'G&X95>67N:/.*4=6IQGM\%=+-U) M::%1Q3$3C;%HU_L`;;Z-W2DY86B%-NZ8K=;>K=UFRPX(TT&K;9JR4QD#KCPS MARR@00;778=J>N46_4Q]><#(YC`3+>5Q$EY$P5T4\S6"GW#`MI6%E\DU9AB@ MV?V'((M,N0MHN\=R$-M@\0"@-&XB!US!S&(,E+]EH<]C4+RS@-:E"13DZ)[Z M0D_,&2()"F@V5QI%=\RJ+V$*D@7"@`8,/EGH`W`C#I)@Y?<@G/+!DP_=\15^ MSD4Y@E*NP'XQC*%C#?8"YW"#8-%R:!'`SYP`*Y)9G'<(GX#:[;YV?]ED0T:6)S-""I MQ4#KAGF&M77'H=&R/&XZ:9!%&Q,RAWCLGW:W'ZG)4)A;!,41V+(+D):.;*+E MH'?P*G(V)[&;L9_U.(O)[]WZ*NO`.=ZX(FZ.,>X@;`XOSB3]MM'%LXV<(QTN M&X\I'8OS>D),WWW-=OCEC[@UP'5?1M>B_^?-X!8H%32Q%0:`^M`ZW(\NLHY] M`^]8[;3/.+YHTU):T99K,VC9DS8AYZE[Z2WZ''ZRGH_>J+GR1-] M!9*^G!13P8:9DIE:+P?2J8'%0;4CAWF+D6.S\&5@JA67HE(^FGW=DRU,A*'" MO`IE,4!M0WV%4][\ZALH:`>] MI@S.`5@X@2J2P^81N(AF40K4Z9)9>U>90SM[J#*(6!SA_?R&61;\*L-H@].B M%^%+I`-GBS`FNL"G+'A"^1*'6=@W\3(`.,@\H(LW/?L[V4S3M#P2R*+`514% M/$Z!]B\P:-.J_8D,GJ1JJU6ZQX9C!*:*_=1*JP@7,36NW,P+&WHUC&\F MQEIA*R@TZ@T!W@0;4\"(@XA%54IC@\:&A/-&GGV@\LC@Q-[*68^K:1R\MU48 M]R;18L5Q%%K@2C9->E4[=)A9O9ITJL41)ZE4%YFNLBB>\#K)H'9OX$'$%2^^ M:1S+D)7G,O0FE-3!%LBNX>(^"[N.E_49EV3*!7VVA1JSE,_.E]$::-2TB>Y> MY!/D[GU;:O3!HJ`T6 M[(S\.1R6M_%O%KW,+;9B5-J[I#0M+RE=,4U?`H\=NH3AQ;K*94'$R)`X5%B4 M87JH.QB`MO(-C//.T/%U#^C5;;Q,AX2FQKQW,G0+\?@S#*HNK["L8:]HU M@\#YOM:7FXS>U"U`-!!GY6:!8#_8KT^JK6IY$.GEB;&A;P^X?I62#4[SERL* M.7:OS>D_M]%F72WGD1+=3*W'KS)&JRV(Z6SB=3XNXYC:?/@%)S@-8EJZXW`=)1&[?(&-:Y97 M87:9;*54\=A0:2R+C=R`P!>BBD.6F#EOS,C+7#"!E3@QVV M&NFWN&KA<4:FLF..Z??F>4"/D:*'-?/:#TC,2( MZX68?,TNJIMR;?3V+^/"+.@67+8P63EZ]RQ,_`7\;76D4XGE.]'7N,=1OJ5!\SRYPFE$PL[M M$J?/.%U%&;ZBK.OUAV9R;]KR@+MWW?8`%]BV]:$F[HAF2G*>5QC5#+DHTK)4 MHNW0]U&"0AH2@K38.)0Q7S]XWA*Y8J9-6^00[9:M$7!)K-HC)U]A#P,5W'3R M3(7W+4:Q">W1*\H.=H>E-(J`:,@K"G&`>A>A505!O"3?XN"L9'K;@7#6E0'. M.B*_4!.Y[!OPAQ^#'->'NT\V6#2P7,['D:S+Y>T0D^6;P"](].S-YAF=&E+6 M)?]]7WL+DX>$28:T1K!IJM$NRR).,Q`VZ+N]II@Z75=EZK?:FX!JV+G1]&V* MDJ%&T1`O&\IIX78]GZ)\RDX/%T&LF(B5DY\LZ7O?YUM4[_+Y6UBW_G"OL']5 M#^U6WV*R'I34L_,^DL"SMRUVKZS&_9R?BR8YP0]L8?$\/1U9Z>=I>L6EZ$\58O4*\0T;8[DW?8GQ[G5ESO3S*GPD)^R)-MZ9UGZ(77=[11/%H<(!HICM[8M,2`P##M(ELO)R/, M2S?Q@MQ]GX*P>Q&K[D814$^3F08[[-]L'^+IHA=0/]%P]EA%TS]^BZ9[&$TG M[Y+L=SCM=V+V-9X>^C]\8_]"^Q!&#Z<<\*F+]M8G;U]'M#[\%JTM/]?^#3F5 M;]I(M53K?=FNO'O8[=&C"S!V.&E$`>9JG`<7V8NMTF-+[Z39'5>HI6:#QNO8 M03V>JA"-'`CX@5JTP64!:;]&?HG]:ZP`&^Q9#_H84CJ/9DWV[*@0F_?9H]T< M8][/]YYK[T@2L^[DZVAF'<<1SSJ:OAQU8E-0WWJ?NL-27D%0WH/U7Z/>;<\B M\J3KR*R'%;^U`WO?#G@\4[0_#<%>+H(3[I3Y)259[UQ2=QZ`QA2%'F8>-!24 MR9].C[:,+L?^9%Y;V\KY*H.]W:9A@'S`(3H-U&#'X`3.(`?9I._B)YWG3Y?U MY9N!RS!IJV+/,O?T+3@``/]S+\NH@2?YW@-EF[U#([-KAH&YXJ^=1&\ MF%'MEL9)9&T[&1]'T1=F$7&3^]I%[T,;(D(*P044#VO;(.&O4]+]"W;F?>_/ M6[:98_JYPK;?Z68!*[_^#R47)=W?75"M\L\\#MPHB]E^IOWN#P^FX;2#IWV$ M3SXJ6A1AXO'.YGOO4QS:R]U#[>)[$X>,]@%]BT+SX/NMA:&]V)"S*^X^[;II ME]J;\#/7_IFB!-\"VL1$>6L!;2_WK&A?]._\+2<_65#LUGF7O>O6VQ:J7="] M.E!06/1Y&BE!49;%;V\A%99P;)*&0X[?J9J-=@FF:35$;[U'(6;^F?"!A?8E MNDRZU+,,9*_^O$"_PMCD_7D_XMA>3L^;'H?(KG#RYY3`(86:ZCQNPT)YV^;9 MO(8_2SU=O-:L!^V:%W3?[S6=-@I,>8"N-830#=@R[% MD%?:C^@YQPGFK'!O_4BKUQ.[YSH7?8^#]^OL*;57;4_6%Q*[G?B&5H^;XW9! M]ZC'(BRX#[?]O;9M;$,I-L/=>/-?:#K'Q7:>)_S]PNY!2B\NM"_A9=:[0K^% ML4DY\K;BV%[FOG7V?IQEVW7Q:M=1]OM9BO$YS0)HZ,VO:98/E?3:^AN;[9K[ MFZL1,BVA%QL(+0OKI-&Q*L.2/7EW3Q_15J!XAE+Z,./9[>,V"5,R MR'7@EP%U@K#?=.T\Z/??\W6$_,XL[W2]`"/'+AH!C6.?6@-E4;UM%DQ*/5G[ MH"_,[@J!H%R^\R8Z#&;\<]5\&"/;83NB+(.S!L7@S?>O9;FL&\LHY3K@BV?T M'H".9A9ZF/DL5T&9?-HDJRVERP-=95Z7_,&K6-5B@'W`\UF[^$GH^1>;Z,LW`Y>!#V=N>-G[E2)>A`9'1S//$QOVG[/,F4,LWV:-5US(?3$PQW@S8.;WD[6T&'1H093DCP%#GB;^3-[5V^U-_%TUN-JWOHFT=<6U6<^&&=_P_I>=J_*UST.PXC])8@_ M1MDJ)AG;)GM\1S]/L,J!![J-?`$->6M\S3Q6IBR=%Y.@%@5U.7JF]]^_+?T: MKX,H8>>G7T3W&'VIQ/?UWATK]@".C!F#%':(3.D6RA"YCML+Q\B8GJ]^K+L7KN+G$#>5@%&79-J`!\!4L']%R`"+>FL`.*-3*7(%$ M6?5[[%^`%2U!/$["3YB^6$AB\O`"/8!A[]'%*F^91Y^6=XO+Z$6@MB[N9`NZ M%:58-L1H)"@B0HASG*[9A<(LK-^SD?8G/D)*[E'&,VQ29=C[/O@Q@'FNUG?K MH>UP8;?8N;,5W:IWW;\&HW\0I*.EW`H/0,,A0@\SCX4(RN3A4FYY*5T.ALB\ M=HY%W^]LW`#]@.,?&KC!#GX(G$&.?$C?Q4]*S[_D0U^^&=@,O)B[X>6U+.:> M-S0X6LP]3VS8Y]4&C8'>SLJ*TV><0ML/<\"S8E%!Y1]S]M_@U(3O>4OPZ?!W] M\F*Q@+L>>-L^?%^[LN]/6U*4R/_^)7,5$BIX.;>-U'H+/` M7+AR%(*;[^$CO[WNFK:+.3F_C;J;W]@-@[]]I[=7?<%=L7SL];5+-SFM7?;D M"B_?@L%(L.Y[,/"Z8Y7)WHC_[Y:6[S@)KR@G/P=K_)&PG:FV?:L1+DR[5X-< MN([0`PHUZ3KCX>4;%:6'NEWRYX@)H"_%[[XO"AZ#?)OP.A)IE@%V@#>K&#OX M;>:+LGF0\Z)?WI\$V>-93+Y*SZ`P$*VBGE)T;/12&`>-0GH_RFBB4U^>D"2D M(.*Y6Y*1.`K90EQ4*V9L4P'315P9??];$FQ#MG#U!W]V%YB`@MA77H?8"JT6 M0;76?2#:690$R2H*XBN2\6,0](33JO2)IU"!(Z#4B2,BZOP9$E)M1D;,#T', M]W#>/&*<>T]'/63$M#2J4BD]I=H2FFJ\S4A7LOJ][!I]PJ)Y&:E`3<6^P&CB M=4W"TDQB74TJH5+WM(GBT>SDD%89,?W(7>!W9=LP%UN:%]3G6;;%X<=M2GOZ MQ=)FGK)FG_%7_B@3`=U8J0E^`R4(0FC=P!]";.-6RQXS0[116J])4FXRI8U2 MB/+'E&P?'OE.U$U*'M)@[=%0OAULN@2TJE0!*;7Z/:(:>IP,L7`;?JQ7H;@@<;,&F# M)`9+R#7RQ4V/9G)^J,C!G2>CJBS.RM:E$H-HW`KA-.LMZF3:50 M?WBB)00W1-$PZZ:5D[DQ'*_H*BZO\8H\)/SLKU63N[@0\H!\\DH5#V!(JD`Z MB-&0EPQD]"PZPPML$R%U,0PL=?^F..WIE>)%%70'`F;VX/E(XI!&E^(R@L\D MQ_S7FTT<]:=?S,2;`54I#D$5A0/;(/N$TSMB$&;U+K4)A?QJ=(L] M\(`^)I7?)9)A!0D8I=#L<4OK90*LP09H`V=C858%[5+L#]7M.TSRH*@#=/-Z MH:>*YH#8\RO"2Z?6=8+2J`XXC2XS#3ZKI_)BQZKV1'F;3IA+^$8>];2W217H M^"*>XE9;]H@B9=MKD0=)-:2D$6B`LZ?GPTVOT\BG':G$5D1)$>)7#/M&,3D> ME%Q35IB.=#UE-?LDOJ8!H<-,2>H/`(&+'00;R1&Z?NT0-$Z4(##H5[JD#?W: M2.^`4]9QG.1!;!?'!X7M(DK?,F]%C/8\$S*CA$T05N/=48AU'%&'!5!5__(X MS]/H;IL'=S$?);L*4IQXU\DT1X=Q?-3#PZ_HQSJSQAU&D;!R*-!AQ[%IWFWG M4>#)?EA&WHFL*.//>FJC:M>.Q`SI5C;U](,PWG8O6>%VMSS>XN?\`_7_NQ&_ M%'I*J@GUG+!.X&FR<7BY;WM*RFR)V.DC)55(T;)34XDF1!68T'-6ZG=*J#H> MQE=X!4.I:F`?[730%Z:%N)J7[8H+$%N-^D.B>-;4;GN7T3X8S;)/G]A&2FFK MHY.K6AFYW%BJRBR[:$4TOI1\5.HN=X]1\7QF>FGKE5A608<],I466]1V70(' M+J;KO`S&S$(`&I\"-!B"9`%X-(1\"K"R7K-&3!)>X7K*$L.@?62U#QN"=/K% M?7KXTBO65:N"&P8]88F&BAB^]'[;Q6('?H@/'M+)B8G1E(-EQLZR0VKTG%AP MHZ/;(X=7A^MH:U?.#W%%*`FR4U$PI&O7%XI<1`D^S_&ZM^M8(R8F2$,,EA^U M88?TZ/JP8$=;M4^.+TP`<0F_N-&O5SDUA'6@9$:MH2!&QZHOO.!G13U'&EIT MI>3-1B$%WV@PNXZ;C(8+RP:CUI0U%TS`+T+T:E3=5'0_O[:A8`J:9F)GTQLR ML)E3#1.:(A(:%"+`'&!&71*@8=\&_;6:H#'@#SV#?:OZ%)CO?FXUX*L9=[TU M7Z`N/FM()2,&.]2)0R*K#N%N?NZ05$\`>#].'U)6HASRVC.(1.(*T'MQ$M%M MBH-LF[[P&86_!_&V"T"Y0/GV(H&18.^;-$:Z^5WJ4BF5=0F1E^VR0J9)2<8`AN/ MEYNWA\^B@9^;`C_\V?[B0#+4/@0(B$LQ7K3UFQ8+T\($J:]PF?E^W:>C41V MRQKXMB&1=16D^_*[@Y3\R&7%-4,,/F@;KBVQ)E`%^M!5#-8F"RU;U>^BKN"] MK5])TVM>P7,VN)W[)8O[3R[OBP#9N!CE8Q1OJ=ANP1,?.);,?<,:K<(>D-&Q M9`(I!F3R`%HB)7GA'"W_<7K^RZ^WIQ_1\=]/KX]_.44GEY\^77Y&-[\>7Y_> MS!P"8.%+7(*G$W-`[+>"%6")O0QRC7?X$&31ZC@)RW>Q"&IZ(P9!3&7$8="2 MNW6P#G-408;&)HWA)?^1#PR%Q<_H:W6;=U#>YKTJ3Z`NNA6D<:6D-WVJD?@T MC%)F:#&/2G)[IE%(5Z+9J`.798\J@AO6L+R]>^5]>3,?N2\/N6[?J[AC66GF M&UUD/8<9^3*L+Q*N\D?6^/[Q_5'9]+)?_NLJQ;?!\T><1D]!'CWA\X2F`UMV MXJOX]$YC^?)[&<@/9+]9\6T;R)"LN#H_*['S+E8>19RV,+"\QAOZXGQA;7&# M`GZ7!\\HK/505"M69SK^."]?S;%!AE1?FX%:548V&R?.83BZL;%S-0Z`M/&@ M(<<>/I8]RJ! M)[F:&1AXP^Y-EB00U=@_Z]>KYDD$`NW)DI;`&&+T[8$G`5(74NQ+-)8W>+5- M^6$DCT&.'FB5%>U]L8^5_S5EB2*KX0U]X\>`';E6]G'OR\/7:/\V6*U(&O(+ M`+]&>7'K$N7SFDNQ?^P8=$!ST&T0QR]HNZ$=YDUYP#^5"U"VP:OH/F+=ZC79 MTE_O25&(%QRD;!W&X\>O+'O.I'MM=BHX`-M-R!)0!H$\SKW<]I77L`2%I5:P"`MIN[-KIT M=A$%=U$L/Q387*%\31.%,8#6VX<+;N:^I%@W-;%L]'>^EO/><27JS297"S20 M8?75)HM>N2:/L1_WX`.,KN8.1R+P\*TC4!*NP1$(&LZK\=OS9+/-L]\R')Z1 ME*W7Y'V(R_NJ1>E@V5:M_"3F:F,X9NH%O'MEZ5A*."L[W1'7I)XJB;@Z[371 M;A'K#SU5%MC#DJ#9S/TB:R"1$97<)J:IA9J>=BZG0C!,HF+K$02[-&GY;(?6 M-P!622+C%*V@4W.[3LC[GS4C:UV!WLC:3@"F"UO9S;R-K[ MG[T96>NAJ=^]%M6_K'==R0IZUVTS\-"$'EGKVK8$97MD[?W/W@VL6-:\=F3- ML.K!1M::1IV,K'4=6`*`CZS1>O=V9,T2`-J1-4,`@';%CK,,Y]EQ$E:]O@AG MG_C.(AP>YV=!Q%MO?)E7TKGSY%X4"`F#I#4#ATC+==Q!J:$ M3J;)CW33Y$>:9'XG`#0?=>1^FOS(-IEO:>Q;,K\X\B:9[Z%),%/M';P>?(I2'_'^54:K?#E_0G? M]B,\AV*0;OGREKIC$&_E"KR-'N)=2A1[8\M;UHHWU-"*Z['&>LTUT8:ILG:W MO<,KW/)$FR^.QVE$PIF;W&%H(V-!T":KE9F:QP.<3PIXF)9_D%LXJ--\X=F3F8NT/,*D9Y!L.VX?#L,UWYCYNDY!VRO/'N7?G3HQU2;HU M$=9!D[3S]298Y9?W5J6X3';+=.KU.1U>P1LN/S:DX3$Q`ZX-&DX0;8 M$T\I(VZS&M49EOS5V(.T6X/F6>#H@"7$*SW;`@_-11T/H8OO#<)A,&+Y, M$W&;YM#GSHC]C<5V$-PS&H-.Y_`C*L]I92;,SQ7%/JWG/XJ/1S<0;5X7+!4= M$X54EL$S!P-GTGBAU>TNTV6/BP."4:V&F-[,K;)1M1/+ZA'+*8;-MNH):KRQMMGU95PV*)9MFVQ9,+IIM-RNQ35P-AE2U M.GO?FNVAD+)IMFTA!=ILGY"O.#E.0MK/WP3)RT6\$C;9.K'R->5B8T@@LPK> M3&L<2=&OU%L>)VR()64C9>PI"F*2/!1K)%D5YR_L#_H\2B@"LB!F%S<]I!BS MHL[<9&NKG5A449L*,HV:!FJ3KO`$TSSK/`Q"$FV6^6.^;+X4.$`7%R>>!%`0 ML$C:XE%H<3`\F65;MM)9MK-%+=3JV_2%QN<+79O0>:?,OB8]$*M5N6;UU)N= M'9I*).:?7)0$=!4ZS;_$'B".64-S7+4S_)I`Z08*(]D*U6K94>!6F8;OLQMX MDP->J[R\:;?TZ.MCM'JD*""_HTT)SY^A6$"&#*[";OIOH-Y)YA+MG6-3VK=T!,Z18[_FC@!'@>V<`D#TD$+T].SLK6!0,C#L#(.P<[RM M'*BZ1Y[*+0RZC7)Q8<]1)`Z7M?>M.^X_2AT:9O`2?:->9*6[CQU)!6K$>;^Z M9E69?U]3DOS+7+B&IXM^I=S3*&`*>I"=:,NIDCP39V6MG`!>34 MLJ&[49`[?,.0DTTW0T(.>-J9+RMGS#>7;84>,KAN M^YF]7K^5V9NZFP:R<$,?YOX`P%H.?53@/-"A\Y6#4S'VX02=`&,?9HZ`QS[, MG0)@]-`2HWQ3?TCB.*#1=\.>LX[X6S0$NP9.D,:507+[]'%R86=@#=1?R"/?PO.%W M)A>Z!6,J;<:!L@V]*=I0:@)=WJ/22'69\LR'/`)<3"%>WM]C=O8.E7](@W6'=S#&RH\\UMB8V#'.-WAR"E(<:3@!L-[=6[HN M3*)-JS%FW=1>W"EZL+A8=$)*VTR1&9\Y307",P%'53L.C;-;!R2(XLU+.IB< M%J8<#NE&L]Q/0`3[QB\Q@#PEV,B4>'P!`'-CF,(XI!G-EH\?'E+\0!.PT40[ MJ-K$;XP3`\I3QL'>B\7G16_)!WQ5WI`2?GBY"M+\A1>B^E$VL3U4O;KYREI] MU%57EM[`D^:!!9!?:37$7G\JO+H;)T1W+VPBA\:*(G#4E^;X,A,^&&X$``*= M.ZDL+>TNH1I4A*EQ#W2GVT#/H(A?U)"G57"'VW"_4L+]#:)==@7;E'`?F5,. M<0F810YU#PKZ0Q7HFS'^+6-=DNE-BG70;.X6I^O+>UW2II$J/X94:@PU)4;! M,RVU'RG35&I+]I#UL+S+BG3U2I'J_RZ(GVFB6'VVBDVG>J]J4`;C#L&H5#M,:![AI#L5YUF26J M'GMSQ(VN*HG%=Q=>;=C5Z-YO*+'H""/P5UW*O`P!RN$.**\('^JK+X?@`S37 M^\QN.A#-UU_QFP[8\8LK4?9GK5>^OH7>&!(8NP'/&6T]2YEB9ZB[KE*ZWN4` M!5E&5A'_L;ZH.JA&\U8X>J(/^&1`O3LV#:*,#?FSB8%R:>93%+`[4%A!Z&-^ MOF/^&"0T:;F+HU6Q]]:#I-8>IF0,@MH<-S91L][2Z60,@4DNK%W"<(,F(&Q- M9+U`[*RU?O+R'I5*J-9Z$YB5)"Z.03LRN;'R!9CN6/N%@>YA`=WV'&W46/I; MA>#-FX*N)*=R#%W0O*NZW_R(`/0RI=?"< MRM"AKM.AUE]^WO(]X9157TOYAH%Q=V(21>!!?H.O+B_VPG4U*,I,%B#&5]1NH`?:-&Z&X6X MPS[BV%;;`F8S[Z]U@C/UJ`P,SD#S!;YA]_*^[;<#3Z5,^:(2F3&$$)H$SP%4 M7J38EROQ\9+[(*KVFP"N,.4$*3..L M-&^/$=H,\V>"C'"O`2%I8PK7FT,`PA>PT8 M26,Y$##@2U6*=O>,I)4OP4(5J4QCF8I`9NSJ@YY))TM49%Z4ZP_$2L7B@[*3 MVXI["?K#5?*?R:?DXVWR*_WCY@_HGJ24!`?L3X2?@_4FQ@=4:O&?__9IAT4YT_LCF)Q**HL>(BN($A<'+W'UJ M-7Z(:77WESSTQ%L+'B3&G$`2;CF,U+P]&!=M-#*458_W&A"*13`#$#&R_97: M!6Q_E3[L<7'8Q\77UX`+23,[$!>.+S=6W_REE)1>;0QZ!YC0,%RL,W!B<5FH MY$JPUC6AOET,IJYC^46AYE>$";44UX2ZNRRL,T]T^HS3590UTEOUZABYO'A5 MC$@><-:T;][U*ABI1]-I4HF!Y76]_:Q[KICQ*I='$H?,!BY$&/P1/+A(,X^A2\GF#SZP33_L*E><9#S& M'C-O#WPIPH>7GUZFT(4!4QV[@M.0%!)H,'1R4#'F-WEJ.,+-RMQ@/I*$,5P M1QG6W^(7`A54:5I!#3-LRRN7*RE5FD+J5ETT3V3`;,Z>;T#3EXDIX M@YZ!Y&X"3RXYQ50=ET`-D0-T M\>/5CYY)'#\%$2U@7%SWH;LYM8/.,29:I[/9FAA_ M88/&ZE>U;=EE\<]WM>W M9=]7MV7[<83Q*&02(*2(3ORQL]8Y]6=(4>:@"N3!;L.\@Y-D=\!;K8NX\NYR M:OD5\F^8"\JCWB8F`VCS>8W70904IZ8"W"$`9:[\S./-C8D;8[V#-[=`!9)& M%1#[W=L$TLKHOM\G`(9MX@!?[;@TUG(=HV"*.#<)81IRJ)(XI=^"\0^*<-_X M9GK'@%>$&SGL#U$$P)%_J.(XI1WP;0-UF_F-@:9W#GC%0-"9A+,@2CL;C:[Q M*@ZR++J/<'A+BF)TJ&RI57Y,8ZTQ`<;0"7CZ;.=7&B]LS'1WX#9W&Z4-I2)4 MQ%%P5_<1&U?%;H(H?!HQ*LDB'(!V9$UIX`DS]++U"0/6PA&H_7%?Q=N9MSA.@4Y)A.42G MBU/'+JK&M"['TRM`7``C\J!JQ/(#'SJSN'1FNC,U3W0 MC!M]'Y,L^X&E1>0AX3M'Z(]10OM-6'`X&4%Z1Q,0`_0D-!-G8RG1.$&^%D6-K&DG_6H1J#X7 M#1*",*>CZ;Q894)/.+TC^B/23'R.A6+CC/I=C[1Y!LSKAZ+ZZ#1(*$)?49GF MT;]X"W]Y?YD^!$GYKQ.2Y=EQ$OY"6]H+VLY>)A^C;$.RJ!"]2@EMWT0KHV#L M[99)C;4W4C:3RDW6:!\NR'(WB.*:I5S%)7!XKQ7:C[,[?YSG@BA53N-&9-%Z& M:95+NXJ%O_QX'3E;_RI6!L M1([9*`;P4Q3RSQ/$Q9'4Q=`); MM`93%+>!J5C.5MMAS&Q:0B=%\*#D_(7W,"]X#Y,^:%AD2I7-;\Q3(\P'`#F6'JIR1A8`&GD&&3OVXCO ML)@U&.H$`'[M@&1KJ8X_PXHP->=@,N>AGD'91O/B0@V=)\U!Y-W4>V.0N=1& MA?H;1+LDP9T4[B/3UR$N`;/5H>Y!07]8@YZV(L(U5[OA;'YSY!N$NB35G!3J MH(GD)=OO_YDDY?!9\E#X.6?;_'&6E\X[E+%3*C^5J=(8&IOY`$\0K=Q*.6MA MI;C(E?8]&#GO2)J2KVP-9+%C=[5B22(N#CT.V-AQ8:!(]+[27XI1YK`_S-Q/ M&JN!8'91["[[+$Z)*#--/G9;MH&%2'90#R:3A.>#+(;P,5V69[)!W=TYEGP8 MER:RF&>H3*^T2Q/4'!?CP9U19;8J,XZ#]`7=;;,HP5GVKKK!UIN5FI8<(8,1 MW(Y$9OIU_+%Q-PTQ8;)(.W\`E*09(Q=&3>DR)425?)4JOG)D2O)!9]`A)%-S!D+0K.P:LP&75%4,NK$/7NQTR_+>C#U^CO(B^^E,I5!5ZDVY%'`6;T!F*%;="=P1H_PV!SV(5-6L*F#(8'Z.'5 MX$>ZF784?F"G"HO6ZI@U3C@L,Y9,>)*FB6@U!:@4'344J[`,/[6G=R8?8]7I M+G=7@C1NN:NR!W(71P_EJKFHR"F*X99-\,+.,SKH9`K%0KYZLHZ-CFPI!E[X M_E7Z]Y1JL`>U+9(@MCR.W76S9:G"SM\!2Q!HMK)=;]FH"2)/[&2WJ!S+X7=E M\<&:*'DBT8KF$_Q"$C9L\T*SF#MVY5Y]/0H3CN*8/[UCI]6PC=VS7X=KA&1B MB;C.F*]":S>^JS7MDBI`,W(&7@:3A,VTE80H9:I!DLR3(T%!H22;*H/`TM@I M,(UYR.DN`U>#$<6.$GD#2)+-1$$@R*)#F(J7AG5DDN#C$T*+/N M;"9)XU`['JC4;UR(5@P))B1Y5Z4E\4[%DQD4+1*Z@X,FM24>%91I]L8#U2Y< M0PYVCD3G:138ZGD1"<8\"^S9W)TJDSHGEG73 M25\46KOT16O:):B`.E4&7@;#B76J=%AZ15"2=:H@L#2V4Z4Q#]FI,G`U&%&' M(D1MV'*'XYN/Q_^'MNC%L6D)R:/[J-R)&N.<71;S?92@D+#U.AE7R=@E0C^\ M(OS)NF(0^(,="B:TG[?:LC7]'\I9PX_!2W9&4IN6?Y21*B<8:&04%P?YA,\C MQA1#3N#A5GGND6QYZLD;B=K2;FXYI+;XP+#W.D[*"!AE: M=6T>FJC7K+/P!<>QOT5YP>LHH?V,^+?>YA2Y0/FJ(H$Q;.G;`\\9I2ZD?)!H M5+=7T4;I=RI1-EF%#-IF>.;L35%WQ.AKM]'97V%*5`HJQ\P.PD"LU/HJ[E6&C+YZ'XU$YME..\N M[AYII?P@@ZV,8<)`I^!QXYS^3LOR@23;[O#/"`M5 MNSK$PBB&V#N$;X\'ET%.K8$FEXV.)YL%KD\18+KL6'QV@A$[CHG=`)!6^NB. M&>#CL_BYFF@F]_?1BJW9;Y_3/W<6,`*B!`8S'?;;&]M%AJ$%F8$Q0!G)<.?0 M7%F,(LN;98$L1YJ>!F-SJV%>(?.NX26`)L/AN);#JY&8&K`<^9,RQE M31+#+]_&OTBZ!KCXT"2)0P"@NMU$OV]CF4A M](LCM*KR%1$*5>#Y)JFG*=8^Z)S;3"VI;6E6.;`EN>Q2.#Z1U&5:?V6#?WO3 M!\%/,:MD!`OM3)+4BFKZ2.-Z2OP[6XR@]0J&_(4,^J*][R7RWQ"4S9<4P&,9 M?O&`TIW;%0-:UV"(EJX-4"#:KS[HI`@WG_>'1SC\&<31*L%BDU/E9PW&U5,ZYX,J"#!N9IR MS?;IFEH/<%SA7BXW?.-+Z>LW=@[B%:WX3,(8*YWR,QCJC&&/D0LX#EFYDS+) MPLJR(%$AO./2EHGS;@?7\89;=B@A@RNQS3,C_9IM-MX`.<>.D?@09#@\(6O6 MX*Q--GVL)&&>9;1&EKR_6N M21R?D91I=)D[O>>*_U-Z'A5%IBLH8"R:OM#RB#9U69;\9\3MH:9/U'"*/KR@ MIESI&''/94S-4,,WJIRCJ_K(F,+`%U8"5!9A[B`[`Z')S$SI!/SI2K%K-B9_ M\SV*:("C!S.4W)>P=MA.][*#;_'(LW@D&2YY`_$(=+#&==DGSH`G3GO];AG` M9P8G*O!LC4`Q`UE'^N(8)G;U*;_4XH'=KLLW2@0)"E;_W$8T^K../S^7,*MN MJRGNP8@R=FT65=^-#_!3G!`IQ@\\N#EK,BY.U4+(ISQ=>YZL*1@_M3I%"?>C M5SU[5WJ6_O.WF.,.[J\XZ'C>";;N^6[X+>6G23A;[W?V+F_9SVT KK?*(L M?D1'BP/$.@M>GL'\*H/(3/W928-(O^?J71`YL@\B-WF0YK.&D:.YP\A1+XQ\ MQ*OB3I(RDAQ]BR230_@51Y*C21#8WR0+'YA;4!BO4AS\*R\S/8K9D$'I^LH8;?=^SZ:!DYFXS;%!4\LVQ:H(I@W,K`O MO3=Q;**A-^@B^Q'!#`?C,K/1N(9G=)Z@PO>^CLN]CN@U=*1NO\.7Z[$[R+). MN7P%NMQ^!+'#[Y:E>+F=9N\ZW:\CU@P=T-OO6%,/\34Q=D'_1G^L?J+_NZ.N MZ"__/U!+`P04````"``:A:=$FKL:,+XW``!N]P,`%0`<`&1C=&@M,C`Q-#`S M,S%?<')E+GAM;%54"0`#5)IJ4U2::E-U>`L``00E#@``!#D!``#M?5ESY#B2 MYON:[7_0YCSG7=TS6=:U8TH=.;)6*F22JFKFJ8QB0`IN,8@H'DJI?_T"/")X MX'"`(`&$XB6/H,/A[OC@.-WQC_]\7L='3RC-(IS\\N;CNP]OCE`2XF64//[R MILC>!ED816_^\__^[__UC__S]NTWE*`TR-'RZ/[EZ#3*PAAG18J.;G%CMT>?/GS\?'2WPNL, M)TQPE?_Y,_[@/,G1$ MI$ZRGY^SZ)?[-&X8?'Z_K8M+0?_WMB%[2W]Z^_'3V\\? MWSUGRS>UB/0SH)*&_'E`7^M$K/?E??EU2TH810+66[6)]8Z.*ONE.$8WZ.&( M_OWKS06W])?WE.)]@O++X![%I,JR>/ZR0;^\R:+U)D;-;ZL4/;#YQ&FZ94.M M\X5:Y^/?J77^;Q&;D+/D-91U4,U[H*U.F%8E\9=+*I)^B M&:SB[., MM,@)7J]QLX2$:UN1)_0RH8E7><<#XKY:8E(9I5I@98&A.-QTA+K.L4;E.8O%"'Y<;*DK;&AB!\AH)RGIJAH M$T1;O0GC1;XB?J1(4\+[.,O0J&ZOQ%Y+@8N$.F2<1J.:G\5%2YQJ_12/$*7/ MP=P(^Z`LH9&?(->M+Q^=ESC'K2R=D9\(MZXO&8636*>N+ M)V4YF4L>(S.<^UB'K"\E@\D8=WR-XRB,]$09L#"R%C&Q"-$4A;KP*"\])&G] M$TPFL\DC2G3M(V2G)>!=\*PG2EW0W(AI;*PT.4H:&Q^-C8QFQD23HZ&Q<=#, M"&A@[#,]ZAD=[R83EETOR0Z\>\1.Q9/2>*/J)_H-J_.GMAX]O&YU1]$=(`T;CN2?'2@,S^YKBO>;LG>_#5=1O$71 M0XK7BHV"01JVI?_Y"%+!48Z/V(QQ2F;NO[SY0.^3$+X/B,RMJM,Z@=:ERG'[ M2&\F;)P0/9%E!4J9CD5"VW$P7%IOX*.B\QB'PZVA!M)G/X#T&XX+8H'TY3R* M49HQ`<2AZ0!G0.,98,0ZC@'*@',-D)_\`$CM,6_0!J=T:YTNB`LV3L2DW8D, MA]0SU(`T'C6MX5108^AO?F"H1/X)&68?<_#(I.HCI47@&%)%^8_#1XUO# MXN]^P*(^H*(G,>4I5;8H(8A!>U'N1QA-37"_MUU MA#4Z[V;ZY^27_K@EH>IM-@VHO`$03$\]U'!YUU#Y#[^@4MU3EX.%0<>$2X?. M4\#P=34!F0[W&C1??`'-'6'+P4G[4P\:U2?OT,#0:!P`*H;-5IWSF[G'1.9E M"=PXZ,]0F-]J(_6^>=/N(IWT&K['L6EYYW=I&_VV05B,+5HA3<\!]&B\001$ MQW$NH<>Y0DH-*"QIA>]9T6OV9"_Z#V_IR!&](IO?A*DZ0M9BI;72?N' M9"IEFA,S6!EK'EK<=EA/Z:Z+9E91GI;!6.N?Q>>#8&P;/2@,<4'TND$A(CK> MQ^@*Y;4U^AT)0-KT)R&INW!24!&((C%'V^?T^KAI+M.^$'5Z.&%]JHW6_>0N M#@0J`-N]R\'V^;I^.W>OWN3MJ]YI?H41M4E`)=\&BKC`00R#&^B?N3RB] MQPZ,0`(LB8SH#3X,(('=YAJ'Z/D@S8XUBTE-Q9FKLTS&M=6.A^T[DV-<,"?R M9SCT0DBW3E=$ZB`V%'23043,2G]2YI1'9;I2I@]ULKF9\L+Z_ICYEA,.4FFO M"4LV:[HV@[#>67(?W.=E%-Q',5&P#$8MZ!S[C]EY&GZ&_OJ&.\QZJ M/82)F&Z'%!Z=^V`!::B(%QY/?S>^3E$:/04T!YT4-1#2YFA42.HX=A3T5(&/ MF*V_6VI2W$BMZ"%&C")#@`>-?3#^E-\.**YP$LIP,:090J--XP\ZN)II`J3- M;\2^F0MG=2VM^,C@X\$G%)AI^S&A(DYL!"@O0IF>%K0Q`*V*[7_W8:,`D)NM MN6H!R.)67["0)VCS!%9PG?5Q):S#WR4#>,\)O,ODY+[2==,HI72L*TH"BMU1 M\)#"XCXLI&?(M>IOP8KZ`).;WTZU#JAB7EKC?&ZYS^YGQ[$@T4<%"$-6_GK` MX^6R/&$(XNL@6EXD)\$FRG?9NYI=-C%5L\?&HW(<&C#M5!#"Y>COWL@-S;R> MH.59D"9D[,^.P[!8%S&]0GZ*'J(PZ@^9\`*U@2$%'$>2LLXJH((PMYWE0Q]? M=VF9@_>%.R#Q"6I;L@@0[4@+S*5MO.;WF1A'A= M9KF\0OGBX2YX'IX.Z93>G1FIE78<;>.LH33^J=9D.W&(R26D=.DH73(ZCR2I M3BI@83'3SQCB[>X@>(M!?Q='5(6_,U.9!12O#RE>&_(,98K:&]F)YE0TQ;F@ MPUHX%CL-4W_7I2RM M^*E$@=0"!+F11%0?1M"\H>I88J4*]?"(I'7N#)Q%*908GNM[.W]2UUKS]%\Z M<[*63-T(R"33)@#E$%3>39C@6FJ"B#M5\O`P9*`6*!QI,9$DR[46#I MS8VLY54W"!3^Q$@AO[BC>=4U<6-F/N1VWG1#]T4JS4071KH4K!LC#87C,)%K MI7UGI.%F.T.ZR1W5&_1$`X0J_3;QX)::0@GN'BNCA.,@4M=ZW($^@[M^1G5^ MQ)?C9Z]NG/";VLT]'+5J'K6.;0#[1ZTZKT_;2X=);YMM)>:N(D!(+:6'\T^ MML5YC>UK6CW9$NE0UG79AQ^511-GX^_[O($9V1V6FO$F0((:;;[9DP:-_02 MZ2/2PR*X01W=6N>7F+/@=4*M;>-`84T3+$,\Q55\*\DO?YRL M@N01723G0926%T@7#[\':1HD>7.H^%+77HG2'UTTBS>CCW)Q:]U(L3WQ:-MT MNQRL^M(K*U?K^2N5]#6]K$P,62ETD1"QR"^#\U4Q6>L50C:91]`#ZJH+,3Y[ M&]-HCF?CJ-/(REYCJ142>^U!(8\`I&4'73A!*QLQ0W?AOA9D(J8S:8#/S8#< M_8T-/.XB4K[\W60$^!MA3 MP.Z&SV]$DC47EAZ_H^AQ1?!P_$1&U$=T5:SO4;IX&$2YU+`YC;(PQEF1H@MB M)-[IF5FF=5N98NJDJ5ORBUWC."8`4XJ86.OQA@&%#=FQZS[,"$F]C:YP^BY= M]+2O6YY]$M\"'@=,U>YOR"`D%2T9)2.$+_3P#ATBJJ_1=O,1ABV-S-&,G32 MO.)PI>[-$@R(BWMELFR_%]<==+E_RNJS2U.1N=I*P$TPYA*[.Y! MF0$JGJD-&/M9HQ38[L%,(+B_5V`8QN!T/`#E+@J?3[DG70!NC2EP+*Q]_Z^) M&A]VU39Q1]:L'UT_7'5[&0KJ1DK>_8X+/21"`/B1L5D0!(Y")06"D:-_MSS! M29"MSF/\PX'X[U88_U8J>HPNX,9[&A`+V.@X03'"0D:L]C&$36NO6D8,!` MJW0]P!0B;>=)#%'\=18WB&@7A7F=@)@;320@VH41,8GV%I<@J\R#2YXH_D8J MG2(B;QB5=NNAD?6IMG;WT]XB3V"!>?#6%%NECD-3_:R+FO@51 M0JVR2$ZC;%-G]%L\$/,0@PR>"S3&KYF&C^>WMUW!M*WGZ2@&I-:_].W$3;SF M;GM(C,>,5.,3]*(XV@1["W.I->;!+4L,C1#S3WH4 M"^X.?\`%'3++=8HV0;0\K=NXB4-)J@>[C[,,Y?TMT7%,N.:",;%YD*0*#&S( M5H/C)J`@59B@G@`:.R^N>X#C,,0%\9[$=Z+H*;B/^\.32A$NC%E%O`>MU`YF M(A-06#1+&@&BY$.S0>H\]ON9F0=>I1V/KQ76T-9WJ.GBA M/8IF\@K#M""B[C+7@QTBA(G418J9>`]<#5M-XT;%`OC[$"+#/LU:IKR^FZL@ M6UZ4/]$7%/4>Q6"[F,6NJ%K#L?%[M*6@O7J=9ZM!13S#C]IYJ<"MJ7[73OF+G;5_0MHVA>VO@RCW/6PFZ\:K4'B#/(ZI6K07VX14' MCK95GJ\1EW8!#,0>1?8[#OXHH1-B@GK! MVCPJ!5USN!`0X!&V`3E<@1"TNZM4[OWV--Q$VKU?UY`KA`,S\`%'#-L4(:&VO8`N10!967\P%`I7LWW6?81+O;:G=7 M;W&J;1L3>%6I_'5/`.!#C)$)@+`Z?Y_).'MX0"$QQ=ES6*:;OR'&6234`#3O M`OF+.LDGXBZ3P14NG:)-KE*EHLXC=(0EU+"I5I&_A[)LC=C94'JHU"G:)!M2 M*NH\*D=80@V5:A6-N)_N0HYJMK+'9,Q(TQS%DE99(3BY9=VVCXY= M=.QA\Q$TK;;F=ENQ,;K]5:EJ?@<>5*F_3MJ4OH#XD33WHO_JX/./3P>$BLPQ M*T8UUD051L\2]JZ^-^,[;#0Q,&+TC'P=9%CU$:'F'F3N9BJ5J!<&E[.T5*3<=UC5&;W\(6C'M M@>`*IW@"SD'?I]OA%+>"X+48NFDX:^J]^CEN:^GTNN'-3?:_*DOR=4O-Q4-M M]2#>)0;DI5$WR;,)*#;#TUY(-4]^^G)"1F/'=SI\+;(H05EVBK(PC3:UEG40 M`(']-2D<1BB[(U#[2F3^$VI_DW7)VL5,7?;22QO%,)ZW47HYJDVH4@:83ZN" MV2=#9O7B[9`SFR^W4AE>=B]]<$/CI92M]UNYE%;?J.U)Q7.%$%*^KBXX(DAC M825%^_$]7/[-Z[1\OAYWV3IZOHZ:SYJP^>J]B+R.GK>7W*TR99EPIHZHB?Z% MEK70W1A_:7\WQ&V;0FXD-\L/VK0;F#N#DE-VGI;A4%IS&J9:'*N8HNM71HJP M>YV!4[6WR=;YEZ$MWJAC2\3Q)V#ZW7TZ&;W-VX1LV>1S"YVB,HNX-?>`-S0> M98ZNYY#66M\I5*C-6V=1Q_DWLQ1[+J+*/)`UJ0>"F+?Y`Z#'P*>TEAP?D M6I#[AI%0Q`ZV-3YNFY#7[599RS;I7>^HXRYW41YD4:)8_6/4A' M&F+]&Q33\"UI<(-RN7:V=5@YN[GE13+*'5BU`&!C9BIZVW`4FRS MSRO7[JWC&3Z69?&UJ+XH5SCG[9/`B+FOI76)'7HJC@HF]R3*Y82&<,MG`%N6 M^88P'Y;CU>+S)NKTR\1T%5*OR2,F:,]A*LS,S;]8!(>U?KV&2 M6G,#++%X71]$*U#7A2X.:C&LIFNW4XMJZ-P/8G/VN!M?H9SF@;HNW\I=X^1V M19K!6C<^"]*$S*.H.*4@G"XL(VO"H+AD]N+!>B+QNJV4CJ.B"]U5VCH8KE^W MF_(XE[%;?(X>=\^[X-GJO0.:)X[(`+AW(*7L/,#,H;29IK0O%?_>@9R4KZL+ M'1326%A)T4%>41[_.L.D@*_'G96.H%&5;[%\5;V\#862T.;5(8%,TDZM5;:) MSE$K:R]>"2(GSQ7H%5:QD`ON0@\&>*1Y>O%,*C*4,36*=?N[(U?<9^BO@G`[ M>[*Z!.\+PMN)DY`U6T]<,GN[;SV1N+MM,CJ.BB[T=6GK8+A^O7TS#N=RQXS/ MT>/I0!W_T5R'/L2!['D<2'U5OG<1_J7ZD^@G^DGUN$*+0N:,G(K7WTUO&P"[CQ;L5@S[087A20MA&4`G]4:O&Q[S/#?"Q[@$.PC\A7<*0M)[5RAZ%4>N`U@*7]BNX99YP1 M@3W*%7N[_S&,5[#L8EYC9,\6;>7EU:]!1@&VIAZ_;.)2\$69:RNK\?H"G(6, M93CP,_H,?0@2,FTWY>@A`P),D:74H'YX\_A&DR[8):%1&A:`L*];5;\H= M8SQS02<9P]S3#F/,GB8ZSQAA3!YC.M*1VKZDG-E$(9G,E(;Y-8GRK+23D2%& MDSMPO%'F[FE?,F=1TR.1LC2&GO&R'^9J>7[\.H-=O[Y\#6+ZON3M"J'\6XJ+ M#5F/2>->@<7Z1I`6\R<:5LT"FH&QTDK\O0VW\X-;;:NCQ>.DO>%8.XCE@CC& ML$CI9D%Y4Q`XAAKD/1A!C?!V'O!3VE*M5QB6Q-_WK[?J`[3^-<'W&4J?J/(7 MR:;(R6>T M3AN3/%I&<4&6.>B6PJZ$XMES&!>D">E;Z'2=5#2WJZ%)'Z:K8'C";*P"I]-, M3&Y1>'Z**43Q]LBI#HT[17D0Q8?(N'V/C#NA+ZEMGU9;I#?1XZJZN]@SGIRP M"9X7$-K+^4G?##]^COHON0]^;ZXV['ZW*_-WM+Y'*4OJ[I>VW,T7:Y)_CY)H M7:R9LC._U=+WOMF[#L&P+Q:+WKO.L&-`!YA>07_W6[X'S_R&97UK&K;[S;F& M%8@N;MAN0<.[`7,;IN,'L/7H84+J^M MP2H>_CH&IHID)HK*QT(A4XD!L6@ZT2)V*./O#7JB<_?RP^TFCN3WH;@EN)>B M&"74"H5HLO-[+C(5SBEH5C]'B:G M;*6ZXE)Z@"RXIJJ($G+V=]^_I=9UD"[2`C%^#H6UP5TP]F$4IS0=4IE8RQO[.UXUG-P%O[TR4QT14OX_Q0:UD);:W M4E]/MI*M5#?!C^\$92F!6W_Q(:3I:]>E<3WI"$0UI0PC'(:>3Z.W6OV.TS\O MDNL4ARCCPH1)U,=)C\@;H(B4TT-*CZ/GM[2W:I'1*\I6:/D-XR47*DRB/E1Z M1-Y`1:2<'E1Z'/5GN:QTHC;!`F< M![';^:EL3_\.":JFL&JWY;N"-LW/R[2C7'*;=4:AI&W+7"2DI>BM<[;Z@\]= M'5N?+>;146\H+%6PGS\'7$>52:?/V]I/TB##`+?$"-5*/:/$`V5%@7[S4Y=*]HJG.Q3=@ MFC'7*+!JBU`#^.\FG>F,+68PI[7^+DJWY0SDME82Q=NX(&X27]O[FZ\YT_4N M!U$"M<"P MA#3]>:N$-0MI/BI^KB$3-^1;58;0MX,?<2PC,:&&L; MHC\CDM9)QTYX7?[&1IP7:1+E=-*0+,^C9_HO-@+EA$W6"P&A+R@#*ZN%*Q%W M?^]N;Y5EPH?SM:_S;PJR-!!#0T*UN[;/IO(% M*C`UM2##93WB[HH+^YN70;+\6A##TSP61'WY-`E@?[ML MQQG**O`\I.,X#(MU4;[]62[\0V&_+$L[&&D M-VY'0^CA'>" MM<;E/F0&4'K]5_,@&`AN=HY564T^1OOW7@*V?B7BU3P%7!O^-H@#FFJ!?2-3 M3+2;E#.)7'_.%Z1M=3>`!;3!B+NNQL'P-B67HQ75!G(]LF`V#\]IJSNA@Z?01:$H M,N).6`J?V'4T*2FKA"899VM'MYQP@#NZ?.]-)7O($)'4)F*3N(X"@&)*;<_F M9_C4U'#L1PW,%E1K!7H@T"G*C_(0%'4=-",,H00FM7I&1!E-$Y(_%/LX28B. MY0S_Y3@[";+5#2+K76J,KS@I!D=R^AR:U:,.!]?A-]XL2BC4JLYDQ-"L6RHW M]`G;(LP+^FZ8*QLK':%(,]V@\B2I?E4WXK[UJERN>"0^F:ILQP$Q"M6%OK(2:+#4J) M)%O'Q+PI*29J5F\<(HN)X"#-@X'J=0]RQ<;AZ>_%.TC/QFJ=`F33YEZC MA+&_AM49//B&5KC,**U.8';?[S&V'Q(7#&E[].B2$XRA4H2U<<,MXH81NJU_55#OM'BXQEE$VSL[BZ-U ME-#/L$TM(!/Q#I>4B;V7,E7`@`U9J=N+(2*4+TMJ5NWO^N26OOE'75;IQ_K; MC;/LL]&C/I\\/-Z17TG6(1H5MJ,@Y0I70B)2T?H3)E8IZA`BA% M>IH_1:WY9U0SYOD8GZ`6E$7@UNOKPT,PJ5+=T4/`E8X7+&ZNG8KN9/SP1=+. M?8)!.^\(_&EGCE*:[;SCYOE;8[5*(D2(P.`9#HQ!8'P2U:E[^;- M/WO6NGRE=+WYYUX[.Q,V=QO0F(G'%)57[;X32ZZX30ZB;2;+8EK7@:"BJA(F M)(P=BK$[P>MUE),U:K76.8^2(`G)XO4\".E=G!=>KF2%0KO4R:!"KH-&2WDE M]$!K<"V*KHOZ4Q26O(451XA,=A\?;\82SY>A^K+)TQO;-09)$SU6>=6_ONQHKH.7,GT9%7ZG0;*D&SN[1V#O9&U*`&"`-7H';A.(4X[%##'\=6SE MF584DNEHJ1<3AD*:]AV%(@A%BDWGPR)'$W^`*]GB*9QEANDW6D:3L^Y-( ML.^S3-$$265FV>/C[ZWD*T'M+8/_'G5!+2]NR*2VHO.8]XA@33K9=XASW+X;)R[3R3*2W[9!-" M*FI_^Z>=BNT/.>H$MO^DYYP6+#AX:@L^-6BS*'-3O;(Q73!.J0SI73;^9C>] M+>XS]%=!U#Y[0M6;:8S!74+5N!T>E4O:L;>`9'1\#>UOQG1E8H\=(AJV;M9' M"WF;8)ABO=4LCVTY>+#9^>L391UW:$(N]J5FW*XU^0S]-21L<('Y295QALO1 M\",SR@XK0^&[1_ST?HFBRE>1?_1=%/GICTOT&,1G9#*6OS`&%L[7Y@':_M>9 M9*ZJ9(X4K$_-.]V=3R;O0OQ`]'4SNG,3)"^7<<#)QM4Y0^=H]`2`,3(/ M?F_.RW:_VY69?>(W_-*6F^W^9I3\>Y30?/1,V9G?FNS_W6_VHA\9]L5BT7L1 MC#L&97[^;D%_CZ/KAP;8#*)XRLO.0DK8,1B^(K+T56590?-+\9Y+$!-U MCJ>&1';OLW6"JV]H(JT,E1]N-W$DC]WFEN`&<#-*V-LG%+<;UM&XMV'(K&%[ M8B?C[._,@(9-X*32A=ZPR8Z+?(73Z%^#M(P`RE;0"I?281#!-82"1\C1WXLV M+;6N@W21EOGHE[\%<8&N45IJR@>/K,001/P2?H`)J+$&J/B<;9SY"J+E=O*6 M()1[C_9K79UO=ATX$.EVGG!Y4R][%`Y&8:I?BQS18LW>11S+K MO2:LR\QA)!JU$Q2A8RNMD?OOKB#W!M$CX4I"`]@UQ6X;LS>6GY;6I;K-OYRN?-YN#"N/SL,,8DN&HO=FDT-@2_J$'A"Z3V>P)$= MKW&1Y'?X*[HNTG!%HQN_OI"E>?Y20KGYD;=)HEN\R:*@7-QAU(RT!115ZM4T MV[S.1'7=H72]>)!A2T*UN\;'IG(8*3#-H(#@@IR&FT=LF8Z:H6$6_;#0B[#3$MQ,-B@W!URH5NOH/NX0!:B6[I2%BY#SX!1P,C4J\O:58@)@;LH M\BP/DB6954)`RB`7`;)#[AWX^,J.`UJ'KVNYS>G>6+6^.,=ITP<8^XQ9M0L%,]Q@::>#;9QI?]ZDSP!RLX7#P&70C38(&)$Z-;EV MBZ"WJF@DW8W6XE4>GYZ]NF/1NPPF575U5W,LQOJ']?X0!U_I9/A\58@J3$ M'FE2UN$R4RA0=FQU81PZ2=76CDZ*3?6$-J^QJ*]X[2W"&:::!\U5Q9ZGR%6] M60$9]?2N5W`XVT[<9^39%ZI3'>C!FDMPB8;/OW2(?$&-3#\MP#"8>KZ'V7OA M@PT8,1'[E1:?``/23Q4P/*93[$_:MBKL\;>A[0V]`-=BK+\=:'O1/,RQ<85S M!-Y;[S8!=T["K8!KW)JQH=GR/]X/[$I:[\_J&_-3Q^;H.4?)4Z%A]B6+B M)U?O0KRN:AYJS!CV3U$>1''VQIW,-JQVYR:U88*$E\^F2VQOEA*NT+*@<2OZ MCQYU\-Y8QS3?QI#F^%I_6N?P+M#A7:##NT"'=X$.[P+9L>#A72#6W-?XP*WR MC)"QVKFO#GF8$^_P*O7A5>HIMRJ>_/F]>&!E,,#*8<'4@X/I!P>2#D\D&)O%(>]IV)T!!\^O^+C M^]:ZE^$N.:^SF&,X]AKDY62OO%3+\>:&>Y5V2W9]'%IFN-4B*N,?;NJMC%;4 MX`V.XW.G:Y4N?_,-TO!W=U]H'(+'7*,&MH;B MKI*6/J-N9?/UT)\B;:I8PCQ(<]MW1,?:Y5N5K2*IPB._I3@S-F++:S#4HYDU M'/KTB!;QI54&:L#&,X1XMJ,%0CV;6<.C1(UK$EQ[- MU$1C_?REZM$)>J2/JOC>I\^>-U%:EIFJ3PMJ,-2GF34<^O2(%O&E3S,UT8CC MVZ\^/?LZ^H]/AY6T2ROI07OXTI_Y:VF-2,MJ+7V6L/OSW#%>X&U8LX#@;S\R MPL1D,AINXHYL^Y"78:AB)QEB\T3M+/O.T)K->VQYS?XTUH"D:Z M6<\*:<#)QEV9SH8]-4=7R_O\+.WRDPXAQ,USLZ6D"YWH.[F*=)W?8; MYI2VMJ'^.J834Z[+#QYBE@G%?$MYIZ84&A?:#LM]]56?_3T`N<"O_-"U9:O? M$;8``M8'B`$6O^.F[J:2S83#J?B:J?R%7S)N`OW9+V%W MCU_-_-?.A&C*#9:##[(W)9IOU\7A2=%A#V;.5;+]K1BPW*\PZ+2VUO%R&=%_ M!/%IE(4QSNA`S@N^G*,N0\..I"Z[[74OU^M>&=TWB.:D(;^?X*34L@AB^LS& M)U8KVI&@W;9S2^#M]`+6:[`+#6MV3B%4?#M2S*VPQ\DBYIY!J/A[2Y,%B8B& M']#QP>M<2EZB`:==,.0,+CF/UXCD\#=UD;:9SH,H_2V("W2<9<6Z!G>R_([R M%5[B&#\.WJ0<.ZE3KW'LU$ZEQOUH0?K8#LT/>4J@OD3)\B;(C>T+J=8W1>NQ MZ_//:6KTA3'CJV;3&?+(<&5'C=!P)0_NOF.Z=???1;,TNLW^ MT=21%;BBL2=3@(I>E5^8H['L.82)M--/#+)GIPVS;TE/ M:T;-^0SGV`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`8[XW8\]!9J/YM)V_!ZDY9DEO:S_'3$NK_,):ME8 M!-:&,8X5,4"/[OC3943'&Q8#_8%CY$Z9M#4_?I*T9I]@T)H[`J=;DZ,'O#5W M#*P=QLM;\[.L-3_+6O.S'ZW)UD.A-3_W6M/H0:`%:W6&,RP9)]AVHBRHE?I% M/7[+9HK%JF`",>&RLUOK*XQP&"SUQYZ9\/8.3#`TY]Q/41H]$0F>4.V\+J/@ MODPBS%DPP0O4^D(*F-.GBM=:/%PDFR+/?B4F/,?EJJVT\N*A<=$]K52+U;K! MBUGS40KMA;7MT'5,\BJIQX%79<,;<>!UG:*[X'FGX&ZKG6;13++^(AI,WZRP MY/2>($E5IP;3+]7R\;G*]0'H5!?+*B+O\B^1ZD?Z*\?`]V\4`&A35. MRA&@[Z2TRM;F52SK":[U]X\`+)>%@JOP.B#TKA:QQ_VR-(ME\94/"2;7*`;ZS(/8:>0&_3 M?K"JHH;:WSW=GS9[M4MYK&C,T/NG0SVQTO MD31NWO"R/*2C/#M.EHU7BE!6W_U:+I(;%!9I&B6/A.`*)VGS7V*0*&/=,C+. MES%)&,G7OLV_OK1NUY'9XE\%2L(7QN4CA1)].XE*V+<`2S;F_26%$GT+B$HX M98%LBUKF=0R5(@(;#(O8'R\`C8JU#,`9$?CU=2;7PGK\O=Z@XDTX9A=W/8[5 M^=7QK#ZH9@^,;FQ`Q#KC`J=IQ@K5:4"1,'LP4_KZ4EKK)`ZR3#Q6L^F&(W2? MSKZ.%1X8""B;_-<$WVFU7,_&T9>KZ^G:?KCYK;;<[##F/DH`(&L2M]`8=A1DS',W2@YO+P-+V MW>_DB,-CCE` M/\^$BR6&X<0F=B9=VW_^5X12TMRKETOTA&+Q[`M0:#@-$Q:R;XKVOOE05/#Y MCK2LZ)2#7]:^?:K0F++)/HJ/>OB4?=U9E/8]F5)K8A7%Y2<[W`H[_HA5T1YL M4K?48H?J`R@%$+,?O&\48I`@?R,0,Y`,P$6(L?,'`"@%$+.?4<`HQ""9!XQ` MS$"&`F]J`'#ZP%W"".KF7A/@UWE8E_#6)?`I\#P+%*$\^Q'MI&NN M2TXVA4EX&[SR=SE%C@61/,?Y5NS^O@8G`8,A;K711G.S!M-*4BH%)ZG^9]F<8%-3[G-+TXOV^&CHX7=@UWM\:?&)T$<%G'Y3\;#'N8O^HCK M,W_1AU>?_;9K[9+]'N6K@1Y95Y'LIM<5ZD/CDA?@\-!8'8)#1@-UV'>JDV.< MLSUKNH$FNX#$5H^W`VQ`+7U'7;WQ=)L':6Y[;:-K&XYIO@51J=Z1_T*CWX#.F;$B/_(B&JIZ_"&_84K'MQ-ZT88 M%4WC-SH5'1R%T:;RWS-T=-.X'_"E<@4)>@QRQ'Y(T@-G8'UI,7C\]+"X<&UQ M(7F?UNG.#UM>:-Q@<.8)V^9EXSW`&=?8@6]DDUYHFN`@SQ^TG,V+K MI]YU!A22%';FP:.3PLZ@%(;Z\:R/E%ZAG*YSKU':2E-N^Y'29JU-I"KEX1SC MR\AJ//#)''B8]#C)HV44%S0$\Y:"JL3=V7.U[7!..A3-IUA4;;UXZ.LB?IW4 M)//!$Z5FF-N[)S9._*\O;`:,2+49:FKNJDU9DV,MQ7VF%4HNM-G(IUP->0GZ MPO:BRDS-C`[A$S2]E4%@[^X(M&$P0+/>11`)ZS)7+8.EO^?Y-X@,8A'-55[J MQ82'D*:V(X?&"Y!`]%/'"8>KY[O^=;YTT2.UHO=IO<*%2!]U//2X>?YH[1R3 M$:P\"$-:Q8B,Y2TPJ6S^WL^<:.[/;=$I9K&\MP5,:,1O?T.:^#NC&&F6P8Z; MF=4/;R//'%M?#7Z\QD4RB.0RR=.,J1N>O@YYS$..*>QL=!#LG&$8DO8P+!H? M%F'G%,Z-@<-S"@\/KZ3;QWCBO=1N(_/$Z;ZS8T8,0SUYUI.*V^(^*_/@YV=/ M]/:-[4.*OCR<0PH96;-3QR6SM_W8%8EYU"`@82MF>]N_+PZIC[%E+Z'BJ+:E MG,''MMR7&&S\WBB)^FX M0Q-RL2\U8[.?)&"X/X8H_/5V$T>#61"0O'UN*21WI6,P=P<4M17VDLY"7LY8 MO\L\H?0>CSFHXJ1X.HEQ1B]*1KO]`_[H,,D5_^/U!+ M`P04````"``:A:=$F?5%K,P,``#0A@``$0`<`&1C=&@M,C`Q-#`S,S$N>'-D M550)``-4FFI35)IJ4W5X"P`!!"4.```$.0$``.U=47/;N!%^[TS_`ZNG=.9D MR79R%WGBNY'M^.JI$VEDI^W;#4Q"$GHDP`-`V^JO[P(@)5"D0%)R$GJ.;Q*Q MN]C=;[$`%A3TX9?G*/0>,1>$T?/>\=&PYV'JLX#0Q7DO$7TD?$)ZO_S\U[]\ M^%N__RNFF".)`^]AY5T1X8=,)!Q[=RQ,)$@0WG0VN;ZY_>B='+T[.CT:>I#1ZY_6]D^'QJ7>_9)%@U)OA1$+?WMCW<9B((V\>2S:`"]O!V> MGAZ#-2&.,)77C$=7>(Z24)[W_DA02.8$!ST/S*?B[%FLI3P]/1T]G1XQO@`A MP^/!?S[=WNE^,]K`E\N*/@TA>$^N8KP1/4?B00O.6A3+27]XW-\PA83^GM/E M^8&'F3:G`]7\@`1>*UZ@3W4';X\&NG5-"H*(0S2A0B+J8YL^D&L&F_C=P#1F MI(0^8K%%*K!_M&"/`]-68BE-HG)M`LD'RCT#H,"<^&L&1FOP,-K?X@LP*5<- M&FR](,H\3\49HI1)I.)9/TH?QC&AVFXTP$XGY!2B$: M0`B+,9<$HF\33(,7,\M'85.S@,5/PE9;%>!Y4ZN`A5#29J-"]-#4*&#!X=>U M1\FY!PL\]>'+[*8TU6IEKIB?J-0^IL%'*HEDV+=;];S M!K&?AY#YAT.8K3()]D=$`\^(\RQY'P;;0K;E)P('$_JS_KP]E%/NE,3%N35: MZC/F`[*<+WV:8;`W-)>,!IB";/@@6$@"M6:X0*&:7^Z6&$OQA:(D(%)-P0JI M)@Q.X``V#=P=^!:GR*V%>[9T+Q7O&?G>FW4/?^^PW`_+*>+@B"66!"QK#&R> MV[8?5IZFT9N!1F?-`=5+2%?0'!\>--Z;G`%=$%4&T=K=8C*?Q&ICH;80D*PO M603^6`(#><2W3-3*%OM(*W+]>TJ!+M=\Y3"IFX@. M%KU'ECH@5BK2V$G]-':`$EV>.R2`+Y%87H?LJ7%**V%T!L/IOME+=>3IGKHT MM0-E4P9+$TOVQ8G&C]E^8E,SZWLI9^=:R[4W]!&L8QPVB<:]]H,*%Y\476QQ M=VZVW#SE.$8D^/@)E=/ M/%JREXKVC.P.MAQLNH*RFL(F1%S[/,'K(6*PV'Y8@<"[(@*IA/40Z7QN^7R&A>2)+Q-.Z"+O^?*F M"O__6/1_3DZ'0AD*=Y+YOR]9&&`N5&Z0*P-!R?,*__]4]+\MQ#-2.N=;SK]& MA/\+A0G^A)%RF5[!&_^7-U5`\+X(@9+C:4&>+:F#P8+A,Y9JBSR%-1&+(D;O MEK`]-C"4-U7`,"K"`'+,-CQ6RR,MRM.R.B`L(.[1A>LMVZGXVBB\`%Y(YJ M7R68]0N'':"U*X@VH"X"%Z`[ZX:5D#8I0G:@.@H%5U@B$N;K!-FSP\L$(V>9 M(.VGPV5'E2"'3Q8*<@`V8?@6I8+1@:6"+BJ:U`JV0J&" MZJM5"T;[5`LZI*O+!3E\=[2]8,%@5*]@T"%7MV*0P\])\>(U@U&3FD&':*VB M00[.WL9J<1`6P#HZ7Q_JD!M8_F(?>6B<] MQW8#N4'I*`>YD^+EBT>C1L6C#M.ZU:,91'PY6H.2.H#HZ M6&SIYX,U\5E")5\U5L7FR[X-=5DSZ4\'ZT`1 M\?6]6<=-E-APF8_]C8#]U!#$;ZQ$QJ,^[*/`]IT\(S-/4+Q`^F?$.W3(L86< MY[CZ2DX?(#G^\7`]9&,=Y#[]YYTJ8]X#KBZDZFF`II:=?NV/WS?/QXV`Z!P%5S-7C,&U?&[_2PMO^RM3O\V MYV?#>/`(*%Y7UTR3_=5PWR>X_Z)"R]HG4Q^JAUU$=#]^CY"OS\B%2-X(:JXI\B2`M_9E&MKD?[K0:M MN6!-WZ=X!KL86/[RU8W$D5HP@E&P0I9$ZOLP?^4LB3-2`B0]CY(P5,?EYST0 M"^0(J#G8==Z;HU!?[*B)89-$6'"O>PH2GEYJ9MH>S!U$T(`?B-QM]K\1YPB6 MZ`K)3SAZP-RRLZS1&&;N63P+6(0(?0&[S'>76;L,V*"0:GM+T`,)B5R-4^F6 M076(;>3@&:&+[VH?I"#P^V1^0^-$BB^P$[EFNOJB^2;S#"/+ROHLMJV$2KS` M_-L$:74X#D>.<-PTMBT*EA_WQ%Y$\'T+2?S1E9,Z";3KE.LY9*7%-J:F=:'@>F::HOG(FI= M71@*;K*V#8I2;8NIVTW6-J,NV1.FZ0UOB*YN0[]@T&Z2MAEC7"]$HJ*T;*+9 M1="R^>,.A:#=@F/]$+*$ORR=2BKHV@:/^36SQ($YJ[PF%&``7\/N1R>XDLBK MQ]`V0_.X7&%?ZZGJ*A40EI&VS;ATGE(C:8K,PNP+#3#/6[*%8AV&W&I`SX-? M<15G*6,_2RIC/&*;U&0Y5X3!_Y4ZZ<]Z+OS5S?,5N M^A-Z)E$2V58J0',6:IC-V)W,YUCE5:!?]6,&`D"MM7?:P;`0U9WTM472/>329NVS?26&;F'7?BAW]V(>% M7WE19B=%RQ8@G]6NI"Q]3?6N1*UJ_6V@&O"\ENC,MNK*%AQ=; M39J#6#_[OM%J2BKSO.*613O:7TNZ57G#`'#->$GE<$=[^[)*R3N&.WEC)69BPTW<5J0S)%*_U7+4^( M!RI4;:@/D].^"`>].(H)G<3J("VA,#/>3@L[)2=5VS9)9L4V?D1$B];+M*K= M;&'!UY3]M:3F&5;XF#7\@9N'PT6]%J=M3D'6J6^&_1`)H?^Z[Y[9%XYJW]3F M:$T"K?+!]DGFVL)Q\-]$R*T%:2WJUMA>,7E`1N"2_"\]UISP!:+IMTLF]-G9 MKS`0U`O%$WI%1,P$,:39K^WRV>506:_%;=E)2W$LK,,B+;W`VHE%]IL/S5E; MXY2J<:1_8?N946;^Z`26@]J"&RHQ;$M*W@*IR_!J/)#[O=O,_+4JJ"1$;F[9 M2?-:)HWLU][Y'X@6Z^Q.LK:MK;)@3+7.O3.P95@U:=N,NPPAV]+%!0GRQ\)J M&6,CYB1K625=_;L.]A.U,;U(0&TLQ!5:"=AWU[5V3P'MV^JX_H*S["6N6N0M MV][_DT@##2S,?11^RP&9:JVL;H!:-) M[N1O'^Z6O0MUSR0*2__)Q11C2IM?";HEP["X0$B-!UN[AJQ>RQ)?_XD> M3(V.(ZI*RI;--EK+2:QGQ%17P MDU^NSV_K[7PHZU]BFQ\2P;?_`U!+`0(>`Q0````(`!J%IT27C-M'.GX``$#8 M!@`1`!@```````$```"D@0````!D8W1H+3(P,30P,S,Q+GAM;%54!0`#5)IJ M4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`!J%IT3&'7YQI@L``'>0```5 M`!@```````$```"D@85^``!D8W1H+3(P,30P,S,Q7V-A;"YX;6Q55`4``U2: M:E-U>`L``00E#@``!#D!``!02P$"'@,4````"``:A:=$+'!2?Z&UL550%``-4 MFFI3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`&H6G1+_:2P:0<```3=@& M`!4`&````````0```*2!<*P``&1C=&@M,C`Q-#`S,S%?;&%B+GAM;%54!0`# M5)IJ4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`!J%IT2:NQHPOC<``&[W M`P`5`!@```````$```"D@4\=`0!D8W1H+3(P,30P,S,Q7W!R92YX;6Q55`4` M`U2::E-U>`L``00E#@``!#D!``!02P$"'@,4````"``:A:=$F?5%K,P,``#0 MA@``$0`8```````!````I(%<50$`9&-T:"TR,#$T,#,S,2YX`L``00E#@``!#D!``!02P4&``````8`!@`:`@`` XML 39 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

Subsequent Events
3 Months Ended

Mar. 31, 2014

Subsequent Events [Abstract]

Subsequent Events
(12) Subsequent Events

Reverse Stock Split

On April 8, 2014, the Company effected a reverse stock split of its shares of common stock at a ratio of one-for-sixteen (1:16). Refer to Note 7 Stockholders’ Equity of these Condensed Consolidated Financial Statements for further information.

NASDAQ Listing Notification Letter

On April 24, 2014, the Company received a notification letter from The NASDAQ Stock Market advising the Company that the closing bid price of the Company’s common stock had been at $1.00 per share or greater for 10 consecutive business days, and accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and the matter was now closed.

The Company completed an evaluation of the impact of any subsequent events through the date financial statements were issued and determined there were no other subsequent events requiring disclosure in or adjustment to these financial statements.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

REVENUES

Product revenues $ 310 $ 81

Other revenues 0 300

Total revenues 310 381

COSTS OF SALES

Costs of goods sold 93 31

Gross profit 217 350

OPERATING EXPENSES

Selling, general and administrative 3,819 6,083

Research and development 1,457 4,469

Total operating expenses 5,276 10,552

Loss from operations (5,059) (10,202)

OTHER INCOME (EXPENSE)

Change in fair value of warrant liability, net (205) (2,272)

Interest income 1 10

Other expenses (15) (381)

Net loss (5,278) (12,845)

LOSS PER COMMON SHARE

Basic and diluted loss per common share (in dollars per share) $ (0.57) ^[1] $ (2.40) ^[1]

WEIGHTED AVERAGE COMMON SHARES

Basic and diluted weighted average common shares outstanding (in shares) 9,300,078 ^[1] 5,342,976 ^[1]

OTHER COMPREHENSIVE INCOME (LOSS)

Foreign currency translation adjustments (2) 364

Comprehensive loss $ (5,280) $ (12,481)

[1] Reflects a one-for-sixteen (1:16) reverse stock split effected on April 8, 2014.

X

- Definition

The amount of gain (loss) recognized in income during the period on warrants outstanding that are classified as derivative instruments subject to mark-to-market adjustments each period.

+ References

No definition available.

+ Details

Name: dcth_ChangeInFairValueOfWarrantLiabilityExpenseIncome

Namespace Prefix: dcth_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cost of borrowed funds accounted for as interest that was charged against earnings during the period and the net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities.

+ References

No definition available.

+ Details

Name: dcth_OtherNonoperatingIncomeInterestExpense

Namespace Prefix: dcth_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=16317811

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(3)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A5

-Appendix A

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate cost of goods produced and sold and services rendered during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CostOfRevenueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Total costs of sales and operating expenses for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Net of tax and reclassification adjustments of the change in the balance sheet adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency of the reporting entity. Also includes the following: gain (loss) on foreign currency forward exchange contracts; foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements; and gain (loss) on a derivative instrument or nonderivative financial instrument that may give rise to a foreign currency transaction gain (loss) that has been designated and qualified as a hedging instrument for hedging of the foreign currency exposure of a net investment in a foreign operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b,c)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OtherNonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Revenues from the sale of other goods or rendering of other services, not elsewhere specified in the taxonomy; net of (reduced by) sales adjustments, returns, allowances, and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a),(d))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_OtherSalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph g

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 4

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6386349&loc=d3e3636-108311

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Paragraph 5A

-Chapter 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Restructuring Expenses
3 Months Ended

Mar. 31, 2014

Restructuring Expenses [Abstract]

Restructuring Expenses
(6) Restructuring Expenses

During 2013, the Company implemented workforce restructurings to better focus its organizational structure, increase efficiency and concentrate financial resources on its clinical development program and European commercialization activity. This resulted in a total reduction in the Company’s workforce by 50 employees. As a result of termination benefits provided to these employees the Company incurred a total restructuring charge of approximately $4.0 million related to severance expenses. At March 31, 2014, the remaining restructuring reserve of $1.4 million is included in Accrued expenses and Other non-current liabilities on the Condensed Consolidated Balance Sheets for $1.2 million and $0.2 million, respectively.

The following table provides the total severance expense incurred and payments made by the Company through March 31, 2014 as a result of the workforce restructurings implemented in 2013:

(in thousands)

March 31,
2014

Restructuring reserve balance, gross

$
3,974

Restructuring expenses paid

(2,606
)
Restructuring reserve balance, net

$
1,368

X

- Details

Name: us-gaap_RestructuringAndRelatedActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 146

-Paragraph 20

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4)

-URI http://asc.fasb.org/extlink&oid=6394695&loc=d3e140904-122747

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 5.P.3)

-URI http://asc.fasb.org/extlink&oid=6394695&loc=d3e140864-122747

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued Expenses
3 Months Ended

Mar. 31, 2014

Accrued Expenses [Abstract]

Accrued Expenses
(5) Accrued Expenses

Accrued expenses consist of the following:

(in thousands)

March 31,
2014

December 31,
2013

Compensation, excluding taxes

$
1,853

$
1,866

Deferred rent

483

485

Professional fees

323

360

Other¹

817

1,029

Total accrued expenses

$
3,476

$
3,740

¹ Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at March 31, 2014 and December 31, 2013.

In November 2013, the Board of Directors approved an Employee Retention Program for certain key employees, including the Company’s executive officers. The executive officers will be eligible to receive a cash retention bonus payment equal to fifty percent (50%) of their current annual salary if they remain employed by the Company through March 31, 2015. The expense related to this program is being accrued ratably over the required service period and has been included in Accrued expenses on the Condensed Consolidated Balance Sheets and in both Selling, general and administrative and Research and development on the Condensed Consolidated Statements of Operations.

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 43 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued Expenses (Tables)
3 Months Ended

Mar. 31, 2014

Accrued Expenses [Abstract]

Schedule of accrued expenses
Accrued expenses consist of the following:

(in thousands)

March 31,
2014

December 31,
2013

Compensation, excluding taxes

$
1,853

$
1,866

Deferred rent

483

485

Professional fees

323

360

Other¹

817

1,029

Total accrued expenses

$
3,476

$
3,740

¹ Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at March 31, 2014 and December 31, 2013.

X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the components of accrued liabilities.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

General (Policies)
3 Months Ended

Mar. 31, 2014

General [Abstract]

Basis of Presentation
Basis of Presentation

These interim Condensed Consolidated Financial Statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all entities controlled by Delcath and all significant inter-company accounts and transactions have been eliminated in consolidation.

The preparation of interim financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim Condensed Consolidated Financial Statements, in the opinion of management, reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended March 31, 2014 and 2013; however, certain information and footnote disclosures normally included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year.

Recently Adopted Accounting Pronouncements
Recently Adopted Accounting Pronouncements

In March 2013, the FASB issued ASU 2013-05, which permits an entity to release cumulative translation adjustments into net income when a reporting entity (parent) ceases to have a controlling financial interest in a subsidiary or group of assets that is a business within a foreign entity. Accordingly, the cumulative translation adjustment should be released into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided, or, if a controlling financial interest is no longer held. The revised standard became effective for fiscal years beginning after December 15, 2013. The Company adopted this guidance effective January 1, 2014. The Company’s adoption of this standard did not have a material impact on its consolidated financial statements.

X

- Definition

Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

No definition available.

+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of the adoption of new accounting pronouncements that may impact the entity's financial reporting.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 45 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Net Loss per Common Share
3 Months Ended

Mar. 31, 2014

Net Loss per Common Share [Abstract]

Net Loss per Common Share
(9) Net Loss per Common Share

Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all common stock options and warrants are deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. However, in certain periods in which the exercise price of the warrants was less than the last reported sales price of Delcath’s common stock on the final trading day of the period and there is a gain recorded pursuant to the change in fair value of the warrant derivative liability, the impact of gains related to the mark-to-market adjustment of the warrants outstanding at the end of the period is reversed and the treasury stock method is used to determine diluted earnings per share. For the three month periods ended March 31, 2014 and 2013, there were no securities that were dilutive.

For the three month periods ended March 31, 2014 and 2013, the following potentially dilutive securities were excluded from the computation of earnings per share because their effects would be anti-dilutive:

March 31,

2014

2013

Stock options

237,829

349,635

Unvested restricted shares

18,663

25,676

Warrants

891,368

340,254

Total

1,147,860

715,565

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=16381557&loc=d3e4984-109258

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders Equity
3 Months Ended

Mar. 31, 2014

Stockholders Equity [Abstract]

Stockholders Equity
(7) Stockholders’ Equity

Stock Issuances

Reverse Stock Split

On February 24, 2014, shareholders of the Company approved, through a shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Delcath’s common stock at a ratio within a range of one-for-eight (1:8) to one-for-sixteen (1:16). The reverse stock split became effective on April 8, 2014 at which time Delcath’s common stock began trading on the NASDAQ Stock Exchange on a one-for-sixteen (1:16) split-adjusted basis. All owners of record as of the close of the NASDAQ market on April 8, 2014 received one issued and outstanding share of Delcath common stock in exchange for sixteen issued and outstanding shares of Delcath common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-sixteen exchange were rounded up to the next whole share. The reverse stock split had no impact on the number of common shares authorized or the par value per share of Delcath common stock, which remain 170,000,000 and $0.01, respectively. All current and prior period amounts related to shares, share prices and earnings per share, presented in these Condensed Consolidated Financial Statements and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split.

At-the-Market (“ATM”) Programs

In December 2011, the Company entered into an agreement with Cowen and Company, LLC (“Cowen”) to sell shares of its common stock, par value $.01 per share, from time to time, through an ATM equity offering program having aggregate sales proceeds of $39.8 million, under which Cowen would act as sales agent. During the three months ended March 31, 2013, the Company sold approximately 0.9 million shares of its common stock under this ATM program for proceeds of approximately $20.9 million, with net cash proceeds after related expenses of approximately $20.8 million, and successfully completed the program. As of March 31, 2014, there were no shares of common stock of the Company remaining for sale under this ATM program.

In March 2013, the Company entered into a new agreement with Cowen to sell shares of the Company’s common stock, par value $.01 per share, from time to time, through an ATM equity offering program having aggregate sales proceeds of $50.0 million, under which Cowen will act as sales agent. During the year ended December 31, 2013, the Company sold approximately 1.0 million shares of its common stock under this ATM program for proceeds of approximately $5.0 million, with net cash proceeds after related expenses of approximately $4.8 million. During the three months ended March 31, 2014 the Company sold an additional 1.0 million shares of its common stock under this ATM program for proceeds of approximately $4.4 million, with net cash proceeds after related expenses of approximately $4.4 million. The shares were issued pursuant to an effective registration statement on Form S-3 (333-187230). The net proceeds will be used for general corporate purposes, including, but not limited to, commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures and working capital. As of March 31, 2014, the Company has approximately $40.4 million remaining under the program.

Committed Equity Financing Facility (“CEFF”) Program

In December 2012, the Company entered into an agreement with Terrapin Opportunity, L.P. (“Terrapin”) for a CEFF program. Under the agreement Terrapin committed to purchase up to $35.0 million of Delcath common stock over a 24-month term. Since inception, the Company has sold approximately 0.5 million shares of its common stock through the program for total proceeds of approximately $11.1 million, with net cash proceeds after related expenses of approximately $10.8 million. As a result, there was approximately $23.9 million available under this CEFF program as of March 31, 2014. The shares were issued pursuant to an effective registration statement on Form S-3 (333-183675). The net proceeds will be used for general corporate purposes including, but not limited to, commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures and general working capital needs.

Warrants

In June 2009, the Company completed the sale of 0.1 million shares of its common stock and the issuance of warrants to purchase 0.1 million common shares (the “2009 Warrants”) pursuant to a subscription agreement with a single investor. The Company received proceeds of $3.0 million, with net cash proceeds after related expenses from this transaction of approximately $2.7 million. Of those proceeds, the Company allocated an estimated fair value of $2.2 million to the 2009 Warrants. As required by the 2009 Warrant agreement, the exercise price of the warrants was adjusted following the Company’s October 2013 sale of common stock and warrants. At March 31, 2014, the 2009 Warrants were exercisable at $2.56 per share with approximately 40,000 warrants outstanding. The 2009 Warrants have a five-year term. The shares and warrants were issued pursuant to an effective registration statement on Form S-3. During the three months ended March 31, 2014, 25,000 2009 Warrants were exercised for net proceeds of approximately $0.1 million.

In May 2012, the Company completed the sale of 1.0 million shares of its common stock and the issuance of warrants to purchase 0.3 million common shares (the “2012 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $21.5 million, with net cash proceeds after related expenses from this transaction of approximately $21.1 million. Of those proceeds, the Company allocated an estimated fair value of $3.4 million to the 2012 Warrants. As required by the 2012 Warrant agreement, the exercise price of the warrants was adjusted following the Company’s October 2013 sale of common stock and warrants. At March 31, 2014, the 2012 Warrants were exercisable at $2.56 per share with 0.3 million warrants outstanding. The 2012 Warrants have a three-year term. The shares and warrants were issued pursuant to an effective registration statement on Form S-3. During the three months ended March 31, 2014, approximately 13,000 2012 Warrants were exercised for net proceeds of approximately $34,000.

In October 2013, the Company completed the sale of 1.3 million shares of its common stock and the issuance of warrants to purchase 0.6 million common shares (the “2013 Warrants”) pursuant to a placement agency agreement. The Company received proceeds of $7.5 million, with net cash proceeds after related expenses from this transaction of approximately $6.9 million. Of those proceeds, the Company allocated an estimated fair value of $1.9 million to the 2013 Warrants. The 2013 Warrants will become exercisable at $7.04 per share on April 30, 2014. The 2013 Warrants have a five-year term. The shares and warrants were issued pursuant to an effective registration statement on Form S-3.

Stock Incentive Plans

The Company established the 2004 Stock Incentive Plan and the 2009 Stock Incentive Plan (collectively, the “Plans”) under which 187,500, and 406,250 shares, respectively, have been reserved for the issuance of stock options, stock appreciation rights, restricted stock, stock grants and other equity awards. The Plans are administered by the Compensation and Stock Option Committee of the Board of Directors which determines the individuals to whom awards shall be granted as well as the type, terms, conditions, option price and the duration of each award.

A stock option grant allows the holder of the option to purchase a share of the Company’s common stock in the future at a stated price. Options granted under the Plans vest as determined by the Company’s Compensation and Stock Option Committee and expire over varying terms, but not more than ten years from the date of grant. Stock option activity for the three months ended March 31, 2014 is as follows:

Stock Option Activity under the Plans

Stock
Options

Exercise
Price
per Share

Weighted Average
Exercise
Price

Weighted Average Remaining
Life (Years)

Outstanding at December 31, 2013

252,133

$
4.80—$248.64

$
57.90

7.36

Granted

—

—

—

Forfeited

(14,304
)

$
7.36—$248.64

$
109.54

Expired

—

—

—

Outstanding at March 31, 2014

237,829

$
4.80—$248.64

$
54.79

7.13

For the three months ended March 31, 2014 and 2013, the Company recognized compensation expense of approximately $0.2 million and $0.5 million, respectively, relating to stock options granted to employees.

There were no options granted during the three months ended March 31, 2014. The estimated fair value of each option award granted during the three month period ended March 31, 2013 was determined on the date of grant using an option pricing model with the following assumptions:

Three months ended
March 31, 2013

Dividend yield

None

Expected volatility

86.16% — 86.51%

Weighted average volatility

86.20%

Risk-free interest rates

1.16% — 1.36%

Expected life (in years)

6.8

No dividend yield was assumed because the Company has never paid a cash dividend on its common stock and does not expect to pay dividends in the foreseeable future. Volatilities were developed using the Company’s historical volatility. The risk-free interest rate was developed using the U.S. Treasury yield for periods equal to the expected life of the stock options on the grant date. The expected option term for grants made during the second half of 2012 and thereafter is based on actual historical results. The expected option term for grants made prior to that was developed based on the mid-point between the vesting date and the expiration date of each respective grant as permitted under ASC 718. This method of determining the expected holding period was utilized at that time because the Company did not yet have sufficient historical experience from which to estimate the period.

Restricted stock activity for the three months ended March 31, 2014 is as follows:

Restricted Stock Activity
under the Plans

Restricted Stock

Weighted Average Grant Date Fair Value

Non-vested at December 31, 2013

20,358

$
16.88

Granted

—

—

Vested

(1,624
)

75.32

Forfeited

(71
)

39.26

Non-vested at March 31, 2014

18,663

$
11.71

For the three months ended March 31, 2014 and 2013, the Company recognized compensation expense of approximately $0.04 million and $0.2 million, respectively, related to restricted stock granted to employees.

X

- Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section B

-Paragraph 7, 11A

-Chapter 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value Measurements
3 Months Ended

Mar. 31, 2014

Fair Value Measurements [Abstract]

Fair Value Measurements
(8) Fair Value Measurements

Derivative Warrant Liability

As disclosed in Note 7 Stockholders’ Equity of these Condensed Consolidated Financial Statements, the Company allocated part of the proceeds of public offerings in 2009, 2012 and 2013 of the Company’s common stock to warrants issued in connection with those transactions. The valuation of the warrants was determined using an option pricing model. This model uses inputs such as the underlying price of the shares issued when the warrant is exercised, volatility, risk free interest rate and expected life of the instrument. The Company has determined that the warrants should be classified as liabilities and has accounted for them as derivative instruments in accordance with ASC 815. Additionally, the Company has determined that the warrant derivative liability should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the option pricing model against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification as called for in ASC 820. There are six inputs: closing price of Delcath stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of Delcath’s stock over that term; annual rate of dividends; and the riskless rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrant agreements. The annual rate of dividends is based on the Company’s historical practice of not granting dividends. The closing price of Delcath stock would fall under Level 1 of the fair-value hierarchy as it is a quoted price in an active market (ASC 820-10). The riskless rate of return is a Level 2 input as defined in ASC 820-10, while the historical volatility is a Level 3 input as defined in ASC 820. Since the lowest level input is a Level 3, Delcath determined the warrant derivative liability is most appropriately classified within Level 3 of the fair value hierarchy.

For the three months ended March 31, 2014, the Company recorded pre-tax derivative warrant expense of $0.2 million. The resulting derivative warrant liabilities totaled $2.4 million at March 31, 2014. In the event of a hypothetical 10% increase in the market price of our common shares on which the March 31, 2014 valuation was based, the value of the derivative liability would have increased by $0.3 million. Management expects that the warrants will either be exercised or expire worthless. The fair value of the warrants at March 31, 2014 was determined by using an option pricing model with the following assumptions:

2013
Warrants

2012
Warrants

2009
Warrants

Expected volatility

91.53%

114.33%

101.78%

Risk-free interest rates

1.52%

0.21%

0.05%

Expected life (in years)

4.58

1.17

0.21

Money Market Funds

The Company has determined that the inputs associated with the fair value determination of its money market funds are based on quoted prices (unadjusted) and, as a result, the investments have been classified within Level 1 of the fair value hierarchy.

The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2014, aggregated by the level in the fair value hierarchy within which those measurements fall.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

(in thousands)
Level 1

Level 2

Level 3

Balance at
March 31, 2014

Assets

Money market funds

$
1,945

$
—

$
—

$
1,945

Liabilities

Warrant liability

$
—

$
—

$
2,399

$
2,399

The table below presents the activity within Level 3 of the fair value hierarchy for the three months ended March 31, 2014:

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

(in thousands)

Warrant Liability

Beginning balance as of December 31, 2013

$
2,310

Total change in the liability included in earnings

205

Fair value of warrants exercised

(116
)
Ending balance as of March 31, 2014

$
2,399

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15C, 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32, 33, 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 3, 10, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-Subparagraph a-d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44A, 44B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15B

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Paragraph 17-22, 27, 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

Taxes
3 Months Ended

Mar. 31, 2014

Taxes [Abstract]

Taxes
(10) Taxes

As discussed in Note 13 Income Taxes of the Company’s Annual Report, the Company has a valuation allowance against the full amount of its net deferred tax assets. The Company currently provides a valuation allowance against deferred tax assets when it is more likely than not that some portion or all of its deferred tax assets will not be realized. The Company has not recognized any unrecognized tax benefits in its balance sheet.

The Company is subject to income tax in the U.S., as well as various state and international jurisdictions. The Company has not been audited by the U.S. Internal Revenue Service, international tax authorities, or any states in connection with income taxes. The Company’s New York State tax returns have been subject to annual desk reviews which have resulted in insignificant adjustments to the related franchise tax liabilities and credits. The Company’s tax years generally remain open to examination for all federal, state and foreign tax matters until its net operating loss carryforwards are utilized and the applicable statutes of limitation have expired. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations.

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 136, 172

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 43, 44, 45, 46, 47, 48, 49

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders Equity (Details) (USD $)
1 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended

Oct. 31, 2013

May 31, 2012

Jun. 30, 2009

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Minimum [Member]

Mar. 31, 2014

Maximum [Member]

Mar. 31, 2014

2004 Stock Incentive Plan [Member]

Mar. 31, 2014

2009 Stock Incentive Plan [Member]

Mar. 31, 2014

Stock Options [Member]

Mar. 31, 2013

Stock Options [Member]

Mar. 31, 2014

Restricted Stock [Member]

Mar. 31, 2013

Restricted Stock [Member]

May 31, 2012

2012 Warrants [Member]

Mar. 31, 2014

2012 Warrants [Member]

Jun. 30, 2009

2009 Warrants [Member]

Mar. 31, 2014

2009 Warrants [Member]

Oct. 31, 2013

2013 Warrants [Member]

Mar. 31, 2014

2013 Warrants [Member]

Apr. 30, 2014

2013 Warrants [Member]

Subsequent Event [Member]

Mar. 31, 2014

Sales Agreement March 2013 [Member]

Cowen and Company, LLC [Member]

Dec. 31, 2013

Sales Agreement March 2013 [Member]

Cowen and Company, LLC [Member]

Mar. 31, 2014

CEFF [Member]

Terrapin Opportunity, L.P. [Member]

Mar. 31, 2013

Sales Agreement December 2011 [Member]

Cowen and Company, LLC [Member]

Mar. 31, 2014

Sales Agreement December 2011 [Member]

Cowen and Company, LLC [Member]

Stock Issuances [Abstract]

Reverse Stock Split Ratio one-for-sixteen (1:16) one-for-sixteen (1:16) one-for-sixteen (1:16) one-for-eight (1:8) one-for- sixteen (1:16)

Common stock, shares authorized (in shares) 170,000,000 170,000,000

Common stock, par value (in dollars per share) $ 0.01 $ 0.01

Common stock, par value under sales agreement (in dollars per share) $ 0.01 $ 0.01

Proceeds from issuance of common stock $ 4,400,000 $ 5,000,000 $ 11,100,000 $ 20,900,000

Proceeds of common stock issued, net of related expenses 4,400,000 4,800,000 10,800,000 20,800,000

Common stock sold through the program (in shares) 1,300,000 1,000,000 100,000 1,000,000 1,000,000 500,000 900,000

Aggregate proceeds from sale of common stock under equity offering program, maximum 50,000,000 39,800,000

Aggregate proceeds from sale of common stock under equity offering program, remaining 40,400,000

Remaining value of common stock 94,000 ^[1] 84,000 ^[1]

Amount to be purchased by party under agreement 35,000,000

Term of purchase agreement 24 months

Amount Available Under Committed Equity Financing Facility 23,900,000

Warrant [Abstract]

Warrants issued (in shares) 300,000 100,000 600,000

Proceeds from issuance of private placement 7,500,000 21,500,000 3,000,000

Net proceeds from issuance of private placement 6,900,000 21,100,000 2,700,000

Estimated fair value allocated to warrants issued 3,400,000 2,200,000 1,900,000

Warrants exercisable per share price (in dollars per share) $ 2.56 $ 2.56 $ 7.04

Number of warrants outstanding (in shares) 300,000 40,000

Term period for warrants 3 years 5 years 5 years

Warrants Exercised (in shares) 13,000 25,000

Net proceeds from exercise of warrants 34,000 100,000

Stock Incentive Plans [Abstract]

Shares reserved for the issuance (in shares) 187,500 406,250

Maximum term of options 10 years

Recognized compensation expense 178,000 467,000 178,000 467,000

Restricted stock compensation expense $ 42,000 $ 197,000 $ 42,000 $ 197,000

[1] Reflects a one-for- sixteen (1:16) reverse stock split effected on April 8, 2014.

X

- Definition

The amount of funds available under the committed equity financing facility program.

+ References

No definition available.

+ Details

Name: dcth_AmountAvailableUnderCommittedEquityFinancingFacility

Namespace Prefix: dcth_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount refers to purchased by party under purchase agreement.

+ References

No definition available.

+ Details

Name: dcth_AmountToBePurchasedByPartyUnderPurchaseAgreement

Namespace Prefix: dcth_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount refers to common stock par value under sales agreement.

+ References

No definition available.

+ Details

Name: dcth_CommonStockParValueUnderSalesAgreement

Namespace Prefix: dcth_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Represents the maximum proceeds from sale of common stock under equity offering program.

+ References

No definition available.

+ Details

Name: dcth_MaximumProceedsFromSaleOfCommonStockUnderEquityOfferingProgram

Namespace Prefix: dcth_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Refers to The cash inflow associated with the amount received from holders exercising their Warrants. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

No definition available.

+ Details

Name: dcth_NetProceedsFromExerciseOfWarrants

Namespace Prefix: dcth_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow, net of related expenses, associated with the amount received from entity's raising of capital via private rather than public placement.

+ References

No definition available.

+ Details

Name: dcth_NetProceedsFromIssuanceOfPrivatePlacement

Namespace Prefix: dcth_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity, net of related expenses.

+ References

No definition available.

+ Details

Name: dcth_ProceedsFromIssuanceOfCommonStockNetOfRelatedExpenses

Namespace Prefix: dcth_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Represents the remaining proceeds from sale of common stock under equity offering program.

+ References

No definition available.

+ Details

Name: dcth_RemainingProceedsFromSaleOfCommonStockUnderEquityOfferingProgram

Namespace Prefix: dcth_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Term of equity-based payment award.

+ References

No definition available.

+ Details

Name: dcth_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm

Namespace Prefix: dcth_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dcth_StockIncentivePlansAbstract

Namespace Prefix: dcth_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dcth_StockIssuancesAbstract

Namespace Prefix: dcth_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Term of purchase agreement.

+ References

No definition available.

+ Details

Name: dcth_TermOfPurchaseAgreement

Namespace Prefix: dcth_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Term period of warrants in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name: dcth_TermPeriodForWarrants

Namespace Prefix: dcth_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The fair value allocated to warrants issued.

+ References

No definition available.

+ Details

Name: dcth_ValueOfWarrantsIssued

Namespace Prefix: dcth_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: dcth_WarrantActivityAbstract

Namespace Prefix: dcth_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of warrants issued during the period to purchase common shares.

+ References

No definition available.

+ Details

Name: dcth_WarrantsIssuedDuringPeriodShares

Namespace Prefix: dcth_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The exercise price of each class of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Subparagraph 4

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: us-types:perUnitItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate amount of each class of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_RestrictedStockExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 54

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

+ Details

Name: us-gaap_StockholdersEquityReverseStockSplit

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph i

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_StockOptionPlanExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 50 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Prepaid Expenses and Other Current Assets (Tables)
3 Months Ended

Mar. 31, 2014

Prepaid Expenses and Other Current Assets [Abstract]

Prepaid expenses and other current assets
Prepaid expenses and other current assets consist of the following:

(in thousands)

March 31,
2014

December 31,
2013

Insurance premiums

$
310

$
407

Professional fees

75

377

Income tax credits receivable

297

326

Kits for clinical use

295

287

Other¹

315

314

Total prepaid expenses and other current assets

$
1,292

$
1,711

¹ Other consists of various prepaid expenses and other current assets with no individual item accounting for more than 5% of the total balance at March 31, 2014 and December 31, 2013.

X

- Details

Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfOtherAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value Measurements (Tables)
3 Months Ended

Mar. 31, 2014

Fair Value Measurements [Abstract]

Schedule of fair value of the warrants
The fair value of the warrants at March 31, 2014 was determined by using an option pricing model with the following assumptions:

2013
Warrants

2012
Warrants

2009
Warrants

Expected volatility

91.53%

114.33%

101.78%

Risk-free interest rates

1.52%

0.21%

0.05%

Expected life (in years)

4.58

1.17

0.21

Assets and liabilities measured at fair value on a recurring basis
The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2014, aggregated by the level in the fair value hierarchy within which those measurements fall.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

(in thousands)
Level 1

Level 2

Level 3

Balance at
March 31, 2014

Assets

Money market funds

$
1,945

$
—

$
—

$
1,945

Liabilities

Warrant liability

$
—

$
—

$
2,399

$
2,399

Fair value measurements using significant unobservable inputs
The table below presents the activity within Level 3 of the fair value hierarchy for the three months ended March 31, 2014:

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

(in thousands)

Warrant Liability

Beginning balance as of December 31, 2013

$
2,310

Total change in the liability included in earnings

205

Fair value of warrants exercised

(116
)
Ending balance as of March 31, 2014

$
2,399

X

- Definition

Tabular disclosure of the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments, assets, and liabilities. Such certain disclosures about the financial instruments, assets, and liabilities include: (1) the fair value of the required items together with their carrying amounts (as appropriate) and (2) the methodology and assumptions used in developing such estimates of fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Paragraph 18

-Subparagraph c(2), d, e, f

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15

-Subparagraph b-d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13467-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13476-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 14

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6447952&loc=d3e13220-108610

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Paragraph 19

-Subparagraph a, b, c(1), d(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32

-Subparagraph a, c(1), c(2), c(3), d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_FairValueByBalanceSheetGroupingTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19279-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19190-110258

+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical)
3 Months Ended 12 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) [Abstract]

Reverse stock split ratio one-for-sixteen (1:16) one-for-sixteen (1:16) one-for-sixteen (1:16)

X

- Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 54

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

+ Details

Name: us-gaap_StockholdersEquityReverseStockSplit

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 53 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Property, Plant, and Equipment
3 Months Ended

Mar. 31, 2014

Property, Plant, and Equipment [Abstract]

Property, Plant, and Equipment
(4) Property, Plant, and Equipment

Property, plant, and equipment consist of the following:

(in thousands)

March 31,
2014

December 31,
2013

Leaseholds

$
1,748

$
1,749

Furniture

957

957

Equipment

1,487

1,552

Enterprise hardware and software

2,009

2,143

Buildings and land

603

603

Property, plant and equipment, gross

6,804

7,004

Accumulated depreciation

(4,066
)

(3,935
)
Property, plant and equipment, net

$
2,738

$
3,069

Depreciation expense for the three months ended March 31, 2014 and 2013 was $0.2 million and $0.3 million, respectively.

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13-14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

Net Loss per Common Share (Tables)
3 Months Ended

Mar. 31, 2014

Net Loss per Common Share [Abstract]

Anti-dilutive Securities Excluded from the Computation of Earnings per Share
For the three month periods ended March 31, 2014 and 2013, the following potentially dilutive securities were excluded from the computation of earnings per share because their effects would be anti-dilutive:

March 31,

2014

2013

Stock options

237,829

349,635

Unvested restricted shares

18,663

25,676

Warrants

891,368

340,254

Total

1,147,860

715,565

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 85 188 1 true 35 0 false 6 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://delcath.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 010000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) false false R3.htm 010100 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) false false R4.htm 020000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) false false R5.htm 020100 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical) Sheet http://delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedParenthetical Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical) false false R6.htm 030000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://delcath.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) false false R7.htm 060100 - Disclosure - General Sheet http://delcath.com/role/General General false false R8.htm 060200 - Disclosure - Inventories Sheet http://delcath.com/role/Inventories Inventories false false R9.htm 060300 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://delcath.com/role/PrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets false false R10.htm 060400 - Disclosure - Property, Plant, and Equipment Sheet http://delcath.com/role/PropertyPlantAndEquipment Property, Plant, and Equipment false false R11.htm 060500 - Disclosure - Accrued Expenses Sheet http://delcath.com/role/AccruedExpenses Accrued Expenses false false R12.htm 060600 - Disclosure - Restructuring Expenses Sheet http://delcath.com/role/RestructuringExpenses Restructuring Expenses false false R13.htm 060700 - Disclosure - Stockholders Equity Sheet http://delcath.com/role/StockholdersEquity Stockholders Equity false false R14.htm 060800 - Disclosure - Fair Value Measurements Sheet http://delcath.com/role/FairValueMeasurements Fair Value Measurements false false R15.htm 060900 - Disclosure - Net Loss per Common Share Sheet http://delcath.com/role/NetLossPerCommonShare Net Loss per Common Share false false R16.htm 061000 - Disclosure - Taxes Sheet http://delcath.com/role/Taxes Taxes false false R17.htm 061100 - Disclosure - Commitments and Contingencies Sheet http://delcath.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R18.htm 061200 - Disclosure - Subsequent Events Sheet http://delcath.com/role/SubsequentEvents Subsequent Events false false R19.htm 070100 - Disclosure - General (Policies) Sheet http://delcath.com/role/GeneralPolicies General (Policies) false false R20.htm 080200 - Disclosure - Inventories (Tables) Sheet http://delcath.com/role/InventoriesTables Inventories (Tables) false false R21.htm 080300 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://delcath.com/role/PrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) false false R22.htm 080400 - Disclosure - Property, Plant, and Equipment (Tables) Sheet http://delcath.com/role/PropertyPlantAndEquipmentTables Property, Plant, and Equipment (Tables) false false R23.htm 080500 - Disclosure - Accrued Expenses (Tables) Sheet http://delcath.com/role/AccruedExpensesTables Accrued Expenses (Tables) false false R24.htm 080600 - Disclosure - Restructuring Expenses (Tables) Sheet http://delcath.com/role/RestructuringExpensesTables Restructuring Expenses (Tables) false false R25.htm 080700 - Disclosure - Stockholders Equity (Tables) Sheet http://delcath.com/role/StockholdersEquityTables Stockholders Equity (Tables) false false R26.htm 080800 - Disclosure - Fair Value Measurements (Tables) Sheet http://delcath.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) false false R27.htm 080900 - Disclosure - Net Loss per Common Share (Tables) Sheet http://delcath.com/role/NetLossPerCommonShareTables Net Loss per Common Share (Tables) false false R28.htm 090100 - Disclosure - General (Details) Sheet http://delcath.com/role/GeneralDetails General (Details) false false R29.htm 090200 - Disclosure - Inventories (Details) Sheet http://delcath.com/role/InventoriesDetails Inventories (Details) false false R30.htm 090300 - Disclosure - Prepaid Expenses and Other Current Assets (Details) Sheet http://delcath.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails Prepaid Expenses and Other Current Assets (Details) false false R31.htm 090400 - Disclosure - Property, Plant, and Equipment (Details) Sheet http://delcath.com/role/PropertyPlantAndEquipmentDetails Property, Plant, and Equipment (Details) false false R32.htm 090500 - Disclosure - Accrued Expenses (Details) Sheet http://delcath.com/role/AccruedExpensesDetails Accrued Expenses (Details) false false R33.htm 090600 - Disclosure - Restructuring Expenses (Details) Sheet http://delcath.com/role/RestructuringExpensesDetails Restructuring Expenses (Details) false false R34.htm 090700 - Disclosure - Stockholders Equity (Details) Sheet http://delcath.com/role/StockholdersEquityDetails Stockholders Equity (Details) false false R35.htm 090702 - Disclosure - Stockholders Equity, Stock Incentive Plans (Details) Sheet http://delcath.com/role/StockholdersEquityStockIncentivePlansDetails Stockholders Equity, Stock Incentive Plans (Details) false false R36.htm 090800 - Disclosure - Fair Value Measurements (Details) Sheet http://delcath.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) false false R37.htm 090900 - Disclosure - Net Loss per Common Share (Details) Sheet http://delcath.com/role/NetLossPerCommonShareDetails Net Loss per Common Share (Details) false false R38.htm 091200 - Disclosure - Subsequent Events (Details) Sheet http://delcath.com/role/SubsequentEventsDetails Subsequent Events (Details) false false All Reports Book All Reports Element dcth_MaximumProceedsFromSaleOfCommonStockUnderEquityOfferingProgram had a mix of decimals attribute values: -5 0. Element dcth_NetProceedsFromExerciseOfWarrants had a mix of decimals attribute values: -5 0. Element us-gaap_CommonStockParOrStatedValuePerShare had a mix of decimals attribute values: 0 2. Element us-gaap_RestrictedStockExpense had a mix of decimals attribute values: -3 0. Element us-gaap_RestructuringReserve had a mix of decimals attribute values: -5 -3. Element us-gaap_StockOptionPlanExpense had a mix of decimals attribute values: -3 0. 'Monetary' elements on report '090600 - Disclosure - Restructuring Expenses (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '090700 - Disclosure - Stockholders Equity (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '090800 - Disclosure - Fair Value Measurements (Details)' had a mix of different decimal attribute values. Process Flow-Through: 010000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Process Flow-Through: Removing column 'Mar. 31, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 010100 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Process Flow-Through: Removing column '3 Months Ended Mar. 31, 2013' Process Flow-Through: 020000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Process Flow-Through: 020100 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical) Process Flow-Through: 030000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) dcth-20140331.xml dcth-20140331.xsd dcth-20140331_cal.xml dcth-20140331_def.xml dcth-20140331_lab.xml dcth-20140331_pre.xml true true XML 56 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8

Subsequent Events (Details) (Subsequent Event [Member], USD $)
3 Months Ended

Mar. 31, 2014

Apr. 24, 2014

Subsequent Event [Member]

Subsequent Event [Line Items]

Reverse stock split one-for-sixteen

Closing bid price per NASDAQ listing notification letter (in dollars per share) $ 1.00

Consecutive business days for closing bid price of common stock 10 days

X

- Definition

The closing bid price of common stock.

+ References

No definition available.

+ Details

Name: dcth_ClosingBidPriceOfCommonStock

Namespace Prefix: dcth_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of consecutive business days for closing bid price of common stock.

+ References

No definition available.

+ Details

Name: dcth_ConsecutiveBusinessDaysForClosingBidPriceOfCommonStock

Namespace Prefix: dcth_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Stock Split

-URI http://asc.fasb.org/extlink&oid=6525746

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section B

-Paragraph 2, 15, 16

-Chapter 7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_StockholdersEquityNoteStockSplit

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 57 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Inventories (Tables)
3 Months Ended

Mar. 31, 2014

Inventories [Abstract]

Schedule of inventories
Inventories consist of the following:

(in thousands)

March 31,
2014

December 31,
2013

Raw materials

$
232

$
249

Work-in-process

268

364

Finished goods

119

106

Total inventory

$
619

$
719

X

- Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

General (Policies)	3 Months Ended
General (Policies)	Mar. 31, 2014
General [Abstract]
Basis of Presentation	Basis of Presentation These interim Condensed Consolidated Financial Statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all entities controlled by Delcath and all significant inter-company accounts and transactions have been eliminated in consolidation. The preparation of interim financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim Condensed Consolidated Financial Statements, in the opinion of management, reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended March 31, 2014 and 2013; however, certain information and footnote disclosures normally included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In March 2013, the FASB issued ASU 2013-05, which permits an entity to release cumulative translation adjustments into net income when a reporting entity (parent) ceases to have a controlling financial interest in a subsidiary or group of assets that is a business within a foreign entity. Accordingly, the cumulative translation adjustment should be released into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided, or, if a controlling financial interest is no longer held. The revised standard became effective for fiscal years beginning after December 15, 2013. The Company adopted this guidance effective January 1, 2014. The Company’s adoption of this standard did not have a material impact on its consolidated financial statements.

Subsequent Events (Details) (Subsequent Event [Member], USD $)	3 Months Ended
	Mar. 31, 2014	Apr. 24, 2014
Subsequent Event [Member]
Subsequent Event [Line Items]
Reverse stock split	one-for-sixteen
Closing bid price per NASDAQ listing notification letter (in dollars per share)		$ 1.00
Consecutive business days for closing bid price of common stock	10 days